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Abstract 
Prostate cancer is the third-leading cause of male cancer-related deaths in developed 
countries. Prostate cancer-associated mortality ensues when the cancer spreads to 
other organs, primarily bone. Novel therapies are required to inhibit prostate cancer 
development and progression to malignant disease. While it is the gland-lining or 
epithelial cells of the prostate that become malignant, these cells must activate the 
surrounding microenvironment to facilitate disease progression. As such, future anti-
cancer therapies should target factors that drive development of the tumour and 
activation of its microenvironment.  
Kallikrein-related peptidase 4 (KLK4) is a prostate epithelial cell-secreted protease, 
which is over-produced in prostate cancer and in a pre-cancerous pathology 
whereupon activation of the tumour microenvironment is believed to initiate. The 
pattern of expression of KLK4 in prostate pathologies suggests that it may function 
in prostate cancer progression. A small number of functional studies performed to 
date have shown that KLK4 induces prostate cancer cell motility and transformation 
to a migratory phenotype, each of which precedes the spread of localised disease and 
metastasis. However, knowledge of KLK4 function in the surrounding tumour 
microenvironment is limited. A greater understanding of KLK4 function in prostate 
cancer and its microenvironment is required to evaluate the utility of KLK4 as an 
anti-cancer target.  
To this end, the present study aimed to use high-depth techniques to identify the pool 
of cell-secreted KLK4 substrates (its degradome) and KLK4-regulated genes (its 
transcriptome) in prostate cancer cells and the tumour microenvironment. This work 
comprises the most extensive omics analyses of KLK4 function to date. Previously, 
KLK4-mediated regulation of only a handful of genes had been assessed. Herein, a 
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gene microarray platform was employed to assess KLK4-regulated expression of 
~20,047 genes. Further, while some KLK4 substrates are known, each has been 
generally selected for screening based on a priori association to cancer, thus 
conferring a literature bias on substrate identification. Moreover, individual 
substrates have been screened by incubation with KLK4 in a test tube, making it 
difficult to ascertain whether KLK4 can cleave each protein in the complex, protein-
rich tumour microenvironment. The PROtein TOpography and Migration Analysis 
Platform (PROTOMAP) approach employed herein overcomes these shortcomings, 
being a low-bias, high-depth technique allowing for simultaneous determination of 
all detectable protein cleavage events within a cell-derived protein pool.  
The KLK4 degradome was first delineated in secretions from LNCaP and PC-3 
prostate cancer cells, representative of early- and late-stage disease, respectively. 
Twenty-nine novel KLK4 substrates were identified, as well as one established 
substrate, urokinase-type plasminogen activator (uPA), which served to validate the 
approach. Matrix metalloproteinase-1 (MMP1) was biochemically validated to be 
activated by KLK4, and in vitro validation was also performed for KLK4-mediated 
hydrolysis of granulin (GRN) and vinculin (VCL/VINC). These and other of the 
novel KLK4 substrates identified have been functionally implicated in tumour-
promoting processes. Such processes include cell migration and blood vessel 
formation, which are established and novel putative KLK4-regulated functions, 
respectively. Surprisingly, transcriptome analyses revealed only three genes to be 
KLK4-regulated in prostate cancer cells, indicating that KLK4 activity does not have 
a major autocrine effect on prostate cancer cell function at the level of gene 
expression, at least under the conditions employed. 
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The above finding led to the supposition that KLK4 may instead have more extensive 
regulatory effects on other cell types within the prostate tumour microenvironment. 
In particular, prostate cancer cells secrete factors that stimulate the activation of 
resting fibroblasts to a tumour-promoting or activated phenotype. Activated 
fibroblasts, in turn, signal to neighbouring epithelium to permit and support tumour 
progression. This process begins in the pre-cancerous prostate pathology in which 
KLK4 is first up-regulated. Thus, KLK4 is well-positioned to act on prostate 
fibroblasts to regulate fibroblast activation and resulting tumour-inductive signalling.  
The KLK4-regulated transcriptome was next assessed in the prostate WPMY-1 
myofibroblast cell line, used to represent tumour-adjacent fibroblasts. KLK4 
regulated 439 genes, with pathway analysis tools identifying transforming growth 
factor beta-1 (TGFβ1) as a significant mediator of KLK4-regulated transcription. 
Accordingly, genes up- and down-regulated by KLK4 in WPMY-1 myofibroblasts 
were similarly regulated by TGFβ1 (Fisher’s exact test, P ≤ 0.01). TGFβ1 signalling 
in activated or cancer-associated fibroblasts (CAFs) promotes an aggressive cancer 
phenotype, suggesting that KLK4 may favour prostate cancer progression via 
induction of TGFβ1 signalling in CAFs. Analysis of the KLK4 degradome identified 
50 novel WPMY-1 myofibroblast-derived substrates, including 11 known to regulate 
TGFβ1 activity. Of these, KLK4 appeared to cleave latent-transforming growth 
factor beta-binding protein 4 (LTBP4) and fibrillin-1 (FBN1) in a manner likely to 
induce TGFβ1 activity, demonstrating a plausible proteolytic mechanism for KLK4-
mediated activation of TGFβ1 signalling in the prostate tumour microenvironment. 
This study constitutes the most comprehensive analysis of the KLK4-regulated 
transcriptome and degradome in prostate cancer to date, and is the first such analysis 
of KLK4 action within the prostate tumour microenvironment. The results obtained 
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affirm KLK4 as a promising anti-cancer target, suggesting that KLK4 inhibition may 
reduce pro-tumourigenic signals from the prostate tumour microenvironment, a 
critical component of prostate cancer progression. 
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1.1 Prostate cancer epidemiology, treatment and aetiology 
1.1.1 Prostate cancer epidemiology and treatment 
Prostate cancer is the third-leading cause of male cancer-related death in developed 
countries (International Agency for Research on Cancer, 2012). Australia is no 
exception, with 3,235 men succumbing to the disease in 2010, second only to lung 
cancer-associated mortality (Australian Institute of Health and Welfare & 
Australasian Association of Cancer Registries, 2012). The greatest risk factors 
associated with prostate cancer are aging, family history of prostatic carcinoma and 
ethnicity (Crawford, 2003). Locally-confined prostate tumours can be successfully 
treated by radical prostatectomy, androgen ablation and/ or radiotherapy, although 
often with debilitating side effects (Wolf et al., 2010). Despite the five-year survival 
rate for patients with localised tumours nearing 100%, there is a high degree of post-
operative recurrence and many cancers progress to advanced disease, predominantly 
forming incurable bone metastases (Schroder et al., 2012a). Although prostate cancer 
progresses through similar molecular and phenotypic ‘hallmarks’ as other endocrine-
related cancers (Hanahan & Weinberg, 2011), the biological mechanisms driving its 
development are poorly understood. There is a need for novel targeted therapies to 
eliminate prostate cancer and to prevent the establishment of metastases. To this end, 
a greater understanding of the mechanisms enabling prostate cancer progression is 
required. 
1.1.2 Prostate cancer aetiology 
Prostate cancer establishes in the male prostate gland, a small organ situated behind 
the rectum. The prostate gland secretes prostatic fluid into ejaculate, facilitating 
liquefaction of the seminal clot, and hence, sperm motility. Within the prostate gland 
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are multiple lumen lined with a bilayer of luminal secretory epithelial cells and 
underlying basal epithelial cells, encapsulated in a proteinaceous basal lamina 
(McNeal, 1988). Sparse distribution of neuroendocrine cells is also found in the basal 
layer (Bonkhoff, 1998). The lumen is surrounded by an extracellular matrix (ECM)-
rich stroma and sparse stromal cells, including smooth muscle, endothelial cells, 
pericytes and fibroblasts (Barron & Rowley, 2012; Tuxhorn et al., 2002). Although 
the cellular origin of prostate cancer is disputed, prostate cancer presents with a 
luminal epithelial phenotype (Abate-Shen & Shen, 2000; Taylor et al., 2012). Cancer 
is characterised by ‘hallmark’ phenotypic processes, including sustained cell 
proliferation, reduced cell death, and increased cell migration and local invasion 
through the basal lamina into surrounding stromal tissue. Further, cancer cells 
interact with stromal cells to induce angiogenesis and pro-tumourigenic 
inflammation, while avoiding immune-mediated destruction. Some cancer cells can 
enter and survive in the circulation, and a fraction of circulating cancer cells may 
establish metastatic deposits at the secondary site (Hanahan & Weinberg, 2011). The 
above-mentioned processes are regulated by a number of molecules, including 
growth factors, cytokines, cell surface receptors, ECM proteins and proteases 
(Hanahan & Weinberg, 2011). Novel therapeutic strategies may target molecules that 
function in any stage of prostate cancer progression, in order to prevent or eliminate 
fatal metastases.  
1.1.3 Proteases as targets for cancer therapy 
Among the proteins aberrantly expressed in prostate cancer, proteases are ideal 
therapeutic targets. Protease function is readily blocked by small molecule inhibitors, 
avoiding the functional and financial limitations of using larger protein-based 
inhibitors, such as, functional blocking antibodies (Imai & Takaoka, 2006; Turk, 
 Chapter 1: Introduction and Literature Review 5 
2006). Furthermore, proteases can regulate many classes of protein in the cellular 
microenvironment, including growth factors, cytokines, cell surface receptors and 
ECM proteins (Fuhrman-Luck, Loessner & Clements, 2014); thus, proteases are 
master regulators of cell signalling. In cancer, proteases were once thought to purely 
facilitate physical clearance through the matrix for cancer cell invasion and 
metastasis. However, even ECM degradation may initiate cell signalling, as cell 
surface receptors, such as integrins, respond to changes in ECM composition 
(Aoudjit & Vuori, 2012) and biomechanical properties (Geiger, Spatz & Bershadsky, 
2009; Kraning-Rush, Califano & Reinhart-King, 2012; Kraning-Rush & Reinhart-
King, 2012). It is now well-recognised that proteases can specifically activate, inhibit 
or modify the activity of (non-)ECM factors (Edwards et al., 2008; Lopez-Otin & 
Matrisian, 2007). This irreversible processing is tightly regulated in healthy tissues. 
As such, it is not surprising that aberrant protease activity in cancerous tissues 
promotes tumour progression (Mavridis, Avgeris & Scorilas, 2014; Zhu & Li, 2014). 
Given the wide range of proteins which may be regulated by a single protease, 
targeting the function of individual proteases in cancer may have far-reaching 
therapeutic benefit.  
Ideal protease targets for anti-cancer therapy: (a) are essential to disease progression; 
(b) execute functions that are not compensated for by other proteases; (c) do not 
possess essential protective functions, directly or as an indirect result of regulating 
other proteases; and (d) exhibit expression restricted to the target organ or non-
essential organs (Overall & Kleifeld, 2006b; Turk, 2006). Shortcomings of the early 
MMP inhibitor trials for cancer therapy highlighted that pre-clinical evaluation needs 
to include delineation of the protease substrate repertoire, known as the degradome, 
as this serves fulfilment of the requirements for (a)-(c) (Lopez-Otin & Matrisian, 
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2007; Overall & Kleifeld, 2006b; Turk, 2006). Determining the protease degradome 
is essential to define the balance of anti-tumourigenic and pro-tumourigenic activity 
often exerted by a single protease, as well as to map interrelationships between active 
proteases within the same tissue, named the protease web (Fortelny et al., 2014). The 
protease web is beginning to be deciphered, but it still requires a greater number of 
protease degradomes to be analysed, which will be aided by application of recent 
high-depth degradomic technologies (Rogers & Overall, 2013). Thus, proteases are 
ideal therapeutic targets and defining the degradome of promising protease 
candidates in cancer, and downstream regulated signalling pathways, is essential to 
validate their therapeutic potential.  
1.2 KLKs and prostate cancer 
Aberrant expression of the KLK family of serine proteases has long been associated 
with prostate cancer (Avgeris, Mavridis & Scorilas, 2012; Fuhrman-Luck, Loessner 
& Clements, 2014; Hong, 2014; Kontos & Scorilas, 2012; Schmitt et al., 2013; 
Thorek et al., 2013). Prostate-specific antigen (PSA) or KLK3 is a current widely-
used clinical biomarker for prostate cancer detection (Ilic et al., 2013). Many other 
KLKs are enriched in the prostate and a number have been functionally associated 
with disease progression (Fuhrman-Luck, Loessner & Clements, 2014; Thorek et al., 
2013). However, there has been limited global profiling of targets of these proteases 
in prostate cancer, and none using the most comprehensive, recent technologies 
(Fuhrman-Luck et al., 2014). The KLK family of proteases holds great promise as 
novel therapeutic targets. Identifying substrates of prostate cancer-associated KLKs 
will serve to elucidate KLK function in this disease. This will also aid in defining 
their role in context of the greater protease web and evaluate the clinical efficacy of 
targeting KLKs as anti-prostate cancer therapy.  
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1.2.1 PSA as a widely-employed prostate cancer biomarker 
PSA is a well-established clinical biomarker for prostate cancer screening (Ilic et al., 
2013). PSA production is largely prostate-specific and PSA serves to liquefy the 
seminal clot upon ejaculation (Lilja et al., 1987). Total circulating PSA is measured 
in the PSA test, which has a positive predictive value of ~25% using a cut-off of 3 
ng/ mL (Bokhorst et al., 2012). Further to the PSA test, histological grading of 
biopsied tissue, using the Gleason grading system, is performed for definitive 
diagnosis. PSA cannot distinguish benign from aggressive disease in this cancer that 
is often slow-growing. As such, PSA testing has contributed to an over-diagnosis 
frequency of 42%, which often leads to over-treatment (Draisma et al., 2009). 
Nonetheless, PSA testing has reduced mortality (Schroder et al., 2012b), although 
many patients present with, or post-surgically develop, metastases, primarily in bone 
(Cooperberg, Broering & Carroll, 2009; Schroder et al., 2012a). Importantly, 
although serum PSA levels are elevated in prostate cancer patients, presumably due 
to disrupted prostate glandular architecture allowing PSA leakage into the 
bloodstream, local tissue levels of PSA in fact decrease with disease progression 
(Pretlow et al., 1991). While PSA is arguably the most well-studied KLK, it remains 
unclear whether this protein functions to support or inhibit tumour progression 
(discussed below, see 1.5-1.7). 
1.2.2 Other KLKs implicated in prostate cancer pathogenesis 
In addition to PSA, many of the other 14 KLKs are associated with prostate cancer. 
KLK4-5, KLK11 and KLK14-15 expression has been correlated with clinical disease 
parameters in prostate cancer tissue. Of these genes, expression of KLK4 and 
KLK14-15 is increased in cancer, while KLK11 expression is decreased (Dorn et al., 
2013). KLK4 expression is associated with increased risk of prostate cancer and 
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tumour stage (Avgeris, Stravodimos & Scorilas, 2011), and KLK14-15 expression is 
positively correlated with pathological stage (Mavridis, Stravodimos & Scorilas, 
2013; Rabien et al., 2010a; Yousef et al., 2003b). Conversely, KLK11 expression is 
inversely correlated with tumour stage and grade (Nakamura et al., 2003), while 
KLK5 expression is inversely correlated with prostatic malignancy and Gleason score 
(Yousef et al., 2002).  
As well as PSA, KLK2, KLK4, KLK11 and KLK14-15 are produced in prostate 
tissue (Dorn et al., 2013; Shaw & Diamandis, 2007) and have been detected in 
biological fluids, including serum (Nanjappa et al., 2014; Planque et al., 2008), 
seminal plasma (Shaw & Diamandis, 2007) and extra-prostatic fluid [KLK2 and 
KLK11 only; (Kim et al., 2012; Principe et al., 2012)]. KLK4 and KLK14 
production is elevated in prostate cancer tissue versus benign tissue. Conversely, 
KLK11 and KLK15 levels are diminished in prostate cancer tissue as compared to 
benign tissue (Dorn et al., 2013). Measurement of KLK2 serum levels may prove 
useful for prostate cancer diagnostics. The predictive accuracy of PSA testing, and its 
ability to discriminate pathologically insignificant from aggressive disease, was 
improved by incorporating serum measurements of KLK2, intact PSA and free PSA, 
with standard total PSA measurements (Carlsson et al., 2013; Vickers et al., 2010). 
This ‘four KLK panel’ is under further examination in a clinical trial for its ability to 
predict biochemical recurrence (Memorial Sloan-Kettering Cancer Center, 2014). 
Similar measurements for KLK4, KLK11 and KLK14-15 levels in circulation, other 
biological fluids, or biopsied prostate tissue may also enhance prostate cancer 
diagnosis.  
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1.2.3 Targeting KLK expression and activity in the clinic 
The tissue-specific and/ or deregulated expression of KLKs has been utilised for the 
design of organ-targeted anti-prostate cancer therapies. A range of pro-drugs have 
been developed, whereby cytotoxic compounds are coupled to KLK2- or PSA-
activatable sequences, as the prostate-restricted production of these KLKs allows for 
selective cytotoxicity in the prostate (Mavridis, Avgeris & Scorilas, 2014). Among 
these is L-377202, a PSA-activatable peptide-doxyrubicin conjugate, which reduced 
tumour growth in a mouse model of prostate cancer and has completed Phase I 
clinical trials (DiPaola et al., 2002). KLKs also have efficacy as antigens for 
immunotherapy. PROSTVAC® is a PSA-based anti-prostate cancer vaccine that is 
currently in Phase III clinical trials. PROSTVAC® consists of vaccinia- and 
fowlpox-based vectors encoding transgenes for PSA and immune co-stimulatory 
molecules, which elicit a T-cell response targeting PSA-expressing cells. Phase II 
clinical trials demonstrated that PROSTVAC® improved the overall three-year 
survival of men with low-symptomatic, multiple castration-resistant prostate cancer; 
however, progression-free survival was not affected (Kantoff et al., 2010). Other 
KLKs may also hold promise as antigens for immunotherapy, as bioinformatics 
analysis has predicted the signal sequences of a number of KLKs to have epitopes for 
cytotoxic T-lymphocytes (Wilkinson et al., 2012). Furthermore, the ability of these 
cells to lyse KLK4-expressing prostate cancer cells was demonstrated in vitro 
(Wilkinson et al., 2012). Thus, novel therapies targeting the prostate cancer-enriched 
expression of certain KLKs hold great promise as anti-cancer therapies. 
It is important to recognise that the above therapies target the organ-enriched 
production of prostatic KLKs, but do not target the functional role of these KLKs in 
cancer progression. Largely, this is dictated by the relatively poor mechanistic 
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understanding of the function of prostatic KLKs, even that of PSA, in prostate 
cancer. Each of the 15 KLK genes encodes a protein with a single functional serine 
protease domain, suggesting a predominantly proteolytic function, although non-
proteolytic interactions may occur (Sun, Donald & Phang, 2001). Certain KLKs have 
been functionally implicated in prostate cancer progression (see 1.5-1.7) and, for 
some, this function has been utilised in the rational design of novel, targeted anti-
cancer therapies. For example, MDPK67b, a variant of alpha-1-anti-chymotrypsin 
that was engineered to inhibit proteases including KLK2, KLK4-5, KLK5 and 
KLK14, is undergoing human trials (Deperthes, 2012). Pre-clinical evidence showed 
that this inhibitor reduced tumour growth in a xenograft model of prostate cancer. 
Further, this compound exhibited low toxicity in a host of animal models (Deperthes, 
2012). This represents the first KLK inhibitor to be evaluated in a human study as a 
putative anti-prostate cancer therapy.  
KLK agonists targeting those KLKs with anti-tumourigenic activity have also been 
proposed as a therapeutic strategy. PSA-binding peptides have been developed, 
which serve as functional agonists of the anti-angiogenic, and hence, anti-
tumourigenic, activity of PSA in prostate cancer (Mattsson et al., 2012). However, 
the efficacy of these peptides is yet to be examined clinically. Similar agonists or 
antagonists may be developed for other KLKs that functionally contribute to prostate 
cancer progression. The informed development and application of such therapies 
requires elucidation of the underlying mechanisms of KLK action in prostate cancer. 
1.3 Functional characterisation of KLK activity and post-
translational regulation 
A greater understanding of the functional contribution of prostate cancer-associated 
KLKs to disease progression is necessary before their efficacy as anti-cancer targets 
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can be realised. To serve this understanding, a review of the biochemical properties 
and post-translational regulation of KLKs will follow, preceding analyses of known 
prostatic KLK substrates, KLK-regulated signalling pathways and KLK-induced 
cellular phenotypes implicated in prostate cancer progression.  
1.3.1 Proteolytic activity and specificity 
The human tissue KLK family is co-localized to a ~256 kb region of chromosome 
19q13.3-13.4 and comprises the largest contiguous cluster of proteases in the human 
genome (Gan et al., 2000; Harvey et al., 2000; Yousef et al., 2001; Yousef et al., 
2000). Along with 15 genes (KLK1-KLK15), one known pseudogene (KLK 
pseudogene 1 or KLP1) exists; the latter does not encode a functional peptidase 
(Kaushal et al., 2008; Lu et al., 2006; Yousef et al., 2004). KLK genes are most 
homologous in their coding regions, comprised of 5 coding exons, which are of 
similar size and arrangement (Gan et al., 2000; Yousef et al., 2000). The high level 
of sequence conservation between KLK genes in the locus and between KLK loci of 
different mammalian species (Lawrence, Lai & Clements, 2010) indicates that each 
KLK likely plays distinct functional roles in cell biology. 
Sequence homology of the 15 KLKs is greatest around the three catalytic site 
residues, histidine (H), aspartate (D) and serine (S), located in exons 2, 3 and 5, 
respectively (Yamasaki et al., 2006; Yousef & Diamandis, 2001). Reflective of this 
homology, all 15 KLKs share trypsin-fold three-dimensional (3D) architecture 
around the catalytic site, consistent with their designation as S1A serine proteases 
(Di Cera, 2009). The residue at the base of the substrate binding pocket (residue 189, 
standard bovine chymotrypsin numbering) separates KLKs into two groups of broad 
substrate specificity. The trypsin-like specificity [preferential cleavage after arginine 
(R) or lysine (K)] of KLK1-2, KLK4-6, KLK8 and KLK10-15 is conferred by an 
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asparagine (N)189 residue (Debela et al., 2008; Lundwall, Clauss & Olsson, 2006), 
for all but KLK15, which has a glutamine (Q) residue in this position (Takayama, 
Carter & Deng, 2001; Yoon et al., 2009). Chymotrypsin-like specificity [preferential 
cleavage after phenylalanine (F), tryptophan (W) or tyrosine (Y)] is conferred by 
S189 and N189 residues in the binding pocket of PSA and KLK7, respectively 
(Skytt, Stromqvist & Egelrud, 1995; Watt et al., 1986). KLK9 is an exceptional case, 
with a glycine (G)189 residue, consistent with cleavage after valine (V) and alanine 
(A) residues, as with human neutrophil elastase (Blow, 1977; Sinha et al., 1987). 
While the S1 binding pocket predominantly dictates substrate specificity, this may 
also be mediated by unstructured loops and exosites (Debela et al., 2008). As 3D 
protein conformation is important to substrate docking to the protease binding pocket 
and other sites determining protease activity, delineation of KLK substrates is best 
examined using protein-centric, rather than peptide-centric, approaches. 
1.3.2 Post-translational regulation 
1.3.2a Regulation by proteolytic processing 
KLKs are irreversible regulators of protein activity through proteolysis, leaving little 
doubt of the requirement for tight regulation of KLK activity in cell biology. KLKs 
are translated as pre-pro-peptidases, with removal of the secretion signal (pre-) 
initiating secretion, after which the pro-domain is cleaved, shifting the substrate 
binding cleft to an active conformation (Hedstrom, 2002). Nearly all KLKs contain 
an R (KLK1-2, PSA, KLK5, KLK9 and KLK11) or K (KLK6-8, KLK10, KLK12-
15) as the terminal pro-domain residue, suggesting activation by trypsin-like 
proteases, including other KLKs. KLK4 is an exception, with Q at P1, a residue not 
preferred by chymotrypsin- or trypsin-like proteases, including other KLKs. While 
the physiological activator of KLK4 in teeth is suggested to be dipeptidyl peptidase I 
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(Tye et al., 2009), this protease has weak prostatic expression (Rao, Rao & Hoidal, 
1997); thus, other prostatic activators must exist in vivo.  
1.3.2b Regulation by inhibitors 
A range of inhibitors exist to regulate KLK-mediated proteolysis, including covalent 
inhibitors like the serine protease inhibitors (serpins), α1-antitrypsin and α2-
antiplasmin (Obiezu et al., 2006). KLKs are found in complexes with serpins and 
other protease inhibitors in serum (Heeb & Espana, 1998; Kapadia et al., 2004b; 
Yousef et al., 2003a; Zhang et al., 1998). Given that serpins inhibit only the active 
protease, this suggests that KLKs are active in cellular secretions at a point prior to 
serpin inhibition. Zinc (Zn
2+
)
 
is a reversible allosteric modulator of a number of 
KLKs, including KLK4 (Debela et al., 2006). Prostatic Zn
2+ 
levels likely inhibit local 
KLK-mediated proteolysis in the healthy prostate (Kavanagh, 1985); however, a 20-
fold decrease in Zn
2+
 levels in prostate cancer (Costello & Franklin, 1998; Feustel & 
Wennrich, 1984; Zaichick, Sviridova & Zaichick, 1997) is suggested to render KLKs 
active (Borgono & Diamandis, 2004; Pampalakis & Sotiropoulou, 2007). Thus, KLK 
activity is tightly regulated in healthy tissues and deregulation of these controls likely 
allows for aberrant KLK function in prostate cancer.  
1.4 KLK function in healthy adult biology 
1.4.1 KLK function in seminal fluid and prostate tissue 
Understanding the function of prostatic KLKs in cell biology may help to underpin 
their putative role in malignant disease. Expression of all 15 protein-coding KLKs 
has been identified in adult prostate tissue, albeit at varying degrees (Shaw & 
Diamandis, 2007). KLK1-2, PSA, KLK4-5, KLK9, KLK11, KLK13-15 have been 
detected at levels > 10 ng KLK/ g prostate tissue, while KLK1-2, PSA, KLK4, 
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KLK11 and KLK13 have been detected in seminal plasma above 10 μg KLK/ L 
fluid. KLK5, KLK7, KLK9-10, KLK12 and KLK14-15 have also been detected at 
low levels therein [(1-10 μg KLK/ L fluid; (Shaw & Diamandis, 2007)]. Those KLKs 
that have been purified from seminal plasma have been found to retain proteolytic 
activity, including KLK2, PSA and KLK11 (Deperthes et al., 1996; Luo et al., 
2006). Moreover, serpins are commonly expressed in seminal plasma (Goettig, 
Magdolen & Brandstetter, 2010) and identification of KLK-serpin complexes 
therein, such as complexes of KLK2 and protein C inhibitor (Deperthes et al., 1996), 
again demonstrates that KLKs are active prior to serpin inhibition, as serpins only 
inhibit the active protease.  
KLKs cleave a range of seminal fluid proteins and are believed to function primarily 
in degradation of the seminal clot, following ejaculation. While KLKs are likely 
inhibited by Zn
2+ 
in prostate tissue, the abundant gel-forming proteins, seminogelin-1 
and -2, in seminal fluid can competitively bind Zn
2+
 to render KLKs active (Jonsson 
et al., 2005). In vitro, PSA, KLK2 and KLK14 degrade seminogelin-1 and -2 
(Emami et al., 2008; Malm et al., 2000) and, as well as KLK4, degrade fibronectin 
(Deperthes et al., 1996; Emami et al., 2008; Takayama et al., 2001), an additional 
component of the seminal clot. KLK4 is further able to degrade the semen-enriched 
glycoprotein, prostatic acid phosphatase, in vitro (Takayama et al., 2001).  
As nearly all KLKs may theoretically be activated by trypsin-like proteases, KLKs 
have been suggested to participate in tissue-specific activation cascades (Clements et 
al., 2004; Lawrence, Lai & Clements, 2010; Paliouras, Borgono & Diamandis, 
2007). Such a cascade may account for the rapid liquefaction of the seminal clot 
following ejaculation (Pampalakis & Sotiropoulou, 2007). In vitro, KLK4 can 
activate pro-KLK2 (Yoon et al., 2007), pro-PSA (Takayama et al., 2001) and pro-
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KLK11 (Yoon et al., 2007). Further, KLK2 auto-activates (Mikolajczyk et al., 1997; 
Yoon et al., 2007) and can activate pro-KLK1-2, pro-PSA and pro-KLK12 in vitro 
(Takayama, Carter & Deng, 2001; Williams et al., 2010; Yoon et al., 2007). KLK2-
mediated activation of pro-PSA has also been confirmed in an animal model 
(Williams et al., 2010). While PSA is a chymotrypsin-like protease, treatment of pro-
KLK4 with relatively high concentrations of PSA induces activation of the pro-
enzyme in vitro (Yoon et al., 2007). Prostatic KLKs may also be activated by other 
proteases present in seminal fluid. For example, KLK11 is activated by uPA (Yoon 
et al., 2008), which is found in seminal fluid (Huang et al., 1997). Conversely, KLK2 
and KLK4 can activate single chain- or pro-uPA in vitro (Beaufort et al., 2006; 
Frenette et al., 1997; Takayama, Carter & Deng, 2001). Thus, biochemical evidence 
suggests that protease activation cascades involving KLKs may function in seminal 
fluid, where Zn
2+
-mediated inhibition of KLKs is abrogated. By extension, similar 
cascades may function in prostate cancer, highlighting the far-reaching functional 
consequences of the deregulated activity of even a single protease. The degree of 
interaction between proteases and protease classes further reinforces the importance 
of defining the protease web in biology and pathology.  
1.4.2 KLK function in tooth enamel maturation 
KLK4 is well-studied in relation to tooth enamel maturation. Hypomaturation enamel 
defects in KLK4 knockout/ LacZ knockin mice (Simmer et al., 2009) are consistent 
with the phenotype observed in humans possessing a rare g.2142G>A mutation in 
KLK4, causative of autosomal recessive amelogenesis imperfecta (Hart et al., 2004; 
Wright et al., 2006). This g.2142G>A mutation is a nonsense mutation, resulting in 
truncation of the KLK4 protein product to exclude the active site residue, S207, as 
well as D201 and S202 in the substrate binding pocket, which dictate substrate 
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specificity (Debela et al., 2006). This nonsense mutation causes hypomaturation of 
the dental enamel due to inefficient proteolytic removal of enamel proteins during 
maturation, thereby disallowing allowing complete mineral deposition (Hart et al., 
2004). Indeed, the only KLK4 substrates that have been confirmed in vivo are the 
murine and porcine orthologues of amelogenin (Moradian-Oldak et al., 1996; Ryu et 
al., 2002) and enamelin (Yamakoshi et al., 2006), both components of the dental 
enamel matrix. Ameloblast-expressed KLK4 degrades these structural dentine 
proteins in the maturation stage of enamel formation in vivo (Hu et al., 2002; Overall 
& Limeback, 1988). These studies demonstrate KLK4 activity in mineralised dentine 
tissue and, by extension, possibly in the mineralised bone matrix of prostate cancer, 
in which other KLKs may also function (discussed below). 
1.5 In vivo studies of KLK function in prostate cancer 
Despite having established tumour-associated expression, few studies have examined 
KLK function in prostate cancer using in vivo models. Interpretation of the results 
from many of these studies is confounded by most studies failing to measure the 
activity of KLKs expressed in experimental model systems. Particularly, as many 
studies have expressed KLKs in their pro-form, and as the physiological activators of 
KLKs in the prostate are unknown, over-expression of pro-KLKs does not guarantee 
protease activity. Some studies employing PSA have used expression systems 
whereupon secreted PSA is confirmed to be proteolytically active. Of those, PSA 
knockdown reduced LNCaP cell proliferation, in vitro, and reduced tumour size by 
10-fold relative to controls in a mouse model (Williams et al., 2011). Moreover, 
LNCaP cells over-expressing a KLK3 construct, in which the produced PSA was 
confirmed to be active in cell secretions, formed larger tumours in mice, compared to 
controls (Williams et al., 2011). Conversely, mice transduced to produce active 
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human PSA in the prostate alongside human KLK2, which is capable of activating 
pro-PSA, did not develop prostate pathologies with age (Williams et al., 2010). 
Finally, in a mouse model of metastatic prostate cancer, injection of recombinant 
active PSA near to the tumour site resulted in reduced tumour burden (Bindukumar 
et al., 2005). Thus, in vivo studies analysing proteolytically active PSA suggest that 
PSA may be pro-tumourigenic in androgen-sensitive prostate tumours, represented 
by the LNCaP xenograft models, however, may be protective against the acquisition 
of a metastatic phenotype.  
The first in vivo analysis of KLK4 function was recently conducted, using LNCaP 
xenograft models of prostate cancer (Jin et al., 2013). Inhibition of KLK4 production 
in these cells significantly reduced tumour growth, suggested to be due to disrupted 
androgen receptor (AR) and phosphoinositide 3-kinase signalling that resulted from 
KLK4 binding the transcriptional repressor, promyelocytic leukaemia zinc finger 
protein (PLZF). The putative interaction of KLK4 with this nuclear protein was 
proposed to be non-proteolytic in nature, as exogenous over-expression of a 
proteolytically inert KLK4 variant (active site S>A mutation) interacted with PLZF 
and induced similar cellular phenotypes to wild-type (wt)-KLK4 (Jin et al., 2013). 
However, the proteolytic activity of KLK4 expressed by either construct was not 
assessed. Further, an interaction between KLK4 and PLZF suggests that the KLK4 
variant being analysed was, in fact, localised within the cell and not secreted. This is 
consistent with a previous paper by that group, which attempted to demonstrate 
KLK4 to be a predominantly intracellular protein (Xi et al., 2004); the technical 
flaws in this article were summarised by Simmer et al. (2004). Previous studies by 
the Clements group have shown that N-terminally truncated KLK4 transcripts exist 
and are localised to the nucleus (Dong et al., 2005), which may explain the nuclear 
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function observed by Jin et al. (2013). However, both prostate cancer cell lines and 
patient tissues also express a transcript encoding full-length KLK4, with an N-
terminal signal peptide (Dong et al., 2005). KLK4 secretion is confirmed by its 
presence in seminal fluid (Dong et al., 2005) and in tooth enamel (Simmer & 
Bartlett, 2004). Further, members of the Clements group have repeatedly produced 
secreted KLK4 in a range of cell lines upon over-expression of the pre-pro-protein, 
including the recombinant KLK4 produced in the present study (see Chapter 3). The 
proposed N-terminally truncated, intracellular KLK4 form lacks 19 N-terminal 
residues (Simmer & Bartlett, 2004), likely affecting proteolytic activity. The 
potential for a functional intracellular KLK4 variant is interesting and may constitute 
a novel role for KLK4 in vivo. However, there is strong evidence to suggest that 
KLK4 functions as a secreted protein, and the present study focuses on the role of the 
proteolytic function of secreted KLK4.  
1.6 In vitro studies of KLK function in prostate cancer 
The majority of remaining evidence for a functional role for KLKs in prostate cancer 
has been generated through in vitro biochemical studies. In vivo studies of PSA and 
prostate cancer bone metastases are an exception, and will also be summarised 
below. The in vitro data to follow includes cell-based studies analysing KLK-
mediated regulation of various tumour-promoting phenotypes; however, as with in 
vivo models, these have been hampered by a failure to measure the proteolytic 
activity of the KLKs analysed. Moreover, while the identification of putative KLK 
substrates has been useful in beginning to delineate KLK function within this 
disease, the list of known KLK4 substrates predominantly constitutes those cleaved 
in biochemical assays. In this approach to substrate screening, a recombinant 
protease is incubated with a single recombinant substrate in a test tube, after which 
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KLK-mediated hydrolysis is analysed. As substrates have often been selected based 
on their association to cancer, this has conferred a literature bias to KLK substrates 
identified to date. Further, this approach does not account for the complexities 
surrounding protease-substrate interactions that exist in vivo. Particularly, within the 
protein-rich extracellular microenvironment, interactions between proteases, 
substrates and other proteins may necessitate or inhibit substrate hydrolysis. For 
example, protein complexation may block the accessibility of protease cleavage sites. 
Alternatively, proteolytic processing may alter the conformation of a protein and 
render it amenable to subsequent hydrolysis. There have been no protein-centric 
high-depth approaches used to determine prostate-derived substrates of KLKs to 
date. This topic was reviewed in a recent paper published by the candidate 
(Fuhrman-Luck et al., 2014). Given the above, the following literature review 
suggests only putative functions of prostatic KLKs in each cancer-associated process, 
where additional elucidation in a more physiologically relevant context is still 
required. Proposed autocrine functions for KLKs will be reviewed first, followed by 
putative roles in regulating the protein-rich extracellular microenvironment. A 
summary of the putative functions regulated by KLK4 is contained in Table 1.1 and 
Figure 1.1. 
1.6.1 KLK function in tumour proliferation 
The direct or indirect activation of mitogenic signals and inactivation of pro-
apoptotic signals is key to sustained tumour growth (Hanahan & Weinberg, 2011). In 
vitro, KLKs can cleave a number of proteins which regulate tumour proliferation or 
apoptosis. In particular, in vitro, KLK2, PSA, KLK4-5 and KLK11 hydrolyse
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 Table 1.1. Summary of KLK4-mediated regulation of cancer-associated functions and putative mechanisms in prostate cancer cells in vitro.  
 
 
Auto-KLK4, auto-activating pre-pro-KLK4 substituted with a KLK4-cleavable trypsin pro-region; CM, conditioned media; Mat-KLK4, mature KLK4 expressed without a pre-pro region 
and likely encoding intracellular protease; PAR, protease-activated receptor; pERK, phosphorylated extracellular signal-regulated kinase. 
* For all studies where a fold-change is given, statistical significance was achieved (P < 0.05) and at least three replicates were performed (excepting ^) 
+ Increased only when osteoblast-like cell CM was used as a chemoattractant 
‡ 
Increased on collagen type-I and -IV but not fibronectin.  
Reference Cell line KLK4 delivery Construct Outcome (magnitude*) Mechanism 
Proliferation:      
(Veveris-Lowe et al., 2005) PC-3 Over-expression pre-pro-KLK4 Decrease (2-fold) - 
(Mize, Wang et al. 2008)^ DU145 Spiked into CM  Auto-KLK4 Increase (1.7-fold) Proteolytic activation of PAR-1 and PAR-2; pERK1/2 
(Klokk et al., 2007) PC-3 Over-expression Mat-KLK4 Increased (10-fold) Transcriptional regulation of cell cycle  
 DU145 Over-expression Mat-KLK4 Increased (20-fold)  
 LNCaP Knockdown αKLK4 siRNA Decreased (60%)  
Anchorage-independent growth:      
(Klokk et al., 2007) PC-3 Over-expression Mat-KLK4 Increased (2.5-fold) - 
 DU145 Over-expression Mat-KLK4 Increased (1.7-fold)  
EMT:      
(Veveris-Lowe et al., 2005) PC-3 Over-expression Pre-pro-KLK4 Increased Decreased focal adhesions (actin/ vinculin); Decreased 
E-cadherin transcription  Migration:      
(Veveris-Lowe et al., 2005) PC-3 Over-expression Pre-pro-KLK4 Increased (2.9-fold) - 
(Gao et al., 2007) PC-3 Over-expression Pre-pro-KLK4 Increased (2.9-fold)
+
 Proteolytic (inhibited by aprotinin) 
(Klokk et al., 2007) PC-3 Over-expression Mat-KLK4 Increased (18%) - 
Invasion:      
(Veveris-Lowe et al., 2005) PC-3 Over-expression Pre-pro-KLK4 No change - 
Attachment:      
(Gao et al., 2007) PC-3 Over-expression Pre-pro-KLK4 Increased
‡ - 
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Figure 1.1. KLKs and in vitro KLK substrates implicated in processes driving prostate cancer 
progression. KLKs and in vitro substrates cited in the text are grouped into cancer-promoting 
functions associated with these substrates. (1) During prostate cancer development and progression, 
KLK-expressing prostate epithelial cells exhibit deregulated proliferation and (2) invade through the 
surrounding basal lamina and ECM. Cancer cells acquire a migratory phenotype, some by undergoing 
an epithelial-to-mesenchymal transition (EMT). (3) Invading cancer cells co-opt host fibroblasts into 
creating a microenvironment that supports tumour expansion and (4) interact with blood vessel 
endothelial cells to gain entry into the vasculature. Cancer cells must also activate blood vessel 
formation or angiogenesis, to supply oxygen and nutrients to the expanding primary tumour. (5) 
Circulating prostate cancer cells may extravasate at the compatible secondary site, primarily bone, 
whereby they degrade the surrounding matrix and form metastases. Arrows denote the physical 
migration of a prostate cancer cell from the primary tumour to a metastatic deposit. Dotted arrows 
represent KLK-mediated interactions between prostate cancer cells and surrounding ECM/ stromal 
cells, as indicated. GH, growth hormone; HGFA, hepatocyte growth factor activator; HMWK, high 
molecular weight kininogen; PAR, protease-activated receptor; PTHrP, parathyroid hormone related 
protein; SHBG, serum hormone binding globulin; uPAR, uPA receptor. References are cited in the 
text. 
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insulin-like growth factor binding protein 3 [IGFBP3; (Borgono et al., 2007; 
Koistinen et al., 2002; Matsumura et al., 2005b; Michael et al., 2005; Sano et al., 
2007)], KLK4-5 hydrolyse IGFBP4-6 (Matsumura et al., 2005b; Michael et al., 
2006), KLK5 and KLK14 hydrolyse IGFBP2 (Borgono et al., 2007; Michael et al., 
2005) and KLK5 cleaves IGFBP1 (Michael et al., 2005). Hydrolysis of IGFBPs can 
reduce the binding of these proteins to the mitogenic insulin-like growth factors 
(IGFs), thereby increasing cell proliferation. Indeed, up-regulated levels of free 
versus bound IGF-1 positively correlates with prostate cancer occurrence (Monti et 
al., 2007). Additionally, KLK2, KLK5 and KLK14 may activate latent TGFβ1, while 
PSA activates TGFβ2, both of which act as tumour suppressors or promoters, 
dependent on the tumour stage [Figure 1.1; (Dallas et al., 2005; Emami & 
Diamandis, 2010)]. 
In other in vitro studies, KLKs have been shown to degrade hormones and hormonal 
regulators to influence tumour cell proliferation. KLK4-5 and KLK13-14 cleave 
human growth hormone [GH; (Komatsu et al., 2007)]. Of note, GH receptor 
expression is increased by 80% in cancerous versus benign prostate tissue (Bidosee 
et al., 2009; Weiss-Messer et al., 2004), suggesting a role for GH signalling in 
prostate cancer. Notably, GH proteolysis from a 22 kDa single-chain form to a 
disulphide-linked 2-chain form may impede cell proliferation and angiogenesis 
(Struman et al., 1999); thus, GH proteolysis may be a KLK-mediated mechanism of 
tumour suppression. KLK4 also cleaves sex hormone binding globulin (SHBG), a 
protein responsible for sequestering sex hormones, like androgen, to mediate their 
uptake by hormone-responsive prostate cells (Hryb et al., 2002). KLK4-mediated 
processing of SHBG resulted in SHBG releasing bound androgen, stimulating 
prostate cancer cell proliferation in vitro (Sanchez, 2009). Further, PSA has been 
 Chapter 1: Introduction and Literature Review 23 
shown to cleave the A and B chains of the hormone insulin, degrading the latter in 
vitro [Figure 1.1; (Hsieh & Cooperman, 2000; Watt et al., 1986)]. Insulin has been 
shown to induce de novo steroid production (Lubik et al., 2011) and is implicated as 
a mechanistic driver of advanced, castrate-resistant prostate cancer (Gunter et al., 
2012); therefore, KLK-mediated processing of insulin may play a role in castrate-
resistant disease. It is clear that paracrine and systemic factors may influence the pro- 
or anti-tumourigenic role of selected KLKs at various stages of disease progression. 
Understanding this full substrate repertoire at each stage and site of cancer 
establishment is important for designing effective KLK-targeted anti-cancer 
therapeutics. 
1.6.2 KLKs and migration 
Cancer cells may transition from an epithelial to a mesenchymal phenotype 
[epithelial-to-mesenchymal transition, EMT; (Thiery, 2002)] and this pro-migratory 
mesenchymal phenotype facilitates cancer cell migration away from the primary 
tumour (Hanahan & Weinberg, 2011). In cellular in vitro assays, late-stage prostate 
cancer PC-3 cells over-expressing PSA or KLK4 underwent EMT, characterised by 
loss of the epithelial cell marker, E-cadherin, and gain of the mesenchymal marker, 
vimentin. These cells also exhibited increased cancer cell migration compared to 
controls or KLK2 over-expressing cells (Veveris-Lowe et al., 2005). This was 
consistent with other studies whereby KLK4 induced cell migration (Gao et al., 
2007; Klokk et al., 2007). KLK4 can cleave both the soluble and membrane-tethered 
uPA receptor (uPAR) to release its ligand-binding domain (Beaufort et al., 2006). 
uPAR has roles in cell adherence, migration and chemotaxis, through a number of 
ECM-derived ligands; hence, KLK4-mediated proteolysis of uPAR may constitute a 
mechanism by which KLK4 regulates cancer cell motility [Figure 1.1; (Blasi & 
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Carmeliet, 2002; Kugler, Wei & Chapman, 2003; Preissner, Kanse & May, 2000; 
Reuning et al., 2003; Sidenius et al., 2002)]. 
In contrast to the pro-migratory effects of KLK4, KLK2 over-expressing cells did not 
undergo EMT, nor exhibit altered cell motility (Veveris-Lowe et al., 2005). Prostate 
cancer cell migration was reduced upon over-expressing a PSA variant, which was 
engineered to be secreted in its mature form, as compared to vector control cells 
(Cumming et al., 2011). In support of this, treatment of PC-3 cells with exogenous, 
active PSA reduced cell migration (Gkika et al., 2010). Interestingly, the latter was 
dependent on PSA-induced membrane presentation of the ion channel protein, 
transient receptor potential melastatin 8 (Gkika et al., 2010). However, over-
expression of secreted pro-PSA induced cell migration and invasion (Cumming et 
al., 2011), where this pro-protease was likely not activated in the KLK2- and KLK4-
deficient cell line employed. Therefore, proteolytically inactive PSA appears to 
induce cell migration, contrary to the anti-migratory effect of proteolytically active 
PSA. In contrast to KLK4 and PSA, KLK2 did not affect cell migration, and must 
have alternative functions in the disease, despite having the biochemical potential to 
cleave a number of similar proteins to KLK4 and PSA. These in vitro cell-based 
studies emphasise the importance of defining the proteolytic activity of KLKs in 
respective cell models, as active protease function may differ from that of the 
corresponding inactive protease.  
1.7 Paracrine effects of KLKs in prostate cancer and the 
importance of the tumour microenvironment  
Malignant expansion of epithelial cells does not occur in isolation, but involves a 
myriad of cell types, the significant contribution of which to prostate cancer is 
gaining recognition (Barron & Rowley, 2012; Hanahan & Coussens, 2012; Hanahan 
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& Weinberg, 2011; Josson et al., 2010). The prostate tumour microenvironment 
consists predominantly of smooth muscle cells, along with fibroblasts, endothelial 
cells, pericytes and immune cells. These cells are situated on the opposite side of the 
basal lamina to the epithelial compartment, amongst a dense ECM (Barron & 
Rowley, 2012; Tuxhorn et al., 2002). In cancer, this stroma becomes activated or 
reactive, similar to the pro-inflammatory and growth-supportive microenvironment 
of wounding (Barron & Rowley, 2012; Tuxhorn et al., 2002). As with stroma in 
wound healing, prostate cancer reactive stroma is characterised by the persistent 
presence of activated fibroblasts, termed myofibroblasts (Gravina et al., 2013; 
Tuxhorn et al., 2002), increased microvessel density (Pascal et al., 2013), increased 
nerve cell density (Ayala et al., 2008), abundance of immune cells (Risbridger et al., 
2014) and elevated ECM production (Tuxhorn et al., 2002). Prostate reactive stroma 
has been found to develop as early as the pre-cancerous condition, prostatic 
intraepithelial neoplasia [PIN; (Tuxhorn et al., 2002)], and its suggested co-evolution 
with initiated epithelium may lead to the co-dependence of each compartment for 
survival (Josson et al., 2010; Polyak, Haviv & Campbell, 2009). The significant 
impact of tumour-stroma cross-talk on the development and progression of prostate 
and other cancers has led to the suggestion that novel therapies need to target these 
bi-directional interactions (Gururajan, Posadas & Chung, 2012; Hanahan & 
Coussens, 2012; Pietras & Ostman, 2010).  
Being secreted proteases, prostate cancer cell-derived KLKs are well-positioned to 
interact with a functionally diverse host of proteins derived from the tumour 
microenvironment. The established roles of selected prostate cancer-derived KLKs in 
cross-talk with blood vessels cells and bone cells in the primary and secondary 
tumour microenvironments, respectively, will follow. Finally, the importance of 
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myofibroblast populations in prostate cancer will be introduced and a rationale 
developed for the putative involvement of prostatic KLKs, particularly KLK4, in 
regulating pro-tumourigenic signalling through cleaving myofibroblast-derived 
factors. 
1.7.1 Correlation of KLK production with prostate reactive stroma initiation 
and roles for KLKs in ECM degradation, local invasion and migration 
ECM homeostasis is critical to healthy tissue, as emphasised by ECM disruptions 
being associated with fibrotic diseases and cancer (Cox & Erler, 2011). In prostatic 
malignancy, cancer cell-secreted proteases break down the basal lamina and facilitate 
physical clearance through the ECM, to foster tumour outgrowth and entry into the 
vasculature (Hanahan & Weinberg, 2011). While some ECM proteins may be 
derived from transformed epithelial cells, myofibroblasts are believed to secrete the 
majority of ECM in prostate reactive stroma (Barron & Rowley, 2012). Prostate cell-
secreted KLKs are well-positioned to act on these components, particularly following 
breach of the basal lamina. 
In contrast to the predominantly luminal expression of almost all other prostatic 
KLKs (Bui, 2006; Petraki et al., 2006), KLK4 is produced in both basal and luminal 
epithelial cells (Bui, 2006); KLK15 is also produced in the basal epithelial layer 
(Rabien et al., 2010b). Disruptions to the basal lamina begin in PIN (Barron & 
Rowley, 2012), and KLK4 levels are elevated in PIN, as compared to normal tissue 
(Bui, 2006). Conversely, KLK15 production was similar in normal and PIN tissues 
(Rabien et al., 2010a). KLK4 production was elevated in both luminal and basal 
epithelial cells in PIN (Bui, 2006); thus, KLK4 may facilitate early breakdown of the 
basal lamina, given its proximity to this proteinaceous layer.  
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In vitro, KLK4 cleaves the basal lamina component (Knox et al., 1994), collagen 
type-IV, and the ECM components, collagen type-I and fibronectin (Obiezu et al., 
2006), supporting a role for KLK4 activity in local invasion. KLKs secreted by 
luminal epithelial cells, including KLK4, may also function in ECM degradation, as 
local invasion eventually brings cancer cells in contact with residual basal lamina 
and the surrounding ECM. Other prostatic KLKs cleave fibronectin (KLK2, KLK5 
and KLK13-14), collagens type-1 (KLK4-5 and KLK13-14), collagen type-IV 
(KLK4-5 and KLK14) and laminin in vitro (PSA, KLK5 and KLK13-14; Borgono et 
al., 2007; Kapadia et al., 2004a; Michael et al., 2005; Obiezu et al., 2006; Webber, 
Waghray & Bello, 1995). KLKs may activate other classes of proteases, or other 
KLKs, to amplify proteolytic degradation of the ECM. For example, KLK4 is able to 
directly activate pro-meprin β, which degrades similar ECM components to KLK4, 
along with cleaving additional growth factors, cytokines and other bioactive ECM 
components (Bertenshaw et al., 2001; Chestukhin et al., 1997; Choudry & Kenny, 
1991; Herzog, Kaushal & Haun, 2005; Kaushal, Walker & Shah, 1994; Kruse et al., 
2004). KLK2 and KLK4 can activate pro-uPA [Figure 1.1; (Beaufort et al., 2006; 
Frenette et al., 1997; Takayama, Carter & Deng, 2001), whereby uPA activates the 
ECM-degrading enzyme, plasminogen (Blasi, 1993). It is important to note that the 
above studies employed in vitro biochemical assays to identify KLK substrates, and 
the in vivo relevance of these findings remains to be determined. 
While the biochemical potential for KLKs to induce invasion and ECM remodelling 
has been established, neither KLK2-, PSA- or KLK4-over-expressing PC-3 cells 
exhibited an altered invasive behaviour (Veveris-Lowe et al., 2005); however, the 
level of KLK activity in these cell models was not confirmed. Somewhat 
paradoxically, prostate cancer cells over-expressing a PSA variant, which was 
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engineered to be secreted in its mature active form, exhibited reduced invasion, while 
those over-expressing pro-PSA displayed enhanced invasion (Cumming et al., 2011). 
Thus, substrates cleaved by direct incubation with KLKs in biochemical assays may 
not truly reflect physiological substrates in the complex protein-rich extracellular 
milieu. Furthermore, it is difficult to draw conclusions regarding the proteolytic 
activity of KLK2 and KLK4 in prostate cancer-mediated invasion, when protease 
activity was not confirmed in the cell models used (Veveris-Lowe et al., 2005). Thus, 
these studies also highlight the need to establish that the protease is active in cellular 
assays of KLK function. 
1.7.2 KLKs, intravasation and angiogenesis 
Tumours must generate new blood vessels for survival, a process called 
angiogenesis. Many cancers cells will interact with blood vessel cells to disseminate 
or intravasate into the blood stream, facilitating spread to distal sites (Hanahan & 
Weinberg, 2000, 2011). In vitro, KLK2 cleaves high molecular weight kininogen 
(HMWK) to release bradykinin, a factor that induces smooth muscle cell contraction, 
facilitating vasodilation and cancer cell intravasation (Charlesworth et al., 1999). In 
seminal fluid, PSA releases a kinin-like molecule from semen, although this likely 
involves activation of a HMWK-activating intermediate, as recombinant PSA did not 
directly activate HMWK (Fichtner et al., 1996). Further, PSA can cleave Lys-
plasminogen to release bioactive angiostatin-like fragments, and these purified 
peptides inhibit human umbilical vein endothelial cell (HUVEC) tube formation 
[Figure 1.1; (Heidtmann et al., 1999)].  
PSA inversely regulated the expression of a number of genes in HUVECs that are 
integral to blood vessel formation (Mattsson et al., 2008a). Further, PSA inversely 
regulated the expression of genes associated with angiogenesis in a bone metastatic 
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prostate cancer cell line. This included the gene encoding the pro-angiogenic, 
vascular endothelial growth factor [VEGF; (Bindukumar et al., 2005)]. Whether the 
role of PSA in angiogenesis is protease-mediated is heavily debated and has been 
hampered by studies failing to monitor the proteolytic activity of PSA in vitro and in 
vivo (Chadha et al., 2011; Koistinen et al., 2008; Mattsson et al., 2008b). Peptides 
that inhibited the proteolytic activity of PSA abolished its anti-angiogenic function 
(Koistinen et al., 2008). This has led to the rationale of using PSA agonists as 
prostate cancer therapy, which are already in development (Mattsson et al., 2012). In 
summary, the role of PSA as an inhibitor of angiogenesis is well-established; 
however, possible roles for other KLKs in this process require investigation. 
1.7.3 KLKs and prostate cancer bone metastases 
Bone is the primary site of prostate cancer metastasis (Schroder et al., 2012a), and 
KLK2, PSA and KLK4 are produced in bone metastatic lesions (Bui, 2006; Gao et 
al., 2007). KLK4 is perhaps the most interesting KLK with regard to bone 
metastases. This is because of its established proteolytic activity in another 
mineralised tissue, namely, tooth enamel matrix in developing mouse molars in vivo 
(Yamakoshi et al., 2011). The association between an inactivating mutation in the 
KLK4 gene and dental enamel hypomaturation is evidence for KLK4 activity in 
human enamel (Hart et al., 2004). Although in vivo studies have yet to be conducted 
for the role of KLK4 in prostate cancer metastases, KLK4 over-expressing PC-3 cells 
exhibited increased migration over controls, towards conditioned media (CM) from 
SaOS2 bone-forming osteoblast-like cells, but not that of neonatal foreskin 
fibroblasts or cell culture media. This was abrogated by the serine protease inhibitor, 
aprotinin, highlighting that predilection of prostate cancer cells to bone may involve 
proteolytically active KLK4 (Gao et al., 2007). KLK4 may proteolytically process a 
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latent chemotactic compound secreted by either bone metastatic prostate cancer cells 
or directly from the bone microenvironment. IGF-1 and -2 are chemotactic to 
prostate cancer cells (Ritchie et al., 1997), and KLK4 can cleave IGFBPs in vitro 
(Matsumura et al., 2005a). Further, in an in vivo model of prostate cancer bone 
metastasis, mice treated with an antibody targeting IGF-1 and -2 exhibited 
significantly reduced tumour area in the bone (Goya et al., 2004). Importantly, the 
human prostate cancer MDA PCa 2b cell line employed in the Goya et al. (2004) 
study expresses KLK4, among other androgen-regulated KLKs (Lawrence, Lai & 
Clements, 2010), inferring that KLK4 may promote the predilection of prostate 
cancer cells to bone via degradation of IGFBPs (Figure 1.1). Moreover, KLK4 over-
expressing cells displayed increased attachment to the bone matrix-derived 
components, collagen type-1 and type-IV (Gao et al., 2007); thus, KLK4 may 
regulate the expression of cell surface integrins or other factors to promote bone 
metastases. 
PSA is mitogenic for human and rodent osteoblast cell lines, where this can be 
abrogated by the addition of a TGFβ1- and TGFβ2-neutralizing antibody (Yonou et 
al., 2001). PSA activates latent TGFβ2 produced by PC-3 cells (Dallas et al., 2005), 
and culturing rat osteosarcoma cells in PSA-treated PC-3 cell CM induced cell 
proliferation, which was reversed by TGFβ neutralisation (Killian et al., 1993). PSA 
over-expressing rat prostate cancer cells, injected into the mouse femur, displayed 
increased bone-forming properties, characteristic of prostatic bone metastases; 
however, overall tumour burden was unchanged (Cumming et al., 2011). PSA 
activity was detected in murine sera following inoculation with at least one of the 
PSA over-expressing clones employed, indicating the possibility that PSA-mediated 
proteolysis may be important for the observed effects (Cumming et al., 2011). 
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Further, direct injection of PSA into a human bone chip, which had been implanted 
into mice, increased bone volume, osteoid surface and the population of bone-
forming osteoblasts, while reducing bone-resorbing osteoclast numbers (Yonou et 
al., 2001). Strikingly, the effect of PSA in osteoblast mitogenesis in vitro, and bone 
formation in vivo, was inhibited by serine protease inhibitors (Yonou et al., 2001), 
suggesting that these outcomes were a result of PSA-mediated proteolysis. Similarly, 
PSA cleaves parathyroid hormone related protein (PTHrP) in vitro, inactivating its 
ability to induce cyclic adenosine monophosphate (cAMP) production in rat and 
murine osteosarcoma and osteoblast cells (Cramer, Chen & Peehl, 1996; Iwamura et 
al., 1996). Thus, PSA-mediated proteolysis appears to contribute toward the 
predominantly osteoblastic phenotype of prostate cancer bone metastases, and this 
may be mediated through PSA substrates, including TGFβ2 and PTHrP (Figure 1.1). 
In a biochemical assay, KLK14 activated latent TGFβ1 (Emami & Diamandis, 2010) 
and so may similarly promote osteoblastic metastases like PSA. Further, KLK2 and 
KLK4 activate pro-uPA, which activates plasminogen, an established activator of 
latent TGFβ1 (Lyons et al., 1990; Takayama, Fujikawa & Davie, 1997; Takayama et 
al., 2001). KLK2 also activates pro-PSA (Takayama, Fujikawa & Davie, 1997), and 
KLK4 activates both pro-KLK2 and pro-PSA (Takayama et al., 2001; Yoon et al., 
2007). This potential proteolytic cascade may serve to amplify TGFβ1 activation, 
indirectly associating KLK2 and KLK4 to function alongside PSA and KLK14 in 
promoting osteoblastic metastases (Figure 1.1).  
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1.7.4 KLKs and regulation of CAFs 
1.7.4a Brief overview of CAF origin, signalling and significance in prostate cancer 
While it is clear that multiple cell types contribute to the reactive stromal milieu 
(Barron & Rowley, 2012; Condon, 2005; Cunha, Hayward & Wang, 2002; Hanahan 
& Coussens, 2012), myofibroblasts are the most abundant cell type in prostate cancer 
reactive stroma, as opposed to smooth muscle cells in normal stroma (Tuxhorn et al., 
2002). Moreover, as with myofibroblasts in wound healing, which serve to close 
epithelial barrier breaches, myofibroblasts in prostate cancer are highly proliferative, 
motile and contractile. These cells further secrete the majority of ECM, an important 
mediator of tumour-stroma signalling (Barron & Rowley, 2012). Myofibroblasts 
surrounding cancerous epithelium have also been called CAFs (Kalluri & Zeisberg, 
2006). Importantly, BPH-1 cells, derived from the non-malignant prostate pathology, 
benign prostatic hyperplasia (BPH), do not form tumours in mice. However, co-
implantation of patient-derived CAFs with BPH-1 cells into mice induced 
carcinogenesis, as compared to co-implantation with resting fibroblasts isolated from 
tissue distal to the tumour, referred to herein as normal prostatic fibroblasts [NPFs; 
(Grossfeld et al., 1998; Olumi et al., 1999; Taylor et al., 2012)]. Further, CAFs can 
only establish prostate cancer in mice when co-implanted with initiated BPH-1 cells, 
and not with uninitiated, normal prostate epithelial cells (Olumi et al., 1999). 
Similarly, NPFs co-implanted with either epithelial cell type did not form malignant 
deposits; thus, carcinogenesis requires both initiated tumour and activated stroma 
(Olumi et al., 1999). BPH-1 cells co-cultured with CAFs exhibited a permanently 
altered phenotype, as BPH-1 cells isolated from co-culture still formed tumours 
when re-grafted into mice (Hayward et al., 2001). Therefore, CAFs permanently alter 
prostatic epithelium and play an integral role in cancer progression. 
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The cellular origin of CAFs is unclear, and may constitute a number of resident and 
recruited cell populations, including resident fibroblasts or recruited mesenchymal 
stem cells (Augsten, 2014; Barron & Rowley, 2012; Madar, Goldstein & Rotter, 
2013). The complex signalling interaction required for CAF initiation and/ or 
expansion is similarly unclear, although some pertinent factors have been identified. 
For example, TGFβ1 is over-produced by prostate epithelium in PIN and is the 
primary factor implicated in the activation of resting fibroblasts to become CAFs 
(Augsten, 2014; Tuxhorn et al., 2002; Untergasser et al., 2005). While it is clear that 
tumour-CAF cross-talk is bi-directional, pro-tumourigenic signals produced in CAFs 
and received by the tumour are the most extensively researched. Signalling 
intermediates of these interactions include ECM proteins, proteases, growth factors 
and cytokines. Specifically, prostatic CAFs secrete large amounts of hyaluronan 
(Josefsson et al., 2011; Lokeshwar et al., 2001; Tuxhorn et al., 2002). Intraprostatic 
injection of hyaluronan caused tumour growth in a rodent model of prostate cancer, 
presumably by hyaluronan signalling through its epithelial cell surface receptors 
(Josefsson et al., 2011). Further, prostate tumour-stimulated induction of 
myofibroblast-derived MMP2 and MMP9 induced EMT in the tumour cells 
(Giannoni et al., 2010). Functional studies regarding the pro-tumourigenic properties 
of CAF-derived growth factors and cytokines are numerous and have been well-
reviewed; these factors include fibroblast growth factor (FGF) 2, connective tissue 
growth factor (CTGF), hepatocyte growth factor (HGF), platelet-derived growth 
factor, interleukin 6 (IL-6), epidermal growth factor, stromal cell-derived factor 1 
(SDF-1), VEGF, IGF-1 and also CAF-derived TGFβ1 (Barron & Rowley, 2012; Niu 
& Xia, 2009). This list is by no means exhaustive but serves to demonstrate the 
variety of pro-tumourigenic signalling factors derived from the tumour 
microenvironment, which may be regulated by prostate cancer cell-derived KLKs. 
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1.7.4b KLKs and tumour-CAF cross-talk 
Some of the above CAF-derived signalling molecules represent proteins cleaved by 
KLKs, at least, in vitro. These include latent TGFβ1 and TGFβ2, and the IGF-1 
regulatory IGFBPs, previously stated to be hydrolysed by KLK2, PSA, KLK4-6, 
KLK11 and/ or KLK14. Further, KLK4 can activate pro-HGF activator (pro-HGFA), 
which can activate stromal cell-derived HGF to induce an invasive cancer phenotype 
(Mukai et al., 2008). Importantly, KLK4 also activated protease-activated receptor 
(PAR)-1 on the surface of prostate WPMY-1 myofibroblasts in vitro [Figure 1.1; 
(Wang et al., 2010)]. This stimulated extracellular signal-regulated kinase (ERK) 1/2 
phosphorylation and increased IL-6 secretion (Wang et al., 2010). IL-6 has been 
implicated in fibroblast activation to myofibroblasts and, further, CM from CAFs or 
NPFs treated with IL-6 or TGFβ1 induced PC-3 cell invasion in vitro (Giannoni et 
al., 2010). Therefore, KLK4-induced IL-6 production in activated fibroblasts may 
activate neighbouring resting fibroblasts and promote tumour invasion. Indeed, the 
proportion of CAFs in the stroma of Gleason grade 4 cancers is significantly higher 
than in that of less aggressive Gleason grade 3 cancers (Tuxhorn et al., 2002), 
indicating that CAFs continue to arise throughout cancer progression. Thus, 
preliminary in vitro data suggests that KLKs may regulate tumour-stroma cross talk 
in the prostate tumour microenvironment.  
1.8 Summary of KLK4 expression and function in prostate cancer 
Combining its established functional effects in prostate cancer, along with its 
increased production in PIN and prostate cancer, KLK4 emerges as a primary target 
for further elucidation of its role in this disease. From the discussed evidence, it is 
clear that abundance of KLK2, KLK4 and KLK14-15 is positively correlated with 
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prostate cancer. However, while PSA is the most highly studied KLK in relation to 
its function in prostate cancer, KLK3 expression is down-regulated in prostate cancer 
tissue versus benign disease. Moreover, at least in local disease, PSA appears to be a 
cancer-protective factor, and efforts to stimulate its cancer-protective effects are 
already underway. While KLK2 is a promising serum biomarker for prostate cancer, 
over-expression of KLK2 in prostate cancer cells did not induce a mesenchymal or 
migratory phenotype. Additionally, despite the positive association of KLK14 and 
KLK15 expression with pathological stage, there is presently no cell-based functional 
evidence for the role of these KLKs in prostate cancer progression. Thus, of the 
KLKs associated with prostate cancer, KLK4 is the only KLK to be positively 
associated with disease progression and for which preliminary functional evidence 
exists to support this association.  
KLK4 expression increases in prostate cancer, and KLK4 is also over-produced at the 
protein level in PIN and prostate cancer. A summary of KLK4 production in prostate 
cancer can be found in Table 1.2. At least in mice, KLK4 expression is restricted to 
maturation-stage ameloblasts and the prostate, with some expression also in the 
salivary gland (Simmer et al., 2011). KLK4 expression in men is similarly prostate-
enriched (Nelson et al., 1999; Yousef et al., 1999), reducing the potential for 
detrimental off-target effects when targeting KLK4 as an anti-cancer therapy. 
Functionally, KLK4 has been shown to induce cancer cell EMT and migration, and 
may also increase cell proliferation in vitro. Further, KLK4 may have important 
functions at the secondary site. Thus, KLK4 is a promising anti-prostate cancer 
target.  
While KLK4 has been implicated in autocrine interactions in the primary tumour and 
paracrine interactions in metastasis, paracrine interactions between KLK4 and local  
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Table 1.2. Summary of studies analysing KLK4 protein abundance in prostate cancer versus benign tissue.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ELISA, enzyme-linked immunosorbent assay; FFPE, formalin-fixed paraffin-embedded; IHC, immunohistochemistry.  
*Antibodies selectively targeted annotated regions within KLK4. 
Reference Sample size Primary 
localisation 
(cellular) 
Primary 
localisation 
(subcellular) 
Quantification method KLK4 abundance    
(cancer vs benign) 
IHC on FFPE tissue:      
(Seiz et al., 2010) 44 benign 
44 cancer 
 
Glandular 
epithelia  
Cytoplasm (0-3 scale) × % positive     
(1-3 scale) = final score (0-9) 
Elevated 
(Ramsay et al., 2008) 6 cancer (included 
neighbouring 
normal glands) 
 
Glandular 
epithelia  
Not stated None Elevated  
(Klokk et al., 2007) 42 benign 
207 cancer 
 
Basal/ luminal 
epithelia 
Nucleus 0-3 scale  Elevated (P < 0. 01) 
(Dong et al., 2005) 2 benign 
6 cancer 
Glandular 
epithelia 
Nucleus (N-, C-) 
Cytoplasm (mid-)* 
None Elevated  
 
 
(Veveris-Lowe et al., 2005) 6 benign 
6 cancer 
 
Glandular 
epithelia  
Cytoplasm None Elevated  
(Day et al., 2002) 4 benign  
4 cancer 
 
Glandular 
epithelia  
Cytoplasm 0-3 scale No difference  
ELISA on frozen tissue:      
(Obiezu et al., 2005) 
 
8 benign 
16 cancer 
 
n/a n/a ng KLK4/ g tissue No difference  
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stroma are poorly elucidated. This study initially set out to further delineate autocrine 
roles for the protease; however, the results from this work led to the investigation of 
a paracrine function for KLK4 in the local stroma. Prostate reactive stroma is not 
subsidiary to the action of cancer cells in disease progression, but it functions as an 
essential co-opted driver of this disease. Bi-directional signalling between the 
prostate epithelium and stroma is an essential component of cancer progression, and 
effective novel prostate cancer therapies must target the stromal compartment, along 
with cancer cells. Hence, understanding the role of KLK4 as a paracrine regulator of 
the tumour microenvironment, in addition to delineating its autocrine functions, is 
integral to determine its potential therapeutic efficacy. There has been little research 
into the interaction between prostate cancer cell-secreted KLK4, or many other 
prostatic KLKs, with the local tumour microenvironment. Thus, this field of research 
is open to novel investigation. 
1.9 Overall summary, hypotheses and aims 
Prostate cancer is a leading cause of male cancer-related deaths world-wide. Many 
patients present with bone metastatic disease, for which only palliative treatments 
exist. A better molecular understanding of prostate cancer progression is required to 
identify novel therapeutic targets. 
KLK4 is a serine protease, which is over-produced in prostate cancer and prostate 
cancer bone metastasis, wherein it is likely active, as per its activity in mineralised 
tissue at other anatomical sites. KLK4 expression is associated with increased 
prostate cancer risk and tumour stage. KLK4 is over-produced in both luminal and 
basal epithelium in the pre-neoplastic prostate gland, whereupon reactive stroma 
originates. Thus, KLK4 may be functionally important in disease progression, 
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including breakdown of the basal lamina, local invasion, induction of a reactive 
stroma and metastasis. The future of anti-prostate cancer therapy involves agents that 
target both cancer cells and stromal tissue; hence, KLK4 is one such promising 
therapeutic candidate.  
Proteases are ideal anti-cancer targets as their function is readily blocked by small 
molecule inhibitors. In vitro evidence has shown that KLK4 may induce prostate 
cancer cell migration, EMT and proliferation, although the substrate intermediates 
and affected signalling pathways have not been elucidated. Determining the substrate 
repertoire of individual proteases is essential to investigate protease redundancy and 
to identify proteases best suited as targets for cancer therapeutics. Predominantly, 
biochemical assays have shed light on putative KLK4 substrates, but a 
comprehensive analysis of the KLK4 degradome in the prostate cancer 
microenvironment has not been performed. Further, few KLK4-regulated genes in 
either prostate cancer or stromal cells have been identified. 
In context of the literature surrounding KLK4 activity in prostate cancer, the 
following hypotheses were developed: 
 KLK4 cleaves a number of extracellular soluble, ECM-derived and 
membrane-associated proteins in the local prostate tumour 
microenvironment, derived from both epithelia and stroma, many of which 
have not been identified; and, 
 KLK4-mediated proteolysis induces downstream signalling and pro-
tumourigenic cellular phenotypes, either in prostate cancer cells or cells of 
the local prostate tumour microenvironment. 
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These hypotheses were examined using the following aims: 
Aim 1 To produce active recombinant KLK4 and optimise treatment 
concentrations for degradomic and transcriptomic experiments; 
Aim 2 To profile the KLK4 degradome in prostate cancer epithelial cells;  
Aim 3 To profile the KLK4-regulated transcriptome in prostate cancer 
epithelial cells;  
Aim 4 To profile the KLK4-regulated transcriptome in prostate 
myofibroblasts;  
Aim 5 To profile the KLK4 degradome in prostate myofibroblasts; and,  
Aim 6 To use pathway analysis software tools to combine degradome and 
transcriptome analyses to frame a global view of the mechanism of 
KLK4 function in prostate cancer and the prostate tumour 
microenvironment.  
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2.1 Mammalian cell culture 
2.1.1  Routine cell culture 
All cell lines were procured from the American Type Culture Collection (ATCC). 
Prostate cancer PC-3 and LNCaP cells were maintained at 37 °C [5% (v/v) CO2] in 
phenol red-free RPMI-1640 media with 2 mM L-glutamine, supplemented with 100 
U/ mL penicillin G sodium, 100 mg/ mL streptomycin sulphate and 10% [(v/v); PC-
3] or 5% [(v/v); LNCaP] fetal bovine serum (FBS; Sigma-Aldrich). Prostate  
WPMY-1 myofibroblasts were maintained as per LNCaP cells. Cells were passaged 
every 3-4 days using trypsin (21 nM)-ethylenediaminetetraacetic acid (EDTA)-
4Na.2H2O (480 nM) in NaCl solution (14.7 mM; Life Technologies). Mycoplasma 
testing was carried out monthly through the IHBI Cancer Program mycoplasma 
testing service using a nested polymerase chain reaction (PCR) approach.  
2.1.2  Cryopreservation 
Cells were pelleted by centrifugation [500 × g, room temperature (RT), 5 min] and 
resuspended in culture media containing 10% dimethyl sulphoxide [DMSO; (v/v); 
Sigma-Aldrich], before transferring to cryovials and cooling to -80 ºC, at a rate of -1 
ºC/ min, using a Nalgene freezing container (Sigma-Aldrich) filled with isopropanol. 
Cells were revived from cryopreservation by immediately washing thawed cells with 
9 × volumes of cell culture media, before plating. 
2.1.3  Cell counting 
Cell counting was performed using NucleoCassettes (ChemoMetec) and measured 
using a NucleoCounter® NC-100™ (ChemoMetec) as per the manufacturer’s 
instruction. Alternatively, trypan blue [4 × 10
-1
% (v/v) final concentration; Life 
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Technologies] was added to cell suspensions prior to manually counting cells using a 
haematocytometer (ProSciTech).  
2.2 Generating mammalian cell CM  
LNCaP (4 × 10
6
 cells/ T-175 flask; passage 25-28) or WPMY-1 cells (1.014 × 10
6
 
cells/ T-175 flask; passage 49-52) were cultured for ~72 h before washing twice in 
serum-free media (15 min, RT) and culturing an additional 48 h, serum-free. CM was 
harvested in the presence of EDTA (50 μM) and phenylmethylsulfonyl fluoride 
(PMSF; 2 mM), and subsequent processing performed on ice or at 4 ºC. Following 
centrifugation to pellet potential residual cells (500 × g, 5 min, 4 ºC), supernatant 
was further centrifuged to pellet cell debris (12,000 × g, 15 min, 4 ºC). Supernatant 
was then filtered through an Acrodisc® syringe filter (4.5 × 10
-1
 μm pore size; Pall 
Corporation), before buffer-exchanging into phosphate-buffered saline (PBS, pH 7.4; 
Life Technologies) using Amicon Ultra-15 centrifugal filter units (Merck Millipore; 
3 kDa molecular weight cut-off). Total protein concentration was determined using 
bichinoic acid (BCA) assay reagents (Sigma-Aldrich), whereby 6.6 × volumes of 
working reagent (1 × volume BCA: 50 × volumes copper sulphate solution) was 
added to diluted CM (sample-dependent dilution) in a transparent 96-well microplate 
and incubated (60 ºC, 30-45 min). Absorption (562 nm) was measured using an 
xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories, Inc.) 
and protein concentration determined, relative to standard dilutions (5-250 ng/ µL) of 
bovine serum albumin (BSA; Sigma-Aldrich), corrected for absorption of PBS buffer 
control. Aliquots of CM were stored at -80 °C. 
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2.3 Whole cell lysis and protein extraction 
Cell mono-layers were washed briefly in Dulbecco’s PBS (DPBS; calcium and 
magnesium-free; Life Technologies) at 4 °C, before lysing in 
radioimmunoprecipitation (RIPA) buffer [50 mM tris, pH 7.4, 150 mM NaCl, 2 mM 
EDTA, 1% (v/v) nonyl phenoxypolyethoxylethanol (NP-40), 1 × 10
-1
% (w/v) sodium 
dodecyl sulphate (SDS), 5 × 10
-1
% (w/v) sodium deoxycholate, 1 mM NaVO3, 1 mM 
NaF; 4°C, 10-15 min], supplemented with Complete EDTA-free protease inhibitor 
cocktail (Roche diagnostics; 1 × final concentration). Whole cell lysates were drawn 
through a 26-gauge needle several times (4 ºC) and centrifuged (12,000 × g, 15 min, 
4 ºC) to pellet cell debris. Protein concentration of the supernatant was quantified 
using a BCA assay and aliquots stored at -80 to -20 °C. 
2.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
silver stain analyses 
SDS-PAGE was performed as per Laemmli et al (Laemmli, 1970), using reagents 
from Bio-Rad laboratories, Inc., unless otherwise stated. SDS-PAGE gels were cast 
using the Mini-Protean III system, producing gels of 750 µm or 1.5 mm thickness, 
each with 12% (w/v) acrylamide: bis-acrylamide (29:1) separating gels and 4% (w/v) 
acrylamide: bis-acrylamide (29:1) stacking gel layers, unless indicated otherwise. 
Unless otherwise specified, protein samples were reduced with tris (2-
carboxyethyl)phosphine (TCEP) hydrochloride solution (25 mM final concentration; 
Sigma-Aldrich), denatured in NuPAGE LDS sample buffer (1 × final concentration; 
Life Technologies) and heated (65 ºC, 10 min) immediately prior to gel loading. 
Protein migration was assessed relative to migration of the Precision Plus Protein™ 
dual colour standard (10-250 kDa).  
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For silver stain analyses, protein samples (amounts specified in specialised Materials 
and Methods section for respective chapters) was resolved by SDS-PAGE, and gels 
fixed [40 % (v/v) methanol; 10 % (v/v) acetic acid] for at least 1 h (RT). Gels were 
washed (2 × 5 min) in MilliQ water before sensitizing (5 min, RT) with potassium 
ferricyanide [2% (w/v); Sigma-Aldrich]/ sodium thiosulphate [2.4% (w/v); Sigma-
Aldrich] solution. Gels were washed until transparent and incubated with silver 
nitrate (Sigma-Aldrich; 15-30 min, RT), before two brief washes in each of MilliQ 
water and sodium carbonate [2.9% (w/v)]. Developer [3.4 × 10
-2
% (v/v) 
formaldehyde in 2.9% (w/v) sodium carbonate] was added until sufficient colour 
production warranted decanting of the developer and incubation with acetic acid [5% 
(v/v)] for at least 30 min (RT) to terminate development. Gels were imaged on a 
Canon flat bed scanner. 
2.5 Western blot analyses 
Denatured, reduced recombinant protein samples (amounts specified in specialised 
Materials and Methods for respective chapters) were loaded in SDS-PAGE gel lanes 
and SDS-PAGE performed as per 2.4. Protein migration was assessed relative to 
migration of the Precision Plus Protein™ dual colour standard. Western blot analyses 
were conducted with a Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad 
laboratories, Inc.) as per the manufacturer’s instruction (SDS-free) using a 
BioTrace™ NT pure nitrocellulose blotting membrane (Pall Corporation). 
Membranes were blocked in Odyssey™ blocking buffer (LI-COR Biosciences; 1 h, 
RT or 24-48 h, 4ºC) prior to incubation with primary antibody, which was diluted in 
blocking buffer (1 h, RT; Table 2.1). Membranes were washed (4 × 8 min, RT) in 
tris-buffered saline with tween [TBS-T; 20 mM tris, pH 7.4, 137 mM NaCl, 5 × 10
-
2
% (v/v) Tween-20] and developed with the appropriate species-specific secondary 
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antibody (45 min-1 h, RT), which was diluted in blocking buffer (Table 2.1). 
Membranes were washed (6 × 4 min, RT) in TBS-T prior to being scanned using an 
Odyssey® CLx Infrared Imaging System (LI-COR Biosciences). 
2.6 Coomassie stain analyses 
These analyses were performed as per 2.4, up to and including fixation, following 
which SDS-PAGE gels were stained with Coomassie Brilliant Blue R-250 (Bio-Rad 
laboratories, Inc.; 3 g/ L in fixative, filtered using Watman filter paper) for >1 h 
(RT). Gels were destained using fixative until a transparent background was 
achieved. Coomassie-stained gels were imaged using the Odyssey Clx Infrared 
Imaging System or Canon flat bed scanner. 
2.7 Gelatine zymography 
Denatured, but non-reduced, protein samples (amount as described in specialised 
Materials and Methods sections in respective chapters) were resolved on an SDS-
PAGE gel, containing 1 × 10
-1
% (w/v) gelatine (Sigma-Aldrich) in the resolving 
layer. Gels were washed thrice in exchange buffer [tris-HCl (20 mM), NaCl (150 
mM), pH 8.8, 5 % (v/v) triton X-100; 20 min, RT], before washing twice in 
developing buffer (as exchange buffer, but without triton X-100; 30 min, RT) and 
incubating in fresh developing buffer up to 48 h (37 °C). Protein clearing was 
visualised by Coomassie staining and gels imaged, as above. 
2.8 RNA extraction 
RNA extraction was performed using the TRIzol® reagent (Life Technologies) as 
per manufacturer’s instruction. Briefly, cells were washed in DPBS (pH 7.4) before 
adding 500 µL TRIzol® per 10 cm
2
 cell culture dish and incubating (2-5 min, RT). 
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Table 2.1. Antibody details for Western blot analyses.  
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TSP1, thrombospondin-1; VCL/VINC, vinculin. 
Species Clonality Target  Immunogen (/ epitope) or description 
(secondary antibodies only) 
Concentration (dilution) Brand; catalogue no. or 
reference 
 Primary antibodies: 
 Rabbit Polyclonal KLK4 LSVRHPEYNRPLL and SEEVCSKLYDPLYHP 1/10,000 dilution of each  (Harvey et al., 2003) 
 Mouse Monoclonal V5 GKPIPNPLLGLDST 1/5,000 dilution  Life Technologies; R960-25 
 Rabbit Polyclonal Flag DYKDDDDK 800 ng/ mL (1:1,000 dilution) Sigma-Aldrich; F7425 
 Mouse Polyclonal MMP1 MMP1 1 µg/ mL (1/1,000 dilution) Abcam; ab89767 
 Rabbit Polyclonal MMP1 Hemopexin domain of MMP1 1 µg/ mL (1/1,000 dilution) Abcam; ab11594 
 Mouse Monoclonal TSP1 Reduced, alkylated platelet-derived TSP1/ D692-
N717 (Annis, Murphy-Ullrich & Mosher, 2006) 
500 ng/ mL (1/200 dilution) Abcam; ab1823 
 Goat Polyclonal TSP1 N-terminal TSP1 peptide, sequence not specified 
but lies within heparin binding domain N19-L240 
(Tabib et al., 2009) 
1 µg/ mL (1/200 dilution) Santa Cruz Biotechnology; sc-
12312 
 Mouse Monoclonal VCL/VINC VCL/VINC 1/200 dilution Sigma; V9131 
 Mouse Monoclonal FGF1 FGF1 1 µg/ mL (1/500 dilution) Abcam; ab117640 
 Rabbit Polyclonal GAPDH GAPDH 500 ng/ mL (1/10,000 dilution) Abcam; ab9485 
 Secondary antibodies: 
 Goat Polyclonal Rabbit Alexa Flour® 680 Goat anti-rabbit IgG (H+L) 200 ng/ mL (1:10,000 dilution) Life Technologies; A-21076 
 Donkey Polyclonal Mouse IR-Dye 800 conjugated affinity purified anti-
mouse IgG (H+L) 
100 ng/ mL (1:10,000 dilution) Rockland™; 610-732-124 
 Donkey Polyclonal Goat Alexa Flour® 680 Donkey anti-goat IgG (H+L) 200 ng/ mL (1:10,000 dilution) Life Technologies; A-21084 
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TRIzol®-lysed cell solution was harvested with cell scrapers or by vigorous pipetting 
and transferred to new RNase- and DNase-free tubes, containing equal volumes of 
isopropanol. RNA was allowed to precipitate (30 min, RT, or overnight, -20 ºC) 
before centrifugation (12,000 × g, 15 min, 4 ºC). RNA-containing pellets were 
washed with 1 mL analytical reagent-grade ethanol [70% (v/v); Sigma-Aldrich) 
before centrifuging (12,000 × g, 10 min, 4 ºC) and air-drying (RT). Pellets were 
resuspended in 20-50 µL nuclease-free water, and RNA concentration and purity 
assessed using a NanoDrop™ 1000 UV-Vis spectrophotometer (Thermo Fisher 
Scientific), with OD (260 nm) 1 = 40 µg/ mL RNA.  
2.9 Quantitative reverse transcription PCR (qRT-PCR)  
For removal of contaminant DNA, RNA (1 µg) was diluted in 10 × DNase buffer, 
made to 1 × with nuclease-free water and DNase I, amplification grade (1 U; 10 µL 
total volume; Life Technologies). After incubating (15 min, RT), the reaction was 
stopped by the addition of EDTA to a final concentration of 2.27 mM before heat 
denaturing (65 ºC, 10 min). First strand synthesis was performed by the addition of 
random hexamers (15 ng/ L) and deoxynucleotide triphosphates (dNTPs) to a final 
concentration of 769 nM (Life Technologies), and incubating 65 ºC, 15 min, before 
resting on ice (1 min). cDNA synthesis was carried out by the sequential addition of 
5 × reverse transcriptase buffer (1 × final concentration), 100 nM dithiothreitol 
(DTT; 10 mM final) and 200 U/ µL SuperScript® III RT (10 U/ µL final; Life 
Technologies) in 20 µL total final volume. The solution was mixed by gentle 
pipetting before incubating (25 ºC, 5 min, 50 ºC, 30-60 min and 70 ºC, 15 min). For 
qRT-PCR, cDNA (equivalent of 1 µg RNA starting material) was diluted 1/5 in 
nuclease-free water (Life Technologies). To 2.5 µL diluted cDNA was added 
SYBR® Green Real-Time PCR Master Mix (1 × final concentration; Applied 
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Biosciences), and forward and reverse primer (50 nM each; Table 2.2) to a final 
volume of 20 µL in nuclease-free water. Reactions were conducted in an ABI 
PRISM 7000 Real-Time PCR System (Applied Biosystems) with the following 
series of thermocycling steps: 95 ºC, 10 min; 40 × cycles of 95 ºC, 15 sec; and 60 ºC, 
10 min. ABI PRISM 7000 SDS Software (Applied Biosystems) was used to 
manually assign baseline and threshold fluorescence values. Relative quantification 
was performed using the ΔΔCT method described by the manufacturer (Applied 
Biosystems). Student t-tests were performed using IBM® SPSS® Statistics 21 
software (IBM® Corporation) to identify differentially expressed genes (P ≤ 0.05).  
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Table 2.2. Primers used for qRT-PCR. 
Target  Forward sequence (5’-3’) Reverse sequence (5’-3’) 
FGF5 CTGCAGATCTACCCGGATGG TGCTGAAAACTCCTCGTATTCCTA 
cMET GGGTCAATTCAGCGAAGTCCT  GGAGTCCAGGAGAAAATTCACAA 
ID2 TCGCATCCCACTATTGTCAGC   AGCCACACAGTGCTTTGCTGT 
HAS2 CACGTAACGCAATTGGTCTTGT  ATGAGGCTGGGTCAAGCATAG 
ITGA4 CAGATGCAGGATCGGAAAGAA  AAAGTGTGACCCCCAACCAC 
PCOLCE2 GGAGAGTCTGGATTTATTGGCAG GAATCGGAAATTGAGAACGACTACT 
 
 
   52 
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells    53 
 
 
 Determining the KLK4 Chapter 3: 
degradome produced by prostate 
cancer cells 
 
  54            54 
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells 55            55 
3.1 Introduction 
Production of KLK4 is increased in prostate cancer, compared to benign tissue 
(Table 1.2). This up-regulation is first observed in PIN, and is maintained with 
progression to metastatic prostate cancer (Bui, 2006; Gao et al., 2007). Elevated 
expression of KLK4 is significantly associated with prostate cancer risk and stage in 
a clinical cohort (Avgeris, Stravodimos & Scorilas, 2011). KLK4 over-expression in 
prostate cancer cell lines was found to induce cancer-promoting phenotypes (Table 
1.1); however, the underlying mechanisms are unknown. KLK4 possesses a serine 
protease domain that may be its sole functional domain (Debela et al., 2008; Debela 
et al., 2006); thus, KLK4 may have predominantly protease-mediated functions. The 
identification of KLK4 substrates is integral to determine the mechanism of KLK4 
action in established KLK4-regulated functions, as well as to highlight additional 
potential roles for the protease in other tumour-promoting processes. Some KLK4 
substrates derived from prostate cancer cells have been determined using in vitro 
biochemical assays. However, such assays suffer from selection bias and do not 
assess protease-substrate interactions within a biologically-mimetic protein 
background. Thus, it is unclear whether established KLK4 substrates are cleaved by 
KLK4 in the complex prostate tumour microenvironment. Further, it is highly likely 
that additional KLK4 substrates exist, which are yet to be identified. Analysis of 
KLK4 action in a complex, prostate cancer cell-derived protein pool is the next step 
toward delineating its in vivo substrates, with the aim of determining the mechanism 
and function of KLK4 in prostate cancer, in order to assess its efficacy as an anti-
cancer target. 
During the candidate’s Honours research program, the first global analysis of 
prostate cancer cell-derived protein substrates of KLK4, or its degradome, was 
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performed. This was conducted using a high-depth proteomic methodology, known 
as PROTOMAP (Dix, Simon & Cravatt, 2008). This single replicate first-pass 
analysis of KLK4 substrates in CM derived from the late-stage prostate cancer PC-3 
cell line successfully identified several novel KLK4 substrates, as well as known 
substrates, validating the approach.  
While this was a positive proof of concept study, in the candidate’s PhD, as 
presented in this chapter, this data was extended to compare substrates of exogenous 
active KLK4 added into PC-3 cell CM with that of a transfected stable PC-3 cell line 
exogenously expressing KLK4 (PC-3:KLK4). This was to inform as to whether 
future assays, such as subsequent transcriptome profiling (Chapter 4), may employ 
the PC-3:KLK4 cell line as a viable means of delivering KLK4 with established 
proteolytic activity in cell CM. Over-expression of KLK4 in prostate cancer cells 
would circumvent the need to produce and purify the large amounts of active KLK4 
presently required when adding the recombinant protease into cell CM for cellular 
assays. Further, this study served as a validation of previous analysis of KLK4 
substrates in PC-3 cell CM using the PROTOMAP approach, improving the 
confidence in identification of KLK4 substrates. The practical component of this 
work was performed during the candidate’s Honours program, and this data was 
analysed and validated as part of this PhD research program. 
As prostate cancer cells are heterogenous and one cell line cannot represent the entire 
disease, PROTOMAP-guided determination of KLK4 substrates was also conducted 
using CM from LNCaP cells, which are derived from early-stage, androgen-
responsive prostate cancer. Hence, in this chapter, the newly performed analysis of 
the KLK4 degradome in LNCaP cell CM was compared to that of PC-3 cell CM, to 
identify prostate cancer cell-derived KLK4 substrates in early- and late-stage disease. 
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells 57            57 
3.2 Materials and Methods 
3.2.1 Recombinant KLK4 production 
3.2.1a Insect cell culture 
SF-9 insect cells, obtained from the ATCC, were routinely cultured in SF9-II media 
(Life Technologies), supplemented with 100 U/ mL penicillin G sodium and 100 mg/ 
mL streptomycin sulphate (Life Technologies).  
3.2.1b Recombinant protein expression and affinity purification 
The KLK4 coding sequence [pre-pro-KLK4; National Centre for Biotechnology 
Information (NCBI) reference sequence (RefSeq): NM_004917.3] was PCR 
amplified from LNCaP cells and sub-cloned into PGEM®-T easy vector (Promega). 
Overlay extension PCR was performed to substitute the KLK4 pre-pro-region (S27-
Q30; c. 1-90) with the trypsin pre-pro-region (c. 1-69; NCBI RefSeq: 
NM_002769.4), which terminates in the preferred cleavage sequence of enterokinase 
(EK), DDDDK. The purified immature protein is referred to as pro-KLK4. In silico 
translation of this nucleotide sequence, performed using the Expasy Translate tool 
(Gasteiger et al., 2003), is presented in Supplementary Figure 3.1. To generate a 
catalytically-inactive mutant KLK4 control protease (pro-mKLK4), site-directed 
mutagenesis was conducted, substituting the active site S to an A residue (S207A; c. 
591C>A). cDNA sequences for both KLK4 forms were further subcloned into the 
pIB/ V5-His vector (Life Technologies) and the sequence of inserts confirmed by 
BigDye Terminator Sequencing (Applied Biosystems), a service provided by the 
Australian Genome Research Facility, University of Queensland. 
Recombinant protein expression in SF-9 cells and affinity purification, conducted by 
the PhD candidate, were performed as described previously (Ramsay et al., 2008), 
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where the resin was washed thrice in NPI buffer (2.7 mM NaH2PO4, 47.3 mM 
Na2HPO4, 500 mM NaCl, pH 8.0) with 10 mM imidazole (NPI-10) and thrice in 
NPI-20 (NPI buffer with 20 mM imidazole), before eluting in NPI-250 (NPI buffer 
with 250 mM imidazole). To confirm protein expression and purity, equal volumes 
(1.7 μL) of NPI-250 elution fractions, NPI-10 washes or the flow-through were 
loaded per lane of an SDS-PAGE gel, following heating (60 ºC, 10 min) in the 
presence of sample buffer and TCEP hydrochloride solution (83.3 mM final 
concentration). Positive controls for KLK4 detection and migration following SDS-
PAGE included wt-pro-KLK4 with a V5-His tag (pro-wt-KLK4; 245 ng) and the 
mutant equivalent (S207A mutation; pro-wt-mKLK4; 245 ng). These purified 
proteins were generous gifts from Dr Scott Stansfield and Mr Carson Stephens. SDS-
PAGE gels were subject to Western blot analyses with antibodies targeting both the 
KLK4 mid- and C-termini, or the V5 tag (Table 2.1). Replicate SDS-PAGE gels 
were visualised by silver staining. 
3.2.1c Optimising EK-mediated activation of recombinant KLK4 and mKLK4 
Affinity-purified protein products (pro-KLK4 and pro-mKLK4) were dialysed into 
EK buffer (20 mM tris-HCl, 50 mM NaCl, 2 mM CaCl2, pH 8.0). Product 
concentration was estimated by performing SDS-PAGE/ silver staining alongside a 
BSA standard curve and interpolating signal intensity to determine approximate 
concentration (data not shown). Activation with EK, light chain (New England 
Biolabs) was optimised, using 444.4 ng/ µL pro-KLK4: 1.1 ng/ µL EK, representing 
a 400:1 ratio of pro-KLK4: EK [(w/w); sample A; 23 °C, 18 h]. The same 
concentration of pro-KLK4 was also treated with EK dilutions corresponding to 
ratios of 2,000:1, 5,000:1 (sample B), 10,000:1, 20,000:1 and 40,000:1. Samples A 
and B were also prepared as 2-fold diluted samples. Pro-mKLK4 (444.4 ng/ µL), 
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digested with EK (1.1 ng/ µL or 222.2 pg/ µL; 23 °C, 18 h) was also analysed. 
Negative controls included EK, pro-mKLK4 or pro-KLK4, alone, at the highest 
employed concentration of each. An additional negative control of EK, at the 
concentration used for sample B, was also analysed. All samples were incubated (23 
°C, 18 h), before the efficiency of pro-peptide processing was assessed by Western 
blot analysis or gelatine zymography.  
3.2.1d Western blot analyses of EK-treated pro-KLK4 and pro-mKLK4 
For Western blot analysis, a standard curve of 2-fold serial dilutions from 416.7 to 
52.08 ng/ lane pro-KLK4 was loaded to define the minimum limit of detection. 
Samples were heated (60 ºC, 10 min) in the presence of sample buffer and TCEP 
hydrochloride solution (41.7 mM), and the equivalent of 20.6 ng of pro-(m)KLK4 
constructs was loaded per lane. Immunodetection was performed with an anti-flag 
antibody, raised against the immunogen, DYKDDDDK (Table 2.1). The anti-flag 
antibody detected pro-KLK4 and pro-mKLK4, but not pro-wt-KLK4 and pro-wt-
mKLK4, which are identical to the former constructs, except for different pro-
regions. Notably, the pro-region of pro-KLK4 and pro-mKLK4 constructs terminate 
in the EK-preferred cleavage site recognition sequence, DDDDK, which is highly 
similar to the flag immunogen and likely the epitope for the antibody. EK-mediated 
processing of pro-KLK4 abrogated immunoreactivity; thus, loss of signal appeared to 
correlate to pro-region processing. An anti-KLK4 antibody (Table 2.1) was 
employed to show equal loading and to detect KLK4 degradation products 
potentially resulting from non-specific processing by EK.  
The flag epitope was removed in EK-treated pro-KLK4, though not pro-mKLK4, 
samples, which indicated that EK-activated pro-KLK4 may initiate activation of 
surrounding pro-KLK4 molecules. To test this hypothesis, pro-KLK4 (444 ng/ µL) 
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was incubated with thermolysin-activated pro-wt-KLK4 (referred to as thermo-
KLK4; 98.6 ng/ µL active or 662.6 ng/ µL total; 23 °C, 18 h) or the equivalent total 
amount of thermolysin-activated pro-wt-mKLK4 control (referred to as thermo-
mKLK4), both kind gifts from Dr Scott Stansfield and Mr Carson Stephens. Thermo-
KLK4 and thermo-mKLK4, alone, were included as corresponding controls. Samples 
were subject to Western blot analyses or gelatine zymography (below).  
3.2.1e Zymography analyses of EK-treated recombinant pro-KLK4 and pro-mKLK4 
Samples prepared above were subject to gelatine zymography to measure the 
gelatinolytic activity of EK-activated pro-KLK4. For zymography analyses, a 
standard curve of 1/3 serial dilutions of thermo-KLK4 (59.5 ng/ lane active or 400 
ng/ lane total to 7.4 pg/ lane active) was freshly prepared, prior to loading samples on 
the gel. This standard curve served to evaluate the minimum detection limit of 
gelatinolytic activity. For gelatine zymography, samples were prepared in sample 
buffer (1 × final concentration), without heat denaturation, and the equivalent of 24.7 
ng pro-(m)KLK4 loaded per lane.  
3.2.1f EK treatment of recombinant pro-KLK4 and pro-mKLK4 stocks 
To ensure the highest level of pro-region processing attainable, the maximum 
practicable quantity of EK was employed to process pro-KLK4 and pro-mKLK4 (23 
°C, 18 h), representing a 12,500:1 ratio of pro-(m)KLK4: EK (w/w). 
3.2.1g Anion exchange chromatography (IEX) purification of EK-activated 
recombinant pro-KLK4 and pro-mKLK4  
EK-treated pro-KLK4 and pro-mKLK4 (referred to as KLK4 or mKLK4, 
respectively) were subsequently dialysed into Na3PO4 (20 mM, pH 7.4), using a 
Slide-A-Lyzer dialysis cassette (Thermo Scientific; 10 kDa molecular weight cut-
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off), preceding IEX using a Resource Q column (GE Life Sciences) with a linear 
elution gradient to 1M NaCl (5 min, 4 mL/ min). To avoid cross-contamination of 
active protease in the mKLK4 purification, mKLK4 was purified before KLK4, and 
multiple blank runs carried out prior to, and following, purification of each protease.  
Equal volumes of IEX elution fractions of mKLK4 and KLK4 were subject to 
Western blot analyses or SDS-PAGE/ silver stain analyses and gelatine zymography. 
Thermo-KLK4 was employed as a positive control for KLK4 migration and activity. 
Similar volumes of flow-through fractions and an aliquot of sample prior to 
purification were also analysed. Western blot analyses were performed using 
antibodies targeting KLK4 and the flag epitope (Table 2.1).  
Fractions containing KLK4 (fractions 12-16, 18-20) or mKLK4 (fractions 13-20), 
and no detectable contaminating proteins, were pooled, concentrated and buffer-
exchanged into PBS, using Amicon Ultra-4 Centrifugal filter units with Ultracel-3 
membrane (Merck Millipore; 3 kDa molecular weight cut-off). Total protein 
concentration was determined using a BCA assay. Enzyme aliquots were stored at     
-80 °C and thawed aliquots re-frozen up to once only prior to use.  
3.2.1h Quantification of KLK4 activity 
To determine the concentration of active KLK4, KLK4 was incubated (37°C, 15 
min) with serial dilutions of α2-antiplasmin (R&D Systems) before fluorescent 
substrate addition (50 µM D-Val-Leu-Arg-7-amido-4-trifluoromethyl coumarin or 
VLR-AFC; Sigma-Aldrich) in PBS. The initial rate of KLK4 activity (Δ relative 
fluorescence units/ min; Δ RFU/ min), measured in a PolarStar Optima microplate 
reader (BMG Labtech; ex 400 nm, em 505 nm; 37 °C), was plotted against respective 
inhibitor concentrations and extrapolated to Δ RFU/ min = 0 to find the concentration 
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of α-2 antiplasmin required for complete KLK4 inhibition, synonymous with the 
concentration of active KLK4 (1:1 stoichiometry; data not shown).  
For the remainder of this document, unless otherwise stated, KLK4 concentrations 
given describe its active component (i.e. 34% of total protein concentration). For 
mKLK4, which was inactive, the total protein concentration will be denoted.  
3.2.2 KLK4 substrate screening in PC-3 cell CM  
This work, from ‘3.2.2a Over-expression of auto-activating KLK4 in mammalian 
cells’ to ‘3.2.2d Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
and data analysis’, was conducted as part of the candidate’s Honours research 
program. However, peptograph analysis, and the subsequent validation of key 
substrate targets, was performed during the PhD research program, where 
corresponding results are presented within this dissertation. 
3.2.2a Over-expression of auto-activating KLK4 in mammalian cells 
Generation of plasmid constructs was performed similar to 3.2.1b, excepting that 
overlay extension PCR was used to substitute the KLK4 pro-region (S27-Q30) with 
that of PSA (A18-R24). This generated auto-activating KLK4 (auto-KLK4), as 
KLK4 activates PSA by removal of its pro-region (Takayama et al., 2001). For 
transfection with catalytically-inactive mKLK4, site-directed mutagenesis was 
performed to substitute the active site S residue to an A residue (S207A). The 
resulting protein was called auto-activating mKLK4 or auto-mKLK4 to demonstrate 
its relationship to auto-KLK4, even though auto-mKLK4 was catalytically inert and 
incapable of self-activating.  
PC-3 cells, which are devoid of detectable endogenous KLK4 expression, were 
transfected with auto-KLK4, auto-mKLK4 or empty vector control constructs, using 
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previously published methods (Veveris-Lowe et al., 2005). The resulting stably-
expressing polyclonal populations were denoted as PC-3:KLK4, PC-3:mKLK4 or 
PC-3:Vector.  
3.2.2b Harvesting and processing PC-3 cell CM 
PC-3 cells were grown to 85-90% confluence, washed twice in PBS, and cultured in 
serum- and phenol red-free media for 24 h, before repeating washes and culturing an 
additional 48 h, serum-free. CM was harvested and cell debris removed by 
centrifugation (12,000 × g, 15 min, 4 ºC). The supernatant was buffer-exchanged into 
assay buffer [50 mM tris-NaCl, 1 × 10
-2
% (v/v) Tween, pH 8.8] using Amicon Ultra-
15 centrifugal filter units (Merck Millipore) and CM was further concentrated using 
micro-concentrators (Vivaspin), pre-passivated in triton X-100 [5% (v/v)]. Protein 
concentrations were determined using the BCA assay.  
3.2.2c KLK4 substrate screening 
For identification of KLK4 substrates in PC-3 cell CM using PROTOMAP analyses, 
concentrated CM (2.7 µg/ µL) from PC-3:KLK4, PC-3:mKLK4 and PC-3:Vector 
cells was treated with 23.2 ng/ µL active recombinant auto-KLK4 (928.7 nM; a gift 
from Dr Scott Stansfield and Mr Carson Stephens) or equivalent total amounts of 
thermo-mKLK4, or treated with assay buffer vehicle control (also called untreated; 
37 °C, 18 h). Reactions were stopped with NuPAGE LDS sample buffer, reduced 
with TCEP hydrochloride solution (20.8 mM; 60 °C, 10 min) and alkylated with 
iodoacetamide (21 mM, RT, 15 min, light-protected; Sigma-Aldrich). The equivalent 
of 36.6 μg of each PC-3 cell CM sample was loaded into individual lanes of a large-
format SDS-PAGE gel (18 × 20 cm, Protean II xi, Bio-Rad laboratories, Inc.) 
comprised of a 10.5-14% (w/v) gradient of 29:1 acrylamide: bis-acrylamide, with 
lanes separated by Precision Plus Protein™ dual colour standard (10-250 kDa) for 
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visualising lane distinctions. The gel was run at 10 mA for ~15 h, then at 250 V until 
completion. To identify bands that underwent a migrational shift upon protease 
treatment, lanes were partitioned by vertical slicing, before subdividing the gel into 5 
mm horizontal sections (32 total). Each slice was further sectioned into ~1 mm
3
 
pieces, with pieces for each slice pooled, then immediately dehydrated with neat 
acetonitrile (Sigma-Aldrich). In-gel digestion was performed, as per Shevchenko et 
al. (2006), excepting that reduction and alkylation steps were omitted as these were 
performed prior to loading samples on the gel. Concentrated peptide extracts were 
resuspended in 12 μL formic acid [5% (v/v)]. One biological replicate of each stated 
PC-3 cell CM sample was analysed by PROTOMAP. 
3.2.2d Liquid chromatography tandem mass spectrometry (LC-MS/MS) and data 
analysis 
LC-MS/MS analysis, and peptide and protein identification from raw tandem mass 
spectrometry (MS/MS) data, was performed as per the candidate’s Honours thesis. 
As per protocols therein, a pictorial representation of peptides (protein coverage on 
X-axis) identified in varied lanes (denoted by colour) and gel slices (Y-axis), similar 
to Dix et al.’s peptograph (2008), was generated by Dr Scott Stansfield, using 
custom scripts. For the present analyses, multiple sets of peptographs were compiled. 
The first set of peptographs was generated to compare: the control group, comprising 
assay buffer-treated and thermo-mKLK4-treated CM from PC-3:Vector and PC-
3:mKLK4 cells; the KLK4-transfected group, comprising sample buffer-treated and 
thermo-mKLK4-treated PC-3:KLK4 cell CM; and the KLK4-treated group, 
comprising auto-KLK4-treated CM from each of PC-3:Vector, PC-3:mKLK4 and 
PC-3:KLK4 cells. Peptides from all samples within each group were represented on 
peptographs as a single colour. Note that samples within each group were analysed 
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by PROTOMAP individually, but results presented as a single group on peptographs. 
Determination of auto-KLK4 substrates, and substrates arising from auto-KLK4 
transfection, was performed using this set of peptographs, as per below. 
To determine whether treatment with thermo-mKLK4 induced hydrolysis of proteins 
in PC-3 cell CM, three additional sets of peptographs were generated, comparing 
thermo-mKLK4 treatment, auto-KLK4 treatment and assay buffer treatment of each 
individual CM (PC-3:Vector, PC-3:mKLK4 or PC-3:KLK4; one set of peptographs 
per CM being analysed). To establish whether PC-3 cell transfection with auto-
mKLK4 altered migration of CM-derived proteins, an additional set of peptographs, 
comparing assay buffer-treated PC-3:mKLK4 CM to PC-3:Vector CM, was also 
generated. Assay buffer-treated PC-3:KLK4 CM was also included as a condition on 
this set of peptographs, although it was not assessed in this analysis. Peptographs 
were analysed, as per below. 
3.2.2e Peptograph analysis 
Only peptographs of those proteins with cell surface or extracellular localisation, as 
denoted by Ingenuity® Pathway Analysis software [IPA; (QIAGEN)], were 
analysed. For determining auto-KLK4 substrates in PC-3 cell CM, migration of 
proteins in the KLK4-treated group was directly compared to that of the control 
group, irrespective of protein migration in the KLK4-transfected group. Similarly, 
for determining substrates arising from auto-KLK4 transfection, migration of 
proteins in the KLK4-transfected group was directly compared to that of the control 
group, independent of protein migration in the KLK4-treated group. In determining 
apparent substrates of thermo-mKLK4, the migration of proteins in this sample was 
directly compared to the assay buffer-treated samples, irrespective of protein 
migration in the auto-KLK4-treated samples. This was assessed separately for each 
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of the three CM pools (PC-3:Vector, PC-3:mKLK4 or PC-3:KLK4) and, for this 
comparison, a protein was classified as an apparent thermo-mKLK4 substrate only if 
determined to be such in at least two of the three CM pools. For determination of 
apparent substrates of PC-3 cell over-expressed auto-mKLK4, protein migration in 
PC-3:mKLK4 CM was compared directly to that of PC-3:Vector CM, without 
consideration of migration in PC-3:auto-KLK4 CM. Respective treatment and 
control groups for each comparison stated will be referred to simply as treatment and 
control in the following description of peptograph analysis. 
To determine proteolysis in the stated comparisons, the following criteria were 
employed. A protein fragment was defined as a theoretical protein or protein 
fragment of sequence including at least two peptides identified within a single gel 
slice (or ± one gel slice) from a single sample. The protein sequence between and 
including these peptides was considered to be part of the protein fragment, even 
though 100% coverage of tryptic peptides along these fragments was not usually 
attained. For proteins to be considered hydrolysed, there was to be at least one 
protein fragment identified in the control sample (control fragment), and not only 
single isolated peptides that did not fit the criterion for being part of a protein 
fragment. The identification of a control fragment/s is essential to provide a reference 
against which migration of the protein in the treated sample may be compared. 
Proteins deemed substrates were to contain at least one protein fragment in the 
treated sample that migrated to at least two gel slices below protein fragments or 
isolated peptides (peptides not theoretically incorporated in a protein fragment) that 
comprised of all, or part, of the sequence of this fragment. A theoretical protein 
fragment that met this criteria was called a KLK4-generated fragment (or mKLK4-
generated fragment in respective comparisons), referred to in this section as a 
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treatment-generated fragment, for clarity. Where control fragments or isolated 
control peptides, that mapped to within the region of the treatment-generated 
fragment, were not identified in any gel slice above the treatment-generated 
fragment, the treatment-generated fragment was required to migrate to at least two 
gel slices below any control fragment identified.  
3.2.2f Comparison of protein localisation with other published studies 
Proteins identified in PC-3 cell CM in other studies, that used similar methods for 
harvesting serum-free CM as were used in this study (Saraon et al., 2012; Sardana et 
al., 2008), were imported into IPA. For those proteins where ontology assignments 
were available in IPA, the number of proteins annotated as being of extracellular or 
plasma membrane origin was presented as a percentage of all proteins identified. The 
proportion of proteins of extracellular or plasma membrane origin identified in PC-3 
cell CM in the present study was similarly calculated. 
3.2.3 KLK4 substrate screening in LNCaP cell CM  
3.2.3a Optimising the KLK4 concentration for digesting LNCaP cell CM 
LNCaP cell CM (1.4 g/ L), harvested, concentrated and buffer exchanged as per 2.2, 
was treated with 1/2 serial dilutions of KLK4 [52.9 ng/ µL or 2.1 µM active (139.7 
ng/ µL total) to 413.6 pg/ µL active], representing ratios of 25:1 to 3,200:1 LNCaP 
cell CM: KLK4 (w/w). Digests were carried out in PBS (18 h, 37 ºC). Controls 
included untreated LNCaP cell CM, and PBS or KLK4 only. The equivalent of 9.4 
µg of LNCaP cell CM was heated (60 ºC, 10 min) in the presence of sample buffer 
and TCEP hydrochloride solution (90.1 mM final concentration), and resolved by 
SDS-PAGE, before visualising by silver staining. The optimal treatment ratio was 
the ratio of LNCaP cell CM: KLK4 (w/w) with the lowest KLK4 treatment 
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concentration whereby CM hydrolysis was visible. This ratio was used for 
subsequent digestion of LNCaP cell CM with KLK4. 
3.2.3b Sample preparation 
For identification of KLK4 substrates in LNCaP cell CM, PROTOMAP analyses was 
employed, as set out by Dix et al. (2008), although with some modifications. 
Concentrated LNCaP cell CM in PBS (402.3 ng/ µL), as per above, was treated with 
KLK4 [1 ng/ µL or 40.2 nM active (3 ng/ µL total)] in PBS (37 °C, 18 h) or with 
mKLK4 (3 ng/ µL total) or PBS buffer controls. Reactions were stopped with SDS 
[8.7 × 10
-2
% (w/v)], before reduction with TCEP hydrochloride solution (9 mM) in 
ammonium bicarbonate (90 mM, pH 8.0; 55 °C, 1 h). Samples were alkylated with 
iodoacetamide (17.6 mM; 25 °C, 30 min, light-protected; Sigma-Aldrich) prior to 
precipitation in 9 × volumes of methanol (100%; -20 °C, 18 h). Protein pellets were 
collected by centrifugation (14,000 × g, 5 min, 4 °C) and washed in methanol [90% 
(v/v)] before subsequent centrifugation (14,000 × g, 10 min, 4 °C). Pelleted protein 
was resuspended in NuPAGE LDS sample buffer (1 × final concentration), and the 
equivalent of 30 µg of each LNCaP cell CM sample was loaded in individual lanes 
of an SDS-PAGE gel, comprised of a 10.5-14% (w/v) gradient of 29:1 acrylamide: 
bis-acrylamide. SDS-PAGE was carried out at 120 V until the dye front migrated to 
the base of the gel. Protein bands were visualised by Coomassie staining, before 
washing twice in MilliQ water, prior to gel slicing, below. To confirm KLK4-
mediated digestion, an aliquot of the above samples containing the equivalent of 10 
µg LNCaP cell CM was resolved on a fixed percentage SDS-PAGE gel and subject 
to silver stain analysis.  
Lanes of the gradient gel, above, were partitioned by vertical slicing, before 
subdividing the gel into horizontal sections, ~3 mm in length (19 total). Each slice 
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was further sectioned into ~1 mm
3 
pieces, and pieces from each slice were pooled 
and frozen (-20 °C), prior to subsequent processing. Gel pieces were destained to 
completion by duplicate washes in 200 mM ammonium bicarbonate, pH 8.0/ 40% 
(v/v) acetonitrile, for 15 min (37 °C), before drying in an EZ-2 personal Evaporator 
or miVac Duo concentrator (Genevac). Dried gel pieces were resuspended in trypsin 
buffer [40 mM ammonium bicarbonate, pH 8.0/ 10% (v/v) acetonitrile], with 
modified, sequencing grade trypsin (10 ng/ μL; Roche), and allowed to absorb 
maximal liquid (4 °C, 30 min). Additional trypsin buffer was added, where 
necessary, to cover gel pieces, prior to digestion (37 °C, 16 h). Excess trypsin buffer 
was collected and later pooled with peptide extracts, after gel pieces were extracted 
with 1% (v/v) formic acid, followed by 1% (v/v) formic acid/ 80% (v/v) acetonitrile, 
each at 37 °C for 1 h. Pooled peptide extracts were dried, near to completion, in a 
vacuum concentrator, as above, and re-suspended in 1% (v/v) formic acid/ 2% (v/v) 
acetonitrile, prior to analysis via LC-MS/MS (below).  
CM was harvested and treated on three separate occasions, representing three 
biological replicates. All three replicates were analysed simultaneously, from the 
point of SDS-PAGE analysis to freezing excised gel slices, in order to avoid error 
derived from technical replication at these important steps. From there onwards, each 
replicate was analysed individually, as it was impractical to perform the subsequent 
steps simultaneously.  
3.2.3c LC-MS/MS 
Resuspended peptide, acidified as above, was subject to capillary reverse-phase 
liquid chromatography (LC) using a Prominence nano high performance LC system 
(Shimadzu) inline with a linear ion trap (LTQ)-Orbitrap XL hybrid mass 
spectrometer (Thermo Fisher Scientific), with a dynamic nano-electrospray ion 
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source (Proxeon) containing a 30 μm inner diameter uncoated silica emitter (New 
Objective). Peptide (10 µL) was applied to 300 Å, 300 μm × 5 mm C18 trap column 
(Dionex Acclaim® PepMapTM μ-Precolumn) in 98% solvent A [1 × 10-1% (v/v) 
aqueous formic acid] with 2% solvent B [80 % (v/v) acetonitrile/ 20% (v/v) H2O 
containing 1 × 10
-1
% (v/v) formic acid] for 5 min, at 20 μL/ min (40 ºC), preceding 
back-flushing (1 µL/ min) onto a pre-equilibrated analytical column (Vydac Everest 
C18 300Å, 150 μm × 150 mm; Alltech). The analytical column was washed in 100% 
solvent A (3.5 min) and peptides resolved using the following linear gradient 
parameters (percentage solvent A/ percentage solvent B; 40 ºC, 1 µL/ min): 70/ 
30 (60 min), 25/ 75 (5 min), 0/ 95 (2 min), before constant 0/ 95 (10 min). LC eluates 
were subject to LTQ-Orbitrap throughout the entire run. The LTQ-Orbitrap XL was 
operated using Xcalibur 2.1.0 SP1.1160 software (Thermo Fisher Scientific). Typical 
spray voltages ranged between 1.4-1.8 kV, with the heated capillary temperature at 
280 °C; no sheath, sweep, or auxiliary gases were used. Mass spectrometry (MS) was 
performed in data-dependent acquisition mode, with a full survey scan acquired in 
the Orbitrap (300-2,000 m/ z, resolving power 60,000 at 400 m/ z, automatic gain 
control target value of 5 × 10
5
 charges, maximum injection time 500 ms) and the 
eight most intense ions selected for MS/MS in the LTQ (automatic gain control 
target value of 10,000 charges, maximum injection time 100 ms). Charge state 
filtering, where unassigned precursor ions were not selected for fragmentation, and 
dynamic exclusion (repeat count, 1; repeat duration, 30 s; exclusion list size, 500; 
and exclusion duration, 35 s) were used. Fragmentation conditions in the LTQ were 
as follows: 35% normalized collision energy; activation q of 0.25; 30 ms activation 
time; and, minimum ion selection intensity 1,000 counts.  
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3.2.3d MS/MS data analysis 
Raw spectra (.raw) for each gel slice were converted to mzXML files using 
MSconvert (Chambers et al., 2012). Spectra were searched using X!Tandem Cyclone 
(release 2011.12.01.1 LabKey, Insilicos, ISB) contained within the trans proteomic 
pipeline [v4.6.2; (Deutsch et al., 2010)] with k-score against the UniProt 
Knowledgebase (UniProtKB) Human protein database [Released May 2013; (2014)] 
supplemented with known contaminants [cRAP database released Feb 2012; (Global 
Proteome Machine Organization, 2012)]. Searches used reverse sequences to inform 
false positive identification frequency. Optimised search parameters were as follows: 
precursor ion mass (monoisotopic) tolerance ± 20 ppm; no. 13C = 2, MS/MS 
tolerance ± 0.8 Da; and, semi-tryptic cleavage allowing for up to 3 missed cleavages. 
Cysteine (C) carbamidomethyl (+ 57.02146) was set as fixed modification and 
methionine (M) oxidation (+ 15.9949), as well as protein N-terminal acetylation (+ 
41.0103), were set as variable modifications. The searches were followed by a 
refinement step that included non-specific and unexpected cleavage, as well as Q and 
N deamidation as variable modifications (0.984916). Resulting tandem.xml files 
were converted to .pep.xml format within the trans proteomic pipeline and each 
.pep.xml file was submitted to Peptide Prophet (v4.6.2) to curate peptide-spectrum 
matches of P ≥ 0.05. Output from this search engine, pertaining to each gel slice, was 
integrated with Interprophet Parser (v4.6.2) and submitted to Protein Prophet (v4.6.2) 
to generate the minimum list of proteins to describe all peptides in the entire gel 
[false discovery rate (FDR) ≤ 1%]. Protein Prophet assigned protein groups where 
the leading, or representative, member was selected as the protein possessing the 
highest number of unique peptides. 
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A pictorial representation of peptides (protein coverage on X-axis) identified in 
varied lanes (denoted by colour) and gel slices (Y-axis), similar to Dix et al.’s 
peptograph (2008), was generated by Dr. Ho, using custom peptogram software (Ho, 
2013). Only leading members of protein groups were presented, in addition to those 
non-leading members possessing unique peptides. Additionally, only peptides with P 
≥ 0.5, assigned by Peptide Prophet, were presented. The number of such peptides 
identified per gel slice were displayed as counts on each peptograph. Separate sets of 
peptographs were generated for comparing peptide/ protein topography and 
migration in KLK4-treated LNCaP cell CM as compared to either untreated (PBS-
treated) or mKLK4-treated LNCaP cell CM controls, for each of three replicate 
experiments (12 sets of peptographs in total).  
3.2.3e Peptograph analyses 
To define KLK4 substrates in LNCaP cell CM, peptographs of those proteins with 
cell surface or extracellular localisation, as denoted by IPA (QIAGEN), were 
manually scrutinised for a change in protein migration in KLK4-treated versus 
control samples, as follows. Only unique peptides were considered in substrate 
analyses. Peptographs comparing peptide migration in KLK4-treated versus 
untreated LNCaP cell CM were first analysed, as per the description of peptograph 
analysis provided in 3.2.2e. Upon a protein being deemed a KLK4 substrate in a 
single replicate of LNCaP cell CM using peptographs comparing KLK4-treated and 
untreated CM, the peptograph comparing KLK4-treatment and mKLK4-treatment for 
that protein, in the same replicate, was then assessed using the substrate assignment 
criteria described above. KLK4 substrates in individual replicates were defined as 
proteins which were deemed KLK4 substrates when analysing both sets of 
peptographs (KLK4-treated versus untreated and KLK4-treated versus mKLK4-
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treated). A protein was also deemed a KLK4 substrate if determined so using the 
peptograph displaying the untreated comparison (first set of peptographs), but for 
which a control fragment was absent in the mKLK4-treated sample (second set of 
peptographs). In the latter scenario, a substrate assignment could not be made, and so 
only the results of the untreated comparison were used to inform substrate 
assignment. A protein was required to be a KLK4 substrate in at least two biological 
replicate experiments to be considered a KLK4 substrate across the entire 
experiment. Note that GeneCards [www.genecards.org; (Safran et al., 2010)] and 
IPA were used to indicate protein type when presenting protein or substrate 
identification results. 
3.2.4 Comparison of KLK4-generated fragments with annotated cleavage 
products in the UniProtKB  
The topography and migration of all possible KLK4-generated fragments for a given 
KLK4 substrate was manually compared with the sequence and expected size of the 
protein cleavage product chains annotated for that protein in the UniProtKB Human 
protein database. Those substrates for which KLK4 putatively generated products 
containing all or part of the sequence of an annotated cleavage product chain were 
recorded. Note that the expected molecular weight of these protein fragments, as well 
as all protein fragments identified in PROTOMAP studies that are listed within this 
thesis, account for carbamidomethylation of C residues (+ 57 Da per C residue).  
3.2.5 Validation of VCL/VINC hydrolysis by KLK4 
PC-3 cell CM (623.4 ng/ µL), harvested and buffer-exchanged into assay buffer as 
per 3.2.2b, was treated with KLK4 (2.4 μM or 62.3 ng/ μL active, 7.2 μM total), 
representing a ratio of 10:1 CM: active KLK4 (w/w), as well as KLK4 dilutions 
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells 74            74 
corresponding to ratios of 20:1, 30:1 and 50:1. As a negative control, PC-3 cell CM 
was left untreated or treated with mKLK4 (7.2 μM total). Samples were incubated 18 
h (37 ºC) and diluted 1.3-fold in TCEP hydrochloride solution and sample buffer, 
prior to heating (10 min, 60 ºC). The equivalent of 25 µg PC-3 cell CM was analysed 
by Western blot analyses, using an antibody raised against VCL/VINC (Table 2.1).  
3.2.6 Validation of pro-MMP1 hydrolysis by KLK4 
3.2.6a Recombinant pro-MMP1 activation assay 
Recombinant pro-MMP1 (412.1 nM; R&D systems) was incubated (18 h, 37 ºC) 
with KLK4 at high (102.6 nM active), medium (20.5 nM) or low (4.1 nM) 
concentrations, representing molar ratios of pro-MMP1: KLK4 of 2:1, 10:1 and 50:1, 
respectively. As negative controls, pro-MMP1 was left untreated or treated with 
mKLK4 (298.2 nM total). Additional controls comprising only of KLK4 (102.6 nM), 
mKLK4 (298.2 nM) or pro-MMP1 (412.1 nM) were also included. Incubations were 
performed in PBS. Following incubation, 1/10th of each sample was diluted 25-fold 
in MMP1 buffer [50 mM tris, 10 mM CaCl, 150 mM NaCl, pH 7.5, 5 × 10
-2
% (v/v) 
brj-350]. For selected samples, the serine protease inhibitor, aprotinin (5 µM final; 
Sigma-Aldrich), or the metal chelator and MMP inhibitor, EDTA (2 mM final), was 
added following digestion with KLK4 but prior to assaying MMP1 activity, to 
demonstrate MMP-specific substrate proteolysis. Samples were incubated (15 min, 
37 ºC) prior to MMP activity analysis, where each was diluted 2-fold in MMP1 
buffer containing the MMP1 fluorogenic peptide substrate, 7-Methoxycoumarin-4-
yl)acety-PLGL-N-3-(2,4-Dinitrophenyl)-L-2,3,-diaminopropionyl-A-R-NH2, at a 
final concentration of 10.5 µM. RFU was measured at 34 s intervals for 20 min in a 
PolarStar Optima microplate reader (Ex 320 nm, Em 405 nm; 37 ºC). A blank 
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sample, consisting only of MMP1 buffer and peptide substrate, served as a 
background control. RFU of all samples was corrected for RFU of the blank at 0 s.  
3.2.6b Western blot and SDS-PAGE/ silver stain analysis of recombinant MMP1 
hydrolysis by KLK4 
Recombinant pro-MMP1 (412.1 nM) was digested with KLK4 (102.6 nM active or 
298.3 nM total), representing a molar ratio of 2:1 pro-MMP1: KLK4. Digests using 
KLK4 concentrations equivalent to molar ratios of 10:1, 50:1, 250:1 and 1,250:1 
were also performed. Pro-MMP1 was left untreated or digested with mKLK4 (688 
nM total), as negative controls. Additional controls were KLK4 (102.6 nM active) or 
mKLK4 (298.3 nM total) alone. Digests were performed in PBS for 18 h (37 ºC) and 
were diluted in sample buffer and TCEP hydrochloride solution, before heating (60 
ºC, 10 min). The equivalent of 214.3 ng (silver staining) or 50 ng (Western blot 
analysis) pro-MMP1 was loaded per SDS-PAGE gel lane. Respective gels were 
analysed by silver staining, or by Western blot analyses using antibodies targeting 
the hemopexin domain of MMP1 and total MMP1 (Table 2.1).  
3.2.7 Validation of GRN hydrolysis by KLK4 
Recombinant GRN (234.3 nM; R&D Systems) was digested with thermo-KLK4 
(117.5 nM active; 790.1 nM total), representing a ~2:1 molar ratio of GRN: thermo-
KLK4. GRN was also digested with molar ratios equating to 4:1, 8:1, 16:1, 32:1, 
64:1, 128:1 and 256:1. GRN was left untreated or treated with thermo-mKLK4 
(790.1 nM total) for 18 h (37 ºC) as negative controls. Alternatively, GRN was 
treated with thermo-KLK4 (117.5 nM active) in the presence of aprotinin (400 nM), 
or with aprotinin only as a corresponding control. Additional controls were samples 
containing only thermo-KLK4 (117.5 nM active) or thermo-mKLK4 (790.1 nM 
total). Digests were performed in assay buffer for 18 h (37 ºC), and were diluted in 
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sample buffer and TCEP hydrochloride solution, before heating (60 ºC, 10 min). The 
equivalent of 220 ng GRN was loaded per SDS-PAGE lane. Protein was visualised 
by silver staining.  
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3.3 Results  
3.3.1 Recombinant KLK4 expression, purification and activation 
For determination of KLK4 substrates in PC-3 cell CM, conducted during the 
candidate’s Honours research program, two alternative exogenous KLK4 delivery 
systems were employed: (1) KLK4 was over-expressed in PC-3 cells and; (2) PC-3 
cells were treated with recombinant KLK4 that was produced in, and purified from, 
SF-9 cells. As the biological activator of KLK4 is unknown and may not be 
expressed in PC-3 cells, an auto-activating KLK4 variant was over-expressed in 
these cells, in preference to wt-KLK4, to promote KLK4 activity. This construct was 
produced for use in the second KLK4 delivery system; however, it appeared to 
cleave its C-terminal tag during the purification process, resulting in low purification 
yields. Therefore, wt-KLK4 was instead generated and activated by thermolysin for 
early biochemical validation studies. The latter method produced active KLK4; 
however, some product was inactivated by thermolysin-mediated proteolysis within 
the mature KLK4 protein. Thus, to improve yields of active KLK4 for use during the 
candidate’s PhD research, an EK-activatable KLK4 construct was produced in order 
to specifically activate KLK4, while minimising adverse cleavage events. For auto-
KLK4, and thermolysin- and EK-activated KLK4 forms, proteolytic activity was 
measured by the same assays, where each induced gelatinolysis (see below for the 
latter two protease forms) and efficiently hydrolysed the KLK4-preferred peptide 
substrate, VLR-AFC (see Figure 4.1 B for EK-activated KLK4). Unless specified in 
Results sections, designation of the KLK4 construct used for each experiment may 
be found in the respective Materials and Methods section. While protocols for the 
generation of KLK4 forms used in both Honours and PhD research studies are 
included herein, results are shown only for the latter.  
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3.3.1a Recombinant KLK4 was produced in, and purified from, insect cells  
KLK4 was isolated from SF-9 cell CM by nickel ion affinity chromatography and its 
presence in the flow-through [lane 10, left (pro-mKLK4); lanes 9-10, right (pro-
KLK4)], NPI-10 washes (lanes 11-13) and NPI-250 elutions [lanes 2-9, left (pro-
mKLK4); lanes 2-8, right (pro-KLK4)] was analysed by Western blot analyses 
(Figure 3.1, top and middle panels). A replicate SDS-PAGE gel was also silver-
stained to visualise total protein (Figure 3.1, bottom panel).  
Western blot analyses using anti-V5 and anti-KLK4 antibodies identified pro-
mKLK4 and pro-KLK4 at 32 kDa in the flow-through [lane 10, left (pro-mKLK4); 
lanes 9-10, right (pro-KLK4); Figure 3.1, top and middle panels], while additional 
bands were detected at 45 kDa by the anti-KLK4 antibodies only (Figure 3.1, top 
panel). Pro-wt-mKLK4 (lane 14, left) and pro-wt-KLK4 (lane 14, right), employed 
as positive controls for KLK4 detection and migration, were identified at 27 kDa 
using all three visualisation methods (Figure 3.1). The native KLK4 pro-region is 
considerably smaller than that of the KLK4 construct employed herein, likely 
contributing to the observed size difference between these recombinant KLK4 forms. 
The identity of the 45 kDa band in the flow-through is unknown, but may represent 
incompletely reduced multimers of KLK4, or KLK4 bound with endogenous SF-9 
cell-derived proteins. Small relative proportions of pro-mKLK4, but not pro-KLK4, 
eluted in the first two NPI-10 washes (lanes 11-12, left), while the majority of pro-
mKLK4 eluted in the first NPI-250 elution fraction, as confirmed by both antibodies 
(lane 2, left; Figure 3.1, top and middle panels). Pro-KLK4 eluted in the first two 
NPI-250 elution fractions (lanes 2-3, right; Figure 3.1). In eluate fractions, both 
KLK4 forms migrated as 32 kDa bands, with lesser intensity bands of pro-KLK4 
also detected between 12 and 32 kDa (lane 2, right; Figure 3.1). These lower 
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Figure 3.1. Western blot (top and middle panels) or silver stain (bottom panel) analyses of pro-
mKLK4 (left) or pro-KLK4 (right) nickel affinity chromatography purification from SF-9 cell 
CM. Anti-KLK4 (top panel) or anti-V5 antibodies targeting the C-terminal V5 tag (middle panel) 
were used to show successful purification of recombinant proteins within the first two elution 
fractions (lanes 2-3), with minimal product in wash fractions (lanes 11-13). Residual pro(m)KLK4 
was observed in the flow-through (lane 10, left; lanes 9-10, right), amongst the complex SF-9 cell-
secreted proteome. Pro-wt-mKLK4 (lane 14, left) and pro-wt-KLK4 (lane 14, right) were employed as 
positive controls. Additional elution fractions are also shown (lanes 4-9, left; lanes 4-8, right). Protein 
standard was loaded in lane 1 of each gel. 
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molecular weight bands likely constitute degradation products of pro-KLK4, which 
may have been cleaved by SF-9 cell-derived proteases. Thus, Western blot analyses 
confirmed that pro-KLK4 and pro-mKLK4 were successfully isolated from SF-9 cell 
CM. 
Silver stain analysis also confirmed that pro-KLK4 and pro-mKLK4 were primarily 
detected in the first NPI-250 elution fraction (lane 2; Figure 3.1, bottom panel). In 
contrast to Western blot analyses, pro-mKLK4 was not detected in any NPI washes 
(lanes 11-13, left; Figure 3.1, bottom panel) by this approach, which is routinely 
sensitive to the low ng detection level in applications conducted in the Clements 
group laboratory. Pro-KLK4 was similarly not detected in NPI washes by silver 
staining (lanes 11-13, right; Figure 3.1, bottom panel). This analysis further indicated 
that bands corresponding to the molecular weight of purified pro-mKLK4 (lane 10, 
left) or pro-KLK4 (lanes 9-10, right) were stained minimally in the flow-through, as 
compared to other protein bands (Figure 3.1, bottom panels). Furthermore, elutions 
containing pro-mKLK4 (lane 2, left) and pro-KLK4 (lanes 2-3, right) appeared 
relatively free of detectable contaminant proteins, as silver staining detected only 
bands of molecular weight consistent with those identified by KLK-specific Western 
blot analyses (Figure 3.1, top and bottom panels). This was excepting the detection 
of two additional faint bands of 34 and 35 kDa in the first pro-KLK4 elution fraction 
(lane 2, right; Figure 3.1, bottom panels). Thus, silver stain analysis confirmed 
isolation of pro-mKLK4 and pro-KLK4 from SF-9 cell CM. NPI-250 elution fraction 
1 (pro-mKLK4) or pooled elution fractions 1 and 2 (pro-KLK4) were buffer-
exchanged into an EK-compatible buffer, preceding activation by recombinant EK.  
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3.3.1b EK activated pro-KLK4 at all concentrations employed 
Optimisation of pro-KLK4 or pro-mKLK4 activation was conducted by treating the 
recombinant full-length proteins with serial dilutions of recombinant EK and 
observing loss of immunodetection using an antibody targeting the flag epitope 
(DYKDDDDK). Despite the recombinant KLK4 forms produced herein not 
containing the complete flag epitope, this antibody was able to detect these proteins, 
likely due to recognising the C-terminal residues of their substituted trypsin pro-
region (DDDK). In support of this, mature thermo-KLK4 (lane 14, left) and thermo-
mKLK4 (lane 15, left) were not recognised by the anti-flag antibody (Figure 3.2 A, 
top panel).  
Flag immunoreactivity was abrogated following EK treatment of pro-KLK4 with 
every concentration of EK tested (lanes 6-7, left; lanes 5-12, right; Figure 3.2 A, top 
panels). Total staining intensity of pro-KLK4 in each of these lanes remained 
consistent, irrespective of the presence of EK, as confirmed by immunodetection 
with anti-KLK4 antibodies (Figure 3.2 A, bottom panels). Thus, loss of flag 
reactivity following EK treatment of pro-KLK4 was not due to unequal protein 
loading or pro-KLK4 degradation. While pro-KLK4 (lanes 2-5, left; lanes 1-4 and 
14, right) migrated as two bands of 31 and 32 kDa, as detected by KLK4-targeted 
antibodies, EK-activated pro-KLK4 (lanes 6-7, left; lanes 5-12, right) was detected at 
27 and 28 kDa (Figure 3.2 A, bottom panels). The size of EK-treated pro-KLK4 was 
similar to that of thermo-KLK4 (lane 14, left). Thus, loss of flag immunoreactivity 
and a 4 kDa molecular weight reduction indicated that the pro-KLK4 pro-region was 
processed by EK.  
To quantify the approximate proportion of pro-KLK4 processed by EK, a standard 
curve of pro-KLK4 dilutions was employed (lanes 2-5, left; lanes 1-4, right), where 
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Figure 3.2. Western blot (A) or gelatine zymography (B) analyses of pro-KLK4 or pro-mKLK4 
treated with EK. (A) Recombinant pro-KLK4 (lanes 6-7, left; lanes 5-12, right) and pro-mKLK4 
(lanes 8-9, left) were treated with EK and subject to Western blot analyses using anti-flag (top panel), 
anti-V5 (middle panel) or anti-KLK4 (bottom panel) antibodies. EK efficiently processed pro-KLK4, 
but not pro-mKLK4. Thermo-KLK4 (lane 12, left), but not thermo-mKLK4 (lane 13, left), also 
processed pro-KLK4, indicating KLK4 may auto-activate following initial activation by EK. A pro-
KLK4 standard curve (lanes 2-5, left; lanes 1-4, right) was included to demonstrate the minimum 
detection limit of each antibody. Additional controls included samples containing only EK (lane 10, 
left; lane 13, right), pro-mKLK4 (lane 11, left), thermo-KLK4 (lane 14, left) or thermo-mKLK4 (lane 
15, left). (B) Zymography analysis supported findings in (A), where EK activated pro-KLK4 (lanes 2-
7, left; lanes 6-9, right). A thermo-KLK4 standard curve (lanes 11-15, left; lanes 10-14, right) 
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indicated that the observed similarity in levels of gelatinolysis in EK-activated pro-KLK4 lanes (lanes 
2-7, left; lanes 6-9, right) was a true reflection of activity and not due to signal saturation. EK also 
induced gelatinolysis (lanes 8-9, left; lanes 3-4 right), where additional gelatinolysis was not observed 
with EK-treated pro-mKLK4 (lanes 1-2, right). Pro-KLK4 (lane 10, left) or pro-mKLK4 (lane 5, right) 
did not exhibit gelatinolytic activity. Gelatine zymography images were colour inverted. For (A) and 
(B), open triangles indicate protease concentrations ranging from high (flat end) to low (pointed end). 
Protein standard was loaded in lane 1 of left hand gels. 
the minimum detection limit of pro-KLK4 by the anti-flag antibody was found to be 
52 ng (Figure 3.2 A, top panels). Importantly, this represents the lowest pro-KLK4 
concentration applied on the standard curve (lane 5, left; lane 4, right); thus, the 
minimum detection limit can only be stated as being ≤ 52 ng. As 52 ng represents 
59% of the amount of pro-KLK4 treated with EK, and as flag immunoreactivity was 
reduced below this detection limit upon EK treatment of pro-KLK4 (lanes 6-7, left; 
lanes 5-12, right; Figure 3.2 A, top panels), a minimum of 41% (100% - 59%) of pro-
KLK4 molecules were processed by EK. As the minimum detection limit of flag 
immunoreactivity may have been lower than 52 ng, EK may have processed > 41% 
pro-KLK4. As flag reactivity was similarly abrogated across all EK treatment 
concentrations tested, the data suggested that 100% of pro-KLK4 molecules may 
have been processed by even the lowest employed concentration of EK. 
In further support that EK activated pro-KLK4, EK-treated pro-KLK4 lost V5 
immunoreactivity (lanes 6-7, left; lanes 5-12, right), in contrast to pro-KLK4 alone 
(lanes 2-5, left; lanes 1-4 and 14, right; Figure 3.2 A, middle panels). Again, this was 
independent of the EK concentration employed. This is consistent with previous 
findings by our group, whereby active recombinant KLK4 proteolytically liberated 
its V5 tag (Carson Stephens, personal communication). Similarly, each of thermo-
KLK4 (lane 14, left) and thermo-mKLK4 (lane 15, left) did not show V5 
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immunoreactivity (Figure 3.2 A, middle panels), also consistent with previous 
observations that thermolysin, used to activate these constructs, similarly liberated 
the C-terminal tag containing the V5 epitope (Carson Stephens, personal 
communication). Of note, EK was not detected by any antibody (lane 10, left; lane 
13, right; Figure 3.2 A). Thus, EK-treated KLK4 was of reduced size to its untreated 
counterpart, and was devoid of both flag and V5 immunoreactivity, indicating pro-
region processing and activity. 
Finally, the proteolytic activity of KLK4 following pro-region processing was also 
demonstrated by gelatine zymography (Figure 3.2 B), where regions void of 
Coomassie Blue staining represent proteolytic degradation of gelatine (note that 
Figure 3.2 B is colour inverted, for clarity). As with Western blot analyses, gelatine 
zymography confirmed activation of pro-KLK4 upon EK treatment, resulting in 
clearings of similar intensity, irrespective of the concentration of activating protease 
employed (lanes 2-7, left; lanes 6-9, right; Figure 3.2 B). The intensity of these 
clearings was within the range of the thermo-KLK4 standard curve employed (lanes 
11-15, left; lanes 10-14, right; Figure 3.2 B), and so a lack of discrimination of signal 
intensities between these samples was not due to signal saturation. Under the non-
reducing conditions used for gelatine zymography, EK-activated pro-KLK4 migrated 
to 25 and 23 kDa (lanes as above; Figure 3.2 B). Both of these bands induced 
gelatine clearing and so were proteolytically active; thus, each may vary in the extent 
of autolytic C-terminal truncation of the protein tag, or may constitute differentially 
glycosylated forms, where glycosylation does not affect gelatinolysis. The positive 
control protease, thermo-KLK4, induced gelatinolysis at 27 kDa (standard curve 
lanes as above; Figure 3.2 B). EK also cleaved gelatine, evidenced by a smeared 
clearing from the top of the gel toward a resolved band of protein clearing at 55 kDa 
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in lanes containing only this protease (lanes 8-9, left; lanes 3-4, right; Figure 3.2 B), 
and in samples of pro-KLK4 treated with the highest concentration of EK employed 
(lane 2, left; lanes 6 and 7, right; Figure 3.2 B). Untreated pro-KLK4 (lane 10, left) 
or pro-mKLK4 (lane 5, right) did not exhibit gelatinolytic activity, and only EK-
mediated activity was visible when pro-mKLK4 was treated with EK (lanes 1-2, 
right; Figure 3.2 B). In summary, gelatine zymography analysis confirmed that EK 
activated pro-KLK4.  
3.3.1c EK incompletely processed the pro-mKLK4 pro-region 
While EK activated pro-KLK4 at all concentrations tested, strikingly, EK treatment 
of pro-mKLK4 did not appear to remove the pro-region of this protein. This was 
indicated by retention of flag immunoreactivity upon EK treatment of pro-mKLK4, 
at all EK concentrations employed (lanes 8-9, left; Figure 3.2 A, top panel). EK-
treated pro-mKLK4 was detected as bands of 29 and 30 kDa. This size is decreased 
in molecular weight in comparison to untreated pro-mKLK4 and pro-KLK4 (31 and 
32 kDa; lanes 2-5, 11, left), although not as small as EK-treated pro-KLK4 (27 kDa; 
lanes 6-7, left), nor thermo-KLK4 (27 kDa; lane 14, left) and thermo-mKLK4 (27 
kDa; lane 15, left; Figure 3.2 A, bottom panel). Thus, EK appeared to cleave pro-
mKLK4 at each concentration employed; however, this did not abrogate flag 
immunoreactivity, indicating that at least the C-termini of the pro-region likely 
remained intact. EK treatment of pro-mKLK4 did not affect V5 immunoreactivity 
(lanes 8-9, left; Figure 3.2 A, middle panels), further supporting that loss of V5 
immunoreactivity with EK-activated pro-KLK4 was due to autolysis of active KLK4, 
and not due to non-specific proteolysis by EK. Additionally, total pro-mKLK4 
abundance did not change with EK treatment (lanes 8-9, left; Figure 3.2 A, bottom 
panels).  
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3.3.1d Pro-KLK4 activation by EK likely required KLK4-mediated autolysis 
As flag immunoreactivity did not diminish upon EK treatment of pro-mKLK4 and as 
EK activated pro-KLK4 to a similar degree across all concentrations of activating 
protease tested, it was hypothesised that mature KLK4 contributed to its own 
activation, following an initial activating event by EK. In contrast, mKLK4 would 
not be able to contribute toward its own activation, potentially explaining the 
considerable difference in apparent pro-region processing of pro-KLK4 and pro-
mKLK4 by EK. To test this hypothesis, pro-KLK4 was treated with thermo-KLK4, 
at a 1.5-fold excess of activating protease and Western blot analyses conducted as 
above. Treatment of pro-KLK4 with thermo-mKLK4 was employed as a negative 
control.  
In support of the above hypothesis, flag and V5 immunoreactivity was lost following 
treatment of pro-KLK4 with thermo-KLK4 (lane 12, left), but not with thermo-
mKLK4 (lane 13, left; Figure 3.2 A, top and middle panels). Neither thermo-KLK4 
(lane 14, left) nor thermo-mKLK4 (lane 15, left) exhibited flag immunoreactivity 
(Figure 3.2 A, top panel), as these proteins represent the mature wild-type KLK4 
sequence, lacking the putative DDDK epitope in the substituted trypsin pro-region of 
pro-KLK4 and pro-mKLK4. As visualised by the KLK4-targeting antibody, thermo-
KLK4 treatment reduced the observed molecular weight of pro-KLK4 (lane 12, left), 
as compared to untreated pro-KLK4 (lanes 2-5, left) or thermo-mKLK4-treated pro-
KLK4 (lane 13, left; Figure 3.2 A, bottom panel). This further supported the 
hypothesis that active KLK4 can activate pro-KLK4, which was engineered with a 
trypsin pro-region. Of note, bands corresponding to pro-KLK4 or its active form 
could be distinguished from thermo-(m)KLK4 in lanes 12 and 13, as thermo-
(m)KLK4 migrated at a lesser molecular weight, as observed in lanes containing only 
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thermo-KLK4 (lane 14, left) or thermo-mKLK4 (lane 15, left; Figure 3.2 A, bottom 
panels). Collectively, this data suggested that KLK4 likely activates pro-KLK4 
following an initial activating event by EK. Conversely, EK-treated pro-mKLK4 is 
not proteolytically active and so was not activated to completion.  
In summary, processing of the produced recombinant mKLK4 form by even the 
highest employed concentration of EK (1 ng/ µL) was not sufficient to abrogate flag 
immunoreactivity. Instead, the pro-region processing observed in EK-treated pro-
KLK4 samples appeared to occur due to subsequent auto-activation by the activated 
protease. Given this, the highest practicable concentration of EK (corresponding to 
35.5 ng/ µL in the above experiment) was chosen to treat pro-KLK4 and pro-
mKLK4, although only pro-KLK4 would be completely activated. Given that 
mKLK4 serves as an inactive protease control for active KLK4, the putative 
retention of some N-terminal residues was not considered detrimental to its 
application as a negative control protease. EK-treated pro-KLK4 and pro-mKLK4 
will be referred to as KLK4 and mKLK4, respectively. 
3.3.1e KLK4 and mKLK4 were successfully purified by IEX 
KLK4 and mKLK4 were purified by IEX to eliminate EK contamination, as well as 
any residual contaminant proteins from SF-9 cell CM. Selected elution fractions that 
exhibited elevated UV light absorbance, as compared to other fractions (data not 
shown), were analysed by Western blot analysis (lanes 4-15), using KLK4- (Figure 
3.3 A, top panels) or flag-directed antibodies (Figure 3.3 A, middle panels), and also 
by SDS-PAGE/ silver stain analysis (lanes 4-15; Figure 3.3 A, bottom panels) and 
gelatine zymography (Figure 3.3 B). Elution fractions 13-20 (lanes 4-11, left) and 
12-20 (lanes 4-12, right) contained detectable levels of mKLK4 or KLK4, 
respectively, as visualised by both immunodetection for KLK4 (Figure 3.3 A, top  
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells 88            88 
   
Figure 3.3. Western blot (A, top and middle panels), silver stain (A, bottom panel) or gelatine 
zymography (B) analyses of mKLK4 (left) or KLK4 (right) purified by IEX. (A) mKLK4 was 
identified in elution fractions 13-20 (lanes 4-11, left) by immunodetection with KLK4-targeted 
antibodies (top panel) or silver stain analysis. Flag-targeted antibodies (middle panel) detected 
mKLK4 in elution fractions 13-18 (lanes 6-11, left). KLK4 was detected in elution fractions 12-20 
(lanes 4-12, right) by KLK4-targeted antibodies and silver staining; flag-targeted antibodies did not 
identify KLK4 or the positive control, thermo-KLK4 (lane 2). Thermo-KLK4 (lane 2) was detected by 
KLK4-targeted immunodetection and silver stain analysis. Elution fractions 9-12 (lanes 12-15, left) 
and 9-11 (lanes 13-15, right) did not contain detectable mKLK4 or KLK4, respectively. (B) 
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Gelatinolytic activity of mKLK4 was not detected in any elution fraction (lanes 2-12, left), in contrast 
to KLK4 activity being observed in elution fractions 12-19 (lanes 5-12, right). KLK4 activity was not 
detected in elutions 9-11 (lanes 2-4, right). Thermo-KLK4 exhibited gelatinolysis (lane 15), as did an 
aliquot of both mKLK4 and KLK4 samples pre-purification (P; lane 14), where the band consistent in 
both of the latter lanes likely represents EK. Protein standard was loaded in lane 1 for all gels. 
panels) and silver staining (Figure 3.3 A, bottom panels). Western blot analyses 
using the flag-targeted antibody detected mKLK4 in elution fractions 13-18 (lanes 6-
11, left); however, KLK4 was not detected by this antibody in any elution fraction 
(lanes 4-15, right; Figure 3.3 A, middle panels). The flow-through (lane 3) did not 
contain any detectable protein bands, visualised by any method, excepting a faint 14 
kDa band of mKLK4 detected by the anti-KLK4 antibodies (lane 3, left; Figure 3.3 
A, top panel). Protein migration of eluted KLK4 and mKLK4 was consistent with 
that of the thermo-KLK4 positive control (lane 2); however, elution fraction 17 of 
purified KLK4 (lane 7, right) also contained proteins appearing as faint 45 and 54 
kDa bands following silver staining (Figure 3.3 A, bottom panel). These bands were 
not detected by Western blot analyses in this lane (Figure 3.3 A, top panel). While 
these bands may have represented multimers of KLK4 and its degradation products, 
this fraction was not pooled with the other KLK4-containing fractions for production 
of the final KLK4 stock. Low molecular weight products of mKLK4 (lanes 7-8, left) 
and KLK4 (lanes 5-9, right) were also identified by silver stain analysis in some 
elution fractions (Figure 3.2 A, bottom panels); however, these were also identified 
using KLK4-targeted antibodies in these fractions and in positive control lanes (lane 
2; Figure 3.2 A, top panels). As these fragments were identified in the mKLK4 
purification as well as the KLK4 purification, they are not likely autolytic cleavage 
products, but may have been generated by EK or SF-9 cell-endogenous proteases. 
Being of small size, it is likely that these fragments remained associated during 
 Chapter 3: Determining the KLK4 degradome produced by prostate cancer cells 90            90 
purification to have eluted from the column with the larger observed products, and 
may have then disassociated under the denatured, reducing conditions employed for 
SDS-PAGE.  
Elution fractions 12-19 from IEX purification of KLK4 showed gelatinolytic activity 
only at 25 kDa (lanes 5-12, right), while elution fractions from mKLK4 purification 
(lanes 2-12, left), as well as the flow-through from both purifications (lane 13), were 
devoid of gelatinolytic activity (Figure 3.3 B). Fragments of KLK4 below 25 kDa, as 
were observed by KLK4 immunodetection, did not induce gelatine clearing (lanes 8-
12, right; Figure 3.3 B). An aliquot of both KLK4- and mKLK4-containing samples 
prior to IEX purification exhibited gelatine degradation at 113 kDa (lane 14; both 
samples) and 25 kDa [KLK4 sample only (right); Figure 3.3 B)]. As the 113 kDa 
band cannot represent active KLK4, given its presence in the mKLK4-containing 
sample, this band likely represents EK, indicating that EK was removed following 
IEX purification. This was confirmed with a replicate gelatine zymogram, which was 
over-developed to demonstrate that this 113 kDa was not present in either KLK4- or 
mKLK4-containing samples following IEX purification (data not shown). 
Elution fractions 13-20 from the purification of mKLK4 were pooled, prior to buffer-
exchanging into PBS, preceding storage of aliquots for use in subsequent 
experiments. Similarly, KLK4-containing elution fractions 12-16 and 18-20 were 
pooled, and handled as above. Peptidolytic activity of purified forms was analysed, 
determining KLK4 to possess 34% activity, relative to the amount of total protein, 
where mKLK4 was not active (data not shown).  
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3.3.2 Identification of the KLK4 degradome in PC-3 cell CM by the 
PROTOMAP approach 
It was sought to evaluate prostate cancer cell-derived substrates of KLK4, 
representing an autocrine role for the protease in cancer progression. A first-pass 
analysis of this work was conducted during the candidate’s Honours program, 
whereupon native PC-3 cell CM was treated with recombinant KLK4 and substrates 
analysed by PROTOMAP. A more detailed approach was also conducted during the 
candidate’s Honours research program and subsequently analysed as part of the PhD 
research project. The aim of the latter approach was to use two different exogenous 
KLK4 delivery systems with which to treat PC-3 cell CM, namely: (1) the addition 
of recombinant protein or the treated condition; and (2) the over-expression of auto- 
KLK4 or the transfected condition. Inactive mKLK4 variants were employed as 
controls for each condition. PROTOMAP analysis was performed on KLK4-treated, 
mKLK4-treated, or sample buffer-treated CM from PC-3 cells transfected with an 
empty vector, or a vector encoding KLK4 or mKLK4. To simplify analysis of KLK4 
substrates across these nine conditions, similar conditions were compiled into three 
groups in silico, for presentation in peptographs: (1) the KLK4-treated group, 
comprising all KLK4-treated CM; (2) the KLK4-transfected group, constituting 
sample buffer-treated and mKLK4-treated PC-3: KLK4 cell CM; and (3) the control 
group, comprising sample buffer-treated and mKLK4-treated CM from PC-3:Vector 
and PC-3:mKLK4 cells (Figure 3.4). In order to plot peptographs and determine 
KLK4 substrates identified using each KLK4 delivery method, proteins were first 
identified from all peptides isolated from each gel slice across all conditions (below).  
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Figure 3.4. Designation of conditions for PROTOMAP identification of KLK4 substrates in PC-
3 cell CM. PC-3 cells were transfected with empty vector (PC-3:Vector), or a vector encoding auto-
KLK4 (PC-3:KLK4) or its catalytically inactive mutant counterpart (PC-3:mKLK4). CM was treated 
with auto-KLK4 (KLK4), thermo-mKLK4 (mKLK4) or sample buffer. For comparisons to be 
employed during PROTOMAP analyses, three conditions were generated by compiling similar 
conditions in silico. The conditions were called control (sample buffer- or mKLK4-treated CM from 
PC-3:Vector and PC-3:mKLK4 cells; yellow), KLK4-treated (KLK4-treated CM from PC-3:Vector, 
PC-3:mKLK4 and PC-3:KLK4 cells; red) and KLK4-transfected (sample buffer- or mKLK4-treated 
CM from PC-3:KLK4 cells; blue). 
3.3.2a One hundred and forty-six extracellular or membrane-localised proteins were 
identified in PC-3 cell CM 
Using MS/MS and bioinformatics, PC-3 cell CM proteins were identified from 
retrieved peptides and their cellular localisation was annotated by IPA. In total, 452 
human proteins were identified across all gel slices and conditions (Figure 3.5). 
Sixty-two additional proteins were matched to decoy protein sequences and so were 
not included in further analyses. Of the 452 human proteins identified, 146 were 
annotated by IPA to be localised to the extracellular space or plasma membrane 
(Figure 3.5), and thus, constitute potential targets of extracellular KLK4. One of 
these proteins was excluded from further analysis, having been identified at the 
protein level with sufficient confidence (P = 1); however, where the confident 
identification of individual peptides was greater than the FDR cut-off employed for  
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Figure 3.5. The number of significantly identified proteins and putative KLK4 substrates in PC-
3 cell CM. Of the 452 proteins identified in at least one condition in PC-3 cell CM (white circle), 146 
were annotated to be extracellular or plasma membrane proteins (light blue circle). One hundred and 
seven such proteins were identified in the necessary conditions to be considered eligible to be 
screened as KLK4 substrates (dark blue circle), where 23 were putative KLK4 substrates (pink circle). 
plotting peptides on peptographs (FDR ≤ 1%). In addition, six proteins possessed no 
annotation in the IPA database and were excluded from subsequent analyses 
(Supplementary Table 3.1). The proportion of proteins annotated as being of 
extracellular or plasma membrane origin (32.3%) is similar to that of other studies 
using similar methods [32.6% (Saraon et al., 2012); 25.9% (Sardana et al., 2008)], 
using ontology assignments in IPA, where annotations were available. Indeed, while 
the remainder of identified proteins may constitute intracellular proteins released 
upon cell lysis, cancer cell secretomes have been shown to contain conventionally 
intracellular proteins released via unconventional pathways (Villarreal et al., 2013). 
Thus, apparent intracellular proteins may, in fact, constitute proteins secreted by non-
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conventional mechanisms by prostate cancer cells and may still be accessible to 
KLK4. Further, some intracellular proteins may be expelled into the CM through 
vesicles such as exosomes (Duijvesz et al., 2013; Hosseini-Beheshti et al., 2012). 
While this is a possibility, only the 145 proteins annotated as being cell surface- or 
plasma membrane-localised, and for which peptides were identified with FDR ≤ 1%, 
were taken for further assessment. 
3.3.2b One hundred and seven proteins were eligible to be screened for KLK4-
mediated hydrolysis 
Before determining which of these 145 proteins were cleaved by KLK4 in PC-3 cell 
CM, it was first sought to review the distribution of proteins identified across the 
different conditions. This is important as protein identification in the control and at 
least one of either KLK4-treated or KLK4-transfected conditions is essential to 
determine whether the protein is cleaved by KLK4, that is, whether a protein is 
eligible for substrate screening. Of the 145 extracellular or cell surface-localised 
proteins identified in PC-3 cell CM, 50 were identified across all three conditions, 
while 57 proteins were identified both in the control and either KLK4-treated (9) or 
KLK4-transfected (48) conditions (Figure 3.6). The remaining 38 proteins 
(6+10+21+1) were identified only in a single condition, or were identified in both 
KLK4-treated and KLK4-transfected conditions, but not the control condition 
(Figure 3.6). As such, these 38 proteins were ineligible to be screened as putative 
KLK4 substrates. Peptographs for the 107 eligible proteins (Figure 3.5) were 
subsequently assessed for hydrolysis by KLK4.  
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Figure 3.6. The number of extracellular and plasma-membrane-associated proteins identified in 
each condition used for PROTOMAP analysis of KLK4 substrates in PC-3 cell CM. One hundred 
and seven (9+50+48) proteins were identified in the control condition and at least one of the KLK4-
treated or KLK4-transfected conditions. These proteins were eligible to be screened for evidence of 
KLK4-mediated hydrolysis using the PROTOMAP approach. Thirty-eight (6+10+21+1) proteins were 
identified only in a single condition or were not identified in the control condition; thus, these proteins 
were ineligible to be screened as KLK4 substrates. 
3.3.2c Twenty-three KLK4 substrates were identified in PC-3 cell CM by 
PROTOMAP analysis 
Peptographs were assessed to identify putative KLK4 substrates in KLK4-treated 
and/ or KLK4-transfected conditions. Briefly, extracellular or membrane-localised 
proteins were considered putative KLK4 substrates if they migrated at least two gel 
slices further in the KLK4-treated or KLK4-transfected condition than in the control. 
KLK4-generated protein fragments were required to consist of at least two peptides, 
isolated from a single gel slice (± one gel slice), where control peptides from the 
same gel slice/s (± one gel slice) were not similarly mapped to these sequences, or to 
within the region between these sequences. Only one KLK4-generated product was 
required for the protein to be considered a KLK4 substrate, although many proteins 
were identified by multiple putative KLK4-generated fragments. From such 
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assessment of peptographs for the 107 eligible proteins, 23 were deemed putative 
KLK4 substrates in one or both of the KLK4-treated and KLK4-transfected 
conditions (Figure 3.5; Table 3.1). These substrates are putative KLK4 substrates 
only, as some of these proteins may have been cleaved, for example, as a result of 
KLK4 activating another protease in the CM. Those substrates validated to be 
cleaved directly by KLK4 will be called direct KLK4 substrates. The ability of 
KLK4 to induce indirect protein hydrolysis, via activating other proteases, is still 
biologically significant, and both direct and indirect KLK4 substrates will be referred 
to as substrates. Peptographs for this comparison of KLK4-treated, KLK4-transfected 
and control conditions are contained within Supplementary Figure 3.2.  
The 23 putative KLK4 substrates identified constituted a host of protein types, 
including peptidases and other enzymes, a peptidase inhibitor, a number of 
glycoproteins, ECM and basement membrane constituents, as well as cell surface 
receptors and growth factors (Table 3.1). Signalling molecules, including the growth 
factor, GRN, and cytokine, chromosome 19 open reading frame 10, were also 
cleaved by KLK4 (Table 3.1). Notably, the established KLK4 substrate, uPA 
[UROK, as per Table 3.1; (Takayama et al., 2001)] was cleaved in PC-3 cell CM, 
validating the approach. Other known KLK4 substrates identified in PC-3 cell CM 
did not meet criteria to be eligible as KLK4 substrates, excepting IGFBP6, which has 
previously been shown to be cleaved by KLK4, albeit to a lesser extent than other 
IGFBP substrates (Matsumura et al., 2005a). In the present study, IGFBP6 was 
identified in the control and KLK4-transfected conditions only, and was not cleaved 
by KLK4 in the latter. The remaining novel putative KLK4 substrates identified have 
not been determined to be prostate cancer cell-derived KLK4 substrates by other 
published approaches. However, some are not unexpected, being substrates of other 
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Table 3.1. KLK4 substrates in PC-3 cell CM.  
(Table 3.1, see over) 
Description Loc Protein type Symbol Group Sib Prob Length % Unique Pep 
activated leukocyte cell adhesion molecule PM cell surface receptor CD166 236 a 1 583 26.8 12 
agrin PM glycoprotein AGRIN 97 a 1 2045 17.8 23 
amyloid beta (A4) precursor protein PM cell surface receptor A4 124 a 1 770 21.7 14 
chromosome 19 open reading frame 10 EC cytokine CS010 253 a 1 173 27.2 4 
collagen, type VI, alpha 1 EC ECM constituent CO6A1 155 a 1 1028 25.9 21 
complement component 3 EC peptidase CO3 116 a 1 1663 12 13 
fibronectin 1 EC enzyme FINC 118 a 1 2386 20.8 31 
G protein-coupled receptor 126 PM G-protein coupled receptor GP126 248 a 1 1221 5.7 5 
glucose-6-phosphate isomerase EC enzyme G6PI 131 a 1 558 36.4 14 
granulin EC growth factor GRN 48 a 1 593 18.2 12 
integrin, beta 1 (fibronectin receptor, beta polypeptide, 
antigen CD29 includes MDF2, MSK12) 
PM transmembrane receptor ITB1 127 a 1 798 12.5 8 
laminin, alpha 5 EC basement membrane 
constituent 
LAMA5 101 a 1 3695 4.7 12 
lectin, galactoside-binding, soluble, 3 binding protein PM transmembrane receptor LG3BP 70 a 1 585 32.3 17 
lipocalin 2 EC transporter NGAL 67 a 1 198 72.2 14 
matrix metallopeptidase 1 (interstitial collagenase) EC peptidase MMP1 16 a 1 469 19 7 
pentraxin 3, long EC other (immune-related) PTX3 181 a 1 381 38.8 11 
plasminogen activator, urokinase EC peptidase UROK* 11 a 1 431 46.2 17 
prosaposin EC glycoprotein SAP 21 a 1 524 24 12 
serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 2 
EC peptidase inhibitor GDN 133 a 1 398 22.4 6 
stanniocalcin 2 EC glycoprotein STC2 107 a 1 302 19.9 5 
thrombospondin 1 EC glycoprotein TSP1 140 a 1 1170 46.3 46 
TIMP metallopeptidase inhibitor 2 EC peptidase inhibitor TIMP2 31 a 1 220 23.6 8 
vinculin PM enzyme VINC 168 a 1 1134 37.4 33 
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Table 3.1 continued.  
Description, UniProtKB recommended name; Loc, subcellular location (PM, plasma membrane; EC, 
extracellular); Protein type, molecule type designation by IPA or GeneCards; Symbol, UniProtKB/ 
Swiss-Prot entry name prefix (all _HUMAN) with (HUGO gene name) for UniProtKB/ TrEMBL 
entries; Group, protein group number; Sib, sibling annotation; Prob, probability of positive protein 
identification; Length, the number of amino acid residues in the protein sequence; %, percentage of 
amino acid residues retrieved, as compared to the reference sequence; Unique pep, the number of 
unique peptides retrieved.  
* Established KLK4 substrate (referenced in text). 
 
KLKs. These include the basement membrane and ECM components, such as 
fibronectin and laminin alpha 5, where each is cleaved by different KLKs (Lawrence, 
Lai & Clements, 2010). Fibronectin hydrolysis by KLK4 was also validated in a 
biochemical assay during the candidate’s Honours research. The KLK6 substrate, 
amyloid beta (A4) precursor protein [APP/A4; (Magklara et al., 2003)], was also 
cleaved by KLK4 in PC-3 cell CM. In addition, MMP2 is a PSA substrate (Pezzato 
et al., 2004) and KLK4 cleaved the related protein, MMP1, in the present analysis. 
Further, galectin-3 is also cleaved by PSA (Kovak et al., 2013) and, herein, KLK4 
was found to cleave its binding protein, lectin galactoside-binding soluble 3 binding 
protein. Thus, in addition to the established KLK4 substrate, uPA, KLK4 cleaved 22 
novel substrates, some of which are cleaved by other KLKs, or related to known 
KLK substrates.   
KLK4 substrate assignment was based on a set of qualitative criteria, where KLK4-
generated protein fragments were identified by the presence of at least two peptides. 
However, even among the putative KLK4 substrates identified, confidence in 
substrate assignment is increased for those proteins from which a greater number of 
peptides were identified, which covered a higher proportion of the protein. For such 
proteins, there is both a reduced likelihood of false positive and false negative 
identification that can arise from failure to recover KLK4-generated fragments (false 
negative) or control-derived fragments (false positive). While elevated peptide 
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retrieval improves confidence when assigning which proteins are KLK4 substrates, it 
should be noted that fewer peptides are able to be recovered from smaller proteins, as 
compared to equivalent concentrations of larger proteins; thus, protein length must 
also be taken into consideration.  
For the 23 putative KLK4 substrates identified in PC-3 cell CM, sequence coverage 
ranged from 4.7% of the large laminin alpha 5 protein, to 72.2% of the small 
lipocalin 2 protein (Table 3.1). The number of unique peptides, that is, peptides 
matched only to that protein and not others also identified in PC-3 cell CM, ranged 
from four (chromosome 19 open reading frame 10) to 46 (thrombospondin-1, TSP1 
or THBS1 as per Table 3.1). These measures assess protein identification and do not 
directly address the quality of substrate assignment, but can inform as to the latter. 
Given this, VCL/VINC and TSP1 were high confidence KLK4 substrates, as each 
was among the top four proteins ranked by both sequence coverage and the number 
of unique peptides retrieved. Notably, the established KLK4 substrate, uPA, was 
retrieved with the third highest sequence coverage, while fibronectin 1, which was 
validated as a KLK4 substrate during the candidate’s Honours research, was 
retrieved with the third highest number of unique peptides.  
3.3.2d More KLK4 substrates were detected in the KLK4-treated than KLK4-
transfected condition 
Finally, it was sought to compare substrate hydrolysis in KLK4-treated and KLK4-
transfected conditions. Of the 23 KLK4 substrates identified, 19 were cleaved in the 
KLK4-treated condition, two in the KLK4-transfected condition, and two in both 
conditions (Figure 3.7 A). Despite only two putative substrates showing evidence of 
proteolysis upon both KLK4 treatment and transfection, 22 (18+2+2) of the 23 
putative KLK4 substrates were detected in all conditions (Figure 3.7 B-D). That is,  
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Figure 3.7. Venn diagrams depicting the number of KLK4 substrates in PC-3 cell CM cleaved in 
each condition (A), corresponding to the conditions in which each protein was detected (B-D). 
(A) Nineteen KLK4 substrates in PC-3 cell CM were cleaved in the KLK4-treated condition, while 
two were cleaved in the KLK4-transfected condition and two in both conditions. (B) For the 19 
substrates cleaved in the KLK4-treated condition, 18 were also identified in, but not cleaved in, the 
KLK4-transfected condition, whereas one was identified and cleaved only in the KLK4-treated 
condition. (C) The two substrates cleaved in both KLK4-treated and -transfected conditions were 
detected in both conditions. (D) The two substrates cleaved only in the KLK4-transfected condition 
were detected in, but not cleaved in, the KLK4-treated condition. 
the two proteins detected as KLK4 substrates only in the KLK4-transfected condition 
(Figure 3.7 A) were also identified in, but not cleaved in, the KLK4-treated condition 
(Figure 3.7 D). Conversely, of the 19 KLK4 substrates cleaved only in the KLK4-
treated condition (Figure 3.7 A), 18 of these were also detected in, but not cleaved in, 
the KLK4-transfected condition (Figure 3.7 B). Thus, comparison of KLK4 
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substrates in KLK4-treated and KLK4-transfected conditions indicated that there was 
not a strong overlap of KLK4 substrates identified by each of the two KLK4 delivery 
systems, with a greater number of putative KLK4 substrates identified by treatment 
with exogenous recombinant KLK4. Exogenous recombinant KLK4 treatment was 
used as the preferred KLK4 delivery system for PROTOMAP analysis of LNCaP 
cell (3.3.4) and WPMY-1 myofibroblast CM (6.3.1), conducted later during the PhD 
research program. 
3.3.3 Determination of the ability of exogenous mKLK4 to catalyse protein 
hydrolysis in PC-3 cell CM 
Prior to validating a selection of the putative KLK4 substrates identified, it was 
sought to confirm whether mKLK4 treatment or transfection induced hydrolysis of 
any extracellular or plasma membrane-localised proteins detected in PC-3 cell CM. 
This was not anticipated, as mKLK4 was inert against gelatine (Figure 3.3 B) and the 
KLK4-preferred peptide substrate, VLR-AFC (see Figure 4.1 B). Nonetheless, 
proteins in the complex PC-3 cell-secreted proteome comprise a rich source of 
putative KLK4 cleavage sites and it was important to identify putative background 
proteolysis induced by this control peptidase, as this may have resulted in false 
negative substrate assignment.  
To first determine the protein migration changes induced by mKLK4 treatment, three 
sets of peptographs were compared, each plotting results from a single type of CM, 
stratified by the three different treatments [KLK4-treated, mKLK4-treated and 
sample buffer-treated; Supplementary Figure 3.3 (PC-3:Vector CM), Supplementary 
Figure 3.4 (PC-3:mKLK4 CM) and Supplementary Figure 3.5 (PC-3:KLK4 CM)]. 
By manual assessment of these peptographs, akin to the criteria used to define KLK4 
substrates, five mKLK4-treated substrates, called pseudo substrates, were identified 
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(Supplementary Figure 3.6 A). Four of these pseudo substrates of exogenous 
recombinant mKLK4 were also deemed substrates in the KLK4-treated condition. In 
each case, KLK4 treatment induced different or additional cleavage products to 
mKLK4 treatment, allowing these proteins to be detected as KLK4 substrates 
(Supplementary Figure 3.6 A). It is unclear whether the remaining fifth protein may 
also be a KLK4 substrate that could not be assigned as such, due to background 
mKLK4-mediated proteolysis being similar to that of KLK4-mediated proteolysis.  
Similar to the above, three pseudo substrates of PC-3 cell over-expressed mKLK4 
were identified (Supplementary Figure 3.6 B) by comparing protein migration in PC-
3:mKLK4 versus PC-3:Vector CM samples, using peptographs whereby only the 
sample buffer-treated samples were plotted, for each of the three CM sources 
(Supplementary Figure 3.7). Two pseudo substrates of over-expressed mKLK4 were 
also substrates of over-expressed KLK4. Again, these proteins were identified as 
KLK4 substrates only due to the differential production of cleavage products by 
KLK4 and mKLK4 (Supplementary Figure 3.6 B). The remaining protein may also 
be a KLK4 substrate that could not be identified as such, if similar fragments were 
produced by mKLK4 and KLK4. 
The mKLK4 control is a particularly important control for the KLK4-treated 
condition, as it represents a protein of similar size and constitution to KLK4, which 
was purified in a similar manner to the active protease. Exogenous mKLK4 serves as 
a control for non-specific hydrolysis due to residual contaminant proteases. All but 
two of the apparent mKLK4 pseudo substrates were KLK4 substrates; however, 
KLK4 generated additional or different products of these proteins as compared to 
those liberated by mKLK4. The observed mKLK4-mediated proteolysis may be real, 
or may be due to protein smearing down the gel in this sample or protein carry-over 
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when processing gel slices, in a manner which mimicked protein hydrolysis. In 
summary, five proteins were putatively cleaved by thermo-mKLK4 and three by 
auto-mKLK4; however, this may have resulted in the negative substrate assignment 
of only two proteins, given that the remainder were determined to be KLK4 
substrates.  
3.3.4 Identification of the KLK4 degradome in LNCaP cell CM using 
PROTOMAP 
One established and 22 novel KLK4 substrate/s were identified in PC-3 cell CM.   
PC-3 cells are androgen-unresponsive and are derived from bone metastatic prostate 
cancer, and thus are representative of the terminal stage of prostate cancer 
progression. In addition to being highly produced in prostate cancer bone metastases, 
KLK4 is also over-expressed in prostate cancer cells from localised disease (Table 
1.2). Thus, it was next sought to identify KLK4 substrates in a CM pool from cells 
representative of early-stage, androgen-responsive disease. To this end, the 
androgen-responsive LNCaP prostate cancer cell line was employed. This cell line 
expresses low to negligible levels of KLK4 under androgen-deprived conditions 
(data not shown). While many proteins were anticipated to be detected in CM from 
both cell lines, thus constituting putative functional players at both androgen-
sensitive and androgen-unresponsive stages of the disease, it was expected that some 
proteins would be secreted uniquely by cells from each disease stage. As such, 
LNCaP cell CM would serve as a putative source of KLK4 substrates unique to the 
former stage, as well as a CM pool with which to confirm KLK4-mediated 
hydrolysis of some of the novel substrates identified in PC-3 cell CM (3.3.2). 
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3.3.4a The optimal ratio of LNCaP cell CM: KLK4 for PROTOMAP studies was 
determined 
In determining the KLK4 degradome in LNCaP cell CM, the optimal KLK4 
treatment concentration was first optimised. As stated previously, the greatest 
number of KLK4 substrates in PC-3 cell CM were determined using exogenous 
KLK4 treatment, in contrast to constitutive over-expression of KLK4. Further, KLK4 
treatment allows for application of specific quantities of active protease over a 
regulated time period; thus, this method was selected for CM treatment in 
PROTOMAP studies performed during the PhD candidature. To detect the most 
specific KLK4 substrates, it was desired to select the lowest concentration of KLK4 
with which protein hydrolysis of KLK4-treated LNCaP cell CM was observed (18 h/ 
37 °C). As visualised by SDS-PAGE/ silver stain analyses, KLK4-mediated 
proteolysis of LNCaP cell CM was observed at a ratio of LNCaP cell CM: KLK4 
(w/w) of 25:1 (lane 7) to a 400:1 ratio (lane 11, Figure 3.8). Specifically, this was 
indicated by the decreased staining intensity of 22, 32, 100 and 280 kDa bands, the 
appearance of 75 and 130 kDa bands, as well as overall decreased intensity upwards 
of 15 kDa (Figure 3.8). The treatment ratio with the lowest KLK4 concentration, 
whereby KLK4-mediated hydrolysis was observed, was 400:1, and this was selected 
for PROTOMAP analysis of KLK4 substrates in LNCaP cell CM. 
3.3.4b KLK4-mediated proteolysis of LNCaP cell CM for PROTOMAP studies was 
confirmed by SDS-PAGE/ silver stain analysis 
To improve confidence of detection of KLK4 substrates in this application of 
PROTOMAP, three biological replicate experiments were performed. Unique 
batches of LNCaP cell CM were prepared for each biological replicate, and each was 
treated on separate days. Prior to performing PROTOMAP analyses, small amounts  
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Figure 3.8. SDS-PAGE/ silver stain analysis of prostate cancer LNCaP cell CM digested with 
KLK4. KLK4 degraded LNCaP cell CM at ratios of 25:1 to 400:1 [CM: KLK4 (w/w); lanes 7-11]. 
Proteolysis was not observed at treatment ratios of 800:1 to 3,200:1 (lanes 12-14). Untreated LNCaP 
cell CM (lanes 4-5 and 15), and KLK4 (lane 3) or buffer only (lane 2) samples served as controls. The 
migration of KLK4 is annotated. Protein standard was loaded in lane 1. 
of each digest were subject to SDS-PAGE/ silver stain analysis to confirm KLK4- 
mediated proteolysis (Figure 3.9). Protein migration was largely similar between 
replicates and similar to the above optimisation experiment, where KLK4 treatment 
induced a loss of staining intensity of bands at 280 kDa, 45 kDa and 32 kDa, 
concomitant with the increased staining intensity of bands at 100 kDa and 28 kDa 
(lanes 3, 5 and 7; Figure 3.9). However, unlike the optimisation experiment, changes 
in protein intensity at 130 kDa, 75 kDa and 22 kDa were not observed (Figure 3.9). 
3.3.4c Identification of extracellular or membrane-localised proteins in LNCaP cell 
CM  
PROTOMAP analysis was performed for all three biological replicates of KLK4-
digested LNCaP cell CM. Preceding determination of KLK4 substrates, proteins 
were identified from peptides recovered from each gel slice within each condition 
across all three biological replicates. In total, 1,074 proteins were identified (FDR ≤ 
1%; Figure 3.10). For many KLK4 substrates, the total number of peptides matched 
to that protein exceeded the number of unique peptides matched to the protein, as 
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Figure 3.9. SDS-PAGE/ silver stain analysis of prostate cancer LNCaP cell CM digested with 
KLK4 or mKLK4 for PROTOMAP experiments. Three biological replicates (Rep) of CM were 
prepared and digested with KLK4 (lanes 3, 5 and 7) or mKLK4 control (lanes 2, 4 and 6). Protein 
standard was loaded in lane 1. The molecular weight ranges corresponding to gel slices (1-19) taken 
for the PROTOMAP experiment are presented, far left. Gel slices corresponding to those with the 
highest relative abundance of KLK4 (spectral counting) identified in PROTOMAP experiments are 
annotated with a bracket. Open or filled arrowheads highlight bands in KLK4-treated LNCaP cell CM, 
which exhibited diminished or elevated intensity, respectively, relative to the control.  
1        2       3        4        5       6       7        
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Figure 3.10. The number of significantly identified proteins and putative KLK4 substrates in 
LNCaP cell CM. Of the 1,074 proteins identified in LNCaP cell CM from at least one replicate 
experiment (white circle), 195 were annotated to be extracellular or plasma membrane proteins (light 
blue circle). One hundred and seventy-three such proteins were identified in the necessary conditions 
to be considered eligible to be screened as KLK4 substrates (dark blue circle), where 10 were putative 
KLK4 substrates (pink circle). 
some identified peptide sequences matched protein sequences within two or more 
proteins identified LNCaP cell CM. Proteins identified by some of the same peptide 
sequences were grouped into protein groups (see 3.2.3d). As it could not be 
unequivocally determined whether non-unique peptides were identified from one or 
all of the protein sequences to which they were matched, only unique peptides were 
used to inform on KLK4-mediated protein proteolysis. Accordingly, only proteins in 
each group to which unique peptides were matched were plotted on peptographs (and 
constituted the above-mentioned 1,074 proteins). One hundred and ninety-five of 
these 1,074 proteins were annotated in IPA as being of extracellular or plasma 
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membrane origin and, representing targets theoretically accessible to active 
extracellular KLK4 (Figure 3.10). The subcellular localisation of 16 proteins was not 
annotated in IPA and these proteins were excluded from further analyses 
(Supplementary Table 3.2).  
A high degree of overlap was observed between extracellular and cell membrane-
associated proteins identified in each of the three replicates of LNCaP cell CM 
(Figure 3.11). In total, 138 extracellular or plasma membrane-localised proteins were 
identified across all three replicates, while an additional 35 (6+22+7) proteins were 
identified in two of the three CM replicates. The remaining 22 (2+9+11) proteins 
were identified only in a single replicate experiment (Figure 3.11). For PROTOMAP 
analysis of KLK4 substrates in LNCaP cell CM, a KLK4 substrate was required to be 
cleaved in at least two replicates. As such, these 22 proteins were ineligible to be 
considered as putative KLK4 substrates. For the remaining 173 (138+35) proteins 
(Figure 3.10 and 3.11), peptographs of each were subsequently assessed for evidence 
of KLK4-mediated hydrolysis.  
3.3.4d The PROTOMAP approach identified 10 novel KLK4 substrates in LNCaP 
cell CM 
In order to identify potential KLK4 substrates in LNCaP cell CM, two peptograph 
pictorial outputs were compiled for every protein identified (FDR ≤ 1%) in each 
replicate experiment. That is, six peptographs were plotted for each protein in total. 
For each set of peptographs, all peptides (P > 0.5) matched to a given protein (in one 
of replicate one, two or three), which were identified in the KLK4-treated sample, 
were plotted on peptographs alongside either those peptides identified in the 
untreated [Supplementary Figure 3.8 (replicate one), 3.9 (replicate two) and 3.10 
(replicate three)] or mKLK4-treated control samples [Supplementary figure 3.11  
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Figure 3.11. The number of extracellular and plasma-membrane-associated proteins identified 
in each condition used for PROTOMAP analysis of KLK4 substrates in LNCaP cell CM. One 
hundred and seventy-three (138+6+22+7) proteins were identified in CM from at least two 
experimental replicates and were, therefore, eligible to be screened for evidence of KLK4-mediated 
hydrolysis using the PROTOMAP approach. In contrast, 22 (2+9+11) proteins were detected in CM 
from a single replicate and thus were ineligible for substrate screening, given the requirement for a 
protein to be identified and cleaved in at least two CM replicates to be deemed a KLK4 substrate. 
(replicate one), 3.12 (replicate two) and 3.13 (replicate three)]. In general, KLK4 
substrates were deemed to be those extracellular or membrane-localised proteins that 
displayed increased migration (i.e. were of decreased molecular weight) in KLK4-
treated samples, versus each control, in at least two of the three biological replicates 
(see 3.2.3e for the detailed approach to substrate determination). Using this approach, 
10 putative KLK4 substrates were identified in LNCaP cell CM (Figure 3.10; Table 
3.2).  
Importantly, each of the KLK4 substrates identified in LNCaP cell CM were novel, 
and included three putative KLK4 substrates that were also identified in PC-3 cell 
CM (3.3.2). These were glucose-6-phosphate isomerase (G6PI), collagen alpha-1(VI) 
chain and TSP1. The only published KLK4 substrate present in LNCaP cell CM, in 
sufficient peptide abundance to examine for KLK4-mediated proteolysis, was 
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Table 3.2. KLK4 substrates in LNCaP cell CM.  
 
Description, UniProtKB recommended name; Loc, subcellular location (PM, plasma membrane; EC, extracellular); Protein type, molecule type designation by IPA or GeneCards; 
Symbol, UniProtKB/ Swiss-Prot entry name prefix (all _HUMAN) with (HUGO gene name) for UniProtKB/ TrEMBL entries; Group, protein group number; Sib, sibling annotation; 
Prob, probability of positive protein identification; Length, the number of amino acid residues in the protein sequence; %, percentage of amino acid residues retrieved, as compared to 
the reference sequence; Pep, the number of peptides retrieved; Unique pep, the number of unique peptides retrieved.  
* Representative data from replicate 3, KLK4-treated versus untreated 
†
 Identified as a novel KLK4 substrate also in PC-3 cell CM. 
Description Loc Protein type Symbol Group Sib Prob Length % *  Pep*.  Unique pep* 
calsyntenin-1 PM protein and calcium binding  B4E3Q1 (CLSTN1) 309 a 1 1002 57.4 962 962 
calsyntenin-3 PM protein and calcium binding CSTN3 984 a 1 956 40.2 124 111 
catenin alpha-1 PM actin and cadherin binding F8W845 (CTNNA1) 425 a 1 803 45.7 185 153 
clathrin heavy chain 1 PM coat constituent in coated 
vesicle and pits  
CLH1 831 a 1 1675 41.3 234 228 
collagen alpha-1(VI) chain EC ECM constituent CO6A1
†
 114 a 1 1028 31.1 131 131 
glucose-6-phosphate isomerase EC enzyme G6PI
†
 577 a 1 558 78.3 280 280 
neuropilin-1 PM transmembrane receptor E7EX60 (NRP1) 376 a 1 641 44.2 229 229 
nicotinamide phosphoribosyltransferase EC cytokine NAMPT 729 a 1 491 26.5 20 17 
thrombospondin-1 EC glycoprotein TSP1
†
 714 b 1 1170 3.6 27 27 
tissue factor pathway inhibitor EC protease inhibitor C9JBB3 (TFPI) 332 a 1 288 35.8 57 57 
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IGFBP6. However, this protein was not cleaved in LNCaP cell CM, and so may not 
be a physiological substrate of KLK4. The 10 novel KLK4 substrates identified 
constitute a diverse set of proteins with wide-ranging cellular functions. These 
substrates included cytokines, enzymes, transmembrane receptors, ECM and vesicle 
components, and cell adhesion molecules (Table 3.2).  
Notably, six of the 10 KLK4 substrates identified are annotated as being plasma 
membrane-localised (Table 3.2). It is important to note that PROTOMAP studies 
were conducted by treating concentrated LNCaP cell CM following its removal from 
cells. As such, KLK4 could not have been responsible for shedding these proteins 
into the cell CM. Instead, these proteins may have been previously shed into the CM 
or expelled from the cell surface by other mechanisms, prior to proteolysis by KLK4. 
In either case, the present application of the PROTOMAP approach examines only 
the ability of KLK4 to cleave soluble forms of plasma membrane-localised proteins, 
although there remains potential for KLK4 to cleave these proteins when tethered to 
the cell. 
Table 3.2 details information pertaining to protein and peptide identification for each 
of the 10 KLK4 substrates detected in LNCaP cell CM. This information indicates 
how confidently peptides and proteins were identified. While not directly informing 
as to the confidence in the protein being identified as a KLK4 substrate, as stated in 
3.3.2c, this information can indirectly indicate the relative confidence of substrate 
identification between all substrates identified. Briefly, more complete peptide 
recovery, which spans a greater proportion of the protein, increases the likelihood 
that both endogenous and KLK4-generated products were detected in the control and 
KLK4-treated samples, respectively. This serves to decrease the respective likelihood 
of false positive and false negative substrate assignment. Of note, sequence coverage 
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depicted in Table 3.2 is from the gel slice in which the greatest number of peptides 
were identified and so may underestimate sequence coverage when considering that 
collectively attained by peptides recovered from all gel slices.  
As shown in Table 3.2, between 17 (nicotinamide phosphoribosyltransferase) and 
962 (calsyntenin-1) unique peptides were plotted on peptographs for each protein 
that was determined to be a KLK4 substrate. For each, protein sequence coverage 
was relatively high and ranged from 26.5% (nicotinamide phosphoribosyltransferase) 
to 78.3% (G6PI), excepting for TSP1 (3.6%). This confers confidence in the 
assignment of KLK4 substrates in LNCaP cell CM.  
3.3.4e Comparison of KLK4 substrates identified in three biological replicate 
samples of KLK4-treated LNCaP cell CM 
While KLK4 substrates were only required to be detected and cleaved in KLK4-
treated LNCaP cell CM from two out of three biological replicate experiments, 
intuitively, higher confidence substrates are those cleaved in every CM replicate in 
which they were identified. Conversely, substrates of lower relative confidence are 
those identified in CM from all three replicate experiments, but found to be cleaved 
by KLK4 in CM from only two of three replicates. Figure 3.12 shows the distribution 
of the 10 KLK4 substrates identified by PROTOMAP analysis, segregated according 
to the LNCaP cell CM replicates in which they were identified (Figure 3.12 B), as 
compared to the replicate experiments in which they were putatively cleaved by 
KLK4 (Figure 3.12 A). Of the 10 KLK4 substrates identified in LNCaP cell CM by 
the PROTOMAP, five were cleaved in all three replicates, thus representing high 
confidence KLK4 substrates. The five remaining substrates were cleaved only in two 
of the three biological replicates (Figure 3.12 A), despite the protein being identified 
in all three replicates (Figure 3.12 B). The recovery/ identification of tryptic peptides  
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Figure 3.12. Replicates of KLK4-treated LNCaP cell CM in which KLK4 substrates were 
identified as being cleaved (A) in comparison to those in which the protein was detected (B). (A) 
Five KLK4 substrates were cleaved in LNCaP cell CM from all three replicates and an additional five 
(4+1) were cleaved in two of three replicates. (B) Each protein (10 total) was detected in LNCaP cell 
CM from all replicates.  
derived from each of these proteins was least in the replicate from which the protein 
was not cleaved. Therefore, it may be that these proteins were present in lesser 
relative abundance in the CM from these replicates and so were not cleaved by 
KLK4, or were cleaved to an undetectable degree. Alternatively, experimental 
variation of peptide recovery between gel slices may have meant that cleavage 
products of these proteins were simply not detected in one of the three replicates, as 
also suggested by lower peptide recovery in replicates where the proteins were not 
assigned as KLK4 substrates. Thus, half of the novel KLK4 substrates identified 
were cleaved in all three experimental replicates and are high confidence KLK4 
substrates. 
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3.3.5 Comparison of the KLK4 degradome in LNCaP and PC-3 cell CM, as 
determined by PROTOMAP 
3.3.5a Three proteins were KLK4 substrates both in LNCaP and PC-3 cell CM  
A large number of proteins were identified in CM from both PC-3 and LNCaP 
prostate cancer cell lines, which are derived from patients with late- and early-stage 
prostate cancer, respectively. It was next sought to identify proteins among this 
group, which were cleaved by KLK4 in CM from both cell lines, so as to ascertain 
additional confidence in the designation of these proteins as KLK4 substrates. In 
total, 47 extracellular or cell surface-associated proteins were identified in both 
LNCaP and PC-3 cell CM (Figure 3.13). While 10 (1+9) of these proteins were 
determined to be putative KLK4 substrates in CM from only one cell line, three 
proteins were KLK4 substrates in CM from both cell lines (Figure 3.13). Sixteen 
(5+11) additional KLK4 substrates were respectively present in CM derived from 
only LNCaP or PC-3 cells, but not from both cell lines (Figure 3.13). 
The three proteins that were cleaved in both LNCaP and PC-3 cell CM, namely 
G6PI, collagen alpha-1(VI) chain and TSP1 (Table 3.2), are high confidence KLK4 
substrates and may be cleaved by KLK4 in both androgen-responsive and androgen-
unresponsive prostate cancers. The 16 (5+11) KLK4 substrates that were detected 
only in CM from a single cell line may be expressed exclusively in either androgen-
responsive or androgen-unresponsive cancer cell phenotypes, and may have KLK4-
regulated functions specific to the phenotype in which they are expressed. The fact 
that 10 (1+9) proteins produced by both cell lines were cleaved only in CM from a 
single cell line does not necessarily detract from the validity of these proteins as 
KLK4 substrates. In particular, different methodology was used for performing 
PROTOMAP determination of KLK4 substrates in PC-3 and LNCaP cell CM, which  
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Figure 3.13. The number of extracellular or plasma membrane-associated proteins detected in 
LNCaP and/ or PC-3 cell CM (top) and the number of KLK4 substrates identified in CM from 
either or both cell lines (bottom). Forty-seven proteins were identified in CM from both LNCaP and 
PC-3 cells, while 148 or 99 were identified in individual cell CM, respectively (top). Three of the 47 
proteins identified in CM from both cell lines were cleaved by KLK4 in both LNCaP and PC-3 cell 
CM, while 10 (1+9) were cleaved only in individual respective cell CM (bottom, centre). Five 
proteins cleaved by KLK4 in LNCaP cells were identified only in LNCaP cell CM (bottom, left), 
while 11 proteins cleaved by KLK4 in PC-3 cells were identified only in PC-3 cell CM (bottom, 
right). VCL/VINC, GRN and MMP1 were selected for validation as KLK4 substrates (see text for 
rationale). 
may have resulted in differing extents of KLK4-mediated proteolysis and differential 
peptide retrieval between each cell CM. Moreover, KLK4-mediated proteolysis of 
these substrates may rely on protease or substrate interaction with other proteins 
produced in CM from individual cell lines. In this manner, KLK4 may cleave certain 
proteins only in the presence of other protein factors. Thus, the identification of three 
substrates common to both LNCaP and PC-3 cell CM adds to the confidence of these 
proteins as physiological KLK4 substrates; the remaining 26 (1+5+9+11) substrates 
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may be cleaved in certain prostate cancer phenotypes, or under certain experimental 
conditions. 
3.3.5b Western blot analyses of KLK4-mediated hydrolysis of VCL/VINC 
demonstrated cleavage in both LNCaP and PC-3 cell CM 
To validate whether one such substrate, VCL/VINC, was cleaved specifically in PC-
3 cell CM, despite apparent detection as an intact protein in LNCaP cell CM, KLK4-
mediated proteolysis of PC-3 and LNCaP cell CM was examined by Western blot 
analyses using antibodies targeted to VCL/VINC (Figure 3.14). VCL/VINC was 
selected due to the high level of sequence coverage and peptide retrieval of this 
substrate in CM from PC-3 cells, in which it was cleaved. Interestingly, Western blot 
analyses demonstrated that VCL/VINC was cleaved by KLK4 in LNCaP cell CM 
(lanes 5-7, B) as well as PC-3 cell CM (lanes 4-7, A; Figure 3.14). The fragmentation 
pattern of this KLK4 substrate was similar in both CM pools, with loss of the 
predominant intact VCL/VINC band at 130 kDa, and appearance of a dominant 70 
kDa fragment, as well as less prominent 65 kDa product (lanes 4-7, A; lanes 5-7, B; 
Figure 3.14). Additional KLK4-generated fragments were observed in LNCaP cell 
CM (lanes 5-7, B; Figure 3.14), possibly due to a higher abundance of VCL/VINC in 
LNCaP cell CM or to more complete processing of the substrate by KLK4. 
VCL/VINC migration in untreated cell CM (lane 2) was similar to that in mKLK4-
treated PC-3 (lane 3, A) or LNCaP (lanes 3-4, B) cell CM (Figure 3.14). Thus, 
Western blot analyses indicated that VCL/VINC was cleaved by KLK4 in both PC-3 
and LNCaP cell CM, despite PROTOMAP detecting KLK4-mediated hydrolysis 
only in the former. While only KLK4 concentrations equivalent to ratios of CM: 
KLK4 (w/w) as low as 50:1 were tested, KLK4 appeared to cleave endogenous VCL/ 
VINC with greater sensitivity in LNCaP cell CM than in PC-3 cell CM. This was  
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Figure 3.14. Western blot analyses of KLK4-mediated hydrolysis of VCL/VINC in PC-3 (A) or 
LNCaP (B) cell CM. Western blot analyses indicated that KLK4 hydrolysed VCL/VINC in CM from 
both PC-3 and LNCaP cells at ratios of 10:1 to 50:1 [CM: active KLK4 (w/w); lanes 4-7, A; lanes 5-7, 
B]. KLK4-mediated hydrolysis of VCL/VINC was dose-dependent. Treatment with amounts of 
mKLK4 corresponding to the annotated treatment ratios (25, 30 or 50:1) did not induce VCL/VINC 
hydrolysis (lane 3, A; lanes 3-4, B), as compared to untreated VCL/VINC (lane 2). Protein standard 
was loaded in lane 1. Open arrowheads denote the relative migration of intact VCL/VINC; filled 
arrowheads denote the relative migration of KLK4-generated VCL/VINC fragments common to CM 
from both cell lines. 
based on the presence of the intact protein clearly visible at ratios of 20:1 (lane 5, A), 
30:1 (lane 6, A) and 50:1 (lane 7, A) in PC-3 cell CM, while intact protein was only 
visible at the 50:1 treatment ratio (lane 7, B) in LNCaP cell CM (Figure 3.14). 
Therefore, it is unlikely that the greater KLK4 treatment ratio employed for 
PROTOMAP analyses of PC-3 cell CM (100:1), as compared to that of LNCaP cell 
CM (400:1), was responsible for VCL/VINC being detected as a KLK4 substrate 
only in PC-3 cell CM. 
Given that KLK4 appeared to cleave VCL/VINC to a greater degree in LNCaP cell 
CM than PC-3 cell CM, it is unclear why KLK4-mediated proteolysis of VCL/VINC 
was not detected by PROTOMAP analysis of KLK4 substrates in LNCaP cell CM. 
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One possible explanation is that the differential protein complement and complexity 
in VCL/VINC and VCL/VINC fragment-containing gel slices in PROTOMAP 
analysis of LNCaP and PC-3 cell CM may have resulted in differential identification 
of VCL/VINC-derived peptides, due to dynamic range and ion suppression effects 
during MS analysis. This finding provides evidence that experimental variation may 
account for 10 of the 13 proteins identified in both PC-3 and LNCaP cell CM 
appearing to be cleaved only in CM from one cell line (Figure 3.13).  
3.3.6 Predicting putative KLK4 substrates in PC-3 and LNCaP cell CM that 
may be hydrolysed into bioactive by-products 
In selecting proteins to validate as direct KLK4 substrates, it was desired to identify 
those which may have been processed into bioactive products by KLK4, to provide 
evidence for putative functional by-products of KLK4-substrate interactions. Indeed, 
many signalling molecules, such as cytokines and growth factors, require proteolytic 
processing in order to become activated. One of the benefits of using PROTOMAP, 
instead of more sensitive N-terminomic substrate profiling techniques, is that 
PROTOMAP provides sequence and size information of protease-generated 
products, thereby informing as to the putative identity of cleavage products. While 
100% sequence coverage and identification of these fragments does not routinely 
occur in practice, an approximation of KLK4-generated protein products can serve as 
a guide to inform subsequent validation studies.  
In the present study, KLK4-mediated hydrolysis of eight of the 30 KLK4 substrates 
identified in LNCaP and PC-3 cell CM yielded putative KLK4 protein fragments 
which possess known bioactive functions (Table 3.3). Of those PC-3 cell-derived 
KLK4 substrates, GRN, MMP1, uPA, prosaposin, APP/A4 and fibronectin 1 were 
hydrolysed following KLK4 treatment, but not transfection, to yield putative 
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Table 3.3. Putative bioactive KLK4-generated cleavage products of substrates identified in PC-3 and LNCaP cell CM, according to the UniProtKB. 
 
 
Description, UniProtKB recommended name; Symbol, UniProtKB/ Swiss-Prot entry name prefix (all _HUMAN) with (HUGO gene name) for UniProtKB/ TrEMBL entries. 
 
Description Symbol LNCaP 
substrate 
PC-3 
substrate 
Putative cleavage product 
chains (KLK4-treated) 
Putative cleavage product 
chains (KLK4-transfected) 
Annotated cleavage product chain 
bioactivity (UniProtKB) 
agrin AGRIN No  Yes Agrin C-terminal 110, 90 and 22 
kDa subunits 
Agrin C-terminal 22 kDa 
subunit 
Induction of dendritic filopodia 
amyloid beta (A4) 
precursor protein 
A4 No  Yes Soluble APP-alpha and -beta none None annotated 
calsyntenin-1 B4E3Q1 
(CLSTN1) 
Yes No Soluble alc-alpha n/a None annotated 
fibronectin 1 FINC No  Yes Ugl-Y3 none None annotated 
granulin GRN  Yes Granulin-3 and -4 none Positive and negative regulation of 
epithelial cell proliferation 
matrix 
metallopeptidase 1 
(interstitial 
collagenase) 
MMP1 No  Yes 22 kDa interstitial collagenase none Peptidase (collagenase activator) 
plasminogen 
activator, 
urokinase 
UROK No Yes Urokinase-type plasminogen 
activator chain B 
none Peptidase (plasminogen activator) 
prosaposin SAP No  Yes Pro-peptides, saposin-C and -D none Glucosylceramide and 
galactosylceramide hydrolysis; 
sphingomyelin phosphodiesterase 
activator 
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bioactive cleavage products. In addition, agrin was hydrolysed by both KLK4 
treatment and transfection to yield putative bioactive protein fragments. Only one 
uniquely LNCaP cell-derived KLK4 substrate, calsyntenin-1, showed evidence to 
have been cleaved by KLK4 into known functional by-products (Table 3.3). Each of 
the putative product chains produced possess a range of annotated biological 
functions. Cancer-associated functions included those for which KLK4 has already 
been implicated, such as, regulation of epithelial cell proliferation and migration 
(Table 3.3; see Table 1.1 for a summary of established KLK4-regulated cellular 
functions). Thus, KLK4 potentially promotes cell proliferation via hydrolysis of 
GRN into its active components and may further promote the latter through 
activating the pro-migratory peptidases, uPA and MMP1. The activation of pro-uPA 
by KLK4 has been previously reported (Takayama et al., 2001), whereas this has yet 
to be demonstrated for pro-MMP1 or GRN. As such, KLK4-mediated hydrolysis of 
recombinant pro-MMP1 and GRN was examined. 
3.3.6a KLK4 directly activated pro-MMP1 
MMP1 was identified as a KLK4 substrate in PC-3 cell CM, following manual 
interrogation of its peptograph. A description of peptograph interpretation can be 
found in 3.2.3e, and precise peptide identity and probability of positive identification 
for all MMP1-derived peptides plotted in Figure 3.15 can be found in Supplementary 
Figure 3.2. Peptographs display peptide matches for each protein as coloured boxes, 
aligned to the amino acid sequence to which they correspond (X-axis), against the 
gel slice from which they were identified (Y-axis). Boxes are coloured according to 
the sample from which they are derived. Correlations between gel slice and 
molecular weight for PROTOMAP studies using PC-3 cell CM can be found in 
Supplementary Figure 3.14. Note that molecular weight annotations found on 
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peptographs in Supplementary Figures 3.2-3.5 and 3.7 were calculated by performing 
linear regression of the theoretical mass of proteins identified across all gel slices and 
interpolating the expected migration of protein standards (calculations are not 
shown); this differed somewhat from the observed migration of protein standards 
presented in Supplementary Figure 3.14. 
As displayed by the MMP1 peptograph, MMP1 was identified in CM from control 
and KLK4-treated, but not KLK4-transfected, conditions (Figure 3.15). The lack of 
MMP1 identification in the latter CM may reflect its complete degradation in CM 
from cells constitutively expressing KLK4, or may be due to a lack of MMP1 
production in these cells. Alternatively, incomplete recovery of MMP1-derived 
peptides from corresponding gel slices may be responsible, where peptide loss is a 
common problem of gel-based proteomics (Speicher et al., 2000). In control lanes, 
MMP1 was isolated in gel slices 9 and 10 (Figure 3.15), corresponding to ~50 kDa, 
that is, similar to the predicted mass of pro-MMP1 (54.2 kDa; top open arrowhead, 
Figure 3.15). Notably, pro-MMP1 is activated by removal of its pro-region, which 
produces a ~42 kDa active protease [blue shading and blue shaded arrowhead, Figure 
3.15; (Grant et al., 1987; Nagase et al., 1992; Saunders, Bayless & Davis, 2005)]. By 
subsequent proteolysis, including autolysis, this may be further processed into an N-
terminal 22 kDa collagenase chain that is also proteolytically active, as well as a C-
terminal proteolytically inactive 27 kDa chain (Vallon et al., 1997). In the control 
sample, MMP1-derived peptides were further retrieved from gel slice 18, where 
these peptides aligned with the C-terminal 27 kDa collagenase chain (bottom open 
arrowhead, Figure 3.15); gel slice 18 is expected to contain products near to this size. 
Control-derived peptides isolated from regions N- or C-terminal to the 27 kDa 
collagenase chain, that is, in the pro-region or the 22 kDa collagenase domain,  
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Figure 3.15. Peptograph for the putative KLK4 substrate, pro-MMP1, in PC-3 cell CM. 
Peptograph displays all significantly identified peptides (coloured boxes) from gel slices (Y-axis, 1-
32), with the corresponding protein amino acid residue (X-axis). A schematic of selected protein 
domains, based on annotations in the UniProtKB, is beneath the X-axis (pale blue boxes), aligned with 
appropriate residues. Peptides are coloured according to the condition from which they were derived: 
KLK4-treated (Tr; red), KLK4-transfected (Tx; blue) or control (Ctr; yellow). Peptides found in 
KLK4-treated and KLK4-transfected conditions are purple, while those found in the control and either 
KLK4-treated or KLK4-transfected conditions are orange and green, respectively. Peptides derived 
from all samples are represented by black boxes (see colour key, bottom left). The appearance of a 
KLK4-generated cleavage product (red boxes, gel slice 21) of topography and migration consistent 
with the active 22 kDa collagenase chain (pink shading and pink shaded arrowhead) infers a putative 
role for KLK4 in activating pro-MMP1. Ctrl samples contained pro-MMP1 (top open arrowhead) and/ 
or active mature MMP1 (blue shading and blue shaded arrowhead), as well as the 27 kDa chain 
(bottom open arrowhead), were identified in the control (yellow boxes, gel slices 9-10, 18). Selected 
residues/ chains are annotated (blue lined arrowheads/ arrows). 
Colour key 
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respectively, were not identified in the control sample in gel slice 18 (± one gel slice; 
Figure 3.15). Thus, it is likely that the fragment detected in gel slice 18 of the control 
sample constituted the 27 kDa chain of MMP1. Therefore, MMP1 appeared to be 
active in control CM, having undergone autolysis, or it may have been processed into 
this form by endogenous proteases in the control sample. Of interest, peptides 
matched to the remainder of the protein, that is, the liberated pro-region and 22 kDa 
collagenase chain, were not detected in any gel slice of the control sample, excepting 
in gel slice 10 (Figure 3.15). These fragments may have undergone additional 
degradation, or may have been unsuccessfully retrieved from the gel. 
In the KLK4-treated sample, tryptic peptides of MMP1 were identified only in gel 
slice 21 at ~22 kDa (Figure 3.15). These peptides spanned the 22 kDa collagenase 
domain (pink shading and pink shaded arrowhead, Figure 3.15), excepting that the 
terminating amino acid residue of the most C-terminal peptide derived from this gel 
slice was K276, while the reference sequence for this 22 kDa collagenase chain ends 
at P269 (annotated in the UniProtKB and in Figure 3.15). Thus, KLK4-mediated 
hydrolysis appeared to result in the 22 kDa chain of MMP1 being liberated from this 
substrate. Intriguingly, once again, the remainder of the protein, that is, the 27 kDa 
collagenase chain and the pro-region, was not identified in the KLK4-treated sample 
in any gel slice (Figure 3.15). This indicated two primary possibilities: (1) MMP1 
autolysis or hydrolysis by PC-3 cell-endogenous proteases favoured biostability of 
the 27 kDa product, while KLK4-mediated MMP1 hydrolysis favoured biostability 
of the 22 kDa chain; or (2) MMP1 was similarly processed by endogenous proteases 
in both the control and KLK4-treated samples, and opposing fragments were 
retrieved from the gel in each sample, making MMP1 appear to be a KLK4 substrate. 
A potential mechanism for (1) may be that KLK4 removed the pro-region from 
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MMP1, which subsequently underwent autolysis into the two collagenase chains. 
Following this, KLK4, or a KLK4-activated protease, may have degraded only the 27 
kDa fragment. Regarding (2), differential retrieval of MMP1 chains generated by 
endogenous processes between KLK4-treated and control samples may have falsely 
identified MMP1 as a KLK4 substrate. 
To confirm whether MMP1 is a direct KLK4 substrate, recombinant pro-MMP1 was 
incubated with KLK4 at molar ratios of pro-MMP1: KLK4 of 2:1 to 1,250:1. Protein 
migration through an SDS-PAGE gel was visualised by silver staining (Figure 3.16 
A). Pro-MMP1 (lane 2) was identified with strongest intensity at its expected 
molecular weight (52 kDa for recombinant, non-carbamidomethylated pro-MMP1), 
while also being clearly detected at 47, 54 and 57 kDa (Figure 3.16 A). The latter 
bands may represent glycosylated forms of the protease (Saarinen et al., 1999). Faint 
bands of untreated pro-MMP1 (lane 2) were also observed at 24, 27 and 42 kDa, 
indicating that a small amount of the recombinant protein was activated prior to 
KLK4 treatment, perhaps prior to purification of the recombinant substrate (Figure 
3.16 A). KLK4 hydrolysed pro-MMP1 at treatment ratios of 2:1 (lane 4), 10:1 (lane 
5) and 50:1 (lane 6), but not at ratios of 250:1 (lane 7) and 1,250:1 (lane 8; Figure 
3.16 A). Dose-dependent reduction of intensity of the 52 kDa pro-MMP1 band was 
observed in lanes where KLK4 cleaved pro-MMP1. The fragments produced with 
different treatment ratios are as follows (* denotes predominant products): 2:1 - 47, 
45* and 43 kDa; 10:1 - 49, 47*, 45* and 43 kDa; and, 50:1 - 49, 47* and 45 kDa. 
Importantly, products around 45 kDa were among the most intense products liberated 
by KLK4 treatment of pro-MMP1, indicating that KLK4 may have activated pro-
MMP1 in these samples. Smaller KLK4-generated products were also observed, with 
a prominent 17 kDa band observed at the 2:1 treatment ratio, as well as 19 kDa and  
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Figure 3.16. SDS-PAGE/ silver stain (A) or Western blot (B, C) analysis of KLK4-treated 
recombinant pro-MMP1. Immunodetection was performed using hemopexin domain-targeting (B) 
or total MMP1-targeting (C) antibodies. KLK4 cleaved pro-MMP1 at molar ratios of substrate: active 
KLK4 ranging from 2:1 (lane 4) to 250:1 (lane 7). Equivalent concentrations of mKLK4 did not 
induce pro-MMP1 hydrolysis (lane 3). Control lanes included only pro-MMP1 (lane 2), KLK4 (lane 
9) or mKLK4 (lane 10). Protein standard was loaded in lane 1. Open arrowheads denote intact pro-
MMP1; filled arrowheads denote KLK4-generated cleavage products. KLK4 migration is annotated in 
(A). (D) Activity assay of KLK4-treated recombinant pro-MMP1. MMP1-mediated hydrolysis of 
a fluorogenic peptide substrate was measured over time. RFU for each condition was normalised to 
the blank sample (cor. RFU). High, medium or low concentrations of KLK4 activated pro-MMP1 in a 
dose-dependent manner. Peptidolytic activity was maintained upon addition of the serine protease 
inhibitor, aprotinin, but not the metal ion chelator, EDTA, when incubated with KLK4-activated pro-
MMP1, just prior to assaying activity. KLK4 or pro-MMP1 alone did not exhibit activity. mKLK4 did 
not activate pro-MMP1, indicating that KLK4-mediated activation of pro-MMP1 requires proteolysis.  
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22 kDa bands at the 10:1 treatment ratio (Figure 3.16 A). These may reflect KLK4- 
or activated MMP1-mediated liberation of the 22 kDa collagenase chain, as observed 
in PROTOMAP studies. However, KLK4 migrated to 24 kDa and it is possible that 
these 17-22 kDa bands may instead constitute products of KLK4 liberated by 
activated MMP1; however, this is unlikely, given that the buffer conditions 
employed were more favourable to KLK4 than MMP1.  
To further examine the pro-MMP1 cleavage products produced by KLK4, Western 
blot analyses was employed using antibodies targeting the C-terminal hemopexin 
domain of MMP1 (Figure 3.16 B) or total MMP1 (Figure 3.16 C). As depicted in 
Figure 3.15, the hemopexin domain of MMP1 is present in full-length pro-MMP1, 
mature active MMP1 and the liberated 27 kDa chain, but not in the liberated 22 kDa 
collagenase chain. KLK4 cleaved pro-MMP1 at the four highest concentrations 
examined (lanes 4-7), as visualised by both antibodies (Figure 3.16 B, C). A dose-
dependent loss of pro-MMP1 was observed with increased KLK4 concentration. 
Each antibody faintly detected the 47 kDa mature protease band present in lanes 
containing untreated (lane 2) or mKLK4-treated pro-MMP1 (lane 3; Figure 3.16 B, 
C), which was also detected by silver stain analysis (Figure 3.16 A), indicating that a 
marginal amount of pro-MMP1 appeared to have been activated prior to KLK4 
treatment. However, mKLK4 did not specifically induce pro-MMP1 hydrolysis (lane 
3; Figure 3.16 B, C). KLK4 treatment of pro-MMP1 induced a dose-dependent 
increase in the intensity of the 47 kDa band, likely corresponding to activated 
MMP1, as compared to controls (10:1, 50:1 and 250:1 treatment ratios; lanes 5-7; 
Figure 3.16 B, C). However, this band was absent, and likely completely degraded, 
in the lane containing pro-MMP1 treated with the highest employed KLK4 
concentration (2:1 treatment ratio; lane 4; Figure 3.16 B, C). As the 47 kDa band was 
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detected by both the hemopexin domain antibody and the total MMP1 antibody, this 
cannot represent a dimer of liberated 22 kDa collagenase, because the latter does not 
possess the hemopexin domain. This supports the likelihood that the 47 kDa band 
represents active mature MMP1.  
No additional degradation products of pro-MMP1 were detected using either 
antibody (lanes 4-8; Figure 3.16 B, C). Thus, the identity of additional high 
molecular products of pro-MMP1 (i.e. > 24 kDa) that were detected by silver stain 
analysis is unclear. It may be that these products lack epitopes for the antibodies 
employed, or that these were masked, for example, due to protein glycosylation. The 
KLK4-generated products > 24 kDa, that were observed with silver staining, may 
represent MMP1-generated degradation products of KLK4.  
In summary, Western blot analyses confirmed that KLK4-mediated hydrolysis of 
pro-MMP1 yielded a product consistent with active MMP1. To validate the above 
findings, an MMP1 activity assay was performed using a fluorogenic peptide 
substrate of MMP1. Pro-MMP1 alone, or treated with mKLK4, did not induce 
peptide substrate hydrolysis over 15 min, consistent with the blank (peptide substrate 
and buffer only) sample (Figure 3.16 D). Strikingly, KLK4 treatment of pro-MMP1 
induced dose-dependent increases in RFU produced over time (Figure 3.16 D). 
KLK4, alone, did not cleave the fluorogenic peptide substrate (Figure 3.16 D). To 
further demonstrate that the assay was detecting only MMP1 activity, the metal 
chelator and MMP inhibitor, EDTA, was briefly incubated with pro-MMP1 
following its 18 h treatment with KLK4, but preceding analysis of MMP1 activity. 
EDTA abolished the observed rate of peptide hydrolysis near to baseline levels 
(Figure 3.16 D). Conversely, incubation of KLK4-treated pro-MMP1 with the serine 
protease inhibitor, aprotinin, instead of EDTA, did not affect the peptidolytic activity 
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observed (Figure 3.16 D); thus, only MMP1 was capable of hydrolysing the peptide 
substrate. This activity assay confirmed that KLK4 directly activated pro-MMP1.  
3.3.6b KLK4-mediated hydrolysis of GRN was limited 
Finally, it was sought to confirm direct KLK4-mediated hydrolysis of GRN. In 
PROTOMAP studies, GRN was identified in gel slices 1-4 in the control and KLK4-
transfected samples. This is at an increased molecular weight to its expected size 
(68.6 kDa; open arrowhead, Figure 3.17). KLK4-generated GRN fragments were 
identified in gel slices 8-18 in the KLK4-treated sample (Figure 3.17). Peptides 
derived from KLK4-generated fragments aligned with regions of the sequences of 
GRN-3 and GRN-4 product chains, and flanked GRN-5 (pink shading, Figure 3.17). 
The expected molecular weight of these peptides is 6.4-6.7 kDa (pink shaded 
arrowhead), which corresponds to gel slices 29/30, despite detection in gel slices 8-
19 (Figure 3.17).  
KLK4-mediated hydrolysis of recombinant GRN was limited (Figure 3.18). As 
determined by SDS-PAGE/ silver stain analysis, GRN migrated as bands of 240, 160 
and 90 kDa when left untreated (lane 2), treated with mKLK4 (lane 11), or treated 
with KLK4 along with aprotinin (lane 14; Figure 3.18). The expected migration of 
recombinant GRN is 90-95 kDa, according to the manufacturer. KLK4 treatment, in 
the absence of aprotinin, yielded a reduction in the intensity of the 240 kDa and 160 
kDa bands, where molar ratios of GRN: KLK4 of 2:1 to 8:1 were employed (lanes 3-
5; Figure 3.18). Faint cleavage products of GRN, ranging from 60-70 kDa, were also 
observed following KLK4 treatment at ratios of 8:1 and 16:1 (lanes 5-6; Figure 
3.18). The mass of the latter products is consistent with detection of KLK4-generated 
GRN fragments in gel slices 7/8 in PROTOMAP analysis (Figure 3.17). However, 
unlike PROTOMAP analysis, where intact GRN was not detected in the KLK4-  
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Figure 3.17. Peptograph for the putative KLK4 substrate, GRN, in PC-3 cell CM. Peptograph 
displays all significantly identified peptides (coloured boxes) from gel slices (Y-axis, 1-32), with the 
corresponding protein amino acid residue (X-axis). The expected molecular weight of proteins in each 
gel slice is annotated, left. A schematic of selected protein domains, based on annotations in the 
UniProtKB, is beneath the X-axis (pale blue boxes), aligned with appropriate residues. These include 
GRN product chains 1-7 and paragranulin (P). Peptides are coloured according to the condition from 
which they were derived: KLK4-treated (Tr; red), KLK4-transfected (Tx; blue) or control (Ctr; 
yellow). Peptides found in KLK4-treated and KLK4-transfected conditions are purple, while those 
found in the control and either KLK4-treated or KLK4-transfected conditions are orange and green, 
respectively. Peptides derived from all samples are represented by black boxes (see colour key, 
bottom left). Peptides isolated from KLK4-generated fragments (red boxes within gel slices 8-18) 
align with components of the GRN-3 and GRN-4 sequences, and flank GRN-5 (pink shading). These 
fragments were larger than expected of GRN-3, -4 and -5 (pink shaded arrowhead). GRN migration in 
control and KLK4-transfected samples (yellow, blue and green boxes, gel slices 2-4) was also larger 
than expected of the GRN monomer (open arrowhead). Selected residues/ chains are annotated (blue 
lined arrowheads/ arrows).  
Colour key 
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Figure 3.18. SDS-PAGE/ silver stain analysis of KLK4-treated recombinant GRN. KLK4 cleaved 
GRN at molar ratios of GRN: active KLK4 ranging from 2:1 to 16:1 (lanes 3-6), but not with lesser 
concentrations of KLK4 (32:1 to 256:1; lanes 7-10). Addition of the serine protease inhibitor, 
aprotinin, abolished KLK4-mediated hydrolysis of GRN (lane 14). Treatment with amounts of total 
mKLK4 equivalent to the annotated treatment ratios did not induce GRN hydrolysis (lane 11). 
Controls included samples containing only GRN (lane 2), KLK4 (lane 12) or mKLK4 (lane 13), as 
well as aprotinin-treated GRN (lane 15). Protein standard was loaded in lane 1. Grey filled arrowhead 
denotes the expected migration of intact recombinant GRN; open arrowheads denote GRN bands 
degraded by KLK4; black filled arrowheads denote KLK4-generated GRN cleavage products. The 
relative migration of KLK4 (predominant band) and aprotinin is annotated. 
treated sample, intact recombinant GRN was the most intensely stained protein band 
upon KLK4 treatment at each concentration employed. Thus, KLK4 induced limited 
direct digestion of GRN, requiring a relatively high amount of activating protease to 
cleave the protein. As such, GRN may not be a direct KLK4 substrate, but may 
instead be cleaved by KLK4-activated proteases produced by prostate cancer cells. 
Alternatively, other factors present in PC-3 cell CM may aid KLK4-mediated 
digestion of GRN, such as binding partners that could expose KLK4 cleavage sites. 
Thus, while KLK4 activates pro-MMP1 to produce an active protease, it is unlikely 
that direct KLK4-mediated proteolysis of GRN produces bioactive GRN products.  
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3.4 Discussion 
The aim of this chapter was to identify prostate cancer cell-secreted substrates of 
KLK4. The identification of the KLK4 degradome serves a two-fold purpose in that 
it aids in: (1) delineating the proteolytic mechanism of KLK4 in established KLK4-
regulated cancer-associated functions; and (2) identifying novel putative functional 
roles for the protease, to target validation assays towards these processes. In the 
present study, 30 KLK4 substrates were identified in prostate cancer cell secretions 
using the PROTOMAP approach. Among these was the known KLK4 substrate, uPA 
(Takayama et al., 2001), the identification of which served to validate this approach. 
The remaining putative substrates identified were novel KLK4 substrates, extending 
the list of established (non-KLK) KLK4 substrates from 18 (Chun et al., 2010; 
Lawrence, Lai & Clements, 2010; Sanchez et al., 2012) to 47. As such, this study has 
made a significant contribution to knowledge of KLK4-mediated proteolysis of 
prostate cancer cell-derived proteins. 
3.4.1 KLK4-mediated substrate hydrolysis determined by PROTOMAP 
provides confidence that substrates are physiological KLK4 targets 
Not only did the present study identify 29 novel targets for KLK4, the method 
employed confers confidence in the ability for KLK4 to cleave these 29 proteins in 
the complex protein milieu of the prostate tumour microenvironment. This has not 
been demonstrated for the majority of previously identified KLK4 substrates. 
Disregarding those KLK4 substrates identified in teeth (Bartlett & Simmer, 2014), 
KLK4 has been demonstrated to cleave only three previously delineated substrates 
within a prostate cancer cell-derived protein background, namely PAR-1, PAR-2 and 
uPAR (Beaufort et al., 2006; Mize, Wang & Takayama, 2008; Ramsay et al., 2008). 
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As KLK4-mediated hydrolysis of the remaining previously established non-KLK4 
substrates has been demonstrated only using in vitro biochemical assays, it is unclear 
whether these are physiological KLK4 substrates.  
Contrary to earlier approaches used to identify KLK4 substrates, the PROTOMAP 
approach allows for simultaneous identification of all detectable protein cleavage 
events in a cell-derived protein pool. KLK4 substrate screening was performed on 
proteins produced by two prostate cancer cell-derived protein pools, as compared to 
screening of individual purified or recombinant proteins in biochemical assays. Use 
of the PROTOMAP approach to delineate KLK4 substrates diminishes bias in 
selecting substrates to be screened. Further, substrates identified are produced and 
secreted by prostate cancer cells, and thus may be accessible to KLK4 in vivo. 
KLK4-mediated proteolysis was demonstrated in a protein landscape mimetic of that 
produced by prostate cancer cells in vivo, a far more physiologically relevant 
background than demonstrating proteolysis of a single protein substrate as in in vitro 
biochemical assays. The former accounts for factors that may influence protease-
substrate interactions, including glycosylation, protein complex formation and 
binding of allosteric mediators or inhibitors. Therefore, as an improvement upon 
substrates identified by in vitro biochemical assays, there is increased confidence for 
KLK4 to hydrolyse the 30 substrates identified in the present study within the 
protein-rich extracellular milieu of the prostate tumour microenvironment. 
3.4.2 Direct and indirect targets of KLK4 were identified 
A further advantage of the PROTOMAP approach, over biochemical substrate 
screening assays, is that both direct and indirect proteolytic activity of the protease is 
measured. While indirect functions most obviously involve proteolytic activity 
resulting from KLK4-mediated activation of other pro-proteases, indirect proteolysis 
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may also result from KLK4-mediated degradation of protease inhibitors or KLK4-
mediated processing of allosteric modulators, cofactors, or other regulators of 
protease-substrate interactions. It is important that these indirect functions are 
identified in addition to direct functions, to avoid perturbing essential survival 
processes. For example, MMP3, -8 and -9 have been called anti-targets for cancer 
therapy, having essential pro-survival functions, albeit in addition to some tumour-
promoting functions (Overall & Kleifeld, 2006a, 2006b). It has been suggested that 
broad spectrum MMP inhibitor trials may have failed because inhibition of the pro-
survival functions of protective MMPs led to unacceptable side-effects (Overall & 
Kleifeld, 2006a, 2006b). As a single protease molecule may catalyse hydrolysis of 
multiple substrates, protease inhibition can have extensive knock-on effects. This is 
further exemplified in the ability of proteases to function in protease activation 
cascades, such as that established in blood coagulation (Lima & Monteiro, 2013) and 
the KLK activation cascade proposed for seminal clot liquefaction (Lawrence, Lai & 
Clements, 2010). Therefore, the need to define the indirect functions of KLK4 is as 
important as defining its direct targets, and the PROTOMAP approach allowed for 
the identification of different types of KLK4 substrates, where examples are 
described below.   
MMP1 was identified as a KLK4 substrate in PC-3 cell CM, and KLK4 was 
validated to directly activate pro-MMP1 in an in vitro biochemical assay. 
Conversely, direct KLK4-mediated cleavage of the mitogenic protein, GRN (Ong & 
Bateman, 2003), was limited, in comparison to KLK4-mediated cleavage of GRN in 
PC-3 cell CM. As such, other CM-derived components may be required to facilitate 
KLK4-mediated processing of this protein. For example, KLK may activate another 
protease which in turn activates GRN; or, another cell-secreted protease may prime 
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GRN for KLK4-mediated proteolysis. Alternatively, GRN may require a protein 
binding partner to promote cleavage site accessibility. Therefore, although direct 
interaction between KLK4 and GRN does not result in efficient GRN hydrolysis, 
KLK4 may indirectly induce GRN processing in the tumour microenvironment to 
regulate cancer growth. Thus, MMP1 and GRN represent direct and, likely indirect, 
targets of KLK4, respectively. 
Indirect KLK4-mediated functions within a cell-derived protein background may 
also abrogate the ability for KLK4 to cleave proteins that were able to be cleaved in 
isolation. For example, IGFBP6 was previously shown to be cleaved by KLK4 in an 
in vitro biochemical assay, albeit with lesser relative efficiency than IGFBP4-5 
(Matsumura et al., 2005a). However, IGFBP6 was not cleaved by KLK4 in prostate 
cancer cell secretions. While the observed result may be attributed to lack of 
detection of KLK4-generated IGFBP6 cleavage products, it may instead indicate that 
IGFBP6 is not a preferred KLK4 substrate when presented to the protease within a 
complex prostate cancer cell-derived protein background. As such, indirect KLK4-
mediated action in PC-3 cell CM may abrogate the ability for KLK4 to otherwise 
cleave individual protein substrates. Apart from uPA, IGFBP6 was the only 
previously published KLK4 substrate (Matsumura et al., 2005a) to be identified in 
prostate cancer cell secretions. Some of these proteins may be secreted by other cell 
types in the prostate tumour microenvironment. Determining indirect KLK4-
mediated functions is essential in defining the full extent of its activity in prostate 
cancer, and these functions must be delineated in a protein landscape similar to that 
observed in the prostate tumour microenvironment. The KLK4 substrates identified 
in PROTOMAP analysis of prostate cancer cell CM included both direct and indirect 
KLK4 targets, cleaved by KLK4 in a complex protein background.  
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The finding that KLK4 directly activated MMP1, which may have contributed to 
observation of indirect KLK4-mediated proteolytic events in PROTOMAP studies, is 
significant when considering KLK4 inhibition as a means of anti-cancer therapy. 
MMP1 has been deemed a well-validated anti-cancer target, primarily for its role in 
promoting breast cancer metastases (Overall & Kleifeld, 2006a, 2006b). MMP1 also 
has pro-tumourigenic functions in prostate cancer, where it promoted tumour growth 
and metastases of prostate cancer xenografts in vivo (Pulukuri & Rao, 2008). MMP1 
is over-produced in high-grade prostate cancer compared to low-grade cancers 
(Cardillo, Di Silverio & Gentile, 2006) and in serum from patients with metastatic 
prostate cancer versus localised disease (Baker et al., 1994). Primary cultures of 
patient-derived prostate cancer cells produce elevated levels of MMP1, as compared 
to BPH cells (Hart et al., 2002). Thus, as with KLK4, MMP1 is over-produced in 
prostate cancer, and is, therefore, a bioavailable target for KLK4 in the prostate 
tumour microenvironment. While selective inhibition of MMP1 may be difficult to 
achieve (Overall & Kleifeld, 2006b), selective inhibitors for KLK4 are being 
developed (Swedberg et al., 2011; Swedberg et al., 2009) and may serve as a means 
to inhibit both KLK4 and MMP1 activity in prostate cancer. As MMP1 appears to 
promote prostate tumourigenesis and metastasis, and KLK4 similarly has been 
associated in pro-tumourigenic activities (Table 1.1), the application of KLK4 
inhibitors as anti-cancer therapies may induce extensive reduction of tumour burden. 
Therefore, while indirect tumour-protective functions of certain proteases has 
prevented these proteases from being inhibited for cancer therapy (Overall & 
Kleifeld, 2006a, 2006b), KLK4-mediated activation of MMP1 and the resulting 
functional consequences will likely serve to increase the therapeutic potential of 
KLK4 inhibitors as drug candidates for prostate cancer.   
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3.4.3  Identification of novel KLK4 substrates suggests mechanisms for KLK4 
in established and novel KLK4-regulated pro-tumourigenic processes  
The aim of identifying KLK4 substrates in the present study was to determine 
proteolytic mechanisms of KLK4 action in established and novel KLK4-regulated 
processes. Cell-based studies have shown a role for KLK4 in important cancer-
promoting processes, including prostate cancer cell migration, EMT, proliferation 
and metastases (see Table 1.1). However, the mechanism by which KLK4 regulates 
these processes is unknown, excepting that KLK4-mediated activation of PAR-1 and 
PAR-2 was suggested to induce prostate cancer cell proliferation (Mize, Wang et al. 
2008). The role of KLK4 in this and other cancer-promoting processes requires 
investigation and may be informed by the identification of KLK4 substrates. This 
study has provided a baseline of substrates hydrolysed by KLK4 in prostate cancer 
cell secretions, where this knowledge may be built upon in future validation studies. 
Selected examples of putative KLK4-mediated regulation of pro-tumourigenic 
functions, via substrates identified herein, are provided below and this is summarised 
in Figure 3.19. 
KLK4 increases prostate cell migration (Gao et al., 2007; Klokk et al., 2007; 
Veveris-Lowe et al., 2005), and a number of KLK4 substrates identified in the 
present study are also implicated in this process. As stated above, MMP1 is a 
promising anti-cancer target. Over-expression of MMP1 in LNCaP cells induced cell 
migration and invasion in vitro and increased tumour burden in vivo (Pulukuri & 
Rao, 2008). These effects were reduced upon inhibition of MMP1 activity in PC-3 
cells, which produce endogenous MMP1 (Pulukuri & Rao, 2008). KLK4 was found 
to directly activate pro-MMP1; thus, KLK4 may promote prostate cancer migration 
via activating pro-MMP1. The KLK4 substrate, uPA, is over-produced in prostate  
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Figure 3.19. KLK4 substrates identified in CM from PC-3 and LNCaP cells implicated in 
various stages of prostate cancer progression. Selected KLK4 substrates discussed in relation to 
cancer-promoting functions are shown (references in text). Through inducing hydrolysis of GRN, 
MMP1 and uPA, KLK4 may initiate cell proliferation, migration and metastasis, processes in which 
KLK4 has previously been implicated. KLK4-mediated processing of TSP1 and MMP1 suggests a 
novel role for KLK4 in promoting angiogenesis.  
cancer (Li & Cozzi, 2007), and induces cell migration and invasion in vitro (Li & 
Cozzi, 2007; Smith & Marshall, 2010). As with MMP1 (Pulukuri & Rao, 2008), 
knockdown of uPA or its receptor, uPAR, in prostate cancer cells reduced tumour 
volume in mice (Zhang et al., 2011). Therefore, KLK4 appears to directly activate 
proteases that enhance prostate cancer migration and invasion. 
KLK4 was implicated in the homing of prostate cancer cells to bone using in vitro 
models (Gao et al., 2007). MMP1 is strongly expressed in prostate cancer bone 
metastases, and KLK4 and MMP1 production is induced upon co-culture of prostate 
cancer cells with bone-forming osteoblasts or bone marrow-derived stem cells, 
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respectively (Hart et al., 2002). Inhibition of MMP1 activity reduced colony growth 
of patient-derived prostate cancer or BPH cell co-cultures with bone marrow-derived 
stem cells (Hart et al., 2002). Further, MMP1 expressing prostate cancer cells 
exhibited increased rates of lung metastasis compared to MMP1-deficient 
counterparts in xenografts (Pulukuri & Rao, 2008). Thus, MMP1 functions to 
promote prostate cancer in both primary tissue and secondary disease. As KLK4 is 
highly produced in both of these stages, it may promote tumour progression through 
activation of pro-MMP1.  
The ability for KLK4 to cleave substrates associated with angiogenesis in prostate 
cancer cell CM implicates the protease to function in this process; KLK4 has not 
previously been associated with angiogenesis. Angiogenesis is integral to the 
survival and progression of expanding tumours (Hanahan & Weinberg, 2000, 2011). 
The KLK4 substrate, TSP1, is a well-established inhibitor of angiogenesis (Lawler & 
Lawler, 2012). TSP1 was cleaved in all three replicates of LNCaP cell CM, as well 
as PC-3 cell CM; thus, TSP1 represents a high confidence KLK4 substrate with 
possible KLK4-regulated functions in both early and late-stage disease. Being an 
inhibitor of angiogenesis, hydrolysis of TSP1 by KLK4 may abrogate its anti-
angiogenic effects, favouring tumour angiogenesis. PC-3 cell-derived MMP1 also 
promoted angiogenesis both in vitro and in vivo (Pulukuri & Rao, 2008). LNCaP 
tumours over-expressing MMP1 were highly vascularised compared to controls 
(Pulukuri & Rao, 2008). Hence, KLK4-mediated activation of MMP1 and putative 
TSP1 degradation implicates KLK4 in tumour-initiated angiogenesis, a process yet to 
be associated with KLK4 function. Thus, the low-bias, high-depth identification of 
KLK4 substrates in this study has outlined putative proteolytic mechanisms of KLK4 
action in established KLK4-regulated processes, as well as highlighting novel roles 
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for the protease in pro-tumourigenic processes, such as, angiogenesis. This work 
allows for informed hypotheses to be developed regarding the seemingly broad 
repertoire of KLK4-regulated functions in the prostate tumour microenvironment.  
3.4.4 Summary 
This study has extended the pool of putative (non-KLK) KLK4 substrates from 18 to 
47, significantly contributing to existing knowledge of KLK4-mediated proteolysis 
in prostate cancer. This is the first published study to perform a high-depth protein-
centric substrate analysis of an individual, proteolytically active KLK, where such 
analysis is necessary to place its activity in context of the greater protease web. This 
work is a benchmark investigation of KLK activity, where similar studies must be 
performed for other of the prostate cancer cell-expressed KLKs to delineate 
individual functions for these proteases in this complex disease.  
The aim of the present chapter was achieved in that the substrates identified herein 
constitute putative mechanistic intermediates of KLK4 activity in prostate cancer. In 
particular, were substrates which function in processes known to be regulated by 
KLK4, such as cell migration and metastases (MMP1, uPA), as well as novel 
putative KLK4-regulated processes, including angiogenesis (MMP1, TSP1). MMP1 
was shown to be directly activated by KLK4, while the pro-proliferative protein, 
GRN, was not an efficient direct KLK4 substrate and may require hydrolysis by 
endogenous proteases. Identification of 29 novel prostate cancer cell-derived KLK4 
substrates has established a baseline of KLK4 activity in prostate cancer, which may 
be built upon in future functional validation studies.  
It was next sought to determine KLK4-regulated signalling pathways in prostate 
cancer cells (Chapter 4), to add an additional level of mechanistic insight into KLK4 
function in prostate cancer. The overarching aim of this element of the study was to 
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combine knowledge of KLK4 substrates (present chapter) with that of KLK4-
regulated genes (Chapter 4) to gain a comprehensive overview of KLK4 action in 
prostate cancer.   
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4.1 Introduction 
KLK4-mediated processing of prostate cancer cell-derived signalling molecules, 
identified in Chapter 3, likely interferes with the downstream signalling pathways 
regulated by these molecules. Indeed, transcriptional regulation via extracellular 
proteolysis of ligands and/ or receptors is a widely accepted mechanism of action for 
a variety of proteases (Fortelny et al., 2014). No studies to date have assessed the 
effect of KLK4-mediated proteolysis on gene expression in prostate cancer cells 
using high-depth approaches. Determining KLK4-regulated genes in the prostate 
tumour microenvironment, which can be linked to a plausible proteolytic 
mechanism, is an important step in gauging the depth and nature of KLK4 function 
in this disease. 
In previous work by the Clements group, KLK4 over-expression in PC-3 prostate 
cancer cells induced vimentin (VIM) expression, while down-regulating E-cadherin 
(CDH1) expression, indicative of an EMT. However, the proteolytic activity of 
KLK4 in this system was not confirmed and putative substrate intermediates not 
determined (Veveris-Lowe et al., 2005). Two additional studies have assessed 
KLK4-mediated effects on gene transcription in prostate cancer cells. However, 
these analysed the exon 1-deficient, intracellular KLK4 isoform, which likely does 
not have any proteolytic activity, but has recently been shown to regulate AR 
regulatory mechanisms in the nucleus (Jin et al., 2013; Klokk et al., 2007). Given 
these limited findings, there is a need for a global assessment of genes regulated in 
response to KLK4-mediated proteolysis in prostate cancer. 
To identify global KLK4-mediated gene expression changes in prostate cancer cells, 
prostate cancer LNCaP and PC-3 cell lines were treated with recombinant active 
KLK4. Gene expression profiling was performed using a custom RNA microarray 
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platform, analysing the expression of ~20,047 genes. It was hypothesised that 
extracellular KLK4-mediated proteolysis activates or inactivates signalling pathways 
in prostate cancer cells, particularly those regulated by the KLK4 substrates 
identified in Chapter 3, resulting in downstream gene expression alterations.  
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4.2 Materials and Methods 
4.2.1 Zymography analysis of KLK4 activity in LNCaP cell CM 
Prior to washing cells in ice cold DPBS (4.1.1), CM was harvested in the absence of 
protease inhibitors and otherwise prepared as per 2.2. Gelatin zymography was 
performed using CM harvested from PBS-treated (called untreated), mKLK4-treated 
or KLK4-treated cells, from two biological replicate experiments. Lanes contained 
CM (25 µL) with the equivalent amount of 0.5 pmol active (1.8 pmol total) KLK4 or 
1.8 pmol total mKLK4 in respective samples. Positive and negative controls for 
zymography analysis constituted freshly defrosted KLK4 diluted in PBS (0.5 pmol 
active; 1.8 pmol total) alone or with the serine protease inhibitor, aprotinin (1.9 µM 
final; 500-fold molar excess to active KLK4). mKLK4 only (1.8 pmol total; freshly 
prepared) was an additional negative control, as well as KLK4-treated CM incubated 
with aprotinin, as above.  
4.2.2 Peptide substrate hydrolysis assay for KLK4 activity in LNCaP cell CM 
Peptidolytic activity of aliquots from all of the above samples was measured using 
the fluorogenic peptide substrate, VLR-AFC (10 µM final; 2,580-fold molar excess 
to active KLK4), as per 3.2.1h. For this analysis, aprotinin was added to samples 10 
min prior to assaying, whereupon all samples were incubated (37 ºC, 10 min). The 
change in RFU per min (ΔRFU/ min) was expressed as percentage of that of the 
positive control. Each sample was analysed in technical duplicates.  
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4.2.3 Harvesting RNA from KLK4-treated prostate cancer cells for gene 
expression analyses 
LNCaP (6.17 × 10
5
 cells/ T-25 flask; passage 26-27) or PC-3 cells [8 × 10
4
 cells/ 
well (6-well plate); passage 29-32] were seeded on tissue culture grade plastic (Nunc, 
LNCaP cells) and grown for 72 h at 37 ºC in humidified conditions and 5% CO2. 
Cells were washed 2 × in DPBS (Life Technologies; 5 min, RT), before culturing in 
serum-free media (30 h). 20 nM (LNCaP) or 25 nM (PC-3) KLK4 was added into the 
respective cell culture media, and cells were cultured for an additional 18 h. For 
control treatments, equivalent total amounts of mKLK4, or PBS buffer control 
[called untreated; 2 × 10
-1
% (v/v) final concentration; Life Technologies], were 
instead added into the cell culture media. Cells were washed in ice cold DPBS prior 
to RNA extraction as per 2.8. Experiments were performed in biological triplicates.  
There have been no studies assessing gene expression alterations following cell 
treatment with recombinant active KLK4; however, the conditions for KLK4 
treatment of LNCaP and PC-3 cells in the present study were selected in accordance 
with those used in other studies where prostate cells were treated with active 
recombinant KLK4 and this elicited a cellular response. Particularly, treatment of 
LNCaP, PC-3 and DU145 cells with 50 nM KLK4 induced ERK1/2 phosphorylation 
within 3 min of treatment; ERK1/2 remained phosphorylated 8 h following DU145 
cell treatment (Mize, Wang & Takayama, 2008). Treatment of serum-starved DU145 
cells with 10 nM KLK4 (24 h) induced cell proliferation (Mize, Wang & Takayama, 
2008). Furthermore, WPMY-1 prostate myofibroblasts treated with active 
recombinant KLK4, at concentrations as low as 1 and 10 nM, exhibited ERK 1/2 
phosphorylation. Treatment with either 10 or 50 nM KLK4 significantly induced IL-
6 protein secretion from these cells (Wang et al., 2010). Gene expression profiling of 
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PSA-treated HUVEC cells was measured on a similar microarray platform to that 
employed in the present study, where 311 genes were differentially regulated 
following 18 h treatment (Mattsson et al., 2008a). Thus, for the present work, 
LNCaP cells were treated with 20 nM KLK4 for 18 h. This was the maximum 
feasible KLK4 treatment concentration, given the large quantity of cells to be treated 
in replicate microarray analyses, which was still within the range of concentrations 
previously shown to elicit a cellular response. Following the poor transcriptional 
response observed upon KLK4 treatment of LNCaP cells, this concentration was 
increased to 25 nM for treatment of PC-3 cells, representing the largest increase 
practicable. 
4.2.4 Sample preparation for RNA microarray analyses 
Potential contaminating DNA in RNA preparations (4.2.3) was degraded using 
DNase (Life Technologies) according to the manufacturer’s instructions. RNA purity 
and quality was assessed using a NanoDrop1000 and Agilent 2100 Bioanalyzer, 
where all samples displayed A260/ 280 > 1.8 and RNA integrity number (RIN) > 
7.5, respectively. RNA (150 ng per sample) was amplified and labelled using the 
Agilent Low Input Quick Amp Labeling Kit for One-Color Microarray-Based Gene 
Expression Analysis. In brief, input RNA was reverse transcribed into cDNA using 
an oligo-dT/ T7-promoter hybrid primer, which introduces a T7 promoter region into 
the newly synthesised cDNA. The subsequent in vitro transcription employs a T7 
RNA polymerase, which simultaneously amplifies the target material and 
incorporates cyanine 3-labeled cytidine triphosphate. cDNA synthesis and in vitro 
transcription were performed at 40 °C for 2 h, respectively. Labelled cRNA was 
purified using the RNeasy Mini Kit (Qiagen) and quantified on a NanoDrop1000. 
Finally, cRNA (1,650 ng) was hybridised (65 °C, 17 h) onto a custom Agilent 180K 
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RNA microarray platform and the microarrays subsequently scanned on an Agilent 
Microarray Scanner G2565CA (biological triplicates analysed).
4.2.5 Microarray data analysis to identify significantly regulated genes 
The microarray raw data were processed using the Agilent Feature Extraction 
Software (v10.7). A quantile between array normalization was applied and 
differential expression was determined using the Baysian adjusted t-statistic linear 
model of the Linear Models for Microarray Data (LIMMA) package in R. The P-
values were corrected for a FDR of 5%. The gene expression levels are presented as 
log2 and were compared between two groups with a t-test. Genes that were 
significantly different between two groups were identified with adjusted P ≤ 0.05, 
and an average fold change ≥ 2.  
4.2.6 Using IPA to identify putative mechanisms of KLK4-induced gene 
transcription in prostate cancer cells 
4.2.6a Elucidating direct mechanisms 
IPA was employed to annotate the cellular localisation of gene-encoded products. 
The Grow tool in IPA was used to draw relationships between KLK4-regulated 
genes in PC-3 or LNCaP cells (above) and prostate cancer cell-derived KLK4 
substrates identified in Chapter 3. These relationships were limited to upstream 
regulation of expression or transcription. This analysis identified those KLK4 
substrates capable of regulating genes that were found to be KLK4-regulated.  
4.2.6b Elucidating indirect mechanisms 
To determine whether KLK4 cleaved one or more substrates which interact with 
other extracellular or cell surface proteins to regulate the expression of genes that 
were found to be KLK4-regulated, the IPA Grow tool was used. A list of all proteins, 
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which can regulate gene expression or transcription of KLK4-regulated genes, was 
developed. Those without extracellular or plasma membrane localisation were 
discarded. The IPA Grow tool was used to draw relationships between KLK4 
substrates capable of directly regulating any of the above proteins; relationships were 
limited to regulation of activity or inhibition. Proteins not regulated by KLK4 
substrates were discarded. This analysis identified KLK4 substrates capable of 
directly regulating the activity of extracellular or plasma membrane proteins, which 
may regulate the expression of those genes found to be KLK4-regulated.  
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4.3 Results 
4.3.1 KLK4 was active in LNCaP cell CM over 18 h 
To ensure that KLK4 was active during LNCaP cell treatment, and was not 
inactivated by secreted endogenous protease inhibitors or other proteases, CM from 
KLK4-treated LNCaP cells was analysed by gelatine zymography (Figure 4.1 A) and 
in a peptide substrate hydrolysis assay (Figure 4.1 B). The equivalent amount of 
stock KLK4 freshly diluted in PBS was employed as a positive control. Gelatinolytic 
activity was observed at 21, 22 and 23 kDa in lanes containing active KLK4, in the 
absence of the serine protease inhibitor, aprotinin (lanes 4-5 and 7; Figure 4.1 A). 
Gelatinolysis was evident in LNCaP cell CM samples after active KLK4 treatment 
(lanes 4-5), although this was reduced in comparison to the freshly prepared protease 
(lane 7; Figure 4.1 A). Aprotinin addition abolished KLK4 activity in PBS (lane 8) or 
in LNCaP cell CM (lane 6; Figure 4.1 A). Samples containing mKLK4 were 
appropriately negative for gelatinolytic activity (lanes 2-3 and 9; Figure 4.1 A). 
Similarly, gelatine clearings were not observed in lanes containing LNCaP cell CM 
treated with PBS buffer control (lane 1; Figure 4.1 A).  
As a complementary approach, KLK4 activity was measured against its ability to 
cleave a KLK4-specific peptide substrate (Figure 4.1 B). Zymography assesses only 
SDS-stable, covalent, or irreversible protease inhibition. Conversely, the peptide 
hydrolysis assay was important in determining whether KLK4 activity may have 
been inhibited by a non-covalent inhibitor in LNCaP cell CM, or an inhibitor 
incapable of forming an SDS-stable complex with KLK4. Active KLK4-containing 
samples demonstrated peptidolysis (samples 4-5 and 7) and this activity was 
abolished by aprotinin (samples 6 and 8; Figure 4.1 B). Samples treated with  
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Figure 4.1. Activity of KLK4 following LNCaP cell treatment, measured using gelatine 
zymography (A) or a fluorogenic peptide substrate hydrolysis assay (B). For (A), white clearings 
indicate gelatinolysis. Superscript numbers describe the biological replicate experiment from which 
the sample was derived. In (B), the corrected (corr.) ΔRFU/ min was expressed as a percentage, 
normalised to that of freshly defrosted and diluted KLK4, which was employed as a positive control 
(sample 7). Error bars indicate range of technical duplicates. For (A) and (B), KLK4 was active in the 
positive control (sample 7) and following LNCaP cell treatment (samples 4-5). This activity was 
abolished with the addition of the serine protease inhibitor, aprotinin, which was added following cell 
treatment, but prior to performing the peptide hydrolysis assay (samples 6 and 8). No activity was 
observed in samples containing mKLK4 alone (sample 9) or on cells (samples 2-3), or LNCaP cell 
CM, treated only with buffer (sample 1). Arrowheads indicate molecular weight regions of KLK4-
induced gelatine clearing.  
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mKLK4 (samples 2-3 and 9) were appropriately negative for peptidolytic activity 
(Figure 4.1 B). LNCaP cell CM, alone, similarly did not induce peptidolysis (sample 
1; Figure 4.1 B).  
KLK4 activity in the presence of background proteins is not comparable to activity in 
PBS alone, where protease access to the substrate is unobstructed in the latter. As 
such, the peptide substrate hydrolysis assay was conducted only as a qualitative 
measure of KLK4 activity following 18 h cell treatment, and does not inform as to 
the fold-change loss in KLK4 activity observed with zymography analysis. 
Nonetheless, two complementary approaches confirmed that KLK4 remained active 
following 18 h treatment of LNCaP cells.  
4.3.2 KLK4 treatment of prostate cancer cells yielded a modest number of 
gene expression changes 
Prostate cancer LNCaP or PC-3 cells were serum-starved and treated with 20 or 25 
nM active KLK4, respectively, and global KLK4-regulated gene expression changes 
analysed. In KLK4-treated LNCaP cells, only one gene, lectin, galactoside-binding, 
soluble 3 (LGALS3), was differentially regulated (Figure 4.2 A). Similarly, in PC-3 
cells, only two genes were differentially regulated by KLK4, namely, adenosine 
deaminase, RNA-specific, B1 (ADARB1) and fms-related tyrosine kinase 1 (FLT1; 
Figure 4.2 B). Each of these genes was up-regulated by KLK4; KLK4 did not down-
regulate expression of any of the genes measured in LNCaP or PC-3 cells. While the 
expression of LGALS3, ADARB1 and FLT1 was assessed by multiple probes, only 
one (of four), four (of 12) and one (of 29) probes, respectively, exhibited up-
regulated gene expression upon KLK4 treatment (Supplementary Table 4.1 and 4.2). 
For ADARB1, the four up-regulated probes target the region spanning the terminal 
exon and the beginning of the 3’UTR of this gene; one of the remaining  
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Figure 4.2. Volcano plot of differential gene expression in KLK4-treated prostate cancer LNCaP 
(A) or PC-3 cells (B). The fold-change gene expression increase or decrease (log2 transformed; X-
axis) in KLK4-treated, versus mKLK4 control-treated, cells is plotted for individual genes (blue data 
points) alongside the corresponding P value statistic (negative log10-transformed; Y-axis). KLK4 
significantly up-regulated (≥ 2-fold, P ≤ 0.05; red boxes) the expression of only one gene, lectin 
galactoside-binding soluble 3 (LGALS3), in LNCaP cells, and two genes, fms-related tyrosine kinase 1 
(FLT1) and adenosine deaminase RNA-specific B1 (ADARB1), in PC-3 cells. KLK4 did not 
negatively regulate (≤ -2-fold, P ≤ 0.05; green boxes) gene expression in either cell line. 
A 
B 
 Chapter 4: Determining the KLK4-regulated transcriptome in prostate cancer cells 154      154 
eight probes, which were not up-regulated, also mapped to this region 
(Supplementary Table 4.2). 
Other than these three genes, no other genes were significantly regulated by KLK4 in 
LNCaP or PC-3 cells (P ≤ 0.05; Y-axis, Figure 4.2), irrespective of the fold-change 
cut-off employed (X-axis, Figure 4.2). That is, even by relaxing the fold-change cut-
off to consider genes regulated by KLK4 ≥ 1.1-fold and ≤ -1.1-fold, only three genes 
remained significantly regulated, as all other genes were regulated with P values > 
0.05. Importantly, treating either cell line with mKLK4 did not induce any gene 
expression changes (Supplementary Table 4.1 and 4.2). Complete, detailed gene 
expression data is presented in Supplementary Table 4.1 (LNCaP) and 4.2 (PC-3). 
Overall, under the conditions employed herein, active KLK4 treatment had little 
effect on regulating the transcriptome of LNCaP or PC-3 cells. 
4.3.3 Elucidating a putative proteolytic mechanism for KLK4-induced gene 
expression in LNCaP and PC-3 cells 
Finally, it was sought to link putative KLK4 substrates identified in LNCaP and PC-
3 cell CM (Chapter 3) with regulation of the three above-mentioned genes in these 
cells. There were no KLK4 substrates produced by either cell line that were 
annotated in the IPA database to be able to regulate the expression of LGALS3, FLT1 
or ADARB1 in respective cell lines. As such, it was hypothesised that KLK4 
substrates may alter the activity of other proteins capable of regulating these genes. 
KLK4-mediated proteolysis of such substrates may be a means by which KLK4 
regulated the expression of LGALS3, FLT1 and ADARB1. Two extracellular or 
plasma membrane-localised proteins were identified that regulate the expression of 
FLT1 and ADARB1, and are themselves directly activated or inhibited by KLK4 
substrates. These proteins were thrombin (F2 in Figure 4.3) and TGFβ1 (TGFB1 in 
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Figure 4.3. Putative proteolytic mechanism for KLK4-mediated gene expression regulation in 
LNCaP or PC-3 cells. KLK4 significantly up-regulated expression of LGALS3 and FLT1 in PC-3 or 
LNCaP cells, respectively (P ≤ 0.05, ≥ 2-fold; red shapes, bottom quadrant). Of the KLK4 substrates 
(white shapes) secreted by these cells (identified in Chapter 3), those KLK4 substrates (top right 
quadrant) that may directly interact with other cell-secreted or plasma membrane proteins (top left 
quadrant) capable of regulating expression of the identified KLK4-regulated genes are shown. Serpin 
peptidase inhibitor clade E (nexin, plasminogen activator inhibitor type 1) member 2 (SERPINE2) 
degradation by KLK4 may have activated (orange filled arrow) thrombin (F2) to up-regulate (orange 
dashed arrow) FLT1 expression in PC-3 cells. Degradation of fibronectin 1 (FN1) and THBS1 by 
KLK4 may have reduced TGFβ1 activity (blue filled arrow) in PC-3 cells, which would result in 
down-regulation of FLT1 expression, contrary to what was observed (yellow dashed arrow). In 
contrast, THBS1 degradation in LNCaP cells may have induced LGALS3 up-regulation via reduction 
of TGFβ1 activity, as TGFβ1 represses LGALS3 expression (blunt-ended arrow).  
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Figure 4.3), which each up-regulate FLT1 expression; TGFβ1 can also down-regulate 
LGALS3 expression.  
Thrombin and TGFβ1 would need to be activated by KLK4 in order to up-regulate 
FLT1 expression in PC-3 cells. Conversely, TGFβ1 would be required to be 
inactivated by KLK4 to induce LGALS3 expression in LNCaP cells (Figure 4.3). 
KLK4-mediated degradation of the thrombin inhibitor, serpin peptidase inhibitor 
clade E (nexin, plasminogen activator inhibitor type 1) member 2 (SERPINE2 in 
Figure 4.3 or GDN in Table 3.1), in PC-3 cell CM is a plausible mechanism by 
which the former may have occurred (Figure 4.3). KLK4 also cleaved TSP1 (THBS1 
in Figure 4.3) and fibronectin 1 (FN1 in Figure 4.3) in PC-3 cell CM. Assuming 
KLK4-mediated proteolysis degraded TSP1 and fibronectin 1, this would be 
expected to reduce TGFβ1 activity, thereby down-regulating FLT1 expression, 
contrary to its observed up-regulation (Figure 4.3). Thus, these substrates do not 
likely mediate regulation of FLT1 expression by KLK4 in PC-3 cells. Conversely, 
TGFβ1 down-regulates LGALS3 expression; therefore, degradation of TSP1 in 
LNCaP cell CM may mediate up-regulation of LGALS3 expression in in LNCaP cells 
(Figure 4.3). 
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4.4 Discussion 
KLK4 regulated only three genes collectively in LNCaP and PC-3 cells. KLK4-
regulated genes in PC-3 cells included ADARB1 and FLT1. ADARB1 encodes a 
double-stranded RNA editing enzyme, double-stranded RNA-specific editase 1 
(ADARB1), and is up-regulated in moderately and poorly differentiated prostate 
tumours, compared to normal glands of the peripheral zone (Shaikhibrahim et al., 
2013). RNA editing events mediated by enzymes such as ADARB1 can result in 
small changes to the translated protein, such as amino acid substitutions, or more 
extensive changes, such as whole exon deletions arising from modified splice sites. 
However, these enzymes more commonly interact with non-coding sequences and 
have been linked to regulation of micro-RNA function (Nishikura, 2010). With 
regards to prostate cancer, PC-3 cells express higher levels of ADARB1 than LNCaP 
cells, and this was concordant with a higher level of editing of AR transcripts. It was 
suggested that ADARB1-mediated RNA editing of AR transcripts may constitute a 
mechanism by which PC-3 cells modify AR activity and convert to a hormone 
refractory phenotype (Martinez et al., 2008). Paradoxically, the level of nucleotide A 
to I substitutions, characteristic of ADARB1-mediated RNA editing, was decreased 
in prostate cancer tissue versus normal tissue (Paz et al., 2007). As KLK4 expression 
is increased in prostate cancer tissue (Table 1.2), the biological significance of 
KLK4-mediated up-regulation of ADARB1 expression in the present study is unclear. 
KLK4 also up-regulated expression of FLT1, which encodes VEGF receptor 1 
(VEGFR1). FLT1 mRNA and VEGFR1 protein levels are elevated in prostate cancer 
and PIN (Jackson et al., 2002; Woollard et al., 2013), concordant with the elevated 
expression of KLK4 in each pathology [Table 1.2 and (Bui, 2006)]. Interestingly, 
single nucleotide polymorphisms in the androgen-response element of FLT1 are 
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associated with increased prostate cancer-specific mortality in patients being treated 
with androgen deprivation therapy (Huang et al., 2012); thus, VEGFR1 may be 
functionally important to prostate cancer progression. While VEGFR1 promotes 
angiogenesis when produced in endothelial cells (Bae et al., 2005), the function of 
prostate cancer cell-produced VEGFR1 has not yet been elucidated. Cell motility of a 
metastatic rat prostate cancer cell line, expressing functional VEGFR1, was 
increased upon stimulation with its ligand, VEGF (Soker et al., 2001). Conversely, 
the non-metastatic cell line, from which these cells were derived, did not produce 
VEGFR1 and did not respond to VEGF stimulation (Soker et al., 2001). Thus, 
KLK4-mediated up-regulation of FLT1 may promote prostate cancer cell motility.  
LGALS3 is methylated in LNCaP cells and prostate cancer tissue (Ahmed, Banerjee 
& Vasta, 2007; Ahmed et al., 2009). Further, abundance of its encoded product, 
galectin-3, is reduced in advanced prostate cancer tissue versus early-stage tumours 
or PIN (Ahmed et al., 2009). Galectin-3 is found in the cytoplasm in advanced 
prostate cancer tissue, as opposed to both nuclear and cytoplasmic expression in 
benign tissue (Ahmed et al., 2009). Cytoplasmic galectin-3 staining in advanced 
cancer was an independent predictor of disease progression (van den Brule et al., 
2000). Over-expression of a galectin-3 form localised to the cytoplasm induced 
LNCaP cell growth (Califice et al., 2004). Thus, KLK4-mediated induction of 
LGALS3 may promote prostate cancer growth. Notably, PC-3 cells also produce 
galectin-3 (Pacis et al., 2000); however, KLK4 induced LGALS3 expression only in 
LNCaP cells. Therefore, the mechanism by which KLK4 may regulate LGALS3 
expression may be specific to the latter cell line. 
The overarching aim of this study was to link putative extracellular KLK4 substrates 
to downstream cellular signalling. Pathway analysis tools were used to show that 
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KLK4-mediated degradation of SERPINE2 may increase thrombin activity, resulting 
in subsequent up-regulation of FLT1 expression. SERPINE2 was present in both 
LNCaP and PC-3 cell CM, but cleaved by KLK4 only in the latter (Chapter 3), 
supporting the hypothesis that KLK4-mediated SERPINE2 degradation may 
indirectly result in up-regulated expression of FLT1. The primary thrombin receptor 
is PAR-1, where PAR-1 and PAR-2 are also activated by KLK4 on the surface of 
both PC-3 and LNCaP cells (Mize, Wang & Takayama, 2008). Thus, another 
possible mechanism for KLK4-mediated up-regulation of FLT1 is via direct PAR-1 
activation. However, FLT1 expression was only induced by KLK4 in PC-3 cells, and 
not in LNCaP cells in which PAR-1 and PAR-2 are also activated by KLK4. This 
suggests that PAR-1 activation may not mediate KLK4-regulated FLT1 expression. 
In addition to FLT1, the mechanisms for KLK4-mediated induction of ADARB1 and 
LGALS3 expression require further investigation. 
Overall, the effect of KLK4 on gene expression in prostate cancer cells was 
surprisingly limited. Previously reported KLK4-mediated expression of VIM or 
CDH1 (Veveris-Lowe et al., 2005) was not confirmed in the present study. KLK4-
mediated regulation of gene expression may be initiated via direct activation of cell 
surface receptors, such as PAR-1 or PAR-2. Alternatively, KLK4 may hydrolyse 
ligands to affect ligand-receptor interactions and perturb downstream gene 
expression. Although some plasma membrane proteins were identified as KLK4 
substrates in Chapter 3, these were released into the CM prior to KLK4-mediated 
proteolysis. As such, it is unknown whether KLK4 may cleave these membrane-
tethered substrates on the cell surface. Nonetheless, KLK4-mediated PAR-1 and 
PAR-2 activation on the surface of LNCaP and PC-3 cells (above) induced ERK1/2 
signalling; however, resulting KLK4-mediated gene expression was not reported. 
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Indeed, transcriptional regulation induced by PAR-1 and PAR-2 signalling in LNCaP 
and PC-3 cells is not well reported. Treatment of either cell line with a PAR-2 
agonist increased the amount of active MMP2 and MMP9 in cell CM (Wilson et al., 
2004). Further, PAR-1 activation on PC-3 cells induced IL-6 and IL-8 secretion 
(Tantivejkul et al., 2005). This also regulated cell attachment, although without 
affecting gene expression of cell surface integrins (Loberg et al., 2007). Regulation 
of genes encoding the above proteins, however, was not observed upon KLK4 
treatment of PC-3 or LNCaP cells.  
Considering the scenario of KLK4 acting on receptor ligands to influence gene 
expression, these receptors or pathways may not be produced in LNCaP or PC-3 
cells. For example, the KLK4 substrate, prosaposin (Chapter 3), was shown to 
activate AR and induce androgen-regulated gene expression in LNCaP cells 
(Koochekpour et al., 2007). In the present study, KLK4 cleaved prosaposin in PC-3 
cell CM; however, PC-3 cells do not express a functional AR. Thus, KLK4-mediated 
gene expression may require a functional AR, or other receptors or signalling 
pathways. Additionally, many KLK4 substrates identified are known regulators of 
other cell types in the prostate tumour microenvironment. For example, as discussed 
in Chapter 3, the novel identified KLK4 substrates, TSP1 and MMP1, interact with 
endothelial cells and have established roles in tumour angiogenesis (Lawler & 
Lawler, 2012; Pulukuri & Rao, 2008). TSP1 also functions in activating stromal 
TGFβ1 signalling (Fitchev et al., 2010). Thus, given the findings of the present 
chapter, it was hypothesised that KLK4 may have a greater regulatory role on gene 
expression in tumour-adjacent stromal cells, and this was investigated in Chapter 5. 
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5.1 Introduction 
The findings from Chapter 4 led to the supposition that KLK4 may have a greater 
impact on regulating cellular signalling cascades in tumour-adjacent stromal cells, as 
compared to prostate cancer cells. KLK4 is over-produced by both basal and luminal 
epithelial cells in the pre-cancerous condition, PIN (Bui, 2006), whereupon the basal 
lamina is breached (Barron & Rowley, 2012; Tuxhorn et al., 2002). Therein, prostate 
cancer cell-secreted proteins, such as KLK4, are positioned to interact with the 
surrounding stroma. The degree of interaction between KLK4 and stromal cell 
components likely increases as the tumour expands and invades further into the 
surrounding stroma. Among prostate stromal cell types, myofibroblasts are highly 
secretory and are believed to secrete the abundance of ECM in the prostate reactive 
stroma (Barron & Rowley, 2012). As such, many proteins likely accessible to KLK4 
in the tumour microenvironment are myofibroblast-derived. Myofibroblasts are 
highly responsive to changes in the surrounding ECM, given the role of these cells to 
repair breaches in the proteinaceous basal lamina (Barron & Rowley, 2012). 
Accordingly, KLK4-mediated proteolysis of myofibroblast-derived ECM and other 
signalling factors would be expected to result in marked changes to myofibroblast 
signalling.  
Given the importance of the bi-directional interactions between prostate cancer cells 
and activated fibroblasts (outlined in Chapter 1), the role of prostate cancer cell-
derived KLK4 in regulating gene expression in the latter cell type is of significant 
interest. As such, KLK4-regulated gene expression in prostate WPMY-1 
myofibroblasts was assessed, as per Chapter 3. While KLK4 may interact with 
prostate cancer and stromal cell-derived factors to regulate myofibroblast gene 
expression, this preliminary investigation assessed the simplified scenario of KLK4 
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acting on myofibroblast-derived factors to regulate myofibroblast gene expression. 
Pathway analysis tools were then employed to identify associated KLK4-regulated 
signalling pathways.  
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5.2 Materials and Methods 
5.2.1 Zymography analysis of KLK4 activity in WPMY-1 myofibroblast CM 
Performed as per 4.2.1. 
5.2.2 Peptide substrate hydrolysis assay for KLK4 activity in WPMY-1 
myofibroblast CM 
Performed as per 4.2.2. 
5.2.3 Harvesting RNA from KLK4-treated WPMY-1 myofibroblasts for gene 
expression analyses 
Performed as per 4.2.3, with WPMY-1 myofibroblasts (passage 47-48) seeded at 1.2 
× 10
5
 cells/ T-25 flask and treated with 20 nM KLK4 (or equivalent total amount of 
mKLK4).  
5.2.4 Sample preparation for RNA microarray analyses 
Performed as per 4.2.4. 
5.2.5 Microarray data analysis to identify significantly regulated genes 
Performed as per 4.2.5. 
5.2.6 Validation of KLK4-mediated FGF1 gene and FGF protein up-
regulation in WPMY-1 myofibroblasts 
5.2.6a qRT-PCR 
qRT-PCR analysis of FGF1 expression was performed as per 2.9, using RNA 
prepared in 5.2.3. Primer sequences are shown in Table 2.2.  
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5.2.6b Western blot analysis 
WPMY-1 myofibroblasts were treated with KLK4, mKLK4, or left untreated, as per 
conditions in 5.2.3. Whole cell lysates were collected as per 2.3 and subject to 
analyses of FGF1 protein expression via Western blot analyses as per 2.5, using 
antibodies described in Table 2.1. ~10 μg of each whole cell lysate was loaded per 
lane. Immunodetection of glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 
Table 2.1) was used as a protein loading control.  
5.2.6c Immunofluorescence (IF) microscopy 
WPMY-1 myofibroblasts were treated with KLK4 or PBS buffer control as per 5.2.3, 
before washing in DPBS and fixing in paraformaldehyde [4% (w/v); 15 min, on ice]. 
Fixed cells were permeabilised in triton X-100 [2.5 × 10
-1
% (v/v); 5 min, RT] and 
washed 2 × in PBS. Immunostaining of FGF1 was performed using antibodies 
described in Table 2.1. Cells were counter-stained with 4',6-diamidino-2-
phenylindole (DAPI; 2 mg/ mL in 1% BSA/ PBS; Invitrogen) and imaged using a 
Zeiss LSM 510 Confocal microscope. 
5.2.7 qRT-PCR validation of KLK4-regulated gene expression in WPMY-1 
myofibroblasts 
qRT-PCR of expression of FGF5, MET, ID2, HAS2, ITGA4 and PCOLCE2 was 
performed as per 5.2.6a, using RNA prepared in 5.2.3.  
5.2.8 Statistical comparison of KLK4-regulated genes with CAF-enriched 
genes 
Gene microarray analysis of CAFs versus NPFs, published by Ellem et al. (2014), 
was compared to that of KLK4-treated myofibroblasts, performed in the present 
study. While only differentially regulated genes (P < 0.01) were reported in the 
 Chapter 5: Determining the KLK4-regulated transcriptome in prostate myofibroblasts 167      167 
former study (Ellem et al., 2014), a publicly available list of all genes measured on 
the same microarray platform employed in the Ellem et al. study 
[HuGene10stv1_Hs_ENTREZG v. 15.1.0; (Dai et al., 2005; Sandberg & Larsson, 
2007; University of Michigan)] was used, in conjunction with the list of CAF-
enriched genes (Ellem et al., 2014), to determine those genes, which were not 
differentially regulated in CAFs versus NPFs. For comparison of KLK4-regulated 
genes and those genes differentially regulated in CAFs versus NPFs, only genes 
measured in both studies were considered, and genes where expression was regulated 
≤ -1.5-fold or ≥ 1.5-fold (P ≤ 0.05) were considered differentially regulated. The 
number of genes regulated, and not regulated, by KLK4 and in CAFs, were compiled 
in 2 × 2 contingency tables, and a Fisher’s exact test was performed using IBM® 
SPSS® Statistics 21 software with default settings. Further, genes up- or down-
regulated by KLK4 and in CAFs, or regulated in different directions by KLK4 and in 
CAFs, were compared using a Fisher’s exact test, as above. 
5.2.9 Pathway analysis of KLK4-regulated gene expression in WPMY-1 
myofibroblasts 
Pathway analysis was performed using IPA. Default settings were selected upon 
entering data into IPA, including that the probe with the highest average fold-change, 
with its corresponding P-value statistic, was taken as representative for the entire 
gene. However, instead of the default human genome background, a user-defined 
background was employed, comprising all genes measured in the present study that 
were annotated in the IPA database. Ninety-four measured genes were not annotated 
in the IPA database and were excluded from further analyses (Supplementary Table 
5.1). IPA was employed to: (a) identify activated or inhibited upstream regulators of 
KLK4-regulated gene expression; (b) present genes co-regulated by TGFβ1 and 
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KLK4 in a diagrammatic representation; (c) identify KLK4-regulated genes that 
regulate TGFβ1 activity, but not expression, and present these interactions in a 
diagram; and, (d) perform enrichment analyses for cellular functions and disease 
states putative regulated by KLK4 alone, or by both KLK4 and TGFβ1.  
For (a), the Upstream Regulator tool in IPA was used, with default settings, 
excepting that chemical regulators were excluded. Significantly enriched upstream 
regulators (P ≤ 0.05) were assigned using an embedded Fisher’s exact test. Only 
upstream regulators with activation scores -2.5 ≤ or ≥ 2.5 were considered to be 
inhibited or activated, respectively.  
For (b), the Grow tool in IPA was used to draw networks between TGFβ1 and 
KLK4-regulated genes. Default settings were used, considering only interactions 
downstream of TGFβ1 affecting expression or transcription.  
For (c), the Grow tool in IPA was used to draw networks between TGFβ1 and those 
KLK4-regulated genes that regulate TGFβ1 by means other than affecting its gene 
expression. Default settings were used, considering only interactions upstream of 
TGFβ1 including all interaction relationships excepting expression or transcription.  
For (d), enrichment analyses of cellular functions and disease states in IPA was 
employed, whereby an embedded Fisher’s exact test is used to define cellular 
functions and disease states significantly (P ≤ 0.05) associated with KLK4-regulated 
genes. Those with activation scores -2 ≤ or ≥ 2 (default cut-off values) were deemed 
to be inhibited or activated by KLK4, respectively. In addition to performing the 
above analysis for all KLK4-regulated genes, genes concordantly and 
disconcordantly regulated by KLK4 and TGFβ1 in WPMY-1 myofibroblasts were 
separately analysed. Gene microarray analysis of TGFβ1-treated WPMY-1 
myofibroblasts was published previously (Solomon et al., 2014) and this data was 
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used for the latter comparisons. A summary of functional analyses performed using 
the denoted input gene list (A) and user-defined background list in IPA (B) is as 
follows (A/ B): KLK4-regulated genes/ all genes measured in the present study 
(20,028); KLK4-regulated genes/ genes measured in both the present study and the 
Solomon et al. study (12,635); KLK4-regulated genes that were regulated in the 
same direction by TGFβ1/ genes measured in both the present study and the Solomon 
et al. study (12,635); KLK4-regulated genes that were not regulated by TGFβ1, or 
were regulated in the opposite direction by TGFβ1/ genes measured in both the 
present study and the Solomon et al. study (12,635). 
KLK4-regulated expression of genes encoding TGFβ1 signalling pathway 
intermediates was also interrogated, where these intermediates were annotated in the 
canonical TGFβ1 signalling pathway in the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database (Kanehisa & Goto, 2000; Kanehisa et al., 2014). 
5.2.10 Statistical comparison of KLK4- and TGFβ1-regulated genes in   
WPMY-1 myofibroblasts 
Gene microarray analysis of KLK4-regulated genes in the present study was 
compared to TGFβ1-regulated genes in WPMY-1 myofibroblasts, as previously 
published (Solomon et al., 2014). The number of genes regulated by both KLK4 and 
TGFβ1, or those genes measured not to be regulated by one or both treatments, were 
compiled in 2 × 2 contingency tables and analysed using a Fisher’s exact test, as with 
5.2.8. A similar analysis was performed for the number of genes up- or down-
regulated by both KLK4 and TGFβ1, or regulated in different directions by KLK4 
and TGFβ1. For both analyses, only genes measured in both studies were included 
and ≤ -1.5-fold or ≥ 1.5-fold change in gene expression (P ≤ 0.05) was considered as 
differential regulation. 
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5.2.11 WPMY-1 myofibroblast confluence, viability and morphology following 
KLK4 treatment 
5.2.11a Cell confluence 
WPMY-1 myofibroblasts were seeded at 1,500 cells/ well of a 96-well plate 
(ViewPlate-96, Perkin Elmer). Cells were serum-starved and treated with KLK4 or 
mKLK4, or PBS buffer control, as per 5.2.3. An additional treatment concentration 
of 40 nM KLK4 was also employed, alongside treatment with an equivalent total 
amount of mKLK4 as a corresponding control. Following cell treatment, phase 
contrast cell images were acquired in the Incucyte ZOOM live cell imaging 
instrument (Essen BioScience) at 2 h intervals for up to 48 h (37 ºC, 5% CO2). Cell 
confluence (%) was automatically determined by accompanying proprietary 
software, from three technical replicates. 
5.2.11b Cell viability 
Cells were seeded, serum-starved and treated as per 5.2.11a, with an additional 
KLK4 treatment concentration of 10 nM. A cell-free media-only blank well was 
included as a control for background absorbance. Following 18 h treatment, WST-1 
cell proliferation reagent [10% (v/v); Roche] was added to each well and incubated 
on cells in existing cell CM for 1 h (37 ºC, 5% CO2). Absorbance was then measured 
with an xMark™ Microplate Absorbance Spectrophotometer at 440 nm (> 660 nm 
reference wavelength). On the day of seeding, a cell standard curve was also 
prepared using 1/2 serial dilutions of 6 × 10
4
 to 469 cells/ well, in addition to a cell-
free media-only blank well. Cells were allowed to attach for 4 h (37 ºC, 5% CO2), 
prior to incubating in serum-free media for an additional 4 h (37 ºC, 5% CO2), before 
incubating with WST-1 reagent (1 h, 37 ºC, 5% CO2) and reading absorbance, as 
above. Absorbance readings for all samples and standards were corrected for that of 
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the corresponding cell-free media-only blank. Linear regression of the cell standard 
curve was performed using Microsoft Excel software. The number of viable cells per 
well was interpolated on this standard curve using corrected absorbance 
measurements, for all samples. Values from six technical replicates, within each of 
three biological replicates, were averaged. 
5.2.11c Cell morphology 
In addition to phase contrast images taken in 5.2.11a, cell morphology of KLK4-
treated myofibroblasts was also assessed by IF microscopy. WPMY-1 
myofibroblasts were seeded on glass coverslips (ProSciTech Pty Ltd) in 6-well plates 
(4.8 x 10
4
 cells/ well; 2-3 coverslips per well). Cells were serum-starved and treated 
with KLK4 or PBS buffer control, as per 5.2.3. Following treatment, cells were 
washed in ice cold DPBS, prior to fixing in paraformaldehyde solution [4%  
(v/v); RT, 10 min] and permeabilising in triton X-100 [1 × 10
-1
% (v/v) in PBS; RT, 5 
min]. Fixed cells were washed thrice in DPBS, before blocking in 1% BSA in PBS 
(RT, 1 h; BSA from Sigma). F-actin filaments were stained with rhodamine415–
conjugated phalloidin (0.3 U/ mL; 20 min, RT; Invitrogen), while nuclei were 
counter-stained with DAPI (2 mg/ mL; 20 min, RT; Invitrogen); each was diluted in 
1% BSA in PBS. Coverslips were mounted onto glass slides with ProLong® Gold 
antifade mountant (Life Technologies). IF images were acquired using a confocal 
187 microscope (TCS SP5 II, Leica) with a 20 × oil immersion objective.  
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5.3 Results 
5.3.1 KLK4 was active in WPMY-1 myofibroblast CM over 18 h 
To validate that KLK4 was active upon treatment of WPMY-1 myofibroblasts, its 
activity was analysed by gelatine zymography (Figure 5.1 A) and in a peptide 
substrate hydrolysis assay (Figure 5.1 B). The equivalent amount of stock KLK4, 
freshly defrosted and diluted in PBS, was employed as a positive control. 
Zymography analysis indicated that KLK4 was active following 18 h incubation with 
WPMY-1 myofibroblasts in culture (lanes 4-5), although this activity appeared 
reduced as compared to stock KLK4 freshly diluted in PBS (lane 7; Figure 5.1 A). 
Gelatinolytic clearings in KLK4-treated samples were observed at 21, 22 and 23 kDa 
(lanes 4-5 and 7). Additional clearings at 95 kDa were observed in WPMY-1 
myofibroblast CM harvested from only the first replicate experiment (lane 1, 2, 4 and 
6). These 95 kDa clearings were present even following aprotinin addition (lane 6), 
which abolished KLK4-mediated gelatinolysis at 21, 22 and 23 kDa, and so may be 
attributed to an endogenous protease in WPMY-1 myofibroblast CM. Clearings at 70 
kDa were also observed in CM from replicate 1, which was incubated with KLK4 
(18 h; lane 4 and 6), and these clearings were not abolished by aprotinin (lane 6). 
Given that aprotinin was added to cell CM only briefly before assaying, these bands 
may be attributed to an endogenous non-serine protease activated by KLK4. 
Alternatively, the 70 kDa clearing could be due to active KLK4, having migrated as 
part of an SDS-stable complex with a non-covalent inhibitor. In this scenario, KLK4 
binding partners may have blocked aprotinin from entering the protease active site in 
solution, where the active site may have been re-exposed to elicit gelatinolysis 
following denaturing SDS-PAGE and in-gel protein re-folding. Gel lanes containing 
mKLK4 (lanes 2-3 and 9) displayed no detectable gelatinolysis (Figure 5.1 A).  
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Figure 5.1. Activity of KLK4 following WPMY-1 myofibroblast treatment, measured using 
gelatine zymography (A) or a fluorogenic peptide substrate hydrolysis assay (B). For (A), white 
clearings indicate gelatinolysis. Superscript numbers describe the biological replicate experiment from 
which the sample was derived. In (B), the corrected (corr.) ΔRFU/ min was expressed as a percentage, 
normalised to that of freshly defrosted and diluted KLK4, which was employed as a positive control 
(sample 7). Error bars indicate range of technical duplicates. For (A) and (B), KLK4 was active in the 
positive control (sample 7) and following WPMY-1 myofibroblast treatment (samples 4-5). This 
activity was abolished with the addition of the serine protease inhibitor, aprotinin (samples 6 and 8), 
which was added following cell treatment, but prior to performing the peptide hydrolysis assay. No 
activity was observed in samples containing mKLK4 alone (sample 9) or on cells (samples 2-3), or 
WPMY-1 myofibroblast CM, treated only with buffer (sample 1). Arrowheads indicate molecular 
weight regions of KLK4-induced gelatine clearing (filled arrowheads) or that induced by endogenous 
proteases (open arrowheads). 
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Similar results were observed when analysing KLK4 activity by measuring hydrolysis of 
a fluorescent peptide substrate, where only uninhibited KLK4-containing samples 
displayed substrate hydrolysis (samples 4-5 and 7; Figure 5.1 B). This activity was 
abolished by aprotinin (samples 6 and 8; Figure 5.1 B). Thus, KLK4 was active on 
WPMY-1 myofibroblasts for the duration of treatment. 
5.3.2  KLK4 treatment of prostate myofibroblasts induced extensive gene 
expression changes 
Following KLK4 treatment of WPMY-1 myofibroblasts, the expression of 187 genes 
was significantly up-regulated, while the expression of 252 genes was significantly 
down-regulated (Figure 5.2; Supplementary Table 5.2). Importantly, mKLK4 did not 
significantly regulate the expression of any genes in WPMY-1 myofibroblasts 
(Supplementary Table 5.2), indicating that KLK4 regulated gene expression through 
its proteolytic activity. Among the top 20 most highly up-regulated genes were those 
encoding growth factors (FGF1, FGF5, ESM1), a growth factor binding protein 
(IGFBP5), transcription regulators and DNA binding proteins (ID1, TNP1, 
SPOCD1), a hormone (NPPB), an apolipoprotein (SAA1), a protein cross-linking 
enzyme (TGM2), a peptidase inhibitor (SERPINE1), cytoskeletal and associated 
proteins (KRT34, ACTG2, TAGLN), an ion channel (KCNQ5) and an ECM protein 
(COL4A4; Table 5.1). Also among this list were genes encoding proteins associated 
with hyaluronan synthesis and regulation (HAS2, KIAA1199), and pro-angiogenic 
(ESM1) or pro-apoptotic (GLIPR1) activity. Further included was KCNQ1DN, which 
encodes a long non-coding RNA and is downstream of another gene that was up-
regulated by KLK4, KCNQ5 (Table 5.1). The fold-change in expression of these 
genes upon KLK4 treatment ranged from 3.6- to 8.8-fold (Table 5.1). Most of the top 
20 most highly up-regulated genes encode extracellular products, while others  
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Figure 5.2. Volcano plot of differential gene expression in KLK4-treated prostate WPMY-1 
myofibroblasts. The fold-change gene expression increase or decrease (log2 transformed; X-axis) in 
KLK4-treated, versus mKLK4 control-treated, cells is plotted for individual genes (blue data points) 
alongside the corresponding P value statistic (negative log10-transformed; Y-axis). KLK4 significantly 
up-regulated the expression of 187 genes (≥ 2-fold, P ≤ 0.05; red box), and down-regulated the 
expression of 252 genes (≤ -2-fold, P ≤ 0.05; green box). 
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Table 5.1. The top 20 most highly up-regulated genes following KLK4 treatment of WPMY-1 prostate myofibroblasts and their regulation in CAFs 
Table 5.1, see over 
Gene symbol Gene name Localisation Molecule type  FC* No. probes up-
regulated (total) 
KRT34 keratin 34 Cytoplasm Cytoskeletal or associated protein 8.8 1 ( 2 ) ↑ 
SAA1 serum amyloid A1 Extracellular  Apolipoprotein 7.6 1 ( 2 ) - 
KIAA1199 KIAA1199 Cytoplasm Hyaluronan synthesis and regulation 7.5 6 ( 17 ) ↑ 
SERPINE1 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
Extracellular  Peptidase inhibitor 7.0 4 ( 4 ) ↓ 
ID1 inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein 
Nucleus Transcription regulator/DNA binding  5.9 3 ( 3 ) - 
ACTG2 actin, gamma 2, smooth muscle, enteric Cytoplasm Cytoskeletal or associated protein 5.5 4 ( 6 ) ↓ 
COL4A4 collagen, type IV, alpha 4 Extracellular  ECM constituent 5.4 1 ( 7 ) - 
ESM1 endothelial cell-specific molecule 1 Extracellular  Growth factor 5.1 5 ( 5 ) ↑ 
NPPB natriuretic peptide B Extracellular  Hormone 5.0 2 ( 2 ) - 
GLIPR1 GLI pathogenesis-related 1 Extracellular  Other 4.8 10 ( 10 ) - 
FGF1 fibroblast growth factor 1 (acidic) Extracellular  Growth factor 4.1 7 ( 10 ) - 
HAS2 hyaluronan synthase 2 Plasma 
Membrane 
Hyaluronan synthesis and regulation 4.1 6 ( 6 ) ↑ 
KCNQ5 potassium voltage-gated channel, KQT-like 
subfamily, member 5 
Plasma 
Membrane 
Ion channel 4.0 2 ( 12 ) - 
KCNQ1DN KCNQ1 downstream neighbor (non-protein 
coding) 
Unknown Long non-coding RNA 4.0 1 ( 1 ) - 
TNP1 transition protein 1 (during histone to protamine 
replacement) 
Nucleus Transcription regulator/DNA binding 4.0 1 ( 2 ) - 
IGFBP5 insulin-like growth factor binding protein 5 Extracellular  Growth factor binding protein 3.9 4 ( 5 ) ↓ 
FGF5 fibroblast growth factor 5 Extracellular  Growth factor 3.9 5 ( 5 ) ↑ 
TAGLN transgelin Cytoplasm Cytoskeletal or associated protein 3.9 6 ( 6 ) - 
TGM2 transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
Cytoplasm Protein cross-linking enzyme 3.7 3 ( 7 ) - 
SPOCD1 SPOC domain containing 1 Unknown Transcription regulator/ DNA binding 3.6 2 ( 2 ) - 
CAF^ 
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Table 5.1 continued 
↑, up-regulated; ↓, down-regulated; -, not differentially regulated or not measured; FC, fold-change. 
* Entries in the table are ordered according to FC, from highest to lowest 
^ Regulation in CAFs versus NPFs, as previously published (Ellem et al., 2014). 
 
encode molecules localised to the cytoplasm, nucleus and plasma membrane (Table 
5.1). 
For proof of principal preliminary validation, and where reagents were readily 
available, qRT-PCR (Figure 5.3 A), Western blot analyses (Figure 5.3 B) and IF 
microscopy (Figure 5.3 C-H) confirmed that KLK4 induced FGF1 expression and 
FGF1 production in WPMY-1 myofibroblasts. IF microscopy showed FGF1 to be 
localised predominantly in the cytoplasm, with some nuclear localisation (Figure 5.3 
C-H).  
The fold-change in expression of the 20 most down-regulated genes ranged from -2.8 
to -9.4-fold (Table 5.2). These genes encode enzymes (METTL7A, CPB1, GLS2, 
INPP5D, B3GALT4, NEIL1), protein-binding molecules involved in regulating ion 
channels (LGI1) and xenophagy (MAP1LC3C), a metal-binding protein (MT1F), a 
growth factor (NTF4), a cell adhesion protein (CDH18), a regulator of the cell 
cytoskeleton (PPL), a transcription regulator (HES1) and a cyclin-dependent kinase 
inhibitor involved in cell cycle regulation (CDKN1C). A long non-coding RNA 
transcript was also among this group (MIAT), as was CELF5, which encodes an 
RNA-binding protein (Table 5.2).  
Of interest, using the top 20 most highly up-regulated genes as an example, each was 
measured by 1-17 probes, which were targeted to different regions of transcribed 
gene products (far right column, Table 5.1; also shown in Supplementary Table 5.2). 
The KLK4-induced expression of 10 of these genes was confirmed by all 
corresponding probes. However, only some of the probes analysing expression of the 
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Figure 5.3. Increased FGF1 mRNA and FGF1 protein production in prostate WPMY-1 myofibroblasts 
treated with KLK4. (A) qRT-PCR showed that KLK4 (red bars) significantly increased FGF1 expression in 
WPMY-1 myofibroblasts (P ≤ 0.05, student t-test), relative to untreated (light blue bars) or mKLK4-treated 
controls (dark blue bars). Triplicate biological replicates were performed and the average fold-change in gene 
expression (ΔΔ Ct) is shown, normalised to the untreated control. Error bars display standard error of the mean. 
(B) Western blot analyses demonstrated that KLK4 induced FGF1 protein abundance in whole cell lysates of 
WPMY-1 myofibroblasts, as compared to mKLK4-treated controls. Three biological replicate experiments are 
shown. GAPDH was used as a loading control. (C-H) IF microscopy showed that KLK4 treatment (F-H) 
induced FGF1 abundance (green) predominantly in the cytoplasm, with some in the nucleus (blue). Negligible 
FGF1 staining was observed in untreated cells (C-E). Scale bar, 20 μm.
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 Table 5.2. The 20 most highly down-regulated genes following KLK4 treatment of WPMY-1 prostate myofibroblasts and their regulation in CAFs 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2, see over 
 
 
Gene symbol Gene name Localisation Molecule type FC* No. probes down-
regulated (total) 
MT1F metallothionein 1F Unknown Metal-binding protein -9.4 2 ( 3 ) ↑ 
RAI2 retinoic acid induced 2 Unknown Unknown -4.4 3 ( 5 ) - 
METTL7A methyltransferase like 7A Unknown Methyltransferase -4.3 1 ( 4 ) ↑ 
CPB1 carboxypeptidase B1 (tissue) Extracellular  Peptidase -4.2 2 ( 7 ) - 
NTF4 neurotrophin 4 Extracellular  Growth factor -3.4 1 ( 2 ) - 
CDH18 cadherin 18, type 2 Plasma Membrane Cell adhesion protein -3.4 2 ( 12 ) - 
MAP1LC3C microtubule-associated protein 1 light chain 3 
gamma 
Cytoplasm Protein binding protein -3.3 1 ( 4 ) - 
LOC728978 uncharacterized LOC728978 Unknown Unknown -3.2 1 ( 1 ) - 
GLS2 glutaminase 2 (liver, mitochondrial) Cytoplasm Glutaminase -3.2 4 ( 7 ) - 
PPL periplakin Cytoplasm Cytoskeletal and 
associated protein 
-3.2 3 ( 5 ) - 
HSPA12B heat shock 70kD protein 12B Unknown Unknown -3.1 1 ( 3 ) - 
HES1 hairy and enhancer of split 1, (Drosophila) Nucleus Transcription regulator -3.1 3 ( 5 ) - 
INPP5D inositol polyphosphate-5-phosphatase, 145kDa Cytoplasm Phosphatase -3.0 3 ( 9 ) - 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 
Cytoplasm Carbohydrate 
synthesising enzyme 
-3.0 2 ( 2 ) - 
CELF5 CUGBP, Elav-like family member 5 Unknown RNA-binding protein -3.0 2 ( 4 ) - 
MIAT myocardial infarction associated transcript (non-
protein coding) 
Unknown (Long non-coding RNA) -3.0 2 ( 6 ) - 
FAM13C family with sequence similarity 13, member C Unknown Unknown -2.9 3 ( 12 ) - 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) Nucleus Protein inhibitor -2.9 3 ( 3 ) - 
NEIL1 nei endonuclease VIII-like 1 (E. coli) Nucleus DNA repair enzyme -2.9 2 ( 5 ) - 
LGI1 leucine-rich, glioma inactivated 1 Plasma Membrane Protein binding protein -2.8 5 ( 11 ) - 
CAF^ 
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Table 5.2, continued 
↑, up-regulated; ↓, down-regulated; -, not differentially regulated or not measured; FC, fold-change. 
* Entries in the table are ordered according to FC, from lowest to highest 
^ Regulation in CAFs versus NPFs, as previously published (Ellem et al., 2014). 
 
remaining 10 genes indicated up-regulation by KLK4. Most notably, only two of 12 
probes targeting KCNQ5 showed that expression of this gene was ≥ 2-fold greater in 
KLK4-treated myofibroblasts, compared to mKLK4 control-treated cells (P ≤ 0.05; 
Table 5.1). Most probes targeting KCNQ5 indicated significantly up-regulated gene 
expression upon KLK4 treatment (P ≤ 0.05), although to a degree less than the 
minimum 2-fold cut-off assigned. Conversely, for COL4A4, only one probe indicated 
significantly up-regulated gene expression upon KLK4 treatment. All other probes 
determined that expression of this gene was not significantly regulated by KLK4 (i.e. 
P > 0.05; Supplementary Table 5.2). Similar discrepancies between probes reporting 
on gene expression regulation was observed in the top 20 most down-regulated genes 
(Table 5.2), and for many other genes analysed (Supplementary Table 5.2). 
Differential signals from probes targeting the same gene are common, and may 
reflect experimental variation or noise. This may also occur as a result of biological 
processes, such as the differential regulation of variant gene transcripts. Detailed 
reporting of KLK4-regulated gene expression in WPMY-1 cells can be found in 
Supplementary Table 5.2.  
5.3.3  KLK4 up-regulated genes enriched in patient-derived prostatic CAFs 
Importantly, a number of KLK4-regulated genes in WPMY-1 myofibroblasts were 
found to be differentially regulated in patient-derived CAFs, as measured in a study 
by Ellem et al. [(2014); far right column, Table 5.1 and 5.2; also shown in 
Supplementary Table 5.3]. Among the 20 genes for which expression was most 
highly up-regulated by KLK4, KRT34, KIAA1199, ESM1, HAS2 and FGF5 
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expression was also up-regulated in patient-derived CAFs, compared to NPFs (Table 
5.1). The remainder of the 20 most highly KLK4-induced genes were either down-
regulated (SERPINE1, ACTG2, IGFBP5), or not differentially regulated (TGM2, 
SPOCD1) in CAFs as compared to NPFs (Table 5.1). Similarly, of the 20 genes for 
which expression was most greatly down-regulated by KLK4, MT1F and METTL7A 
expression was up-regulated in CAFs versus NPFs (Table 5.2). The remainder of 
these genes were not assessed by Ellem et al. [(2014); Table 5.2].  
KLK4-mediated up-regulation of HAS2 and FGF5 was selected for validation by 
qRT-PCR. KLK4-induced expression of additional genes (MET, ITGA4, ID2 and 
PCOLCE2) was further validated by qRT-PCR, as expression of these genes was 
also increased CAFs as compared to NPFs (Supplementary Table 5.3). qRT-PCR 
confirmed that KLK4 up-regulated expression of HAS2, FGF5, MET, ITGA4, ID2 
and PCOLCE2 in WPMY-1 myofibroblasts (Figure 5.4). The fold-change in gene 
expression following KLK4 treatment, as assessed by qRT-PCR, was similar to that 
determined using the microarray platform (Figure 5.4; Supplementary Table 5.2).  
Genes for which expression was regulated or not regulated by KLK4 in WPMY-1 
myofibroblasts were similar to those genes for which expression was respectively 
regulated or not regulated in CAFs versus NPFs (P = 1 × 10
-64, Fisher’s exact test; 
Supplementary Table 5.4). Of all genes with differential expression in CAFs versus 
NPFs, 20% were also regulated by KLK4 in WPMY-1 myofibroblasts 
(Supplementary Table 5.4). However, of these genes, there was no relationship 
between the direction of gene expression regulation by KLK4 and in CAFs (P = 2.3 
× 10
-1
, Fisher’s exact test; Supplementary Table 5.5). That is, considering genes 
differentially regulated in both studies, genes regulated by KLK4 were not more 
likely to be regulated in the same direction, or in the opposite direction, in CAFs.  
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Figure 5.4. qRT-PCR validation of KLK4-induced expression of CAF-enriched genes in 
WPMY-1 myofibroblasts. KLK4 (red bars) significantly up-regulated the expression of each gene in 
WPMY-1 myofibroblasts, relative to untreated controls (light blue bars; P ≤ 0.05, student t-test). 
mKLK4 treatment did not significantly affect gene expression (dark blue bars). Triplicate biological 
replicates were performed and the average fold-change in gene expression (ΔΔ Ct) is shown, 
normalised to untreated controls. Error bars display standard error of the mean. 
Similarly, genes regulated in CAFs were not more likely to be similarly or inversely 
regulated by KLK4. Therefore, while KLK4 regulates the expression of similar genes 
to those with differential expression in CAFs versus NPFs, the similarity between the 
functional consequence of KLK4-mediated gene expression perturbations, and that 
observed in CAFs, is unclear. 
5.3.4 TGFβ1 was predicted to be the most highly activated upstream regulator 
of KLK4-mediated gene expression 
To elucidate putative cell signalling pathways mediating KLK4-regulated gene 
expression, and to identify potential downstream functional consequences, IPA was 
employed. The Upstream Regulator tool in IPA was first used to identify putative 
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mediators of KLK4-regulated gene expression, which may have been activated or 
inhibited following KLK4 treatment. Although termed upstream regulators, these 
molecules would have been activated or inhibited downstream of extracellular 
KLK4-mediated proteolysis, but upstream of the resulting gene expression 
alterations. Thereby, this tool identifies what may be better described as signalling 
pathway intermediates or effectors of the observed gene expression changes. The 
Upstream Regulator tool operates by applying a Fisher’s exact test to select 
molecules that regulate (or do not regulate) the expression of a significant proportion 
of genes that were regulated (or were not regulated) in the test condition. In the 
present analysis, the test condition was KLK4-treated WPMY-1 myofibroblasts. The 
direction in which genes were regulated in the test condition (up or down) is 
compared to the direction genes are annotated to be regulated by each putative 
upstream regulator. This information is incorporated into an activation score, where 
scores ≥ 2.5 or ≤ -2.5 indicate that a putative upstream regulator was activated or 
inhibited in the test condition, respectively.  
Using this approach, TGFβ1 was predicted to be the most highly activated upstream 
regulator in KLK4-treated WPMY-1 myofibroblasts (activation score = 4.1, P = 3.6 
× 10
-10
; Table 5.3). Other putative activated upstream regulators included the 
peptidase, thrombin (F2 in Table 5.3), kinases, v-src avian sarcoma and 
bromodomain containing 4, as well as growth factors and cytokines, including 
platelet-derived growth factor, VEGF, endothelin 1, and the tumour necrosis factor 
family (Table 5.3). Conversely, the upstream regulator with the lowest negative 
activation score, indicating its putative inhibition upon KLK4 treatment, was 
predicted to be the transcriptional regulator, tumour protein p73, with an activation 
score of -3 (Table 5.3). Other transcription regulators were also predicted to have  
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Table 5.3. The top five most likely activated, or inhibited, putative upstream regulators of KLK4-mediated gene expression in WPMY-1 myofibroblasts.  
 
 
 
 
 
 
 
 
 
 
FC, fold-change in gene expression. 
* Expression was not measured in the present study (n/a) 
^ Entries are ordered from highest to lowest activation score.  
Upstream regulator Description Gene 
expression FC 
Molecule type Predicted 
activation state 
Activation score^ P-value  
TGFβl transforming growth factor, beta 1 1.2 Growth factor Activated 4.1 3.6E-10 
F2 coagulation factor II (thrombin) 1.1 Peptidase Activated 3.9 2.4E-06 
SRC v-src avian sarcoma (Schmidt-
Ruppin A-2) viral oncogene 
homolog 
-1.3 Kinase Activated 2.9 5.5E-04 
PDGF (complex) platelet-derived growth factor 
(complex) 
n/a* Growth factor 
complex 
Activated 2.7 5.3E-04 
TNF (family) tumour necrosis factor (family) n/a* Cytokine Activated 2.7 1.3E-05 
VEGF vascular endothelial growth factor n/a* Growth factor Activated 2.7 4.5E-08 
BRD4 bromodomain containing 4 1.8 Kinase Activated 2.6 2.8E-04 
EDN1 endothelin 1 1.7 Cytokine Activated 2.6 3.7E-02 
let-7a-5p (and other miRNAs 
w/seed GAGGUAG) 
microRNA let-7a-5p n/a* Mature 
microRNA 
Inhibited -2.6 4.3E-02 
FOXO3 forkhead box O3 n/a* Transcription 
regulator 
Inhibited -2.6 1.3E-02 
BRCA1 breast cancer 1, early onset 1.3 Transcription 
regulator 
Inhibited -2.6 6.0E-04 
IRF7 interferon regulatory factor 7 -1.4 Transcription 
regulator 
Inhibited -2.8 1.6E-02 
TP73 tumor protein p73 -1.3 Transcription 
regulator 
Inhibited -3.0 1.9E-05 
 Chapter 5: Determining the KLK4-regulated transcriptome in prostate myofibroblasts 185 
been inactivated or inhibited by KLK4 treatment, including interferon regulatory 
factor 7, breast cancer 1 early onset and forkhead box O3 (Table 5.3). The 
microRNA, let-7a-5p, was also among inhibited upstream regulators (Table 5.3). 
Importantly, none of these putative upstream regulators were themselves 
significantly regulated by KLK4 at the level of transcription (fold-change gene 
expression ranged from > -2 to < 2, Table 5.3); genes encoding forkhead box O3 and 
let-7a-5p were not assessed in the present study (fold-change = n/a, Table 5.3). 
Therefore, KLK4 activated or inhibited these upstream regulators by means other 
than regulating the transcription of each, indicating that these molecules may indeed 
represent signalling intermediates or effectors of KLK4-regulated gene transcription. 
The overlap between KLK4-regulated genes in WPMY-1 myofibroblasts and genes 
regulated by TGFβ1, the upstream regulator most significantly associated with 
KLK4-mediated gene expression, is pictorially shown in Figure 5.5. Thirty-six genes 
up-regulated by KLK4 treatment are annotated as being up-regulated by TGFβ1, 
while five genes down-regulated by KLK4 treatment are annotated as being down-
regulated by TGFβ1. IPA also recorded 11 genes, which were regulated by TGFβ1 in 
a direction opposite to their regulation by KLK4 in the present study. This indicated 
that KLK4 may regulate these genes via pathways other than the TGFβ1 signalling 
pathway. Finally, the direction TGFβ1-regulated expression of 18 genes was not 
annotated in IPA (Figure 5.5); thus, these genes contributed toward statistical 
assessment of the relationship between KLK4- and TGFβ1-regulated genes, but did 
not inform the assigned activation score. In summary, IPA analysis indicated that 
KLK4 appeared predominantly to activate TGFβ1 signalling in prostate 
myofibroblasts. 
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Figure 5.5. Schematic of all KLK4-regulated genes in WPMY-1 myofibroblasts annotated in 
IPA to be regulated by TGFβ1. Proteins encoded by genes up- (red) or down-regulated (green) by 
KLK4, which are also annotated to be regulated by TGFβ1, are represented as coloured shapes. 
TGFβ1 is represented as an orange box to indicate its predicted activation by KLK4. Dotted lines 
indicate gene expression regulation by TGFβ1, where lines are coloured according to whether genes 
were up- (orange dashed arrows; 36 genes) or down-regulated (blue dashed blunt-ended arrows; five 
genes) by KLK4 in a direction consistent with TGFβ1 activity. Where the direction of KLK4-
mediated gene expression was inconsistent with TGFβ1 activity, relationships are represented with 
yellow dashed arrows (up-regulated) and blunt-ended arrows (down-regulated; 11 genes total). Grey 
dashed lines indicate that the direction of gene expression regulation by TGFβ1 is not annotated in 
IPA (18 genes). Shapes of coloured boxes represent the molecule type encoded by each gene (see key, 
top right). Definitions for gene symbols can be found in Supplementary Table 5.2.  
TGFβ1 was the most highly activated upstream regulator and those most 
significantly associated with KLK4-mediated gene transcription (Table 5.3). As 
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stated in Chapter 1, TGFβ1 is a well-established inducer of fibroblast activation and 
TGFβ1 signalling in established CAFs has pro-tumourigenic effects on neighbouring 
epithelium. Thus, the potential for KLK4 to activate TGFβ1 in WPMY-1 
myofibroblasts is highly significant and was further interrogated.  
5.3.5  KLK4-mediated gene expression regulation is significantly similar to that 
of TGFβ1 in WPMY-1 myofibroblasts 
To support the finding that KLK4 activates TGFβ1 signalling in WPMY-1 
myofibroblasts, KLK4-regulated genes identified in the present study were compared 
with TGFβ1-regulated genes in the same cell line, the latter dataset being previously 
published by Solomon et al. (Solomon et al., 2014). For comparison of this dataset 
with KLK4-regulated genes identified herein, only genes whereby expression was 
assessed in both studies (12,635 genes) were included. For this comparison, the fold-
change gene expression cut-off used to determine differentially regulated genes was 
relaxed to 1.5-fold. A Fisher’s exact test demonstrated a significant similarity (P = 
1.2 × 10
-24
) between genes regulated by, and genes not regulated by, both KLK4 and 
TGFβ1 (Supplementary Table 5.6). Further, genes regulated by both KLK4 and 
TGFβ1 were significantly likely to have expression regulated in a similar direction 
by both molecules (P = 1.6 × 10
-6, Fisher’s exact test; Supplementary Table 5.7). 
That is, a gene up-regulated by KLK4 was significantly likely to be up-regulated by 
TGFβ1, and vice versa for down-regulated genes. Of all TGFβ1-regulated genes, 
30.1% were also regulated by KLK4 and, of those, 70.4% were regulated in 
consistent directions (Figure 5.6). That is, a significant number of genes for which 
expression was regulated by both KLK4 and TGFβ1 were either up-regulated or 
down-regulated by both molecules. Therefore, KLK4 and TGFβ1 appeared to 
similarly regulate gene expression in WPMY-1 myofibroblasts. A list of genes for  
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Figure 5.6. The proportion of genes regulated by KLK4 and/ or TGFβ1 in WPMY-1 
myofibroblasts. Relative proportions of TGFβ1-regulated genes (grey) or genes regulated by both 
KLK4 and TGFβ1 (red and blue) are expressed as percentages. A significant proportion (P < 0.01, 
Fisher’s exact test) of TGFβ1-regulated genes were also regulated by KLK4 (30.1%; red). Of these, a 
significant proportion (P < 0.01, Fisher’s exact test) were regulated in the same direction by both 
treatments (70.4%; dark blue).  
which expression was concordantly and discordantly regulated by KLK4 and TGFβ1 
can be found in Supplementary Table 5.8. 
5.3.6  Putative functional implications of KLK4-regulated gene expression in 
WPMY-1 myofibroblasts and associations with TGFβ1 signalling 
It was next sought to predict which cellular phenotypes were being regulated by 
KLK4. The aim of this analysis was to allow the conducted high-depth analysis of 
KLK4-regulated gene expression to inform hypotheses regarding KLK4 function on 
prostate myofibroblasts, where these hypotheses may be validated in future studies. 
Of particular interest were pathways associated with a CAF phenotype, such as cell 
contraction, motility and proliferation (Barron & Rowley, 2012). Given that TGFβ1 
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was predicted to mediate KLK4-regulated gene expression, it was also sought to 
determine which KLK4-regulated cellular functions may be mediated by TGFβ1.  
Analysis of the relationship between KLK4-regulated gene expression and gene 
expression changes associated with cellular phenotypes was performed using IPA. 
This analysis requires a sample list, consisting of all genes regulated by the given 
treatment, along with a background list, comprising all genes for which expression 
was assessed. The software determines whether gene expression regulation in the 
treatment condition was similar to gene expression regulation associated with 
cellular phenotypes annotated in the IPA database. The analysis compares genes that 
were regulated, as well as genes that were not regulated, in the treatment condition 
with those that were regulated, and not regulated, in each annotated cellular function 
or disease state. As such, the background list is important in specifying the list of 
genes which were measured but were not regulated by the treatment, as these are 
incorporated into statistical analyses.  
For determining cellular functions associated with the observed KLK4-mediated 
gene expression changes, a background of all genes measured in the present study, 
and annotated in the IPA database, was employed. This incorporated 20,278 genes 
and was named the full background. The corresponding sample list comprised the 
2,171 genes from this list that were KLK4-regulated (gene expression fold-change ≥ 
1.5 or ≤ -1.5, P ≤ 0.05). However, to determine which cellular functions associated 
with KLK4 may be TGFβ1-regulated, only the 12,635 genes measured in both the 
present study and the Solomon et al. study (Solomon et al., 2014) were included for 
analyses. These genes comprised the background list for such analyses, called the 
shared background. Two separate analyses were performed using this background 
list. Firstly, it was sought to identify cellular functions or disease states similarly 
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regulated by KLK4 and TGFβ1; TGFβ1 may mediate KLK4-regulated activation or 
inhibition of these cellular functions. The sample list for this analysis was comprised 
of the 100 KLK4-regulated genes which were regulated in the same direction by 
TGFβ1, called co-regulated genes. Secondly, it was determined to identify cellular 
functions or disease states regulated by KLK4, but not similarly regulated by TGFβ1. 
Such cellular functions would likely not be mediated by TGFβ1. The sample list for 
this analysis comprised KLK4-regulated genes, which were not regulated by, or were 
regulated in an inverse direction by, TGFβ1 (labelled as not co-regulated).  
A control analysis was included using the shared background list and a sample list 
comprised of all 1,596 KLK-regulated genes therein. The cellular functions or 
disease states identified as being KLK4-regulated by this analysis were compared to 
those cellular functions or disease states that were KLK4-regulated, when 
considering all genes measured in the present study. This control was necessary to 
identify any cellular functions or disease states that were only appearing to be 
significantly associated with KLK4 when using the smaller shared background, 
required for TGFβ1 comparisons, and not the more comprehensive full background. 
That is, this control would identify cellular functions enriched only as an artefact of 
reducing the size of the background list, as was required for TGFβ1 comparisons.  
The results from each condition are represented as four columns in Table 5.4. To 
summarise, the conditions used for each column, from left to right, were: (1) KLK4-
regulated genes within the full background; (2) KLK4-regulated genes within the 
shared background; (3) genes co-regulated by KLK4 and TGFβ1 within the shared 
background; and, (4) genes not co-regulated by KLK4 and TGFβ1 within the shared 
background.  
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Table 5.4. Putative KLK4-regulated cellular functions and disease states in WPMY-1 myofibroblasts, including those that may be mediated by TGFβ1.  
 
Table 5.4 shows cellular functions and disease states associated with KLK4-regulated genes (1, 2) or KLK4-regulated genes similarly (3) or not/ not similarly regulated by TGFβ1 (4). 
BG, background; orange shading, activated cellular function or disease state (activation score ≥ 2; P ≤ 0.05); blue shading, inhibited cellular function or disease state (activation score ≤ -
2; P ≤ 0.05). 
* Similar functions and disease states were manually curated into single categories 
^ Full BG, the 20,028 genes measured in the present study that were annotated in IPA 
† Shared BG, the 12,635 genes measured in both the present study and the study analysing TGFβ1-regulated genes (Solomon et al., 2014) that were annotated in IPA. 
 
Cellular function or disease state (IPA)* 
(1) KLK4 
(full BG^) 
(2) KLK4  
(shared BG
†
) 
(3) KLK4 + 
TGFβ1  
(shared BG
†
) 
(4) KLK4 not 
TGFβ1  
(shared BG
†
) 
Putative dependency of KLK4-
regulated functions or disease states 
on TGFβ1 signalling 
Increased growth/ cell cycle regulation/ hyperplasia         TGFβ1-dependent and -independent   
Increased migration/ invasion/ EMT         TGFβ1-dependent and -independent   
Increased cell attachment         TGFβ1-independent 
Increased morphology alterations         TGFβ1-dependent 
Increased angiogenesis/ endothelial cell 
activation/systolic pressure 
 
      
TGFβ1-independent  
Increased seizures/ number of neurons/ morphology 
of nervous system 
 
      
TGFβ1-independent 
Increased organismal injury or death/ perinatal death 
 
      TGFβ1-independent 
Increased stem cell activation 
  
    -  
Increased dyspnea (respiratory) 
  
    - 
Decreased cell death 
 
      TGFβ1-dependent and -independent  
Decreased growth/ developmental functions 
 
      TGFβ1-independent 
Decreased differentiation of brain cells 
  
    TGFβ1-independent 
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Firstly, as depicted in Table 5.4, column 1, a number of cellular functions were 
predicted to be induced in WPMY-1 cells upon KLK4 treatment. These included 
functions associated with increased cell growth, migration, attachment, neurogenesis, 
stem cell activation, injury and dyspnea. Conversely, KLK4-mediated inhibition of 
functions associated with development and cell death was also predicted (Table 5.4, 
column 1).  
As shown in Table 5.4, column 2, when decreasing the number of KLK4-regulated 
genes and the background gene list to include only those genes measured in both the 
present study and the Solomon et al. (Solomon et al., 2014) study, some perceived 
differences in putative KLK4-regulated cellular functions were observed (Table 5.4, 
column 2 versus column 1). For instance, increased dyspnea and stem cell activation 
were no longer significantly activated (Table 5.4, column 2). In contrast, increased 
angiogenesis-related functions and decreased brain cell differentiation were 
significantly regulated only when considering shared genes (Table 5.4, column 2). 
This is likely to be an artefact of far fewer genes being considered for analysis. Thus, 
the latter two processes are likely not regulated by KLK4, as these processes were 
not significant when assessing a greater number of genes. The former two processes, 
on the other hand, are likely significantly regulated by KLK4, as these were 
significantly enriched when considering all KLK4-regulated genes amongst the large 
list of genes analysed in the present study. The exclusion of KLK4-regulated genes 
relating to these functions, upon reducing genes analysed to consider only genes also 
measured in the Solomon et al. (Solomon et al., 2014) study, was likely was 
responsible for these functions no longer appearing significant in column 2 (Table 
5.4). All other cellular functions or disease states were significantly associated with 
KLK4-regulated gene expression in either comparison (Table 5.4, columns 1 and 2).  
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It was next considered to predict whether KLK4 may have regulated any of the 
above processes through activating TGFβ1 signalling. Genes associated with 
increased cell growth and migration, and decreased cell death, were significantly 
enriched in conditions (3) and (4) (Table 5.4, columns 3 and 4). That is, KLK4 may 
regulate these cellular functions both via TGFβ1 signalling (3) and other signalling 
pathways (4). Cellular functions exclusively associated with genes regulated by 
KLK4, that were not similarly regulated by TGFβ1, included increased cell 
attachment, neurogenesis-related functions and organismal/ perinatal death, as well 
as decreased growth/ developmental functions (Table 5.4, column 4). Thus, KLK4 
likely regulates these processes independently of TGFβ1 signalling. Conversely, 
increased morphology alterations was enriched in condition (3) but not condition (4) 
(Table 5.4, column 3). Therefore, KLK4 was predicted to induce cell morphology 
alterations via TGFβ1 signalling. Notably, this cellular process was not enriched 
when considering all KLK4-regulated genes, using either background (Table 5.4, 
columns 1 and 2). That is, KLK4 did not regulate a sufficient proportion of genes 
associated with this phenotype to reach significance when considering all KLK4-
regulated genes measured in the present study, or those also measured in the  
Solomon et al. (2014) study. Therefore, while KLK4 may activate TGFβ1-mediated 
cellular morphology alterations, it did not regulate a sufficient proportion of 
additional genes associated with this phenotype (mediated by other signalling 
pathways), for this process to have been significantly enriched when considering all 
KLK4-regulated genes. As the cellular function, increased morphology alterations, 
may comprise a pool of genes regulated by various pathways, which may affect 
specific morphological processes, KLK4 may specifically regulate those cellular 
morphology alterations induced by TGFβ1 signalling.  
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In summary, by assessing the KLK4 transcriptome using a low-bias approach, KLK4 
was predicted to regulate cellular morphology, cell growth and cell migration, as 
well as reducing cell death, via TGFβ1 signalling. KLK4 may also regulate cell 
growth, migration and cell death by other non-TGFβ1-mediated pathways. These 
hypotheses may be validated in future cell-based studies targeting each specific 
function. As a preliminary example of cell-based validation, the ability of KLK4 to 
regulate prostate myofibroblast growth and morphology was examined (below). 
5.3.7 KLK4 altered cellular organisation and morphology, but did not affect 
cell growth 
To determine whether KLK4 regulated cell growth, under the conditions employed, 
cell confluence was measured over time, following KLK4 treatment. As a 
complementary measure of cell proliferation, cell viability was also assessed. Despite 
pathway analysis of KLK4-regulated gene expression predicting that KLK4 induced 
growth in WPMY-1 myofibroblasts, cell confluence (Figure 5.7 A) and viability 
(Figure 5.7 B) were not affected by KLK4.  
While KLK4 did not regulate cell proliferation and viability, as predicted, brightfield 
(Figure 5.7 C, D, F, G) and IF (Figure 5.7 E, H) microscopy demonstrated that 
WPMY-1 myofibroblasts underwent morphological changes upon KLK4 treatment. 
KLK4-treated WPMY-1 myofibroblasts were tightly organised into clusters (Figure 
5.7 F-H), where control-treated cells were more uniformly scattered (Figure 5.7 C-
E). Additionally, control-treated cells appeared stressed, as expected under serum-
free conditions, reflected by protruding stress fibres (white arrowheads, Figure 5.7 C-
E). This was not observed in KLK4-treated cells, which possessed smooth edges 
(black outlined arrowheads, Figure 5.7 F-H). F-actin staining supported these 
findings (Figure 5.7, E, H). Interestingly, KLK4-treated cells appeared similar to  
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Figure 5.7. Cell confluence (A), cell viability (B) and morphology (C-H) of WPMY-1 
myofibroblasts after KLK4 treatment. KLK4 did not alter cell confluence up to 48 h, or cell 
viability at 18 h, following treatment. The time point in (A) to which (B) corresponds is circled. Cells 
were treated with 10-40 nM KLK4 (or with mKLK4 or left untreated in controls), as denoted. Error 
bars display standard deviation of three technical (A) or biological (B) replicates. Cells were more 
tightly clustered and appeared more organised in KLK4-treated (F-H) versus mKLK4-treated (D) and 
untreated (C, E) samples. KLK4-treated cells were smooth in appearance (white arrowheads, black 
outline), in contrast to the stressed appearance of control-treated cells, reflected by protruding stress 
fibres (white arrowheads). In (E) and (H), F-actin is stained red and nuclei are stained blue. Scale bars, 
200 μm. 
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cells grown in full serum (data not shown). Collectively, this data supported 
bioinformatic predictions that KLK4 altered myofibroblast morphology, under 
serum-free conditions. This serves as a proof of principal validation, to be 
interrogated in future studies. 
5.3.8 Putative mechanisms of KLK4-mediated TGFβ1 activation 
While KLK4 was predicted to activate TGFβ1 signalling in WPMY-1 cells, the 
expression of TGFB1 was unchanged (Supplementary Table 5.2). Thus, it was 
sought to develop testable hypotheses regarding the mechanism of KLK4-activated 
TGFβ1 signalling, for validation in future studies. Mechanisms dependent upon 
regulation by altering gene expression are presented herein, while proteolytic 
regulation of TGFβ1 activity is covered in Chapter 6. Three putative mechanisms for 
KLK4-mediated induction of TGFβ1 signalling in WPMY-1 myofibroblasts were 
considered. These included KLK4-mediated regulation of genes encoding: (1) 
TGFβ1 receptors; (2) molecules which activate or inhibit TGFβ1; (3) TGFβ1 
signalling pathway intermediates. The plausibility of each, based on the gene 
expression data obtained, will be briefly presented, below. 
Fore mostly, KLK4 may have activated TGFβ1 signalling by regulating the 
expression of its receptors. TGFβ1 signals through TGFβ receptor type-2 (TGFβR2), 
which recruits TGFβR1 to initiate downstream signalling. TGFβ1 can also bind the 
decoy receptor, TGFβR3, where this receptor may activate or inhibit TGFβ1-
TGFβR2 binding, depending on whether it is localised to, or shed from, the cell 
surface, respectively (Gatza, Oh & Blobe, 2010). In the present study, TGFBR1 and 
TGFBR2 expression was not differentially regulated by KLK4 (Supplementary Table 
5.2); however, TGFBR3 expression was down-regulated by KLK4 treatment (Table 
5.5). Thus, KLK4 may induce TGFβ1 signalling through down-regulation of  
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Table 5.5. KLK4-regulated genes that putatively mediate KLK4-induced TGFβ1 signalling.   
 
 
 
 
 
 
FC, fold-change in gene expression. 
* TGFBR3 expression was significantly down-regulated by KLK4 (P ≤ 0.05), although not ≤ -2-fold, 
but was included due to its important influence on TGFβ1 signalling 
^ Down-regulation of TGFBR3 expression may result in activated or inhibited TGFβ1 signalling, 
depending on whether the encoded TGFβR3 product is respectively attached to, or shed from, the cell. 
 
TGFβR3, assuming that this protein is shed from the cell surface under the 
conditions employed. Alternatively, KLK4 may have regulated the expression of 
gene-encoding proteins capable of indirectly or directly regulating TGFβ1 activity, 
but not expression. IPA was used to identify KLK4-regulated genes fitting this 
description, which included genes encoding TGFβ1 inhibitors (DCN, SERPINE1, 
S1PR1, LTBP1) and activators (IL11RA). SERPINE, S1PR1 and LTBP1 were up-
regulated by KLK4 and, given that these genes encode TGFβ1 inhibitors, KLK4-
mediated up-regulation of these genes not likely responsible for the observed 
induction of TGFβ1 signalling (Table 5.5). Similarly, IL11RA was down-regulated 
by KLK4, likely resulting in decreased production of IL11RA protein, an activator of 
TGFβ1 activity (Table 5.5). DCN, however, was down-regulated by KLK4, which 
may, therefore, have resulted in increased TGFβ1 activity outside of the cell and 
subsequent increased TGFβ1 signalling (Table 5.5). A diagrammatic representation 
of the interaction between molecules encoded by these genes and TGFβ1 is depicted 
in Figure 5.8. Of interest, DCN expression is down-regulated by TGFβ1 (Figure 5.8), 
Gene FC Putative effect of KLK4 
regulation on TGFβ1 signalling 
Receptors: 
TGFBR3* -1.8 Activated/ Inhibited^ 
Regulators of TGFβ1 activity and not expression: 
SERPINE1 7.0 Inhibited 
S1PR1 2.4 Inhibited 
IL11RA -2.1 Inhibited 
LTBP1 2.3 Inhibited 
DCN -2.5 Activated 
PLAT 2.6 Activated 
Canonical TGFβ1 signalling pathway intermediates: 
SMURF2 2.7 Inhibited 
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Figure 5.8. Schematic of KLK4-regulated genes in WPMY-1 myofibroblasts capable of 
regulating TGFβ1 activity but not expression. Proteins encoded by genes up- (red) or down- 
regulated (green) by KLK4 are represented as coloured shapes. TGFβ1 is represented as an orange 
box, to indicate its predicated activation by KLK4. Each surrounding molecule activates (arrow) or 
inhibits (blunt-ended arrow) TGFβ1 activity, but not expression, in a direct (full line extending toward 
TGFβ1) or indirect (dashed line extending toward TGFβ1) manner. TGFβ1 can also up- or down-
regulate expression of DCN and SERPINE1, respectively (dashed lines extending from TGFβ1). 
These lines are coloured according to whether interactions are inhibited (blue) or activated (orange) in 
a direction consistent with activated TGFβ1 signalling, or inconsistent (yellow) with activated 
signalling. Shapes of coloured boxes represent the molecule type encoded by each gene (see key, 
bottom left). Definitions for gene symbols can be found in Supplementary Table 5.2.  
which suggests that there may be cyclic induction of TGFβ1 signalling initiated by 
KLK4. Further, while not annotated as a regulator of TGFβ1 activity in IPA, tissue 
plasminogen activator (tPA) activates plasminogen to the TGFβ1-activating protease, 
plasmin (Collen & Lijnen, 2009; Lyons et al., 1990; Saharinen et al., 1998), and 
KLK4 up-regulated tPA expression (PLAT) in the present analysis (Table 5.5). Thus, 
KLK4-mediated up-regulation of PLAT expression may constitute an additional 
mechanism by which KLK4 activated TGFβ1 signalling.  
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Of all measured genes encoding canonical downstream signalling intermediates of 
TGFβ1, as annotated in the KEGG database, only SMURF2 was significantly 
regulated by KLK4 (Table 5.5; Supplementary Figure 5.1). However, up-regulation 
of this intracellular inhibitor of TGFβ1 signalling would reduce, and not induce, 
TGFβ1 signalling (Table 5.5); thus, KLK4-mediated up-regulation of SMURF2 
expression does not constitute a viable mechanism for promoting TGFβ1 activity.  
Thrombin (F2) was considered the second-most highly activated upstream regulator 
of TGFβ1 activity (Table 5.3) in the present study. Thrombin is a PAR-1 activating 
protease, which induced TGFβ1 activation in murine lung fibroblasts in a PAR-1 
dependent manner (Jenkins et al., 2006). Thus, KLK4 appeared to directly or 
indirectly activate thrombin-mediated signalling, potentially initiating thrombin-
mediated PAR-1 activation and subsequent TGFβ1 activation. This represents a 
plausible means by which KLK4 may have activated both thrombin- and TGFβ1-
mediated signalling. Of note, KLK4 directly activates PAR-1 on the surface of 
WPMY-1 myofibroblasts (Wang et al., 2010). Thus, genes apparently regulated as a 
result of thrombin activity may instead reflect KLK4 activity through direct 
activation of PAR-1. Accordingly, KLK4-mediated activation of PAR-1 constitutes 
an additional putative mechanism by which KLK4 may have indirectly induced 
TGFβ1 signalling. 
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5.4 Discussion 
The goal of this aspect of the study was to use a low-bias, high-depth approach to 
identify KLK4-regulated genes in prostate myofibroblasts. The KLK4-regulated 
transcriptome of the prostate WPMY-1 myofibroblast cell line was successfully 
analysed, in which KLK4 differentially regulated 439 genes. This represents the first 
study to analyse KLK4-regulated gene expression in prostate myofibroblasts and is 
among only a handful of studies to examine KLK4 activity on components of the 
prostate tumour microenvironment. KLK4-mediated gene expression in prostate 
myofibroblasts was extensive and provides evidence of an important regulatory role 
for KLK4 in prostate stroma. 
5.4.1 KLK4 may contribute to tumourigenesis through activating TGFβ1 
signalling in prostate myofibroblasts 
An aim of the present work was to use the high-depth KLK4-regulated gene 
expression data obtained to formulate hypotheses regarding KLK4-mediated 
regulation of prostate myofibroblasts and inform future validation studies. These 
hypotheses would not be biased by a priori knowledge of KLK4 action on 
myofibroblasts. The most significant finding from this analysis was that KLK4-
mediated proteolysis activated TGFβ1-regulated gene transcription in prostate 
myofibroblasts. The importance of stromal TGFβ1 signalling in regulating the 
prostate tumour microenvironment is discussed below.  
5.4.1a KLK4-mediated induction of TGFβ1 signalling in CAFs may promote 
aggressive disease 
TGFβ1 is a well-established initiator of fibroblast activation in a range of tissues 
(Pickup, Novitskiy & Moses, 2013), including the prostate (Tuxhorn et al., 2002). 
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The importance of activated fibroblasts or CAFs in prostate cancer progression was 
summarised in Chapter 1, which highlighted CAFs as an essential cellular 
component for prostate cancer progression. While KLK4 may be able to activate 
TGFβ1 signalling in resting fibroblasts, the WPMY-1 cell model employed herein is 
an activated fibroblast or myofibroblast cell line (Webber et al., 1999). Despite 
derivation of these cells from normal prostate tissue (Webber et al., 1999), 
myofibroblasts in wounding are believed to be similar, if not identical, to CAFs; 
although, the exact likeness between wound healing myofibroblasts and CAFs in 
cancer is unknown (Barron & Rowley, 2012). As such, WPMY-1 myofibroblasts 
possess a CAF, or at least CAF-like, phenotype; thus, results obtained using this cell 
model suggest a role for KLK4 to induce TGFβ1 signalling in established CAFs. The 
above-mentioned role for TGFβ1 signalling in resting prostate fibroblasts to promote 
fibroblast activation is well-established; however, less is known of the functional 
consequences of TGFβ1 signalling in established prostatic CAFs on prostate cancer 
progression.  
Stromal TGFβ1 signalling is important in breast cancer, where breast cancer cells 
cultured in CAF CM underwent EMT, which was abrogated by addition of a TGFβ1 
functional blocking antibody (Yu et al., 2014). CAFs grown in CM from colon 
cancer cells exhibited hyperactive TGFβ1 signalling (Hawinkels et al., 2014), and 
treatment of colon cancer-derived CAFs with TGFβ1 conferred a survival advantage, 
favouring the selection of more metastatic colon cancer cells in co-culture (Calon et 
al., 2012).  
Stromal TGFβ1 signalling does not appear to be required for prostate 
tumourigenesis, as co-implantation of BPH-1 cells with fibroblasts from a patient 
with BPH, that were engineered to lack TGFβR2, still produced tumours in mice 
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(Franco et al., 2011). In stromal tissue from patients, only a subset of fibroblasts are 
TGFβR2- positive, and thus, TGFβ1-responsive (Franco et al., 2011; Li et al., 2008). 
However, Franco et al. showed that co-implantation of BPH-1 cells with a 
heterogenous mix of BPH-derived fibroblasts, which were either positive or negative 
for TGFβR2 expression, resulted in invasive carcinoma in mice. This was in 
comparison to development of benign tumours when co-implanting a homogenous 
population of TGFβR2-negative BPH-derived fibroblasts with BPH-1 cells (Franco 
et al., 2011). The TGFβ1-insensitve fibroblasts expressed elevated levels of TGFβ1, 
which acted through TGFβ1-sensitive fibroblasts and neighbouring cancer cells to 
exert pro-tumourigenic effects (Franco et al., 2011). The authors concluded that 
TGFβ1 signalling in prostate stroma promotes invasive adenocarcinoma (Franco et 
al., 2011).  
Supporting the above putative functional importance of TGFβ1 signalling in 
established CAFs, there is elevated TGFβ1 signalling in cancer-adjacent stroma 
compared to benign-associated stroma and distal normal prostate tissue stroma 
(Franco et al., 2011). Moreover, a higher degree of TGFβ1 signalling in peritumoural 
fibroblasts is associated with more aggressive disease (Carstens et al., 2014). Thus, 
as with breast and colon cancer, it appears that stromal TGFβ1 signalling, although 
not required for prostate cancer development, may select for aggressive prostate 
cancer. In support of this, prostate stromal cells from a patient with BPH, that were 
engineered to over-express TGFβ1, grew invasive adenocarcinomas in mice when 
recombined with BPH-1 cells, in contrast to vector control cells (Franco et al., 2011). 
Further, PC-3 cells cultured with CM from TGFβ1-treated CAFs or NPFs underwent 
EMT, in vitro (Giannoni et al., 2010). Finally, patient-derived CAFs were shown to 
secrete greater amounts of TGFβ1 than NPFs, and mice pre-loaded with a TGFβ1 
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neutralizing antibody formed smaller tumours arising from implantation of prostate 
epithelial organoids with CAFs, compared to mice pre-loaded with IgG (Ao et al., 
2007). Thus, stromal TGFβ1 signalling appears to promote aggressive prostate 
cancer and, as such, the ability of KLK4 to induce TGFβ1 activity in surrounding 
stroma is highly significant. 
The pattern of KLK4 expression in prostate pathologies supports its role in 
regulating stromal TGFβ1 signalling. Prostatic epithelial KLK4 production is 
elevated as early as PIN, whereupon a reactive stroma develops (Bui, 2006). TGFβ1 
signalling is an integral factor in induction of prostate cancer reactive stroma 
(Tuxhorn et al., 2002). Prostatic KLK4 expression is associated with tumour stage 
(Avgeris, Stravodimos & Scorilas, 2011), and TGFβ1 signalling is increased in 
peritumoural fibroblasts (Carstens et al., 2014). KLK4 is also over-expressed in 
prostate cancer (see Table 1.2), and stromal TGFβ1 signalling may select aggressive 
phenotypes in neighbouring tumour epithelium (discussed above). Furthermore, 
TGFβ1 signalling in prostate stromal cells induced KLK4 expression in LNCaP cells 
in co-culture (Yang et al., 2014). This was blocked by inhibition of TGFβR1, 
whereby functional TGFβR1 was produced only by the prostate stromal cells and not 
the LNCaP cells. Moreover, TGFβ1 did not induce KLK4 expression in LNCaP cell 
mono-cultures (Yang et al., 2014). Additionally, PAR-1 activation can induce 
TGFβ1 signalling (discussed in Chapter 6) and CM from WPMY-1 myofibroblasts, 
that had been treated with a PAR-1 agonist, induced KLK4 expression in prostate 
cancer cells (Wang et al., 2010). Notably, KLK4 expression was also shown to be 
TGFβ1-regulated in teeth (Cho et al., 2013; Suzuki et al., 2014). Thus, KLK4 may 
activate TGFβ1 signalling in prostate myofibroblasts, which may in turn induce 
epithelial KLK4 expression, resulting in the cyclic induction of stromal TGFβ1 
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signalling. This warrants further investigation, as it serves to highlight the putative 
extensive pathological implications of KLK4-induced stromal TGFβ1 signalling in 
prostate cancer.  
The apparent ability of KLK4 to induce TGFβ1 signalling in WPMY-1 
myofibroblasts relied on endogenous secretion of TGFβ1 for the observed effects. 
WPMY-1 cells are TGFβ1-responsive (Wang et al., 2008; Yu et al., 2011) and 
express TGFβ1 mRNA (Ayala et al., 2013), as well as protein, at similar or greater 
levels than patient-derived BPH-associated stromal cells (Yu et al., 2011). In 
accordance, TGFβ1 was identified in WPMY-1 myofibroblast CM in the present 
study (see Chapter 6). WPMY-1 myofibroblasts produce sufficient levels of TGFβ1 
to initiate downstream signalling (Wang et al., 2008) and KLK4 appeared to induce 
TGFβ1 signalling in WPMY-1 myofibroblasts, without the exogenous addition of 
recombinant TGFβ1 routinely used in cell culture assays. Importantly, prostate 
cancer epithelium also produces large amounts of TGFβ1 (Cardillo et al., 2000); 
thus, the extent by which KLK4 was found to regulate gene expression in the present 
study may be amplified in the prostate tumour microenvironment, where additional 
TGFβ1 is present. 
In summary, while some interactions between tumour cells and resting fibroblasts 
have been determined (Barron & Rowley, 2012), less is known of the interactions 
between tumour cells and CAFs, despite such interactions being integral to 
tumourigenesis (Olumi et al., 1999). Indeed, xenografts of mixed prostate stromal 
and epithelial cells only formed cancers when initiated epithelial cells and activated 
fibroblasts were used (Olumi et al., 1999). That is, CAFs implanted with naive 
epithelium did not form prostate cancers; nor did initiated epithelial cells or tumour 
cells implanted with resting fibroblasts (Olumi et al., 1999). Hence, the bi-directional 
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signalling between tumour cells and mature CAFs is important in cancer progression. 
The present study suggests KLK4 to be a tumour-derived signalling factor that is 
over-produced in prostate cancer (see Table 1.2) and interacts with CAF-derived 
products to induce TGFβ1 signalling in the latter cell population. Stromal TGFβ1 
signalling may then regulate the production of stromal cell-derived signalling factors, 
which act on the tumour cells to favour an aggressive phenotype. This novel 
hypothesis was generated from the successful application of low-bias, high-depth 
KLK4-regulated transcriptome analysis, creating a data-informed foundation for 
future analysis of KLK4 function in the prostate tumour microenvironment.  
5.4.1b KLK4-mediated induction of TGFβ1 signalling did not appear consistent with 
CAF initiation 
KLK4 regulated, and did not regulate, similar genes to those respectively regulated 
and not regulated in CAFs, as compared to NPFs; however, there was no significant 
association of the direction in which genes were regulated by KLK4 and in CAFs. As 
such, the association between KLK4-mediated gene expression regulation and that 
observed in CAFs is unclear. It should be noted that the CAF population analysed 
was derived from a single patient (Ellem et al., 2014), and better definition of a CAF 
gene expression signature across patient populations will be useful in future to assess 
the role for KLK4-mediated gene expression in promoting a CAF phenotype.  
5.4.1c KLK4-mediated induction of TGFβ1 signalling may promote myofibroblast 
morphology changes 
Confirming predictions by pathway analysis tools, KLK4-treated WPMY-1 
myofibroblasts exhibited a disparate morphology to control-treated cells. Notably, in 
wound healing, whereupon myofibroblasts play a key functional role in closing the 
epithelial barrier, myofibroblasts possess contractile properties and form tight 
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junctions to close breaches in the epithelial barrier (Barron & Rowley, 2012). The 
reactive stroma in prostate cancer is believed to be similar to that found in wound 
healing (Barron & Rowley, 2012). Notably, myofibroblasts treated with KLK4 were 
highly organised and formed tight cell clusters, in comparison to control-treated 
cells, and pathway analysis indicated that this may be TGFβ1-mediated. Importantly, 
cell proliferation and viability were not changed upon KLK4-treatment; thus, the 
altered morphology observed was not due to increased cell viability upon KLK4 
treatment. WPMY-1 myofibroblasts have previously been shown to be growth-
inhibited by TGFβ1; however, this was only when the cells were cultured in cell 
media containing 1% (w/v) FBS (Webber et al., 1999). In serum-free media, TGFβ1 
did not affect cell proliferation (Webber et al., 1999), consistent with results 
observed herein. 
5.4.1d KLK4 may induce TGFβ1 signalling in prostate myofibroblasts through 
regulating production of TGFβ1-activating and -inhibitory proteins  
KLK4 induced extensive gene expression changes in prostate myofibroblasts, while 
only regulating a handful of genes in prostate cancer cells. In particular, PC-3 cells 
are TGFβ1-sensitive (van der Poel, 2005); hence, putative mechanisms for KLK4-
induced TGFβ1 activation in WPMY-1 myofibroblasts may be specific to 
myofibroblasts. As another manner in which the collected gene expression data may 
be utilised to generate data-informed hypothesis for future functional studies, 
putative mechanisms of KLK4-mediated induction of TGFβ1 signalling were 
identified. These included KLK4-mediated down-regulation of genes encoding the 
TGFβ1 inhibitors, decorin (DCN) and TGFβR3, as well as up-regulation of the gene 
encoding the plasminogen-activating protease, tPA. The involvement of tPA in this 
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axis will be discussed in Chapter 6, while that of DCN and TGFβR3 are summarised, 
below. 
DCN is primarily expressed by prostate stromal cells, except for heterogenous 
epithelial expression observed in PIN (Banerjee et al., 2003). DCN binds TGFβ1 and 
is able to attenuate TGFβ1-mediated signalling in hepatic fibroblasts (Baghy, Iozzo 
& Kovalszky, 2012), skeletal muscle cells (Cabello-Verrugio et al., 2012), 
hypertrophic scar fibroblasts (Zhang et al., 2009) and hepatic stellate cells (Shi et al., 
2006). Importantly, DCN expression is lost in cancer-associated stroma in the 
prostate (Banerjee et al., 2003; Henke et al., 2012), mirroring the down-regulation of 
DCN expression observed upon KLK4 treatment of myofibroblasts in the current 
study. Moreover, DCN is tumour-suppressive in a Pten null mouse model of prostate 
cancer (Hu et al., 2009). Thus, KLK4-mediated repression of DCN expression may 
constitute a mechanism by which KLK4 induced TGFβ1 signalling. 
TGFβR3, once shed from the cell surface, can inhibit TGFβ1 signalling (Elderbroom 
et al., 2014). KLK4-mediated down-regulation of TGFBR3 may, therefore, be a 
means by which KLK4 induced TGFβ1 signalling in prostate myofibroblasts. 
However, while KLK4 production in prostate cancer is elevated (see Table 1.2), 
stromal production of TGFβR3 is also high (Turley et al., 2007). Thus, the clinical 
significance of a KLK4-mediated reduction in TGFBR3 expression is unclear. 
Additional information regarding the mechanism of KLK4-induced TGFβ1 
signalling, as informed by KLK4 substrates, is discussed in Chapter 6.  
5.4.2 Conclusion 
In summary, gene expression microarray analysis was used to provide a global 
snapshot of KLK4-regulated signalling in prostate myofibroblasts and cancer cells. 
In contrast to the minimal effect of KLK4 treatment on gene expression in prostate 
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cancer cells, KLK4-mediated signalling in prostate myofibroblasts was extensive, 
where 439 genes were differentially regulated. This is the first analysis of KLK4-
mediated gene expression in prostate myofibroblasts, and provides a useful data 
platform which may be interrogated to delineate the function of KLK4 in the prostate 
tumour microenvironment. Toward this end, KLK4 appeared to induce TGFβ1 
signalling in prostate myofibroblasts, where this may promote acquisition of an 
aggressive prostate cancer phenotype, implicating KLK4 as a key regulator of cancer 
progression through its paracrine actions on prostate myofibroblasts. Proteolytic 
substrates of KLK4 in prostate myofibroblast secretions were next determined, with 
the aim of identifying mechanistic contributors to TGFβ1 activation, as well as 
highlighting putative additional roles for this cancer-enriched protease in the prostate 
tumour microenvironment. 
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6.1 Introduction 
In the previous chapter, KLK4 was shown to induce a number of transcriptomic 
alterations to prostate WPMY-1 myofibroblasts, which were predicted to affect 
various cell signalling pathways and associated cellular functions. In particular, 
KLK4 appeared to activate TGFβ1 signalling, where TGFβ1 signalling in established 
CAFs is linked to aggressive cancer (discussed in Chapter 5). It was next important 
to define KLK4 substrates in WPMY-1 myofibroblast CM, in order to establish a 
putative proteolytic mechanism for KLK4-mediated regulation of TGFβ1 signalling 
and other of the identified KLK4-regulated signalling cascades (Chapter 5). As with 
analysis of the prostate cancer cell-secreted KLK4 degradome in Chapter 3, the 
identification of KLK4 substrates in CM from prostate myofibroblasts was expected 
to highlight additional putative functions for the protease. Determining KLK4-
regulated targets and associated functions within the tumour microenvironment is 
essential to understand the depth of KLK4 function in prostate cancer.  
Present knowledge of prostate stromal cell-derived KLK4 substrates is limited, with 
PAR-1 being the only putative myofibroblast-derived substrate of KLK4 (Wang et 
al., 2010). KLK4 has been shown to directly process PAR-1 on the surface of other 
cell types (Gratio et al., 2010; Wang et al., 2010) and siRNA-mediated PAR-1 
knockdown significantly attenuated KLK4-induced IL-6 production in WPMY-1 
myofibroblasts (Wang et al., 2010). To date, other putative KLK4 substrates that 
may be derived from the tumour microenvironment have only be inferred from the 
ability of KLK4 to cleave recombinant proteins in a biochemical setting. For 
example, IGFBP5 was cleaved by KLK4 in vitro (Matsumura et al., 2005a) and is 
produced in prostate fibroblasts (Tennant et al., 1996); thus, IGFBP5 constitutes a 
potential KLK4 target within the prostate tumour microenvironment. To date, a high-
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depth, low-bias profile of KLK4 substrates derived from prostate myofibroblasts is 
yet to be conducted. Given the importance of defining protease substrates to 
elucidate protease-mediated function, an analyses of the KLK4 degradome produced 
by prostate myofibroblasts was performed. 
Following the successful application of the PROTOMAP approach to delineate the 
KLK4 degradome in prostate cancer cell secretions (Chapter 3), this approach was 
used in the present chapter to define the KLK4 degradome in CM from WPMY-1 
myofibroblasts. Particularly, given that myofibroblasts are highly secretory and 
produce an abundant proportion of ECM, growth factors, cytokines and other 
signalling molecules in the reactive stroma (Barron & Rowley, 2012; Frantz, Stewart 
& Weaver, 2010), it was expected that this approach would identify a number of 
novel KLK4 substrates, altogether possessing diverse regulatory functions within the 
tumour microenvironment. Such substrates were anticipated to include either TGFβ1 
itself, or proteins known to regulate TGFβ1 activity. This study represents the first 
global analysis of KLK4 substrates derived from the prostate tumour 
microenvironment, towards establishing the repertoire of proteolytic intermediates 
through which KLK4 regulates this cellular compartment. 
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6.2 Materials and Methods 
6.2.1 KLK4 substrate screening in WPMY-1 myofibroblast CM  
6.2.1a Optimising the KLK4 concentration for digesting WPMY-1 myofibroblast CM 
This was performed as per 3.2.3a, excepting that WPMY-1 myofibroblast CM (311.6 
ng/ µL) was treated with 1/2 serial dilutions of KLK4 (12.3 ng/ µL to 192.6 pg/ µL 
active), corresponding to ratios of WPMY-1 myofibroblast CM: KLK4 (w/w) from 
25:1 to 1,600:1. Protein samples were prepared in sample buffer and TCEP 
hydrochloride solution (56.7 mM final concentration), and 3.7 µg was resolved by 
SDS-PAGE. 
6.2.1b Sample preparation 
Sample preparation was performed as per 3.2.3b. 
6.2.1c LC-MS/MS and MS/MS data analysis 
LC-MS/MS was performed as per 3.2.3c. MS/MS data analysis was performed as per 
3.2.3d.  
6.2.1d Peptograph analysis 
Peptograph analysis was performed as per 3.2.3e. 
6.2.2 Validation of TSP1 hydrolysis by KLK4 
Recombinant TSP1 (92.6 nM; R&D Systems) was digested with thermo-KLK4 (92.3 
nM active; 620.6 nM total), or 1/10 serial dilutions thereof, representing molar ratios 
of TSP1: KLK4 (w/w) from 1:1 to 1,000:1. TSP1 was left untreated or treated with 
thermo-mKLK4 (614.4 nM total) as negative controls. Controls of only thermo-
KLK4 (92.3 nM active) or thermo-mKLK4 (614.4 nM total) were also employed. 
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Digests were performed in assay buffer (18 h, 37 ºC). Samples were reduced with 
TCEP hydrochloride solution (47.6 mM final concentration; 60ºC, 10 min) and 
alkylated with iodoacetamide (43.5 mM; RT, 15 min, light-protected), before adding 
sample buffer (1 × final concentration). The equivalent of 296 ng TSP1 was loaded 
per SDS-PAGE gel lane for Western blot analyses, which was performed using 
antibodies targeting the N- or mid-termini of TSP1 (Table 2.1). The equivalent of 
475 ng TSP1 was loaded per gel lane for protein visualisation by silver staining.  
6.2.3 Validation of SPARC hydrolysis by KLK4 
Recombinant SPARC (R&D systems) was incubated with 1/3 serial dilutions of 
thermo-KLK4, reflecting ratios of SPARC: KLK4 (w/w) from 100:1 to 2.4 × 10
4
:1. 
Untreated or mKLK4-treated (equivalent total amount to the highest KLK4 
concentration employed) SPARC served as controls. Digests were analysed by SDS-
PAGE and silver stain analysis.  
6.2.4 Comparison of KLK4-generated fragments with annotated cleavage 
products in the UniProtKB and the literature 
Peptograph analyses for bioactive products were performed by manual comparison 
of the size and topography of control and KLK4-generated protein fragments with 
those protein and product chains annotated in the UniProtKB and in the literature, as 
cited.  
6.2.5 Analysis of KLK4 substrates interacting with TGFβ1 
The Grow tool in IPA was used to select all KLK4 substrates interacting directly or 
indirectly with TGFβ1. Only molecules upstream of TGFβ1 were included; 
molecules capable only of regulating TGFβ1 transcription or expression were 
excluded. The Molecule Activity Predictor (MAP) tool in IPA was used to predict 
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whether KLK4-mediated activation or degradation of each substrate would induce 
TGFβ1 activation. To this end, the in silico activation/ inhibition tool within the 
MAP platform was used to apply states of activation or inhibition to each of the 
TGFβ1-interacting KLK4 substrates, to predict which state renders TGFβ1 active. 
This was only able to be determined for TSP1 and CTGF using IPA, as IPA 
annotations for the interactions between the remaining above-mentioned KLK4 
substrates and TGFβ1 did not include the resulting outcome on TGFβ1 activity. For 
the remaining substrates, literature interrogation revealed whether activation or 
inhibition of these substrates has been shown to induce TGFβ1 activity (references in 
text).  
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6.3 Results 
6.3.1 Identification of the KLK4 degradome in WPMY-1 myofibroblast CM 
using PROTOMAP 
6.3.1a The optimal ratio of WPMY-1 myofibroblast CM: KLK4 (w/w) for 
PROTOMAP studies was determined 
As with LNCaP cell CM (3.3.4a), the optimum ratio of WPMY-1 myofibroblast CM: 
KLK4 (w/w) for assessing the KLK4 degradome was determined to be 400:1 (lane 2; 
Figure 6.1). This represented the lowest concentration of active KLK4 whereby 
hydrolysis of WPMY-1 myofibroblast CM was apparent, following molecular weight 
separation by SDS-PAGE and visualisation by silver staining (lane 8; Figure 6.1). 
Specifically, KLK4-mediated proteolysis was indicated by the decreased staining 
intensity of protein bands at 17, 23, 30, 45, 55 and 72 kDa, corresponding to cleaved 
products, as well as an increased staining intensity of bands at 16, 22, 57 and 70 kDa, 
corresponding to protein cleavage fragments liberated by proteolysis (lane 8; Figure 
6.1). Further, at the 400:1 treatment ratio, there was an overall decreased staining 
intensity of gel lanes, particularly upward of 23 kDa (lane 8; Figure 6.1), as 
compared to untreated control CM (lane 3; Figure 6.1). KLK4, alone, was weakly 
stained at 27 and 29 kDa (lane 8; Figure 6.1). Hence, a 400:1 treatment ratio was 
selected as optimal for treating WPMY-1 myofibroblast CM for subsequent 
PROTOMAP analysis. 
6.3.1b KLK4-mediated proteolysis of WPMY-1 myofibroblast CM for PROTOMAP 
studies was confirmed by SDS-PAGE/ silver stain analysis 
KLK4-mediated digestion of three different batches of WPMY-1 myofibroblast CM 
was performed for PROTOMAP analysis of the KLK4 degradome, where each CM 
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Figure 6.1. SDS-PAGE and silver stain analysis of WPMY-1 myofibroblast CM digested with 
KLK4. KLK4 degraded WPMY-1 myofibroblast CM at ratios of 25:1 to 400:1 [CM: KLK4 (w/w); 
lanes 4-10]. Proteolysis was not observed at treatment ratios of 800:1 to 1,600:1 (lanes 9-10). 
Untreated LNCaP cell CM (lane 3) and KLK4 only (lane 2) samples served as controls. The migration 
of KLK4 is annotated. Protein standard was loaded in lane 1. 
batch was harvested and treated on different days (three biological replicates). 
Sample aliquots were analysed by fixed percentage SDS-PAGE/ silver stain analysis 
to confirm KLK4-mediated proteolysis (Figure 6.2). Protein migration was similar 
between replicates of the KLK4-treated samples (lanes 3, 5 and 7; Figure 6.2). 
Protein migration was also similar across mKLK4-treated control replicates (lanes 2, 
4 and 6; Figure 6.2). KLK4 treatment predominantly reduced staining intensity 
throughout the gel, with the exception of increased staining intensity of bands at 18 
and 19 kDa, which likely correspond to KLK4-generated protein cleavage products 
(lanes 3, 5 and 7; Figure 6.2). As KLK4 was confirmed to hydrolyse proteins in each 
replicate of WPMY-1 myofibroblast CM, these samples were subject to 
PROTOMAP analysis. A schematic representation of the molecular weight regions 
corresponding to each of the 19 gel slices taken for PROTOMAP analyses is shown 
in Figure 6.2. It should be noted that polyacrylamide gradient gels were employed to 
achieve more linear protein separation for PROTOMAP studies, whereas a fixed 
percentage polyacrylamide gel is shown in Figure 6.2.  
 1       2      3      4      5      6      7      8      9     10 
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Figure 6.2. SDS-PAGE/ silver stain analysis of prostate cancer WPMY-1 myofibroblast CM 
digested with KLK4 or mKLK4 for PROTOMAP experiments. Three biological replicates (Rep) 
of CM were prepared and digested with KLK4 (lanes 3, 5 and 7) or mKLK4 control (lanes 2, 4 and 6). 
Protein standard was loaded in lane 1. The molecular weight ranges corresponding to gel slices (1-19) 
taken for the PROTOMAP experiment are presented, far left. Gel slices corresponding to those with 
the highest relative abundance of KLK4 (spectral counting) identified in PROTOMAP experiments 
are denoted with a bracket. Filled arrowheads highlight bands in KLK4-treated WPMY-1 
myofibroblast CM, which exhibited elevated intensity relative to the control. Protein digestion was 
apparent in KLK4-treated, but not mKLK4-treated, CM.  
6.3.1c Identification of extracellular or membrane-localised proteins in WPMY-1 
myofibroblast CM 
In total, 1,467 proteins were identified in at least one biological replicate of WPMY-
1 myofibroblast CM (FDR ≤ 1%; Figure 6.3). Similar to description of proteins 
identified in LNCaP cell CM in 3.3.4c, this number represents only proteins for 
which unique peptides were identified and, therefore, those proteins plotted onto 
peptographs. IPA determined 392 proteins identified in WPMY-1 myofibroblast CM 
to be localised to the plasma membrane or extracellular space (Figure 6.3), that is, 
targets theoretically accessible to KLK4. The subcellular localisation of 19 proteins 
19 
18 
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Figure 6.3. The number of significantly identified proteins and putative KLK4 substrates in 
WPMY-1 myofibroblast CM. Of the 1,467 proteins identified in WPMY-1 myofibroblast CM from 
at least replicate experiment (white circle), 392 were annotated to be extracellar or plasma membrane 
proteins (light blue circle). Three hundred and six such proteins were identified in the necessary 
conditions to be considered eligible to be screened as KLK4 substrates (dark blue circle), where 50 
were putative KLK4 substrates (pink circle). 
was not annotated in IPA, and these proteins were excluded from further analyses 
(Supplementary table 6.1).  
A high degree of overlap was observed between extracellular and cell membrane-
associated proteins identified in each of the three replicates of WPMY-1 
myofibroblast CM (Figure 6.4). In total, 222 extracellular or plasma membrane-
localised proteins were identified in CM from all three replicates, while another 84 
(22+50+12) proteins were identified in CM from two of three replicates. The 
remaining 86 proteins (30+22+34) were identified only in a single replicate 
experiment (Figure 6.4). The requirement for a KLK4 substrate to be cleaved in at 
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Figure 6.4. The number of extracellular and plasma-membrane-associated proteins identified in 
each condition used for PROTOMAP analysis of KLK4 substrates in WPMY-1 myofibroblast 
CM. Three hundred and six (222+22+12+50) proteins were identified in CM from at least two 
experimental replicates and were, therefore, eligible to be screened for evidence of KLK4-mediated 
hydrolysis using the PROTOMAP approach. In contrast, 86 (30+22+34) proteins were detected in CM 
from a single replicate and thus were ineligible for substrate screening, given the requirement for a 
protein to be identified and cleaved in at least two CM replicates to be deemed a KLK4 substrate. 
least two replicates meant that these 86 proteins were ineligible to be considered as 
putative KLK4 substrates. Peptographs for the remaining 306 (222+84) proteins were 
assessed to determine whether these proteins were hydrolysed by KLK4 in WPMY-1 
myofibroblast CM.  
6.3.1d  The PROTOMAP approach identified 50 novel KLK4 substrates in WPMY-1 
myofibroblast CM 
To identify potential KLK4 substrates, two peptograph pictorial outputs were 
compiled for every protein identified (FDR ≤ 1%) in each replicate experiment. That 
is, six peptographs were plotted for each protein in total. For each peptograph, all 
peptides matched to a given protein (in one of replicate one, two or three), which 
were identified (P > 0.5) in the KLK4-treated sample, were plotted alongside either 
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those peptides identified in the untreated [Supplementary Figure 6.1 (replicate one), 
6.2 (replicate two) and 6.3 (replicate three)] or mKLK4-treated [Supplementary 
Figure 6.4 (replicate one), 6.5 (replicate two) and 6.6 (replicate three)] control 
samples. In general, KLK4 substrates were deemed to be those extracellular or 
membrane-localised proteins that displayed increased migration in KLK4-treated 
samples, versus each control, in at least two of the three biological replicates (see 
3.2.3e for the detailed approach to substrate determination). Using this approach, 50 
putative KLK4 substrates were identified in WPMY-1 myofibroblast CM (Figure 6.3 
and Table 6.1). The putative KLK4 substrates identified included enzymes, growth 
factors, transmembrane receptors, peptidases, transporters, ion channels, kinases, 
phosphatases, peptidase inhibitors, growth factor binding proteins and ECM 
components (Table 6.1).  
Of the 50 extracellular or plasma membrane-localised KLK4 substrates identified, 
none were known KLK4 substrates, although IGFBP7 belongs to the same family of 
proteins as the established KLK4 substrates, IGFBP3-6 (Matsumura et al., 2005a). 
IGFBP3, IGFBP4 and IGFBP6 were identified in all three replicates of WPMY-1 
myofibroblast CM; however, these proteins were not found to be cleaved by KLK4 
in the present study (see respective peptographs in Supplementary Figures 6.1-6.6). 
Two additional proteins, which have been established as KLK4 substrates in the 
literature, were identified only by only a single peptide in one CM replicate herein 
(uPAR and HGF); thus, conclusions could not be drawn regarding whether KLK4 
may have cleaved these proteins. All other KLK4 substrates, published in the 
literature (Lawrence, Lai & Clements, 2010) and discussed in Chapter 1, were not 
identified in prostate myofibroblast secretions and so may not constitute 
myofibroblast-derived targets of KLK4. 
  
 
 
 
Chapter 6: Determining the KLK4 degradome produced by protate myofibroblasts                                                   222 
 
Table 6.1. KLK4 substrates in WPMY-1 myofibroblast CM. 
 
Description     Loc Protein type Symbol   Group   Sib Prob Length     %*      Pep*     Unique Pep* 
72 kDa type IV collagenase EC peptidase MMP2 593 a 1 660 42.1 250 166 
isoform 6 of Agrin PM glycoprotein AGRIN 491 a 1 2045 32.9 198 108 
annexin A1 PM 
phospholipid 
binding protein 
ANXA1 558 a 1 346 46.2 92 92 
basement membrane-specific heparan sulfate 
proteoglycan core protein 
EC enzyme PGBM 829 a 1 4392 22.9 494 494 
calsyntenin-1 PM protein binding 
B4E3Q1 
(CLSTN1)
†
 
309 a 1 962 25.2 154 154 
chloride intracellular channel protein 4 PM ion channel CLIC4 1054 a 1 253 35.2 35 35 
chondroitin sulfate proteoglycan 4 PM proteoglycan CSPG4 185 a 1 2322 19.1 82 82 
collagen alpha-1(I) chain EC ECM  CO1A1 548 a 1 1464 76.7 1001 1001 
collagen alpha-1(III) chain EC ECM  CO3A1 550 a 1 1466 25.9 221 117 
collagen alpha-1(IV) chain EC ECM  CO4A1 551 a 1 1669 9.2 33 33 
collagen alpha-1(VI) chain EC ECM  CO6A1
†
 114 a 1 1028 39.1 344 344 
collagen alpha-1(XII) chain EC ECM 
D6RGG3 
(COL12A1) 
355 a 1 3073 35.4 851 851 
collagen alpha-2(I) chain EC ECM  CO1A2 108 a 1 1370 62.4 704 704 
collagen alpha-2(IV) chain EC ECM  CO4A2 594 a 1 1712 12.5 137 137 
collagen alpha-2(V) chain EC ECM  CO5A2 102 a 1 1499 32.5 137 137 
collagen alpha-2(VI) chain EC ECM  CO6A2 615 a 1 1019 12.8 55 21 
connective tissue growth factor EC growth factor CTGF 132 a 1 349 15.8 35 35 
C-type lectin domain family 11 member A EC growth factor CLC11 1042 a 1 323 28.8 12 10 
elastin microfibril interface-located protein 1 EC glycoprotein EMIL1 1055 a 1 1016 21.9 125 125 
extracellular matrix protein 1 EC transporter ECM1 904 a 1 555 60.2 285 285 
fibrillin-1 EC glycoprotein FBN1 715 b 1 2877 27.1 354 347 
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fibrillin-2 EC glycoprotein FBN2 715 a 1 2918 27.8 627 598 
fibulin-1 EC glycoprotein FBLN1 664 a 1 721 22.9 202 76 
follistatin-related protein 1 EC protein binding FSTL1 858 a 1 324 60.8 479 340 
galectin-1 EC glycoside binding LEG1 596 a 1 135 68.9 178 131 
galectin-3-binding protein PM 
transmembrane 
receptor 
LG3BP
†
 850 a 1 585 35.7 173 113 
glucose-6-phosphate isomerase EC enzyme G6PI
†
 577 a 1 558 29.7 58 58 
inactive tyrosine-protein kinase 7 PM kinase PTK7 862 a 1 1070 21.7 38 35 
insulin-like growth factor-binding protein 7 EC transporter IBP7 898 a 1 282 44.3 29 29 
laminin subunit alpha-4 EC glycoprotein LAMA4 899 a 1 1824 14.5 128 128 
latent-transforming growth factor beta-binding protein 4 EC protein binding 
E7ENG9 
(LTBP4) 
364 a 1 1586 10.7 35 35 
lysyl oxidase homolog 2 EC enzyme LOXL2 1048 a 1 774 22.9 27 21 
moesin PM membrane binding MOES 673 a 1 577 63.6 289 234 
neuropilin-1 PM 
transmembrane 
receptor 
E7EX60 
(NRP1)
†
 
376 a 1 641 14.2 41 41 
nidogen-1 EC glycoprotein NID1 627 a 1 1248 40.6 239 239 
pentraxin-related protein PTX3 EC 
pattern recognition 
receptor 
PTX3
†
 129 a 1 381 39.6 286 286 
periostin EC protein binding 
B1ALD8 
(POSTN) 
264 a 1 809 56.6 313 313 
peroxidasin homolog EC enzyme PXDN 953 a 1 1479 42.2 386 377 
plasminogen activator inhibitor 1 EC protease inhibitor PAI1 565 a 1 402 63.2 313 313 
proactivator polypeptide EC glycoprotein 
B1AVU8 
(PSAP) 
267 a 1 559 44.5 213 213 
procollagen C-endopeptidase enhancer 1 EC protein binding PCOC1 178 a 1 465 61.1 383 383 
prolow-density lipoprotein receptor-related protein 1 PM 
transmembrane 
receptor 
LRP1 849 a 1 4544 5.6 44 44 
proprotein convertase subtilisin/kexin type 9 EC peptidase PCSK9 945 a 1 692 32.4 186 126 
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Description, UniProtKB recommended name; Loc, subcellular location (PM, plasma membrane; EC, extracellular); Protein type, molecule type designation by IPA or GeneCards; 
Symbol, UniProtKB/ Swiss-Prot entry name prefix (all _HUMAN) with (HUGO gene name) for UniProtKB/ TrEMBL entries; Group, protein group number; Sib, sibling annotation; 
Prob, probability of positive protein identification; Length, the number of amino acid residues in the protein sequence; %, percentage of amino acid residues retrieved, as compared to the 
reference sequence; Unique pep, the number of unique peptides retrieved.  
* Representative data from replicate 3, KLK4-treated versus untreated 
†
 Identified as a novel KLK4 substrate also in LNCaP and/ or PC-3 cell CM. 
receptor-type tyrosine-protein phosphatase S PM phosphatase 
E9PDC5 
(PTPRS) 
606 b 1 1949 11.4 35 35 
SPARC EC protein binding SPRC 598 a 1 339 76.7 291 189 
spectrin beta chain, non-erythrocytic 1 PM 
cytoskeleton 
binding 
SPTB2 833 a 1 2364 6.6 76 73 
testican-1 EC proteoglycan TICN1 852 a 1 439 42.4 71 55 
thrombospondin-1 EC glycoprotein TSP1
†
 714 b 1 1170 9.0 36 36 
thrombospondin-2 EC glycoprotein TSP2 714 a 1 1172 12.7 80 80 
transforming growth factor-beta-induced protein ig-h3 EC protein binding 
G8JLA8 
(TGFBI) 
437 a 1 686 49.9 449 430 
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Although each of the 50 identified KLK4 substrates were novel, some are not 
unexpected, being targets of other KLKs (Table 6.1). KLK4 cleaved chains of 
collagen type-1 and -4 in WPMY-1 myofibroblast CM, which are substrates of 
KLK1, KLK5, KLK6, KLK8 and KLK13-14 (Lawrence, Lai & Clements, 2010). A 
number of other collagens and other ECM proteins were also targeted by KLK4 
(Table 6.1). Additionally, galectin-3 is a target of PSA in seminal plasma (Saraswati 
et al., 2011) and, herein, KLK4 was shown to cleave its binding partner, galectin-3-
binding protein, as well as related protein, galectin-1 (Table 6.1). Finally, some 
proteins identified as KLK4 substrates in the present chapter were also found to be 
KLK4 substrates in prostate cancer cell CM (annotated in Table 6.1), and thus, are 
not unexpected targets of KLK4 in WPMY-1 myofibroblast CM. 
All KLK4 substrates were identified from varying numbers of peptides and degrees 
of sequence coverage. As shown in Table 6.1, between 10 (CLIC11) and 1,001 
(COL1A1) unique peptides were plotted on peptographs for each protein that was 
determined to be a KLK4 substrate. Protein sequence coverage ranged from 5.6% 
(LRP1) to 76.7% (COL1A1 and SPARC). As previously stated, this information 
indicates how confidently peptides and proteins were identified, and does not directly 
inform as to the quality of KLK4 substrate designation. However, for reasons 
detailed in 3.3.2c, those substrates from which a larger number of peptides were 
identified, which covered a higher proportion of the protein sequence, are intuitively 
more high confidence substrates than those identified by fewer peptides. Of note, 
protein sequence coverage listed in Table 6.1 depicts that from the gel slice in which 
the greatest number of peptides were identified and so may underestimate collective 
sequence coverage when considering peptides retrieved from all gel slices. Over half 
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of the 50 proteins determined to be KLK4 substrates were identified by at least 120 
unique peptides and/ or with sequence coverage ≥ 30%. 
6.3.1e Comparison of KLK4 substrates identified in three biological replicates of 
KLK4-treated WPMY-1 myofibroblast CM 
While KLK4 substrates were only required to be detected and cleaved in KLK4-
treated WPMY-1 myofibroblast CM from two out of three biological replicates, 
intuitively, higher confidence substrates are those cleaved in every CM replicate in 
which they were identified. Conversely, lower confidence substrates are those 
identified in CM from all three replicates, but only putatively cleaved by KLK4 in 
CM from two of three replicates. Figure 6.5 shows the distribution of the 50 KLK4 
substrates identified by PROTOMAP analysis, segregated according to the WPMY-1 
myofibroblast CM replicates in which the putative substrate proteins were identified 
(Figure 6.5 B), as compared to the replicate experiments in which they were 
putatively cleaved (Figure 6.5 A). Forty-nine putative KLK4 substrates were 
identified as present in CM from all three replicates, while one substrate was 
identified only in CM from replicates two and three (Figure 6.5 B). However, while 
49 KLK4 substrates were present in WPMY-1 myofibroblast CM from all three 
replicates, and thus, able to be cleaved by KLK4 in each of these replicates, only 27 
were in fact cleaved in all three replicates (Figure 6.5 A). This leaves 22 [(21-1)+2] 
KLK4 substrates, which were identified in all three CM replicates, but that were 
cleaved by KLK4 in only two of the three replicates. For many of these 22 proteins, 
the number of unique peptides retrieved from each protein was lowest in the replicate 
experiment in which the protein was detected, but not cleaved by KLK4. As 
explained in 3.3.4d, differential protein retrieval between replicates may account for 
why some KLK4 substrates appeared cleaved in only two of the three CM pools in  
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Figure 6.5. Replicates of KLK4-treated WPMY-1 myofibroblast CM in which KLK4 substrates 
were identified as being cleaved (A) in comparison to those in which the protein was detected 
(B). (A) Twenty-seven KLK4 substrates were cleaved in WPMY-1 myofibroblast CM from all three 
replicates and an additional 23 (22+1) were cleaved in two of three replicates. (B) Forty-nine KLK4 
substrates were detected in WPMY-1 myofibroblast CM from all replicates, in addition to a KLK4 
substrate detected only CM from replicate 2 and replicate 3. 
which they were identified, particularly for proteins whereby KLK4-mediated 
proteolysis was minimal and cleavage products were of low abundance.  
In summary, KLK4 induced hydrolysis of a range of substrates of varied functions in 
WPMY-1 myofibroblast CM, all of which were not previously reported as KLK4 
substrates in the literature. Next, it was sought to examine the topography and 
migration of KLK4-generated products derived from selected substrates, to begin to 
define the manner in which proteins were cleaved by KLK4 and the putative 
functional outcomes. Of particular interest were those proteins able to regulate 
TGFβ1, potentially serving as substrate intermediates for the observed KLK4-
mediated induction of TGFβ1 signalling WPMY-1 myofibroblasts (Chapter 5). To 
this end, the depth of information provided by the PROTOMAP approach regarding 
KLK4-mediated proteolysis within this myofibroblast-derived protein pool served to 
A B 
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generate novel hypotheses regarding the mechanism of KLK4 function within the 
prostate tumour microenvironment. 
6.3.2 KLK4-mediated proteolysis of selected substrates in WPMY-1 
myofibroblast CM may regulate TGFβ1 activity 
In Chapter 5, it was shown that KLK4 induced TGFβ1 signalling in WPMY-1 
myofibroblasts, although gene expression of TGFβ1 itself was not altered. Given 
this, it was hypothesised that KLK4 may activate TGFβ1 directly, or may do so 
indirectly, by activating or degrading proteins which regulate TGFβ1 activity. To 
accompany presentation of the associated results, an overview of the varied 
mechanisms of TGFβ1 activation will first be given.  
6.3.2a Brief literature summary of TGFβ1 activation mechanisms 
TGFβ1 activation is a complex, multistep process, which can occur via a number of 
mechanisms, summarised in Figure 6.6. The process begins intracellularly, where 
TGFβ1 homodimers form within the cell by disulphide bridge formation between 
mature peptide sequences (Brunner et al., 1989), and also between the latency 
associated peptide (LAP) pro-regions (Brunner et al., 1992), where the latter 
interaction is mediated by a number of hydrophobic residues (Walton et al., 2010). 
The LAP or pro-region of TGFβ1 is often liberated from TGFβ1 by intracellular 
furin-mediated proteolysis (Dubois et al., 2001; Dubois et al., 1995), although this 
can occur extracellularly in some systems (Annes, Munger & Rifkin, 2003). The 
LAP remains non-covalently associated to mature TGFβ1, inhibiting its activity 
(Walton et al., 2010). It also binds the N-terminal sequence of latent-transforming 
growth factor beta-binding proteins (LTBPs) via disulphide bridges (Saharinen & 
Keski-Oja, 2000) and TGFβ1 is most often secreted with an LTBP chaperone, in 
what has been termed the large latency complex (LLC). Small latency complexes  
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Figure 6.6. Summary of key integrin-dependent (yellow) and integrin-independent (green) 
mechanisms of TGFβ1 activation. Myofibroblasts secrete furin-processed LAP-TGFβ1 dimers 
bound with an LTBP molecule. This is collectively called the large latency complex or LLC. The LLC 
incorporates into the matrix by interactions with ECM proteins and fibrillins (i.e. FBN1). Yellow: 
Matrix-bound LLC interacts with integrin molecules, which induces cytoskeletal contraction, resulting 
in conformational change in the LAP-bound integrin. This is sufficient to force LAP to release mature 
TGFβ1. This processes depends on the LLC being matrix-tethered. Green: Proteolysis of LTBPs, by 
proteases such as MMP2 (green Pacman), liberates the LLC from the ECM. LTBP-mediated 
proteolysis may be sufficient to induce a conformational shift in LAP to release mature TGFβ1 (green 
dotted arrow), or may require an additional activation event (solid green arrows). This may take the 
form of proteolytic degradation of LAP (e.g. by MMP2) or conformational alteration to LAP induced 
by TSP1 binding, each of which result in the release of mature TGFβ1. Both: Mature TGFβ1 signals 
through its receptor, TGFβR2, which recruits TGFβR1 to initiate downstream signalling. 
(SLCs), consisting only of LAP-bound TGFβ1, can be secreted by some cell types 
(Hayashi & Sakai, 2012). However, LTBPs generally chaperone TGFβ1 to the ECM, 
to which it is tethered via covalent links between LTBP proteins and ECM proteins, 
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such as fibronectin and fibrillin microfibrils (Hyytiainen, Penttinen & Keski-Oja, 
2004; Munger & Sheppard, 2011). Subsequent activation may occur through a 
number of mechanisms, as described below. Once liberated, mature TGFβ1 binds 
TGFβR2, which engages TGFβR1 to initiate downstream signalling, canonically via 
Smads (Massague & Chen, 2000).  
Mice lacking the ability to activate TGFβ1, via integrin αVβ6- or TSP1-dependent 
processes, phenocopy pathologies in TGFβ1-null mice, suggesting integrin αVβ6 and 
TSP1 to be key mediators of TGFβ1 activation in vivo (Annes, Munger & Rifkin, 
2003; Munger & Sheppard, 2011). Integrin αVβ6-mediated activation involves LLC-
integrin binding to induce cytoskeletal rearrangements that essentially force the LAP 
peptides apart from mature TGFβ1 dimers (Munger & Sheppard, 2011).  
As with its localisation in other tissues, integrin αVβ6 production in benign and 
malignant human and mouse prostate tissue is restricted to the epithelium (Garlick et 
al., 2012; Sutherland et al., 2012); hence, integrin αVβ6-mediated TGFβ1 activation 
is not likely to have occurred in KLK4-treated myofibroblasts. As an alternative or 
complementary mode of TGFβ1 activation, TSP1 may bind the LAP to induce a 
conformational shift in this peptide, disrupting interactions between the LAP and 
TGFβ1 to allow release of the mature growth factor (Crawford et al., 1998; Murphy-
Ullrich & Poczatek, 2000). While the forces required to activate TGFβ1 via integrin-
dependent mechanisms require the SLC to be matrix-bound, TSP1-dependent 
activation of TGFβ1 in a soluble complex can occur (Schultz-Cherry et al., 1995).  
As yet an additional TGFβ1 activation mechanism, proteases, such as plasmin 
(Lyons et al., 1990) and MMP2 (Ge & Greenspan, 2006), possess the ability to 
directly cleave the LAP in vitro. This is believed to induce a conformational shift in 
the LAP, resulting in release of the mature growth factor. However, the in vivo role 
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of proteases in this complex process is unknown, as studies using mice lacking 
TGFβ1-activating proteases, such as plasmin and MMP2, do not phenocopy TGFβ1-
null mice (Annes, Munger & Rifkin, 2003; Munger & Sheppard, 2011). Similarly, 
KLK4-deficient mice do not share gross phenotypes consistent with TGFβ1-null 
mice (Bartlett & Simmer, 2014). Collectively, this has been attributed to 
inappropriate experimental models or that protease redundancies enable different 
proteases to compensate for the inactivity of other proteases (Annes, Munger & 
Rifkin, 2003). Alternatively, the role for proteases in TGFβ1 activation may be more 
prominent in cancer, where protease expression and activity is often deregulated, 
cellular compartmentalisation is breached and aberrant protein-protein interactions 
can occur. Apart from the ability for proteases to directly liberate TGFβ1 from the 
LLC via LAP hydrolysis, proteases may serve to regulate TSP1- and integrin-
mediated TGFβ1 activation in vivo (Annes, Munger & Rifkin, 2003). For example, 
proteases can process LTBPs and fibrillins, which are required for integrin-
dependent activation of TGFβ1 (Annes et al., 2004; Fontana et al., 2005; Scotton et 
al., 2009). Each of the above processes are summarised in Figure 6.6 and data 
implicating KLK4 in certain of these mechanisms is presented, below.   
6.3.2b KLK4-mediated activation of TGFβ1 did not involve LAP hydrolysis 
As both TSP1- and integrin-mediated mechanisms of TGFβ1 activation merely 
disrupt the non-covalent bond between the LAP and mature TGFβ1, activation of 
TGFβ1 by such mechanisms would be indistinguishable using PROTOMAP. That is, 
monomers of mature TGFβ1 and the LAP would be expected to migrate as two 
distinct bands that would resolve to the same molecular weight, regardless of 
whether TGFβ1 was immature or activated within the CM sample. Conversely, 
should KLK4 have regulated TGFβ1 by directly cleaving the LAP from TGFβ1, or 
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by activating another protease capable of degrading the LAP, LAP degradation 
products would theoretically be identifiable by PROTOMAP analysis. Thus, to gain 
insight into putative mechanisms of TGFβ1 activation, its peptograph was assessed. 
TGFβ1 was not identified as a KLK4 substrate by PROTOMAP analysis and no 
degradation products of LAP were observed in KLK4-treated WPMY-1 
myofibroblast CM (Figure 6.7). In both the KLK4-treated and control samples, LAP-
derived peptides were isolated only in gel slice 6, consistent with the migration of 
this glycosylated peptide as observed previously (~38 kDa; Emami & Diamandis, 
2010). No LAP-derived peptides were identified in gel slices 8-19, suggesting that 
LAP was not degraded in either sample (Figure 6.7). However, it should be noted 
that in only one CM replicate were TGFβ1-derived peptides recovered in sufficient 
detail to draw conclusions regarding KLK4-mediated hydrolysis of the protein. 
Further, a maximum of four TGFβ1-derived peptides were retrieved from any gel 
slice (Supplementary Figure 6.2). Thus, LAP degradation products may have been 
present and simply undetected, despite data suggesting that KLK4 did not induce 
LAP degradation.  
As expected, peptides isolated from apparently intact TGFβ1 monomers were also 
identified in both KLK4-treated and control samples. These peptides were retrieved 
from gel slices 12 and/ or 13, and, therefore, migrated near to the theoretical 
molecular weight of the TGFβ1 monomer (13.3 kDa; gel slice 13/ 14; Figure 6.7). 
Further, the sequence of these peptides spanned residues C-terminal to, and 
including, A279, the N-terminal residue of the mature product (Figure 6.7). Thus, 
under the denaturing and reducing conditions employed for SDS-PAGE analysis 
using PROTOMAP, TGFβ1 appeared to resolve as distinct products constituting the 
LAP and the mature TGFβ1 chain. Further, KLK4-mediated degradation of LAP, 
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Figure 6.7. Representative peptograph (replicate 2) for TGFβ1 in WPMY-1 myofibroblast CM. 
Peptograph aligns all significantly identified peptides (coloured boxes), matching a select protein, 
from gel slices (Y-axis, 1-19) in the KLK4-treated (red boxes) or untreated (green boxes) samples, or 
peptides identified in both samples (grey boxes; see colour key, bottom right), with the corresponding 
protein amino acid residue (X-axis). Peptides from KLK4-treated and control samples are shown in 
the top and bottom row of each gel slice, respectively. The Y axis also consists of a bar graph (dark 
grey bars) of the relative spectral count of all identified peptides in each gel slice, for each sample, 
relative to the sample slice with the highest spectral count (annotated in light grey at the top of the 
graph). A schematic of selected protein domains, based on annotations in the UniProtKB, is beneath 
the X-axis (blue boxes), aligned with appropriate residues. Residue numbers are given for selected 
residues/ motifs (blue text/ arrows). TGFβ1 resolved into its LAP and mature TGFβ1 peptide (orange 
shading) at the expected molecular weight of each (open arrowheads, as denoted). LAP degradation 
products were not visible in either the KLK4-treated or control sample, indicating that KLK4-induced 
TGFβ1 activation may have occurred through mechanisms that do not involve LAP hydrolysis. 
 
Colour key 
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either by direct proteolysis or activation of another LAP-degrading protease, does not 
constitute a likely mechanism by which KLK4 may induce TGFβ1 signalling. 
6.3.2c KLK4 hydrolysed 11 extracellular protein regulators of TGFβ1 activity in 
WPMY-1 myofibroblast CM  
While KLK4 did not appear to activate TGFβ1 by inducing LAP degradation, it was 
sought to examine whether KLK4 cleaved proteins that regulate TGFβ1 activation or 
activity, independently of LAP degradation. IPA was used to show that 11 putative 
KLK4 substrates in WPMY-1 myofibroblast CM can regulate TGFβ1 activity by 
means other than regulating its expression (Figure 6.8 A). The latter criterion was 
important as TGFB1 expression was not affected in KLK4-treated myofibroblasts 
(Chapter 5). The nature of interactions between KLK4 substrates and TGFβ1 
included protein-protein binding, regulation of binding and proteolytic interactions, 
as well as those affecting localisation or activity (Figure 6.8 A).  
Of the 11 identified KLK4 substrates found to mediate TGFβ1 activity, it was 
important to determine: (1) whether each positively or negatively regulates TGFβ1 
activity and; (2) whether KLK4 would be required to activate or inhibit the function 
of each protein to induce TGFβ1 activity. For example, KLK4 would be required to 
activate a protein activator of TGFβ1 to induce TGFβ1 activity. Conversely, KLK4 
would be required to inactivate a protein inhibitor of TGFβ1 to induce TGFβ1 
activity. As stated above, TSP1 and MMP2 can activate TGFβ1. In addition, CTGF 
and SPARC have also been shown to induce TGFβ1 signalling (Figure 6.8 A). While 
proteins such as LTBP4 and fibrillin-1 (FBN1) are required for integrin-dependent 
mechanisms of TGFβ1 activation (Annes et al., 2004; Fontana et al., 2005; Scotton 
et al., 2009), expression of the primary integrin implicated in this process, integrin  
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Figure 6.8. Putative KLK4 substrates which may be involved in KLK4-mediated activation of  
TGFβ1. TGFβ1 was predicted to be activated upon KLK4 treatment of WPMY-1 myofibroblasts 
(Chapter 5), although TGFβ1 expression was not KLK4-regulated. 11 novel KLK4 substrates (white 
shapes) identified in the present chapter can interact with TGFβ1 (orange square) to directly (straight 
arrows) or indirectly (dashed arrows) affect TGFβ1 activity (IPA and literature analysis; references 
within text). This was by means other than regulating TGFβ1 expression, including mediating 
proteolysis (L), localisation (LO) and activity (A), regulation of binding (RB) and protein-protein 
binding (PP). (A) Interactions were coloured according to whether substrate activation (orange) or 
inhibition (blue) induces TGFβ1 activity. KLK4 is required to activate (orange, +) or inhibit (blue, -) 
these substrates to induce TGFβ1 activity. The influence of certain substrates on TGFβ1 activity could 
not be determined (IPA or literature analysis; grey), and the required effect of KLK4 on these 
substrates to activate TGFβ1 is unknown (grey question mark). (B) Substrate peptographs were 
analysed to predict whether KLK4 (red Pacman/ dotted red line) activated or inhibited (-) each 
substrate. Where this differed from (A), interactions were coloured yellow indicating that KLK4 did 
not likely activate TGFβ1 through cleaving these substrates. KLK4 may cleave LTBP4 or FBN1 to 
induce TGFβ1 activity. Note that the SPARC (SPRC)-derived product generated by KLK4 may have 
similar activity to intact SPARC; thus its proteolysis by KLK4 may be of overall neutral consequence 
to TGFβ1 activity (grey).  
  
A B 
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αVβ6, is restricted to epithelial cells (Annes, Munger & Rifkin, 2003; Garlick et al., 
2012; Munger & Sheppard, 2011; Sutherland et al., 2012). Loss of LTBP4 induces 
TGFβ1 activation (Chaudhry et al., 2007; Heydemann et al., 2009) and matrix 
localisation of the LTBP4/ LAP-TGFβ1 complex is FBN1-dependent (Massam-Wu 
et al., 2010; Zilberberg et al., 2012); thus, LTBP4 and FBN1 are shown, in Figure 
6.8 A, to inhibit TGFβ1 activation. For KLK4 to act through proteolysis of one or 
more of these substrates to induce TGFβ1 activity, it would need to have cleaved 
TSP1, MMP2, CTGF or SPARC in a manner which induces the TGFβ1-activating 
capacity of these proteins, while inactivating LTBP4 and/ or FBN1 (Figure 6.8 B). 
To the candidate’s knowledge, there was no literature describing whether agrin 
(AGRN), collagen alpha-1 (I) chain (COL1A1), follistatin-related protein 1 (FSTL1), 
periostin (POSTN) and prolow-density lipoprotein receptor-related protein 1 (LRP1) 
activate or inhibit TGFβ1 activity, apart from demonstrating the capacity of these 
proteins to bind TGFβ1. To analyse the outcome of KLK4-mediated proteolysis on 
TSP1, MMP2, CTGF and SPARC, KLK4-generated protein fragmentation was 
examined in substrate peptographs.  
6.3.2c(i) KLK4 appeared to inactivate TSP1 in WPMY-1 myofibroblast CM  
TSP1 binds the LAP to induce a conformational shift which liberates active TGFβ1. 
Chymotrypsin-mediated proteolysis of TSP1 can inactivate the TGFβ1-activating 
capacity of this protein upon producing a 120 kDa fragment [yellow shading, Figure 
6.9; (Galvin et al., 1985; Schultz-Cherry, Lawler & Murphy-Ullrich, 1994)]; 
however, processing to a 50 kDa fragment activates TGFβ1 to a greater degree than 
intact TSP1 (Schultz-Cherry, Lawler & Murphy-Ullrich, 1994). The authors 
concluded that chymotrypsin-mediated proteolysis may adjust conformational 
exposure   of    the    RFK    activating    sequence    to    the     LAP     peptide  
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Figure 6.9. Representative peptograph (replicate 2) for TSP1 in WPMY-1 myofibroblast CM. 
See Figure 6.7 for peptograph description. The motif required for activating TGFβ1 is highlighted 
(orange shading), along with the sequence of the chymotryptic fragment unable to activate TGFβ1 
(yellow shading). Arrowheads indicate the migration of TSP1 retrieved from the control (open) and 
KLK4-generated fragments of TSP1 (filled). H, heparin-binding; V, Von Willebrand factor, type-C; 
TSP1/3, TSP type-1/ -3 repeat; E, epidermal growth factor-like; TSP C-, TSP C-terminal. 
(Schultz-Cherry, Lawler & Murphy-Ullrich, 1994). Thus, should KLK4 produce a 
similar product to the above-mentioned 50 kDa fragment, this constitutes a plausible 
mechanism by which KLK4 may have induced TGFβ1 activation. 
In PROTOMAP experiments, the apparent intact TSP1 monomer migrated to gel 
slices 1 and 2, consistent with its expected molecular weight of 133.4 kDa (open 
arrowhead, Figure 6.9). KLK4-generated cleavage products of TSP1 were identified 
in gel slice 3 and in gel slices 7/8 (filled arrowheads, Figure 6.9); more peptides were 
isolated from the latter product. Peptides from this fragment spanned residues N-
terminal to, and including, R228, and so were N-terminal to the previously described 
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(Ribeiro et al., 1999; Schultz-Cherry et al., 1995) TGFβ1-binding domain of the 
protein [orange shading, Figure 6.9; (Ribeiro et al., 1999; Schultz-Cherry et al., 
1995)]. Peptides isolated from the KLK4-generated product in gel slice 3 were of a 
sequence C-terminal to, and including, R299, spanning either side of the TGFβ1-
binding region (Figure 6.9). Thus, PROTOMAP analysis suggested that KLK4 
liberated the N-termini of TSP1 (gel slice 3), with the remaining protein fragment 
constituting a high molecular weight product containing the TGFβ1-binding domain 
of the protein (gel slice 8; Figure 6.9). This is of similar molecular weight and 
topography to the 120 kDa produced by chymotrypsin, which cannot activate 
TGFβ1, and not the reported 50 kDa TGFβ1-activating fragment also described 
(Schultz-Cherry, Lawler & Murphy-Ullrich, 1994). As TSP1 is an important in vivo 
activator of TGFβ1, KLK4-mediated hydrolysis of TSP1 was further examined in a 
biochemical assay. 
Biochemical validation of KLK4-mediated hydrolysis of recombinant TSP1 (lanes 6-
9; Figure 6.10) confirmed that KLK4 induced dose-dependent TSP1 cleavage, 
producing products of similar size to those observed with application of the 
PROTOMAP (Figure 6.9). While TSP1 was completely degraded by the highest 
concentration of KLK4 employed (lane 6), TSP1-derived products were visualised 
by each method at a 10:1 (lane 7) and 100:1 (lane 8) molar ratio of TSP1: KLK4, but 
not at a 1,000:1 ratio (lane 9; Figure 6.10). Specifically, silver stain analysis, which 
theoretically detects all protein products, identified TSP1-derived products at 130 
kDa and 30 kDa, with a faint product also at 110 kDa (lanes 7-8; Figure 6.10 A). Of 
these, Western blot analysis, using an antibody targeting the N-termini of TSP1, 
detected only the 30 kDa product (lanes 7-8; Figure 6.10 B). Conversely, Western 
blot analysis, using an antibody targeting the mid-terminal region of TSP1, detected  
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Figure 6.10. KLK4-mediated digestion of recombinant TSP1, analysed by SDS-PAGE/ silver 
staining (A) or Western blot analyses (B, C). The molar ratio of TSP1: KLK4 (or mKLK4, negative 
control) is shown, normalised to the amount of KLK. KLK4 cleaved TSP1 (open arrowheads) into 
130, 110, 30 and 15 kDa fragments (filled arrowheads, lanes 6-9; A-C). Controls included untreated 
(lane 4) or mKLK4-treated (lane 5) TSP1, and lanes containing only mKLK4 (lane 3) or KLK4 (lane 
2). The migration of KLK4 is annotated in (A). Protein standard was loaded in lane 1. 
Immunodetection with antibodies targeting the N-termini (B) or mid-termini (C) of TSP1, 
respectively, indicated that KLK4 removed the N-termini of TGFβ1. Residual activity of mKLK4 was 
observed in (B).  
130 kDa and 110 kDa fragments (lane 8; Figure 6.10 C). As visualised by each 
method, untreated (lane 4) or mKLK4-treated (lane 5) TSP1 migrated to 160 kDa, 
corresponding to the expected migration of monomers of the protein, as indicated by 
the manufacturer (Figure 6.10). Thus, KLK4-mediated hydrolysis of TSP1 was 
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similar to that observed in the PROTOMAP analysis, indicating that KLK4 likely 
proteolytically processes the N-termini from TSP1. Resulting products were of 
similar molecular weight to those chymotryptic products with reduced ability to 
activate TGFβ1, as compared to intact TSP1 (Galvin et al., 1985; Schultz-Cherry, 
Lawler & Murphy-Ullrich, 1994).  
A 15 kDa product of TSP1 was also detected using the N-terminal-targeted antibody 
in both the mKLK4- and KLK4-treated samples (lane 5, 7-8; Figure 6.10 B). This 
product was not detected by silver staining, which did not capture this molecular 
weight region. Nonetheless, loss of staining intensity of the 160 kDa TSP1 monomer 
in the mKLK4-treated sample was observed with all employed detection methods 
(lane 5; Figure 6.10). The extent of signal reduction appeared less than that induced 
by KLK4 treatment at a 100:1 (lane 8) molar ratio of TSP1: KLK4; however, this 
was greater than the loss observed at a 1,000:1 treatment ratio (lane 9; Figure 6.10). 
As mKLK4 was applied at concentrations equivalent to the KLK4 concentration used 
in the sample containing a 1:1 molar ratio of TSP1: KLK4, this mutated protease 
possessed at least 1 × 10
-1
% to 1%
 
of the proteolytic activity of KLK4 against TSP1. 
A small degree of residual proteolytic activity of thermo-mKLK4 is not unexpected, 
as previous analysis of this enzyme by our group identified, albeit limited, 
peptidolytic activity of thermo-mKLK4 (Clements, Gorman et al., unpublished data). 
In Chapter 3, thermo-mKLK4 was found to putatively cleave TSP1 in PC-3 cell CM, 
although this produced different products as compared to TSP1 hydrolysis by 
thermo-KLK4. Given the limited extent of mKLK4-mediated proteolysis in contrast 
to KLK4-mediated proteolysis, this likely had only a minor impact on substrate 
detection using the PROTOMAP, as discussed in 3.3.3 
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6.3.2c(ii)KLK4 may negatively regulate the TGFβ1-activating protease, MMP2 
MMP2 has been shown to directly cleave LAP, thereby liberating TGFβ1 (Ge & 
Greenspan, 2006). Should KLK4 activate MMP2, this may constitute a putative 
mechanism for KLK4-induced TGFβ1 activation. Although LAP degradation 
products were not identified in WPMY-1 myofibroblast CM, these products may 
simply have been present below the limit of detection of the method (6.3.2b). As 
KLK4 was shown to activate MMP1 in Chapter 3, it is plausible that KLK4 may 
activate MMP2, which is worth investigating in context of TGFβ1 activation. Thus, 
peptographs for MMP2 in KLK4-treated WPMY-1 myofibroblast CM were 
examined.  
PROTOMAP analysis identified MMP2 in multiple gel slices in the control (Figure 
6.11, open arrowheads, dashed bracket), although greatest sequence coverage was 
retrieved in gel slice 4, at the expected molecular weight of intact MMP2 (75 kDa; 
Figure 6.11, top open dashed arrowhead). KLK4 generated a series of MMP2-
derived products, identified in gel slices 6-12 (Figure 6.11, black filled arrowhead, 
dashed bracket). Using the PROTOMAP approach, the processed 72 kDa 
collagenase (Figure 6.11, pink filled dashed arrowhead) could not be distinguished 
from intact MMP2, due to the small 9.1 kDa molecular weight difference between 
these protein forms, which did not resolve at least two gel slices apart. Detecting 
processing events, which confer a small molecular weight change, has before been 
shown before to be a limitation of PROTOMAP (Simon, Dix & Cravatt, 2009). 
Moreover, the presence of a KLK4-liberated pro-peptide of MMP2 was not detected 
at its anticipated molecular weight (9.1 kDa; Figure 6.11, bottom open dashed 
arrowhead). The PROTOMAP approach, however, favours detection of larger 
protein fragments, as a greater number of peptides derived from larger products may  
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Figure 6.11. Representative peptograph (replicate 2) for MMP2, in WPMY-1 myofibroblast 
CM. See Figure 6.7 for peptograph description. The active protease region, able to activate LAP-
TGFβ1 (pink shading), along with the anti-angiogenic PEX peptide (purple shading), are highlighted. 
The expected migration of intact MMP2 and its product chains is shown, right (dashed open 
arrowheads). Endogenous MMP2 (open arrowheads/dashed bracket) was cleaved into a series of 
fragments (filled arrowhead/dashed line) by KLK4. It cannot be determined whether KLK4 activated 
MMP2, as the 72 kDa collagenase would be expected to migrate to only a single gel slice below the 
intact protein, and not the two gel slices required according to KLK4 substrate selection criteria. 
Further, a KLK4-liberated pro-region at its expected molecular weight was not detected. KLK4-
generated MMP2 fragments included those of similar topography and migration (middle dashed open 
arrowhead) to liberated PEX. Thus, KLK4 appeared to liberate PEX or a similar peptide from MMP2, 
likely inactivating the collagenase and its TGFβ1-activating potential. 
be retrieved and identified. Being of small size, there remains a possibility that the 
MMP2 pro-region was liberated by KLK4, but went undetected. Further, should 
KLK4 have liberated the pro-region from MMP2, this N-terminal peptide may have 
been degraded by KLK4 or endogenous cell-secreted proteases. 
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KLK4-generated products of MMP2 identified in gel slices 6-12 spanned sequences 
including the pro-region, collagenase domain and PEX domain. Given that some 
products may resolve over multiple gel slices, it is unclear how many products were 
generated by KLK4. However, taking gel slice 8 as an example, peptides putatively 
belonging to KLK4-generated products in this gel slice ranged from F235 to C663 
(Figure 6.11). Thus, should these peptides match to a single KLK4-generated 
fragment, its expected size would be 49.1 kDa, corresponding to gel slice 5/6, and 
not gel slice 8, which contains proteins of 25-37 kDa. Thus, two KLK4-generated 
products must be present in gel slice 8, where these products must be of similar size, 
i.e. ~25 kDa. As such, it is possible that KLK4 liberated the C-terminal PEX domain 
(Figure 6.11, grey filled dashed arrowhead, as denoted) from MMP2, via proteolysis 
toward the centre of the protein. PEX is a truncated product devoid of proteolytic 
activity and, importantly, recombinant MMP2 lacking PEX exhibited markedly 
reduced proteolytic activity against fibronectin (Steffensen et al., 2011). Thus KLK4-
mediated hydrolysis of MMP2 may reduce its ability to degrade LAP in WPMY-1 
myofibroblast CM. Moreover, PEX is required for one mechanism of pro-MMP2 
activation (Xu et al., 2011) and so KLK4-mediated proteolysis of pro-MMP2 may 
also indirectly reduce MMP2 activation. As MMP2 activates TGFβ1, PROTOMAP 
analysis indicated that KLK4 may be a negative regulator of TGFβ1 activity. As with 
MMP1 (3.3.6a), it was attempted to confirm whether KLK4 affected the proteolytic 
activity of MMP2; however, results were inconclusive (data not shown). 
6.3.2c(iii) KLK4-mediated LTBP4 proteolysis may liberate TGFβ1-bound LTBP4 
from the ECM and induce TGFβ1 activation 
LTBPs play an important role in multiple mechanisms of TGFβ1 activation, where 
LTBP4 binds TGFβ1 (Saharinen & Keski-Oja, 2000) and tethers this growth factor 
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to the ECM, for example, through an N-terminal fibronectin binding domain [green 
shading, Figure 6.12; (Kantola, Keski-Oja & Koli, 2008)]. LTBP4 binding to the 
microfibril component, FBN1, through its C-terminus, is also important for ECM 
localisation of this protein [blue shading, Figure 6.12; (Ono et al., 2009)]. Proteolysis 
of LTBP4 by proteases, such as plasmin, can release LTBP4 from the ECM 
(Saharinen et al., 1998), by cleaving within its protease-sensitive region (Heydemann 
et al., 2009; McNally, Heydemann & Ceco, 2014). Plasmin-mediated proteolysis 
within this region of LTBP4 induced TGFβ1 activity (Heydemann et al., 2009). This 
may favour subsequent TGFβ1 activation via integrin-independent mechanisms (Ge 
& Greenspan, 2006), or may be sufficient to induce a conformational shift in bound 
LAP, releasing mature TGFβ1 (McNally, Heydemann & Ceco, 2014). Either way, 
proteolysis of LTBP4 has resulted in increased TGFβ1 signalling; thus, KLK4 may 
similarly cleave LTBP4 to induce TGFβ1 activity. 
LTBP4 was identified in replicate 2 and 3 CM. LTBP4-derived peptides isolated 
from the control were primarily restricted to gel slice 1 (Figure 6.12, open 
arrowhead), consistent with the expected molecular weight of intact LTBP4 (178.3 
kDa). One or more KLK4-generated N-terminal LTBP4 cleavage product/s were 
retrieved from gel slices 5-7, where these peptides included sequences between V203 
and R387, thus aligning to the fibronectin-binding domain of LTBP4 (Figure 6.12). 
KLK4-generated cleavage fragments were also identified in gel slices 3-6, which 
consisted of sequences between S207 and K1228, that is, C-terminal to the protease-
sensitive region (purple shading) and the fibronectin-binding domain (Figure 6.12, 
filled arrowheads and dashed brackets) 
As KLK4-generated cleavage products were present in consecutive gel slices 3-7, it 
is difficult to determine how many cleavage fragments were present. Protein  
 Chapter 6: Determining the KLK4 degradome produced by protate myofibroblasts   245 
 
Figure 6.12. Representative peptograph (replicate 3) for LTBP4 in WPMY-1 myofibroblast CM. 
See Figure 6.7 for peptograph description. The motifs required for binding fibronectin (green), TGFβ1 
(orange) and FBN1 (blue) are highlighted, along with the protease-sensitive region (purple). E, 
epidermal growth factor-like; T, TGFβ-binding domain. KLK4 appeared to cleave LTBP4 (open 
arrowhead) within the protease-sensitive region, to generate at least two fragments (filled arrowheads/ 
dashed brackets), likely liberating the LTBP4/ LAP-TGFβ1 complex from the ECM. 
resolution of particular protein bands during SDS-PAGE can result in the same 
protein or protein fragment being detected in multiple consecutive gel slices. 
However, it appeared that KLK4 cleaved LTBP4 between residues R387 and S706, 
within the protease-sensitive region, which contains many KLK4-preferred K and R 
residues (Swedberg et al., 2009). The expected molecular weight of the resulting N-
terminal product (M1-R387) is 42.6 kDa, which corresponds to gel slice 6/7. As 
peptides which spanned this sequence were derived from these gel slices only in the 
KLK4-treated sample, KLK4 may indeed cleave LTBP4 within its protease-sensitive 
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region. Proteolysis within this region would release the LLC from the ECM, which 
may result in LAP destabilisation and release of mature TGFβ1, or may favour 
subsequent activation by integrin-independent processes. As such, KLK4-mediated 
proteolysis of LTBP4 constitutes a putative proteolytic mechanism by which KLK4 
may activate TGFβ1. 
6.3.2c(iv) KLK4-mediated FBN1 proteolysis may also liberate bound LTBP4/ LAP-
TGFβ1 complexes from the ECM  
FBN1 binds both LTBP4 and TGFβ1 and is another KLK4 substrate involved in 
localisation of TGFβ1 to the ECM. FBN1 incorporation into microfibrils is 
dependent on fibronectin binding, predominantly via the C-termini of FBN1 [orange 
shading, Figure 6.13; (Sabatier et al., 2009)]. Importantly, matrix incorporation of 
the LTBP4/ LAP-TGFβ1 complex is FBN1-dependent (Massam-Wu et al., 2010; 
Zilberberg et al., 2012). LTBP4 binds FBN1 via what is also known as its hybrid 
domain (D180-D246; purple shading, Figure 6.13), while LTBP1 has a different, as 
yet undetermined, binding site near to, and potentially including, this region (Ono et 
al., 2009). Notably, an FBN1-derived peptide (D1766-Q2054), that binds the N-
termini of FBN1 molecules (green shading, Figure 6.13), disrupted FBN1-LTBP1 
binding, leading to subsequent activation of TGFβ1 (Chaudhry et al., 2007). 
Similarly, proteolytic degradation of FBN1 may also abrogate LTBP1 binding and 
induce TGFβ1 signalling. Thus, FBN1 hydrolysis may constitute a mechanism by 
which KLK4 induced TGFβ1 activity in the previous chapter. 
PROTOMAP analysis showed FBN1 to be C-terminally truncated by endogenous 
processes, with a small C-terminal fragment identified in gel slices 4 and 5 in the 
control samples (bottom open arrowhead, Figure 6.13). FBN1 was otherwise 
identified in its apparent intact form (top open arrowhead, Figure 6.13) in the control 
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sample in gel slices 1 and 2, with identified peptides spanning residues A25-R2792 
of this large 2,871 amino acid protein. KLK4-mediated proteolysis of FBN1 did not 
appear to yield the above-mentioned LTBP1-liberating peptide, expected to migrate 
to 34.1 kDa or to gel slice 7/8. Instead, KLK4 generated multiple high molecular 
weight products of FBN1 that migrated to gel slices 2-7 and mapped to both N- and 
C-terminal regions of the protein (Figure 6.13, filled black arrowhead, dashed 
bracket). Peptides were isolated from the N-termini of FBN1 in gel slices 4 and 5, 
which both flanked and spanned residues of the LTBP4-binding domain (Figure 
6.13). Notable of gel slice 4 is that this slice must contain at least two KLK4-
generated fragments. This can be deduced as, if only a single product was identified 
therein, it would at least span residues T207 to R2481, with an expected molecular 
weight of 265 kDa. Given that this is at least 2-fold greater than the size of molecules 
expected to migrate to gel slice 4 (Figure 6.13), KLK4 cleaves FBN1 at least at one 
site towards the centre of the protein. This would produce an apparent N-terminal 
fragment which retains the LTBP4 binding domain, and at least one C-terminal 
product, retaining some or all of the necessary residues to bind fibronectin. Such a 
cleavage event may disrupt FBN1 microfibril assembly, thereby indirectly inhibiting 
LTBP/ LAP-TGFβ1 matrix deposition and inducing aberrant activation of TGFβ1 
(Massam-Wu et al., 2010). 
6.3.2c(v) Summary  
TGFβ1 appeared to be activated by processes working independently of LAP 
degradation. KLK4 cleaved LTBP4 to liberate separate fragments containing ECM- 
and TGFβ1-binding domains, which may translate into the ability of KLK4 to 
liberate the LLC from the ECM in the tumour microenvironment. KLK4-mediated 
FBN1 hydrolysis further suggests that KLK4 negatively regulates ECM  
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Figure 6.13. Representative peptograph (replicate 3) for FBN1 in WPMY-1 myofibroblast CM. 
See Figure 6.7 for peptograph description. Motifs required for binding LTBP4 (purple shading) and 
fibronectin (orange shading) are highlighted, along with the sequence of a proteolytically-liberated 
FBN1-derived peptide capable of disrupting LTBP-FBN1 binding (green shading). E, epidermal 
growth factor-like; T, TGFβ-binding domain. KLK4 did not appear to liberate the above-mentioned 
peptide (filled green arrowhead at its expected molecular weight), but degraded intact FBN1 (top open 
arrowhead) into multiple higher molecular weight fragments (filled arrowhead/ dashed bracket). 
FBN1 was C-terminally truncated by endogenous processes (bottom open arrowhead). 
incorporation of the LTBP4/ LAP-TGFβ1 complex, which may induce TGFβ1 
activation. In contrast, putative KLK4-induced fragmentation of TSP1 and MMP2 is 
likely to abolish or reduce the TGFβ1-activating potential of these proteins. KLK4-
mediated proteolysis of CTGF and SPARC (detailed in Appendix A) also did not 
appear to constitute substrate intermediates of KLK4-induced TGFβ1 signalling. 
Therefore, by exploiting the depth of protein product information obtained from 
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PROTOMAP analyses of the KLK4 degradome in WPMY-1 myofibroblast CM, 
LTBP4 and FBN1 hydrolysis was identified as the most plausible mechanism by 
which KLK4 activates TGFβ1 signalling in these cells. This constitutes a data-
informed hypotheses for the mechanism of KLK4 function in the prostate tumour 
microenvironment. 
6.3.3 Comparison of KLK4 substrates identified using the PROTOMAP 
approach in prostate myofibroblast and cancer cells 
Finally, it was sought to determine those proteins cleaved by KLK4 in prostate 
myofibroblast and cancer cells, to identify substrates that are theoretically highly 
accessible to KLK4 in the prostate tumour microenvironment. In total, PROTOMAP 
identified 50 KLK4 substrates in WPMY-1 myofibroblast CM, while 10 and 23 were 
identified in CM from LNCaP and PC-3 cells, respectively. Three KLK4 substrates 
were common to all three CM pools, namely, G6PI, TSP1 and collagen alpha-1(VI) 
chain (Table 6.2). Pentraxin 3 long, was a substrate in PC-3 cell and WPMY-1 
myofibroblast CM, and this protein was also detected in LNCaP cell CM; however, it 
was not a substrate in the latter. Lectin, galactoside-binding soluble 3 binding protein 
was similarly cleaved in PC-3 and WPMY-1 cell CM, but not identified in LNCaP 
cell CM. Calsyntenin 1 and neuropilin 1 were identified as substrates of KLK4 in 
LNCaP cell and WPMY-1 myofibroblast CM, while these proteins were not detected 
in PC-3 cell CM (Table 6.2). As such, each of these proteins may be highly abundant 
and available for KLK4-mediated proteolysis in the tumour microenvironment, being 
secreted by both prostate cancer and stromal cells. Thus, these proteins represent key 
targets for KLK4 in the tumour microenvironment. While the proteolysis of only 
TSP1 was validated biochemically in the present study, the identification of each of 
the proteins in Table 6.2 as KLK4 substrates in at least two cell lines serves to  
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Table 6.2. KLK4 substrates identified in CM from WPMY-1 myofibroblasts as well as LNCaP 
and/ or PC-3 cells. 
Substrate Symbol* LNCaP PC-3 WPMY-1 
glucose-6-phosphate isomerase  G6PI + + + 
thrombospondin 1 TSP1 + + + 
collagen, type VI, alpha 1 CO6A1 + + + 
pentraxin 3, long PTX3 × + + 
lectin, galactoside-binding, soluble, 3 binding protein LG3BP - + + 
calsyntenin 1 CSTLN1^ + - + 
neuropilin 1 NRP1^ + - + 
+, substrate in respective CM; -, not identified in respective CM; ×, identified but not cleaved in 
respective CM.  
* Symbol, UniProtKB/ Swiss-Prot entry name prefix (all _HUMAN) or HUGO gene name for 
UniProtKB/ TrEMBL entries (^). 
 
provide strong evidence that each is indeed cleaved by KLK4. Particularly, for those 
proteins identified as KLK4 substrates in CM from LNCaP cells and WPMY-1 
myofibroblasts, each was detected as being cleaved by KLK4 in 4-6 technical 
replicate experiments. This confers high confidence that each of the proteins in Table 
6.2 represent targets of KLK4-mediated proteolysis.  
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6.4 Discussion 
KLK4 was found to cleave 50 extracellular and plasma membrane-localised 
substrates in WPMY-1 myofibroblast CM. These substrates included enzymes, 
growth factors, growth factor-regulatory proteins and ECM proteins, some of which 
have established roles in cancer progression (below). None of these 50 proteins have 
previously been published to be KLK4 substrates. Thus, where only one 
myofibroblast-derived KLK4 substrate, PAR-1, was previously known, the present 
study identified an additional 50 novel putative KLK4 substrates. Among these, 
TSP1 was validated as a direct KLK4 target. Additionally, G6PI, TSP1 and collagen 
alpha-1(VI) chain were found to be KLK4 substrates in CM from both PC-3 and 
LNCaP cells, while four more of the KLK4 substrates identified were also cleaved in 
CM from at least one of these cell lines. This served as an internal validation of the 
method and provided additional confidence that these proteins are KLK4 substrates. 
This work has contributed extensively to knowledge of the KLK4 degradome 
produced by myofibroblasts and constitutes a resource around which future studies of 
KLK4 function in the prostate tumour microenvironment may be based. Herein, this 
resource was utilised to develop hypotheses regarding the mechanism of KLK4-
mediated TGFβ1 activation, which will be discussed below. Additional putative 
KLK4-regulated functions in the prostate tumour microenvironment, based on the 
nature of substrates identified herein, will also be discussed . 
6.4.1 KLK4-mediated proteolysis of LTBP4 and FBN1 may induce TGFβ1 
activation  
In Chapter 5, it was demonstrated that TGFβ1 signalling was the primary activated 
signalling pathway in KLK4-treated prostate myofibroblasts. The importance of 
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TGFβ1 in promoting a CAF phenotype was discussed in the previous chapter, while 
the present discussion centres on putative proteolytic mechanisms for KLK4-
mediated induction of TGFβ1 signalling. In Chapter 5, it was suggested that KLK4 
may activate TGFβ1 signalling by down-regulating genes encoding TGFβ1 
inhibitors, TGFβR3 and DCN; the mechanism by which this occurred is unknown 
(Figure 6.14). As an alternative, KLK4 may have induced TGFβ1 signalling by 
increasing TGFβ1 activation or its bioavailability. Indeed, KLK4 cleaved several 
proteins in WPMY-1 myofibroblast CM known to influence TGFβ1 activity. An 
overview of how each protein affects TGFβ1 activity and how each was cleaved by 
KLK4 was discussed in the Results section (6.3.2), and is summarised in Figure 6.15.  
KLK4 did not appear to activate TGFβ1, directly or indirectly, by processing other 
TGFβ1-activating proteases. Of interest, KLK14 can digest recombinant LAP at two 
sites and can activate rTGFβ1 as well as TGFβ1 in seminal fluid, ex vivo (Emami & 
Diamandis, 2010). KLK4 and KLK14 share trypsin-like specificity and 85% 
sequence homology within 5 Å of the catalytic triad (de Veer et al., 2012; Swedberg 
et al., 2009). However, despite the similarity between KLK4 and KLK14, KLK4 did 
not appear to degrade LAP in the present study. TGFβ1 was only identified with 
sufficient peptide detail in one biological replicate experiment. No degradation 
products of LAP were identified in this sample, in comparison to a ~30 kDa form 
generated by KLK14 and semen proteases, as reported by Emami and colleagues 
(Emami & Diamandis, 2010). However, recovery of TGFβ1-derived peptides was 
very low and, should KLK4-generated LAP degradation products have been present 
in lesser abundance than intact LAP, they would likely not have been detected. The 
LAP-degrading protease, MMP2, was detected as a KLK4 substrate in PROTOMAP 
analyses; however, the topography and migration of MMP2 cleavage products  
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Figure 6.14. Summary of putative mechanisms of KLK4-mediated TGFβ1 activation informed 
by gene expression studies (Chapter 5). KLK4 may activate the established KLK4 substrate, PAR-
1, on prostate myofibroblasts to induce cytoskeletal contraction and a resulting conformational change 
in LAP, which releases non-covalently bound TGFβ1 (yellow shading). Through unknown 
mechanisms, KLK4 up-regulated gene expression of the TGFβ1 inhibitor, DCN, as well as TGFβR3, 
which inhibits TGFβ1 when liberated from the cell surface. Similarly, KLK4 induced tPA expression, 
where tPA converts plasminogen to the TGFβ1-activating protease, plasmin (green shading). 
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Figure 6.15. Summary of KLK4-mediated regulation of TGFβ1 signalling in prostate 
myofibroblasts. TGFβ1 signalling occurs as described in Figure 6.6. Prostate cancer cells secrete 
KLK4 (black dotted arrow; multiple red Pacmen), which appeared to hydrolyse LTBP4 and FBN1 in a  
manner which would disrupt the association of LLC with the matrix. This would prevent integrin-
dependent mechanisms of TGFβ1 activation (yellow shading, red ×), which require the LLC to be 
matrix-bound in order to generate the required mechanical forces to liberate TGFβ1. Instead, integrin-
independent activation mechanisms (green shading; red arrows) would be favoured. Of these, KLK4 
appeared to cleave both TSP1 and MMP2 in a manner that would render each incapable of releasing 
TGFβ1 from the liberated LLC (red × on green arrow). Thus, either KLK4-mediated hydrolysis of 
LTBP4 was sufficient to induce a conformational change in LAP and release mature TGFβ1 (red 
dotted arrow), or other integrin-dependent activation mechanisms (not shown) must be responsible for 
the induction of TGFβ1 signalling observed in prostate myofibroblasts (orange box).  
suggested that KLK4-mediated proteolysis attenuated its LAP-degrading activity. 
Together, this implies that KLK4 did not induce TGFβ1 signalling by activating 
MMP2, and that TGFβ1 activation may have been independent of LAP degradation. 
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By evaluating peptographs of each KLK4 substrate able to mediate TGFβ1 activity, 
LTBP4 was the most likely protein to have been cleaved by KLK4 to induce TGFβ1 
activity. LTBP4 is not an unexpected KLK4 substrate, given that LTBP1 has been 
shown to be a substrate for other prostatic KLKs (Emami & Diamandis, 2010). 
LTBPs covalently interact with the LAP-binding domain and are required for TGFβ1 
folding and secretion (Miyazono et al., 1991), as well as playing an integral role in 
ECM localisation (Hyytiainen, Penttinen & Keski-Oja, 2004; Taipale et al., 1994). 
ECM localisation is important for integrin-mediated activation mechanisms (Annes 
et al., 2004; Fontana et al., 2005; Scotton et al., 2009), while in contrast, TSP1- 
(Schultz-Cherry et al., 1995) or protease-dependent (Ge & Greenspan, 2006; Lyons 
et al., 1990) activation can occur via soluble SLC/ LLC complexes. In fact, bone 
morphogenetic protein 1 (BMP-1) liberated the LLC from the ECM by LTBP 
proteolysis, producing liberated LLC or l-LLC [i.e. cleaved LTBP-bound LAP-
TGFβ1 complex; (Ge & Greenspan, 2006)]. However, subsequent MMP2-mediated 
proteolysis of LAP was required for TGFβ1 activation (Ge & Greenspan, 2006). 
Intriguingly, MMP2-mediated activation of BMP-1-processed LLC was more 
efficient than activation of the non-processed LLC (Ge & Greenspan, 2006). Thus, 
KLK4-mediated processing of LTBP4 may favour integrin-independent mechanisms 
of activation and alter the product to be more accessible to selected subsequent 
activation mechanisms. It has been suggested that specific hydrolysis of LTBPs 
within the LLC complex may alone be sufficient to induce a conformational shift in 
LTBP-bound LAP to release mature TGFβ1 (McNally, Heydemann & Ceco, 2014). 
In the present analysis, KLK4 appeared to cleave LTBP4 in its protease-sensitive 
region, which would potentially liberate the l-LLC and induce TGFβ1 activity, as 
with plasmin-mediated LTBP4 proteolysis (Heydemann et al., 2009; Saharinen et al., 
1998). Thus, KLK4-induced proteolysis of LTBP4 to liberate the l-LLC is a 
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plausible mechanism by which KLK4 may have induced activation of TGFβ1 
signalling in prostate myofibroblasts (Figure 6.15).  
KLK4-mediated hydrolysis of FBN1 may have also contributed toward TGFβ1 
activation. FBN1, is required for LTBP4 matrix incorporation in lung fibroblasts 
(Zilberberg et al., 2012). Consistent with the premise that FBN1 functions to localise 
the LLC to the ECM, mutations in the FBN1 gene are associated with pathologies 
like Marfan Syndrome, which present with increased TGFβ1 activity [discussed in 
detail by (Munger & Sheppard, 2011)]. KLK4 was found to liberate high molecular 
weight cleavage products of FBN1, with evidence for proteolysis toward the centre 
of the protein. Thus, KLK4-mediated FBN1 hydrolysis may disrupt microfibril 
formation and shed the l-LLC from the ECM, thus favouring subsequent integrin-
independent mechanisms of TGFβ1 activation.  
A subsequent activating event may be required for activation of TGFβ1 following 
KLK4-mediatd LTBP4 proteolysis. KLK4 was found to cleave a key prostatic 
activator of TGFβ1, TSP1. TSP1 knockout mice exhibited reduced levels of active, 
but not total, TGFβ1 in the dorsal lobe of mouse prostate tissues. This is the lobe 
most synonymous with the peripheral zone of human prostates in which most 
prostate cancers occur (Fitchev et al., 2010). Castration of these mice induced 
stromal and epithelial TSP1 expression; however, TGFβ1 activity increased only in 
the stroma. Thus, TSP1 appears to be an important modulator of stromal TGFβ1 
activation in the prostate. In the present study, KLK4 appeared to cleave TSP1 into a 
fragment similar to the 120 kDa chymotrypsin-generated product previously shown 
to be ineffective in generating TGFβ1 activity in a cell-based assay (Galvin et al., 
1985; Schultz-Cherry, Lawler & Murphy-Ullrich, 1994). Of note, KLK4 is a trypsin-
like protease with a cleavage site specificity different from chymotrypsin (Swedberg 
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et al., 2009), and it appears that KLK4 cleaved TSP1 C-terminal to the chymotrypsin 
cleavage site. Thus, the KLK4-generated product likely has a truncated N-terminus, 
as compared to the 120 kDa chymotryptic product, which may differentially affect 
the exposure of the RFK motif to the LAP and subsequent TGFβ1 activation. 
Moreover, the aforementioned animal models do not assess the cancer context, 
whereupon prostate epithelial cells breach the basal lamina, providing KLK4 access 
to stromal cell-derived TGFβ1 and its protein regulators. Although TSP1 did not 
appear to be the substrate by which KLK4 induced TGFβ1 signalling, KLK4-
mediated inactivation of TSP1 may favour alternative mechanisms of TGFβ1 
activation (Figure 6.15). 
Thus, should an additional activation step follow KLK4-mediated liberation of the l-
LLC, PROTOMAP results indicated that this is likely not TSP1- or MMP2- 
mediated. One KLK4-regulated mechanism, which may be responsible for release of 
TGFβ1 from the l-LLC, was suggested by transcriptomic analysis of KLK4-treated 
WPMY-1 myofibroblasts in Chapter 5. Therein, KLK4 up-regulated the gene 
encoding tPA (PLAT), which processes plasminogen to plasmin. Plasmin may both 
degrade LAP directly and liberate LLC from the matrix (Lyons et al., 1990; 
Saharinen et al., 1998). LAP degradation products were not detected by 
PROTOMAP; however, the abundance of these products may have been below the 
limit of detection. As plasmin can activate soluble TGFβ1 complexes (Lyons et al., 
1990), this activation mechanism may follow KLK4-induced l-LLC liberation.  
Other putative mechanisms of TGFβ1 activation exist, which were not assessed in 
this study. These included activation by reactive oxygen species and acidification 
(Annes, Munger & Rifkin, 2003; Munger & Sheppard, 2011). A secondary activation 
process may be required for releasing TGFβ1 from the l-LLC following LTBP4 
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hydrolysis. This process is not required to be KLK4-regulated, to explain the 
increase in TGFβ1 signalling observed in KLK4-treated WPMY-1 myofibroblasts. 
Instead, KLK4-mediated proteolysis may increase the affinity of the now l-LLC to 
the activator, as shown previously with BMP-1-mediated hydrolysis of LTBP4 (Ge 
& Greenspan, 2006). Thus, at the very least, KLK4-mediated induction of TGFβ1 
signalling in WPMY-1 myofibroblasts likely involves hydrolysis of LTBP4 and 
FBN1, where up-regulation of tPA expression may also be involved. In summary, by 
combining transcriptomic and degradomic approaches, this study has generated a 
data-informed hypothesis regarding the function of KLK4 in the tumour 
microenvironment and proposed a potential mechanism driving KLK4-induced 
TGFβ1 activation.  
6.4.2 The nature of substrates identified implicates KLK4 in ECM 
remodelling and angiogenesis 
KLK4 cleaved a number of collagens and other ECM proteins in WPMY-1 
myofibroblast CM. ECM degradation facilitates invasion of tumour cells into the 
surrounding microenvironment and is an important step in cancer progression 
(Hanahan & Weinberg, 2000, 2011). While a single previous study did not indicate a 
role for KLK4 in invasion through a synthetic ECM (Veveris-Lowe et al., 2005), the 
current study suggests that KLK4 processes a number of myofibroblast-derived 
proteins, believed to secrete the majority of ECM in the tumour microenvironment. 
Particularly, the KLK4 substrate, collagen type-1, is secreted in high abundance by 
myofibroblasts in reactive stroma, making it a likely KLK4 target in the tumour 
microenvironment (Barron & Rowley, 2012; Tuxhorn et al., 2002). Notably, KLK4 
also cleaved basement membrane-specific heparin sulphate proteoglycan core 
protein, a matrix cross-linking enzyme, as well as lysyl oxidase homolog 2, which 
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also belongs to a family of matrix cross-linking proteins. Aberrant matrix cross-
linking is characteristic of reactive stroma and may facilitate tumour spread 
(Levental et al., 2009; Lu, Weaver & Werb, 2012). Thus, the effect of KLK4 on 
these proteins, and as a regulator of the matrix as a whole, warrants future 
investigation. 
KLK4 processed a number of proteins involved in angiogenesis, another key 
‘hallmark’ of a developing tumour (Hanahan & Weinberg, 2000, 2011). The 
involvement of KLK4 in regulating this process was also supported by its hydrolysis 
of MMP1 and uPA in PC-3 cell CM (Chapter 3), and regulation of a significant 
proportion of genes in WPMY-1 myofibroblasts implicated in angiogenesis (Chapter 
5). Many of these genes code for secreted proteins, thus constituting paracrine 
regulators of angiogenesis. In WPMY-1 myofibroblast CM, KLK4 appeared to 
liberate the PEX domain from MMP2. This fragment is anti-angiogenic, disrupting 
the ability for MMP2 to localise with integrin αvβ3 on the surface of endothelial cells 
to promote angiogenesis (Brooks et al., 1998). Moreover, exogenous delivery of PEX 
cDNA to xenograft tumours in mice reduced tumour growth and angiogenesis 
(Duvshani-Eshet et al., 2007). Thus, KLK4-mediated PEX generation may be 
tumour-protective. Conversely, KLK4 also cleaved TSP1, which is a well-
established negative regulator of angiogenesis in prostate and other cancers (Fitchev 
et al., 2010; Lawler & Lawler, 2012; Ren et al., 2006). TSP1 degradation may have 
promoted angiogenesis. Further, release of an N-terminal-derived product of the 
protein, similar to that liberated by KLK4, has been found to have pro-angiogenic 
properties (Ferrari do Outeiro-Bernstein et al., 2002; Nunes et al., 2008). Thus, 
KLK4 may regulate angiogenesis through cleaving and/ or regulating the expression 
of WPMY-1 myofibroblast-derived proteins. 
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6.4.3 Summary 
In summary, the KLK4 degradome in CM from prostate myofibroblasts was 
successfully determined, with 50 novel KLK4 substrates identified. The functional 
diversity of these substrates indicates a diverse array of functions for KLK4 within 
the prostate cancer microenvironment. KLK4-mediated proteolysis of these 
substrates informed a putative mechanism for KLK4-induced TGFβ1 signalling in 
WPMY-1 myofibroblast cells. This novel putative mechanism involves KLK4-
mediated proteolysis of LTBP4 and FBN1 (present chapter), which may be sufficient 
to liberate active TGFβ1, or may require a subsequent activation step. KLK4-
mediated up-regulated expression of PLAT (Chapter 5), which encodes tPA, may be 
involved in the latter. The nature of KLK4 substrates identified further suggests a 
role for KLK4 in promoting angiogenesis, a process not yet studied in relation to its 
regulation by KLK4. In addition, the role for KLK4 in ECM remodelling was 
supported, challenging a previous study that suggests KLK4 influences only prostate 
cancer cell motility, but not ECM invasion (see Table 1.1). The present study 
represents the first large-scale analysis of KLK4 substrates derived from prostatic 
stroma and is a successful beginning in order to delineate the function of this cancer 
cell-derived protease therein. 
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7.1 Contribution to knowledge of the KLK4-regulated transcriptome and 
degradome in prostate cancer and putative functional implications 
The aim of the present study was to delineate the function of KLK4 in prostate 
cancer. In achieving this, a high-depth protein-centric protease substrate profiling 
approach was used to conduct the first protein-centric analysis of the KLK4 
degradome. This was performed using CM from cell lines that were representative of 
early and late-stage prostate cancer, and prostate myofibroblasts. Gene expression 
profiling was conducted to determine the downstream transcriptional response to 
extracellular KLK4-mediated proteolysis, in an effort to construct a comprehensive, 
multi-dimensional view of KLK4 function in prostate cancer. This is the first study 
whereby such analysis was conducted for KLK4, as well as the first study of any 
KLK to combine both substrate and transcriptome profiles to gain a comprehensive 
mechanistic understanding of KLK function. Delineating these mechanisms is an 
essential step in gauging the efficacy of KLK4 as an anti-cancer target, and serves as 
a benchmark for future research. 
The three different applications of PROTOMAP performed in this study more than 
doubled the number of established (non-KLK) KLK4 substrates that had been 
previously reported. Additionally, only two genes were previously known to be 
regulated by full-length KLK4 in prostate cancer cells, and there were no reports of 
KLK4-mediated gene expression in the prostate tumour microenvironment. The 
present study identified three putative novel KLK4-regulated genes in prostate 
cancer cells, and 439 in prostate myofibroblasts. Thus, this study has greatly 
contributed towards knowledge of the KLK4 degradome and KLK4-regulated 
transcriptome in prostate cancer and the surrounding microenvironment. Further, it 
provides a valuable data resource, which may be interrogated for future studies 
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analysing KLK4 function in this disease. Such knowledge is imperative for the 
development of proteases as an anti-cancer therapy (Fortelny et al., 2014). 
As the present approach combined two big data platforms, the study was 
purposefully designed to be hypothesis-generating. High-depth technologies, such as 
those employed herein, allow for a global snapshot of protease action. Provided that 
the data is interrogated in its entirety, and not ‘cherry-picked’ for the most logical or 
‘fashionable’ hits, the most significant biological events occurring in the system may 
be identified. Particularly for degradome analyses, the methodologies used confer an 
advantage over previous in vitro biochemical substrate screening approaches, where 
substrates had been selected based on an a priori association to cancer. Instead, the 
high-depth, low-bias substrate screening approach employed in the present study is 
capable of determining all detectable KLK4 substrates within a prostate cell-derived 
protein background. The method identified both direct and indirect KLK4 substrates, 
both of which must be elucidated when assessing proteases as anti-cancer targets. 
The gene microarray platform employed was a similarly high-depth platform, 
assessing the KLK4-regulated expression of ~20,047 genes. The primary hypothesis 
generated from this analysis was that KLK4 activates TGFβ1 signalling in prostate 
myofibroblasts, a signalling pathway that is known to be strongly associated with 
prostate cancer initiation and progression.  
7.2 KLK4-mediated induction of TGFβ1 signalling: putative mechanisms 
and functional implications in prostate cancer 
As discussed in Chapter 5, stromal TGFβ1 signalling in prostate and other cancers 
promotes an aggressive phenotype in the neighbouring epithelium. Thus, KLK4 may 
have a functional role as a paracrine signalling factor regulating aggressive disease. 
Strikingly, KLK4 expression is induced in prostate cancer epithelial cells upon co-
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culture with stromal fibroblasts, a process dependent on stromal TGFβ1 signalling 
(Yang et al., 2014). KLK4 expression is further induced upon prostate cancer cell co-
culture with thrombin-stimulated prostate myofibroblasts. Thrombin activates PAR-1 
on these cells, where PAR-1 is also a KLK4 substrate (Wang et al., 2010), and its 
activation can induce TGFβ1 signalling (Jenkins et al., 2006). KLK4-mediated 
activation of PAR-1 produced by WPMY-1 myofibroblasts releases IL-6 (Wang et 
al., 2010), and IL-6 treatment of fibroblasts additionally induced KLK4 expression in 
co-cultured prostate cancer cells (Yang et al., 2014). Thus, there appears to be a 
cyclic induction of KLK4 expression and TGFβ1 activity in prostate cancer.  
Both IL-6 and TGFβ1 treatment of prostate cancer cells induced KLK4 expression by 
activating AR (Yang et al., 2014). Notably, activation of AR in prostate epithelial 
cells abrogated cell responsiveness to TGFβ1-induced apoptosis by down-regulation 
of the TGFβ1 signalling pathway intermediate, Smad 3 (Song et al., 2010). Stromal 
TGFβ1 signalling was shown to induce prostate epithelial cell production of C-X-C 
chemokine receptor type 4, through which stromal myofibroblast-derived SDF-1 
signalled to activate the Akt cascade. This abrogated the ability for prostate epithelial 
cells to undergo apoptosis in response to TGFβ1 (Ao et al., 2007). Further, prostate 
cancer cells cultured in CM from TGFβ1-stimulated CAFs underwent EMT and 
acquired an invasive, migratory phenotype (Giannoni et al., 2010). Thus, combined 
with results identified herein, there appears to be a cascade whereby prostate cancer 
cells over-produce KLK4, which activates stromal TGFβ1 signalling, in turn 
inducing AR activation. This stimulates KLK4 expression, upon which the cycle may 
repeat, while also priming epithelial cells to have a tumour-promoting, versus 
tumour-suppressive, response to TGFβ1. Further, KLK4-activated stromal TGFβ1 
signalling may induce the secretion of additional paracrine signalling molecules 
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which favour cancer cell migration and invasion. The cyclic nature of this cascade 
suggests a substantial role for KLK4 in tumour progression, through modulating the 
prostate tumour microenvironment. This novel hypothesis, which was informed by 
the KLK4-regulated transcriptome and degradome profiles generated herein, should 
be validated in future studies. 
The ability for KLK4 to activate stromal TGFβ1 signalling may have implications 
beyond the primary cancer site. KLK4 expression is induced upon prostate cancer co-
culture with bone-forming osteoblast-like cells, such as those present at the site of 
bone metastases (Gao et al., 2007). In tooth enamel, which is a mineralised tissue 
like bone, ameloblast KLK4 expression is up-regulated by TGFβ1 (Cho et al., 2013). 
By extension, TGFβ1 may mediate the observed up-regulation of KLK4 expression 
upon co-culture with bone-forming cells (Gao et al., 2007), and this could be a 
putative mechanism for the strong production of KLK4 in prostate cancer bone 
metastases (Bui, 2006). TGFβ1 is also a well-established bone-derived growth factor 
with roles in promoting bone metastases (Juarez & Guise, 2010). The potential for 
KLK4 to induce TGFβ1 signalling in the bone stroma may further promote 
metastatic growth. Indeed, many of the KLK4 substrates identified in the present 
study have functions in bone metastases and also interact with non-myofibroblastic 
cells at the primary site. Thus, extrapolation of the present analyses of the KLK4 
degradome may serve a greater understanding of KLK4 action in both local and 
secondary prostate cancer.  
A large focus of the discussion throughout this document was centred around the 
putative substrate intermediates of KLK4-mediated TGFβ1 activation in prostate 
myofibroblasts. At the level of protein proteolysis, there was some evidence to show 
that KLK4-mediated hydrolysis of LTBP4 and FBN1 may induce TGFβ1 activation. 
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Liberation of the l-LLC from the ECM, following hydrolysis of these substrates, may 
favour plasmin-mediated activation of TGFβ1. KLK4 was found to up-regulate tPA, 
which processes plasminogen to active plasmin. As an alternative mechanism, KLK4 
may have induced TGFβ1 activation via down-regulating gene expression of its 
inhibitors, DCN and TGFβR3, through an as yet unknown pathway. Therefore, not 
only was the KLK4-regulated transcriptome dataset useful in determining novel 
putative signalling pathways perturbed by extracellular KLK4-mediated proteolysis, 
both transcriptomic and degradomic results could be interrogated to form plausible 
hypotheses regarding mechanisms by which KLK4 regulates these pathways. 
There were multiple other pathways by which KLK4 may be regulating prostate 
myofibroblasts. While these are beyond the scope of the present discussion, they 
highlight the vast contribution to future research made by the high-depth analyses 
conducted in the present study, filling the void of knowledge that previously 
surrounded KLK4 action in the prostate tumour microenvironment. 
7.3 KLK4 function within the protease web and targeting KLK4 as a 
prostate cancer therapy  
The present study centred on the role of a single prostatic KLK, KLK4, in regulating 
prostate cancer and surrounding myofibroblasts. As discussed in Chapter 1, KLK4 
was selected, among other prostatic KLKs, to be investigated herein as its expression 
is associated with prostate tumour stage and risk, and preliminary functional studies 
had suggested pro-tumourigenic actions for the protease. Further, unlike PSA and 
KLK2, KLK4 is over-expressed in both the basal and epithelial cells in prostate 
cancer and it is over-expressed in PIN. Reactive stroma initiates in PIN and KLK4 
over-production in the basal epithelium situates KLK4 in a prime position to act on 
the basal lamina and surrounding stromal tissue when the barrier is breached. Thus, it 
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was predicted that KLK4 constitutes both a stromal and epithelial cell regulator in 
prostate cancer, where targeting both cell types has been determined to be integral 
for successful future anti-cancer therapy. 
Other prostatic KLKs are associated with prostate cancer and, at least in a 
biochemical setting, KLK4 cleaves a number of similar proteins to these KLKs. 
Further, in vitro, KLKs participate in activation cascades, where such cascades are 
suggested to function both in seminal plasma and in prostate cancer. KLK4 also 
activates other proteases in vitro, including uPA and MMP1, the latter being a novel 
KLK4 substrate identified herein. As KLK4-targeted inhibition will likely have 
effects on the greater web of proteases, this presents both promise and caution when 
aiming to target KLK4 as an anti-cancer strategy. MMP1 has well-established 
tumour-promoting functions and, while it may be difficult to specifically inhibit only 
MMP1 in prostate cancer, targeting KLK4 may serve to reduce the tumour-
promoting properties of MMP1. KLK4 was found to cleave additional proteases in 
prostate cancer cell and myofibroblast CM; however, the functional implications of 
these interactions are unknown. KLK4 is an established activator of PSA in vitro, 
where PSA has anti-angiogenic functions. Thus, KLK4 inhibition as anti-cancer 
therapy may have to be administered alongside an inhibitor of angiogenesis. Thus, 
the present results highlight KLK4 to be a promising anti-cancer target in the 
protease web; although, a greater understanding of its indirect effects in the tumour 
microenvironment is required. 
KLK4-mediated inhibition may take the form of a functional blocking antibody or 
antibody fragments, or small molecule inhibitors, as discussed in Chapter 1. A KLK 
inhibitor, which simultaneously inhibits a number of prostate cancer-associated 
KLKs, is undergoing human trials (Chapter 1). The present results suggest that 
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KLK4 inhibition may inhibit CAF-mediated selection of an aggressive prostate 
cancer phenotype. Therefore, KLK4 inhibitors may be better applied at an early, pre-
metastatic stage. As discussed, extrapolation of the present results suggests a similar 
function for KLK4 in activating TGFβ1 in stroma at the bone metastatic site, to 
promote metastatic growth. Thus, there is potential for KLK4 inhibition to also be 
useful in reducing metastatic burden. Future research will provide insight into the  
optimal stage at which a KLK4 inhibitor may be applied as an anti-cancer therapy.  
7.4 Limitations and future directions 
Using complementary approaches to validate substrate hydrolysis identified herein is 
the next step in defining the KLK4 degradome. An example of such validation was 
given in the present study, where by antibodies were used to detect VCL/VINC 
digestion in KLK4-treated prostate cancer cell CM. Similar approaches will be useful 
in validating that KLK4 does induce hydrolysis of its putative substrates in a cell-
derived protein pool. Further, the KLK4 substrates identified by PROTOMAP 
analysis comprise both direct and indirect targets of KLK4. While this is useful in 
defining the full extent of protease action on a protein pool, it can complicate 
elucidation of the direct role of an individual protease among the greater protease 
web. As such, complementary approaches to discriminate between direct and indirect 
substrates targets should be employed. For example, KLK4-mediated proteolysis of 
recombinant MMP1 was performed to show that this was a direct KLK4 substrate. 
The same was not true for KLK4-treated recombinant GRN. While PROTOMAP has 
advantages over other protein-centric substrate profiling approaches, as described in 
Chapter 1, it does not identify precise substrate cleavage sites. In contrast, N-
terminomic analyses of a protease degradome provides this information, allowing 
comparison against the preferred cleavage site specificity of the protease to infer 
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whether substrates are direct or indirect targets (Kleifeld et al., 2010). Thus, N-
terminomic approaches may be employed as a complementary approach to 
PROTOMAP, to determine whether putative KLK4 substrates are cleaved directly by 
the protease.  
Further, N-terminomics approaches or N-terminal sequencing of recombinant 
cleaved substrates must be used to determine precise cleavage sites and the sequence 
of KLK4-generated cleavage products. These cleavage products may then be 
synthesised and applied in cell-based functional assays to determine if they are 
biologically relevant fragments. Further, approaches to specifically identify substrate 
hydrolysis or cleavage products in patient tissue, extra-prostatic fluid, or serum, will 
be important for in vivo validation of KLK4-mediated proteolysis. This may take the 
form of immunoprecipitation and subsequent purification of the precise cleavage 
product, coupled with sequence characterisation by N-terminal sequencing and 
MS/MS. Such an approach was used to identify a cleaved product of C-X-C motif 
chemokine 10 in ovarian cancer tissue (Rainczuk et al., 2014). Alternatively, 
Fahlman et al. (2014) recently described an approach to quantify substrate hydrolysis 
within a protein background. MS/MS-based quantification of a tryptic peptide, which 
spans the protease cleavage site, is performed alongside that of a control peptide of 
differential sequence. The former is unique to the intact substrate; thus, a reduction in 
its abundance, relative to the control, is consistent with an increase in substrate 
hydrolysis at this site (Fahlman, Chen & Overall, 2014). Application of these 
techniques will serve to support the in vivo interaction between KLK4 and selected 
identified substrates. 
While the aim of the present study was to identify secreted KLK4 substrates, some 
plasma membrane substrates were identified in cell CM. These proteins would have 
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been shed from the cell surface prior to KLK4-mediated hydrolysis. Thus, the 
present study did not assess the ability for KLK4 to cleave membrane-tethered 
substrates, but only the role of KLK4 in cleaving soluble forms of membrane 
proteins. KLK4 can cleave cell surface proteins, exemplified by its ability to activate 
the membrane tethered PAR-1 and PAR-2 on the surface of prostate cancer cells and 
myofibroblasts. As with KLK4-mediated hydrolysis of selected soluble ligands 
identified herein, KLK4-mediated proteolysis of membrane-tethered receptors and 
other membrane proteins would be expected to perturb downstream intracellular 
signalling and gene expression. Thus, membrane substrates of KLK4 should be 
delineated in future studies, to better define its mechanism of action in regulating 
gene expression.  
A gene microarray was employed to determine KLK4-regulated genes in the present 
study. Validation of KLK4-mediated gene expression regulation using qRT-PCR was 
performed for a selection of genes, where this should now be carried out for 
additional genes, in particular, those downstream of TGFβ1 signalling. Further, the 
correlation of gene expression perturbations with changes at the protein level should 
also be examined, as was performed herein with Western blot analysis and IF 
microscopy, which showed KLK4-mediated up-regulation of FGF1 in WPMY-1 
myofibroblasts. Demonstrating the association between KLK4/ KLK4 levels in 
patient prostate cancer tissue, and that of the KLK4-regulated genes (or encoded 
protein) identified herein, will serve to support KLK4-mediated regulation of these 
genes in vivo. Particularly, qRT-PCR or Northern Blot analysis of the expression of 
KLK4-regulated reporter genes for TGFβ1 signalling, such as SERPINE1, or 
immunodetection of the TGFβ1 signalling intermediate, pSmad2 (Kiskowski et al., 
2011), may be performed in stromal tissue isolated from patients tumours producing 
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high versus low amounts of KLK4. Increased SERPINE1 expression and pSmad2 
levels in patients with higher KLK4 production would support a role for KLK4 in 
activating stromal TGFβ1 signalling in vivo. 
In validating the role for KLK4 to induce TGFβ1 signalling in prostate 
myofibroblasts and favour prostate cancer progression, a number of animal models 
may be employed. Prostate cancer cells over-expressing KLK4 may be implanted 
into mice with fibroblast-specific knockout of TGFβ1, TGFβR2, or the TGFβ1 
pathway signalling mediators, Smad 2 and 4. Controls may include mKLK4- or 
vector control-expressing prostate cancer cells and mice pre-loaded with a functional 
KLK4 blocking antibody or KLK4 inhibitor, as has been developed (Swedberg et al., 
2011; Swedberg et al., 2009). The fibroblast-specific protein promoter has previously 
been used for utilised for abrogation of TGFBR2 expression selectively in the stroma 
(Li et al., 2008). Alternatively, KLK4 over-expressing cells, or corresponding 
controls, may be co-implanted with WPMY-1 myofibroblasts or patient-derived 
CAFs into mice pre-loaded with a TGFβ1 neutralising antibody or inhibitor, the latter 
being similar to previous studies (Ao et al., 2007). Prostate cancer cell lines may be 
substituted for patient-derived cancer cells expressing high levels of KLK4, versus 
those with negligible KLK4 expression, to further validate the clinical applicability 
of these findings. Finally, KLK4 knockout mice have been developed (Bartlett & 
Simmer, 2014) and may be crossed with Pten null mice (Wang et al., 2003), which 
form prostate cancer metastases, to elucidate the roles for KLK4 in the metastatic 
cascade. This may also be conducted with the application of TGFβ1 signalling 
inhibitors. 
In each of the above experimental models, readouts would involve measuring tumour 
volume and metastatic burden, as well as IF or immunohistochemistry for EMT 
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markers in the prostate cancer cell compartment using tissue sections, where markers 
may include E-cadherin, vimentin, Twist and Snail (Giannoni et al., 2010). 
Additional readouts would be immunodetection for the nuclear localisation of AR, 
which is activated by TGFβ1, as well as the proliferative and apoptotic markers, 
Ki67 and TUNEL (Wang et al., 2003), where stromal TGFβ1 reduces epithelial 
response to TGFβ1-induced apoptosis (above). KLK4-mediated activation of TGFβ1 
signalling would be monitored using pSmad2 immunodetection, as above. Inhibition 
or knockout of LTBP4, FBN1, DCN or TGFβR3 in implanted fibroblasts may also 
be performed to determine which are important for the functional response to KLK4-
initiated stromal TGFβ1 signalling. Further, detection of substrate hydrolysis in 
tumour tissue and biological fluids, by methods outlined above, could provide 
evidence for KLK4-mediated hydrolysis in these models.   
As a precursor to animal studies, the candidate has previously established a 3D co-
culture model of prostate cancer cells and myofibroblasts. This model better mimics 
prostatic morphology and mechanical properties than conventional 2D co-culture 
(Dong et al., 2012). Similar models have been used to study the interactions between 
prostate cancer and bone cells (Sieh et al., 2014). These 3D models may be used to 
conduct co-cultures of the above prostate cancer cells and myofibroblasts or CAFs, 
and perform similar molecular readouts. Co-culture with other stromal cells, such as 
endothelial cells or stroma at the site of bone metastases, may also be investigated. 
Further, while the present analysis analysed the role for KLK4 in regulating 
established myofibroblasts, it would be interesting to determine whether KLK4 may 
induce TGFβ1 signalling and an activated phenotype in resting prostate fibroblasts. 
KLK4 is over-produced in PIN, whereupon a reactive stromal phenotype develops 
and TGFβ1 signalling promotes fibroblast activation. Thus, it is plausible that the 
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present findings may extend to naive fibroblasts. Future work should also confirm 
the observed KLK4-mediated regulation of TGFβ1 signalling in patient-derived 
CAFs. Finally, quantitative in vitro analysis of a CAF phenotype using another 3D 
cell culture model has been described (Clark et al., 2013) and these models may be 
used for additional analyses of the ability for KLK4 to promote a CAF phenotype, 
dependent on TGFβ1 signalling. 
7.5 Summary 
In summary, by performing analysis of the KLK4-regulated transcriptome and 
degradome in cell lines representative of early and late stage prostate cancer, as well 
as prostate myofibroblasts, 75 novel KLK4 substrates were collectively identified, 
and KLK4-mediated regulation of three and 439 genes in cancer and stromal cells 
determined, respectively. Such analyses have contributed extensively to knowledge 
of the KLK4-regulated transcriptome and degradome in the prostate tumour 
microenvironment. Pathway analysis indicated that KLK4 appears to activate TGFβ1 
signalling in prostate myofibroblasts, identifying a putative novel role for this 
protease in prostate cancer progression via paracrine signalling. With its established 
pro-tumourigenic autocrine effects, coupled to its putative novel role as a regulator of 
the prostate tumour microenvironment, KLK4 is a promising anti-cancer target. 
KLK4-mediated proteolysis may in future be inhibited to induce optimal disease 
regression, through disrupting pro-tumourigenic signals from prostate cancer and the 
surrounding microenvironment. 
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Appendix A- Supplementary results (Chapter 6): The effect of KLK4-mediated 
proteolysis of CTGF and SPARC on TGFβ1 signalling  
A.1 KLK4 cleaves CTGF, which may reduce CTGF-induced TGFβ1 signalling 
A 20 kDa N-terminal chymotryptic fragment, but not smaller fragments, of CTGF 
induced TGFβ1 activity, albeit to a lesser extent than intact CTGF (Grotendorst & 
Duncan, 2005). PROTOMAP analysis of KLK4-treated WPMY-1 myofibroblast CM 
showed KLK4 to liberate a 15 kDa peptide from CTGF, constituting peptides of the 
Von Willebrand factor type-C region (filled arrowhead, Figure A.1). This fragment is 
topographically similar to, but smaller than, the peptide used in the Grotendorst study 
(Grotendorst & Duncan, 2005). Thus, KLK4 may reduce TGFβ1 signalling through 
proteolysis of CTGF. 
A.2 KLK4-mediated proteolysis of SPARC may not affect SPARC-induced 
TGFβ1 signalling 
SPARC has been shown to induce TGFβ1 activity. A C-terminal peptide of murine 
SPARC, which is almost completely homologous with human SPARC in this region 
and retains its TGFβ1-activating domain, possessed similar potential to activate 
TGFβ1 signalling (Schiemann, Neil & Schiemann, 2003). In the present study, 
SPARC was isolated from the control sample in its apparent intact form in gel slice 
5-7, with additional control-derived fragments isolated from gel slice 3 (Figure A.2 
A). This may have reflected poor resolution of the protein band, possibly due to high 
abundance, and/ or the retrieval of numerous endogenous protein fragments with 
small size differences. Gel slice 7 corresponds to the expected molecular weight of 
SPARC at 35.5 kDa. KLK4-generated cleavage products were observed in gel slices  
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Figure A.1. Representative peptograph (replicate 2) for the putative KLK4 substrate, CTGF, in 
WPMY-1 prostate myofibroblast CM. See Figure 6.7 for peptograph description. The region 
responsible for activating TGFβ1 signalling is highlighted (pink shading). IGFBP N-term, IGFBP N-
terminal; VWFC, Von Willebrand factor type-C; Heparin, heparin-binding. KLK4 cleaved 
endogenous CTGF (open arrowheads/ dashed bracket) to produce a 15 kDa peptide (filled arrowhead) 
similar to that which can activate TGFβ1 signalling, albeit to a lesser extent than intact CTGF 
(references in text). 
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Figure A.2. (A) Representative peptograph (replicate 1) for the putative KLK4 substrate, 
SPARC, in WPMY-1 prostate myofibroblast CM. See Figure 5.5 for peptograph description. The 
region responsible for activating TGFβ1 signalling is highlighted (green shading), as well as a 
fragment which retains the ability to activate TGFβ1 signalling (orange; references in text). FST, 
follistatin-like; EF, EF-hand; Ca, calcium-binding. KLK4 cleaved endogenous SPARC (open 
arrowheads/ dashed bracket) to produce C-terminal peptides (filled arrowheads) similar to that which 
can activate TGFβ1 signalling.  (B) SDS-PAGE/ silver staining of KLK4-treated recombinant 
SPARC. The molar ratio of rSPARC: (m)KLK4 is shown, normalised to the amount of active KLK4. 
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Open and filled arrowheads indicate protein bands which decrease or increase in staining intensity, 
respectively, following KLK4-mediated proteolysis. KLK4 produced additional fragments from 
rSPARC (B) as compared to proteolysis of endogenous SPARC (A). KLK4 cleaved SPARC down to 
a ratio of 8.1 × 10
3
:1. 
 
14 and 16. These KLK4-generated products represented C-terminal fragments, of 
sequence at least including L206 to K293, which has an expected molecular weight 
at least 10.4 kDa. As gel slice 16 represents regions < 10 kDa, migration of the 
KLK4-generated cleavage products in this gel slice was slightly elevated, compared 
to its expected molecular weight. Peptides spanning the TGFβ1-activating sequence 
(green shading, Figure A.2 A) of the protein were retrieved with 100% sequence 
coverage in these cleavage product fragments (gel slices 14 and 16).  
Thus, KLK4 appears to cleave SPARC into a smaller peptide, similar to the murine 
TGFβ1-activating peptide, incorporating the TGFβ1-activating domain. The 
remainder of the cleaved protein was not detected, however, a 10 kDa change in 
protein migration following KLK4-mediated proteolysis may have been too small to 
detect, given that, for example, gel slice 5 spans approximately a 25 kDa range. 
Alternatively, the remainder of the cleaved protein may have been completely 
degraded by KLK4 or other endogenous proteases upon liberation.   
Direct proteolysis of SPARC by KLK4 was confirmed by digesting rSPARC with 
KLK4 and visualising by SDS-PAGE/ silver staining. rSPARC was identified in two 
predominant forms of 35 and 40 kDa, the lower band consistent with the expected 
molecular weight of the protein (Figure A.2 B). KLK4 treatment of rSPARC yielded 
21, 23 and 27 kDa products at the highest KLK4 concentration tested, which 
represented a 100:1 molar ratio of rSPARC:KLK4. Interestingly, the intensity of 
these bands appeared to increase with KLK4 concentration, and so these KLK4-
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generated SPARC cleavage products may be stable, bioactive products, as opposed 
to cases where products are often degraded to beyond the limit of detection at high 
doses of protease. rSPARC digestion was observed down to a ratio of 8.1 × 10
3
:1, 
where upon 23, 25 and 30 kDa bands were weakly identifiable. Notably, all KLK4-
generated products of rSPARC were elevated in molecular weight when compared to 
the migration of KLK4-derived products observed in PROTOMAP analyses, 
excepting feint cleavage products at 11 kDa present at ratios of 300:1 to 2.7 × 10
3
:1. 
The size of the latter products is similar to that that of cleavage products detected in 
PROTOMAP analysis. As expected, mKLK4 treatment did not show evidence of 
SPARC hydrolysis (Figure A.2 B). Thus, proteolysis of rSPARC differed with that 
observed by endogenous SPARC in WPMY-1 myofibroblast CM, and may indicate 
the involvement of endogenous protease in degrading KLK4-liberated SPARC 
fragments. Persistence of 8/15 kDa cleavage products of SPARC in WPMY-1 
myofibroblast CM, which retain the SPARC TGFβ1-activating domain, may indicate 
that KLK4-mediate proteolysis of SPARC is not detrimental to the TGFβ1-activating 
potential of the protein. 
  
 Appendices 323 
Appendix B- Supplementary Tables and Figures (Chapter 3)  
B.1 Tables 
Supplementary Table 3.1. Proteins identified in PC-3 cell CM which were not mapped in the 
IPA database. 
 
Description SeqID 
Ras-related protein Rap-1b-like protein A6NIZ1 
Putative protein mago nashi homolog 3 A8MXB0 
Calmodulin P62158 
Histone H4 P62805 
Ubiquitin P62988 
Histone H3.1 P68431 
 
Description, UniProtKB recommended name; SeqID or sequence identifier, UniProtKB accession. 
  
 Appendices 324 
Supplementary Table 3.2. Proteins identified in LNCaP cell CM which were not mapped in the 
IPA database.  
 
Description SeqID 
AP-2 complex subunit alpha-2 E9PJJ7 
Basigin I3L4S8 
Chromobox homolog 5 (HP1 alpha homolog, Drosophila), isoform CRA_a G3V1X9 
DNA replication licensing factor MCM4 E7ER43 
Enoyl-CoA delta isomerase 1, mitochondrial (Fragment) H3BP91 
Eukaryotic initiation factor 4A-III (Fragment) I3L2M0 
HCG2043275 C9J1V9 
Heat shock 70 kDa protein 1A/1B P08107 
Histone H4 P62805 
Lupus La protein E9PFH8 
Proliferation-associated protein 2G4 F8VTY8 
Ras-related protein Rap-1b-like protein A6NIZ1 
Serine/arginine-rich-splicing factor 2 B4DN89 
Small nuclear ribonucleoprotein G-like protein A8MWD9 
Uncharacterized protein Q6ZU42 
Uncharacterized protein (Fragment) I3L4J1 
 
Description, UniProtKB recommended name; SeqID or sequence identifier, UniProtKB accession. 
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B.2 Figures 
 
 
Supplementary Figure 3.1. Amino acid sequence of recombinant EK-activatable KLK4 (top), 
aligned with the consensus wild-type KLK4 sequence (bottom). cDNA sequencing results from the 
vector containing the coding sequence for enterokinase-activatable KLK4 were translated, in silico, to 
determine the encoded amino acid sequence. Using the ClustalW2 multiple protein sequence 
alignment tool, this sequence was aligned with that of the consensus KLK4 coding region, obtained 
from the UniProtKB. Perfect alignment is denoted by ‘*’, while ‘:’ and ‘.’ represent substitutions of 
groups with strongly or weakly similar properties, respectively. ‘-’ is used to denote an absent amino 
acid residue and [Stop] represents the site of a non-translated stop codon. Coloured lines indicate the 
regions denoted by similarly coloured, neighbouring labels. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.2. Peptographs for proteins identified by the PROTOMAP approach, 
in PC-3 cell CM, comparing KLK4-treated, -transfected and control conditions. For comparisons 
to be employed during PROTOMAP analyses for KLK4 substrates, three conditions were compiled: 
Control, PC-3:Vector or PC-3:mKLK4 CM treated with sample buffer or mKLK4; KLK4-transfected, 
PC-3:KLK4 CM treated as per control and; KLK4-treated, each CM treated with KLK4. Peptides 
identified in individual samples were plotted as a single condition when peptographs were compiled, 
in silico. KLK4 substrates were those proteins which displayed decreased migration, following KLK4 
treatment and/ or transfection, relative to the control condition. Figure legends for individual 
components are contained within this figure, however, please note the following correction for 
sentence 3 of all peptograph figure legends: “Peptograph colour key (left) for peptides found in 
control (yellow), KLK4-transfected (blue) and/ or KLK4-treated (red) lanes of PC-3 cell conditioned 
media (PC-3 CM) digest.” For peptide matches tables, fractions, annotated [A-I][1-32], represent 
[sample][gel slice], where samples are as follows: A, PC-3:Vector + sample buffer; B, PC-3:Vector + 
mKLK4; C, PC-3:Vector + KLK4; D, PC-3:mKLK4 + sample buffer; E, PC-3:mKLK4 + mKLK4; F, 
PC-3:mKLK4 + KLK4; G, PC-3:KLK4 + sample buffer; H, PC-3:KLK4 + mKLK4 and; I, PC-3: 
KLK4 + KLK4. The text string atop each peptograph figure, as well as the second sentence of each 
peptograph figure legend and the opening line of each FASTA sequence or header line of tables 
continued over additional pages, all display the following protein information (from left to right): 
UniProtKB from which the protein was identified [UniProtKB/ Swiss-Prot (sp) or UniProtKB/ 
TrEMBL (tr)], UniProtKB identifier, UniProtKB accession, (‘xxxxxx’_HUMAN), protein name, 
organism (OS), gene name (GN), protein existence score (PE; evidence at protein (1) or transcript (2) 
level, inferred by homology (3), predicted (4) or uncertain (5); not annotated for isoforms), sequence 
version (SV; 1-i; not annotated for isoforms).  
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.3. Peptographs for proteins identified by the PROTOMAP approach, 
in PC-3 cell CM, transfected with empty vector, comparing sample buffer-treated, mKLK4-
treated and KLK4-treated conditions. To determine whether relative migration of proteins derived 
from CM from PC-3:Vector cells treated with mKLK4 was similar to that treated with sample buffer 
alone, 3 conditions were compared: Untreated, PC-3:Vector cell CM treated with sample buffer; 
mKLK4, PC-3:Vector cell CM treated with mKLK4 and; KLK4, PC-3:Vector cell CM treated KLK4. 
See Supplementary Figure 3.2 figure legend for additional detail.  
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.4. Peptographs for proteins identified by the PROTOMAP approach, 
in PC-3 cell CM, transfected with mKLK4, comparing sample buffer-treated, mKLK4-treated 
and KLK4-treated conditions. To determine whether relative migration of proteins derived from 
CM from PC-3: mKLK4 cells treated with mKLK4 was similar to that treated with sample buffer 
alone, 3 conditions were compared: Untreated, PC-3: mKLK4 cell CM treated with sample buffer; 
mKLK4, PC-3:mKLK4 cell CM treated with mKLK4 and; KLK4, PC-3:mKLK4 cell CM treated with 
KLK4. See Supplementary Figure 3.2 figure legend for additional detail.  
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.5. Peptographs for proteins identified by the PROTOMAP approach, 
in PC-3 cell CM, transfected with KLK4, comparing sample buffer-treated, mKLK4-treated 
and KLK4-treated conditions. To determine whether relative migration of proteins derived from 
CM from PC-3:KLK4 cells treated with mKLK4 was similar to that treated with sample buffer alone, 
3 conditions were compared: Untreated, PC-3:KLK4 cell CM treated with sample buffer; mKLK4, 
PC-3:KLK4 cell CM treated with mKLK4 and; KLK4, PC-3:KLK4 cell CM treated KLK4. See 
Supplementary Figure 3.2 figure legend for additional detail.  
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Supplementary Figure 3.6. The number of proteins eligible to be screened as KLK4 substrates 
in PC-3 cell CM (white circle), which were apparent substrates of mKLK4 treatment (A) or 
transfection (B; blue circle). Of the 107 proteins eligible to be screened as KLK4 substrates in PC-3 
cell CM, using the PROTOMAP approach, five and three were apparent substrates of mKLK4 
treatment and transfection, respectively. All but one of each were also deemed KLK4 substrates, as 
KLK4 fragmented these proteins differently to mKLK4. The remaining proteins may have been 
cleaved only in mKLK4-treated/ transfected conditions, or may constitute KLK4 substrates given 
false negative substrate assignment should KLK4-mediated proteolysis have been undetectable above 
background mKLK4-mediated proteolysis of these proteins. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.7. Peptographs for proteins identified by the PROTOMAP approach in 
sample buffer-treated CM from PC-3 cells transfected with KLK4 forms or vector control. To 
determine whether relative migration of proteins derived from CM from PC-3:mKLK4 cells was 
similar to that of PC-3:Vector cells, 3 conditions were compared: Vector, PC-3:Vector cell CM treated 
with sample buffer; mKLK4, PC-3:mKLK4 cell CM treated with sample buffer and; KLK4, PC-
3:KLK4 cell CM treated with sample buffer. See Supplementary Figure 3.2 figure legend for 
additional detail.  
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.8. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 1 (untreated comparison). Peptographs (centre panel) were compiled, 
following bioinformatic peptide and protein identification, to align all significantly identified peptides 
(coloured boxes), matching a select protein, from gel slices (Y-axis, 1-19) in the KLK4-treated (red 
boxes) or untreated (green boxes) samples, or peptides identified in both samples (grey boxes), with 
the corresponding protein amino acid residue (X-axis, range is protein-dependent). The y axis also 
consists of a bar graph (dark grey bars) of the relative spectral count of all identified peptides in each 
gel slice, for each sample, relative to the sample slice with the highest spectral count (annotated in 
light grey at the top of the graph). A list of all peptograph-eligible proteins identified below a 1% FDR 
is listed in the left panel and may be sorted according to various parameters, selected in the drop-down 
menu at the top of the panel (sort by:). For all proteins, the false positive error (FPE) is set to 0.01. 
Protein information in the left panel (derived from the UniProt knowledge base (UniProtKB) 
hyperlinks to protein-specific information to appear in the remaining panels. When sorted according to 
the protein group identification number (group_id), each string of protein information consists (from 
left to right) of an arbitrary protein number (1- i, changes according to the sorting parameter selected), 
group_id ([1]-[1478], missing groups were not eligible for peptograph analyses (see Chapter 2 – 
Materials and methods), UniProtKB identifier or sequence identifier (seq_id), UniProtKB from which 
the protein was identified [UniProtKB/ Swiss-Prot (sp) or UniProtKB/ TrEMBL (tr)], seq_id, 
UniProtKB accession, (‘xxxxxx’_HUMAN), protein name, organism (OS; Homo sapiens), gene name 
(GN), protein existence score (PE; evidence at protein (1) or transcript (2) level, inferred by homology 
(3), predicted (4) or uncertain (5); not annotated for isoforms), sequence version (SV; 1-i; not 
annotated for isoforms). This information string is also displayed at the top of the centre panel, for 
each protein. The centre panel also contains additional protein-specific information, including the total 
number of peptides matched to each protein (n_peptide), the number of gel slices in which peptides 
were identified (n_slice_populated), the number of unique peptides matched to each protein 
(n_unique_peptide), alternative sequence identifiers for the protein (other_seqids), the probability of 
protein identification (probability) a letter assigned to discriminate between sibling proteins in protein 
groups (sibling). Each gel slice in the centre panel hyperlinks to information in the right panel. The 
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right panel displays all identified peptide sequences numbered arbitrarily for each gel slice (1-i, 
column 1, header, #) and prefaced with the protein residue number corresponding to the first peptide 
residue (1-i, column 2, header, i). Residues highlighted in pink indicate residues identified to have 
modifications. Each peptide sequence in the right panel (top) hyperlinks to specific peptide 
information in the right panel (bottom). For selected peptides, the right panel (bottom) contains 
information including whether the peptide is unique (is_unique; true or false), peptide mass (mass; 
Daltons), the number of ions matched to each peptide out of the total number of ions selected for 
fragmentation (i/k), the number of missed cleavages (missed_cleavages), mass modifications 
(modifications; Daltons; following colon) for modified amino acids (residue number (peptide) 
preceding colon), corresponding identification number for pep.xml file (pepxml_id), peptide 
probability (probability), peptide LC retention time (retention_time; seconds), the MS/MS scan 
identification number (scan_id). 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.9. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 2 (untreated comparison).  Figure legend as per Supplementary 
Figure 3.8. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.10. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 3 (untreated comparison). Figure legend as per Supplementary Figure 
3.8. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.11. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 1 (mKLK4-treated comparison). Figure legend as per Supplementary 
Figure 3.8, excepting the mKLK4-treated sample appears in green, as opposed to the corresponding 
untreated sample. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.12. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 2 (mKLK4-treated comparison). Figure legend as per Supplementary 
Figure 3.8, excepting the mKLK4-treated sample appears in green, as opposed to the corresponding 
untreated sample. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 3.13. Peptographs for proteins identified by the PROTOMAP approach, 
in LNCaP cell CM, replicate 3 (mKLK4-treated comparison). Figure legend as per Supplementary 
Figure 3.8, excepting the mKLK4-treated sample appears in green, as opposed to the corresponding 
untreated sample. 
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Supplementary Figure 3.14. Correlation between gel slice and migration of protein standards in 
PROTOMAP analyses of KLK4 substrates in PC-3 cell CM. The molecular weight of protein 
standards (kDa; left) is shown alongside the gel slice/ slices to which each standard migrated (1-32; 
right). The migration of the dye front is also indicated. 
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Appendix C- Supplementary Tables and Figures (Chapter 4)  
C.1  Tables 
Supplementary Table 4.1. Detailed list of microarray probes (RefSeq) and corresponding target 
genes regulated by KLK4 treatment of LNCaP cells.  
avg.L[U,M,K], average log2 probe intensity; Chr., chromosome to which the probe is 
mapped; Coef.L[U,M,K]vsL[U,M,K], average fold-change expression values; Diff., the gene 
is up-regulated (1) or down-regulated (-1) by KLK4 treatment versus mKLK4 treatment; 
Gene ID, Entrez Gene ID; Orientation, the probe maps to the strand sense (s) or antisense (a) 
to the reference transcript; p.value.adj.L[U,M,K]vsL[U,M,K], P-value statistic (corrected for 
FDR); probeClassification, the genomic region to which the probe is mapped; probeID, 
unique probe identifier; probeSource, internal assignment for source of the probe design; 
refseqProbe, the probe does (1) or does not (0) map to a transcript in the RefSeq database; 
start/end, probe localisation beginning and terminal residue coordinates; strand, the strand 
toward which the probe is targeted. 
 
Please view this table in Supplementary Material accompanying this published 
thesis. 
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Supplementary Table 4.2. Detailed list of microarray probes (RefSeq) and corresponding target 
genes regulated by KLK4 treatment of PC-3 cells.  
avg.P[U,M,K], average log2 probe intensity; Chr., chromosome to which the probe is 
mapped; Coef.P[U,M,K]vsP[U,M,K], average fold-change expression values; Diff., the gene 
is up-regulated (1) or down-regulated (-1) by KLK4 treatment versus mKLK4 treatment; 
Gene ID, Entrez Gene ID; Orientation, the probe maps to the strand sense (s) or antisense (a) 
to the reference transcript; p.value.adj.P[U,M,K]vsP[U,M,K], P-value statistic (corrected for 
FDR); probeClassification, the genomic region to which the probe is mapped; probeID, 
unique probe identifier; probeSource, internal assignment for source of the probe design; 
refseqProbe, the probe does (1) or does not (0) map to a transcript in the RefSeq database; 
start/end, probe localisation beginning and terminal residue coordinates; strand, the strand 
toward which the probe is targeted. 
 
Please view this table in Supplementary Material accompanying this published 
thesis. 
 
. 
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Appendix D- Supplementary Tables and Figures (Chapter 5)  
D.1 Tables 
Supplementary Table 5.1. Genes measured in microarray analyses which were not mapped in 
the IPA database.  
ID, Entrez gene ID. 
 
Please view this table in Supplementary Material accompanying this published 
thesis. 
 
  
 Appendices 343 
Supplementary Table 5.2. Detailed list of microarray probes and corresponding target genes 
regulated by KLK4 treatment of WPMY-1 myofibroblasts.  
avg.W[U,M,K], average log2 probe intensity; Chr., chromosome to which the probe is 
mapped; Coef.W[U,M,K]vsL[U,M,K], average fold-change expression values; Diff., the 
gene is up-regulated (1) or down-regulated (-1) by KLK4 treatment versus mKLK4 
treatment; Gene ID, Entrez Gene ID; Orientation, the probe maps to the strand sense (s) or 
antisense (a) to the reference transcript; p.value.adj.W[U,M,K]vsL[U,M,K], P-value statistic 
(corrected for FDR); probeClassification, the genomic region to which the probe is mapped; 
probeID, unique probe identifier; probeSource, internal assignment for source of the probe 
design; refseqProbe, the probe does (1) or does not (0) map to a transcript in the RefSeq 
database; start/end, probe localisation beginning and terminal residue coordinates; strand, the 
strand toward which the probe is targeted. 
 
Please view this table in Supplementary Material accompanying this published 
thesis. 
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Supplementary Table 5.3. Comparison of gene regulation by KLK4 with CAF-enriched* genes.  
Co-regulated by 
KLK4 and in CAFs 
Both 
up 
Both 
down 
ALCAM 1 
 AMIGO2 1 
 ANKRD1 1 
 ANTXR2 1 
 ARHGAP18 1 
 ARHGAP22 1 
 ASB5 1 
 ATP8B1 1 
 C2CD2 1 
 C5orf30 1 
 CA12 1 
 CCND1 1 
 CORO1C 1 
 CORO2B 1 
 CRIM1 1 
 CTGF 1 
 DCAF4 1 
 DDAH1 1 
 DSP 1 
 DUSP5 1 
 EMP1 1 
 ERGIC1 1 
 ERRFI1 1 
 ESM1 1 
 FGF5 1 
 FOXD1 1 
 FST 1 
 GPR176 1 
 GREM1 1 
 HAS2 1 
 HBEGF 1 
 HHIP 1 
 HMGA2 1 
 ID2 1 
 IFT57 1 
 IGFBP3 1 
 IL18 1 
 ITGA4 1 
 KCNMA1 1 
 KRT19 1 
 KRTAP1-5 1 
 LIPG 1 
 MAP2K3 1 
 MECOM 1 
 MET 1 
 MICAL2 1 
 NAV3 1 
 NCEH1 1 
 NEK7 1 
 NOL6 1 
 NPR3 1 
 NRP2 1 
 NT5E 1 
 OXTR 1 
 PCOLCE2 1 
 PNP 1 
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POLR3G 1 
 PSG4 1 
 PSG5 1 
 PTX3 1 
 PYGL 1 
 RGMB 1 
 RGS4 1 
 SCN9A 1 
 SEL1L3 1 
 SEMA7A 1 
 SERPINB7 1 
 SERPINE1 1 
 SLC6A15 1 
 SMAGP 1 
 SMURF2 1 
 STEAP3 1 
 TBC1D4 1 
 UAP1 1 
 UCHL3 1 
 VEPH1 1 
 WNK4 1 
 ANKRD10 
 
1 
ARHGAP28 
 
1 
ASTN2 
 
1 
BDKRB2 
 
1 
CASP1 
 
1 
CHN1 
 
1 
COL4A5 
 
1 
CPE 
 
1 
CYGB 
 
1 
DENND2A 
 
1 
DNM1 
 
1 
ECH1 
 
1 
EFNA1 
 
1 
ERAP2 
 
1 
F11R 
 
1 
GBP2 
 
1 
GDF15 
 
1 
GNG11 
 
1 
GRTP1 
 
1 
H1F0 
 
1 
HINT3 
 
1 
JUP 
 
1 
LIF 
 
1 
LSAMP 
 
1 
MAN1A1 
 
1 
MCC 
 
1 
MFAP4 
 
1 
MSC 
 
1 
MT1F 
 
1 
OSR2 
 
1 
PCMTD1 
 
1 
PDE7B 
 
1 
PGF 
 
1 
PIK3C2B 
 
1 
PIK3R3 
 
1 
PLD1 
 
1 
PMP22 
 
1 
PODN 
 
1 
PPAPDC2 
 
1 
PRICKLE2 
 
1 
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PSMB9 
 
1 
PTCH1 
 
1 
SLC9A9 
 
1 
SNCA 
 
1 
TMEM140 
 
1 
TMEM37 
 
1 
TRPS1 
 
1 
WNT5A 
 
1 
XAF1 
 
1 
ZNF608 
 
1 
 
A ‘1’ indicates that the gene was significantly regulated in the respective condition. 
* CAF expression data was taken from the Ellem et al. study (2014). 
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Supplementary Table 5.4. Fisher’s exact test comparing regulated genes with non-regulated 
genes in KLK4-treated WPMY-1 myofibroblasts and in CAFs versus NPFs.  
 
KLK4 
Total Regulated Not regulated 
CAF Regulated Count 144a 578b 722 
Expected Count 79.8 642.2 722.0 
% within CAF 19.9% 80.1% 100.0% 
% within KLK4 7.7% 3.9% 4.3% 
% of Total 0.9% 3.4% 4.3% 
Adjusted Residual 7.8 -7.8   
Not regulated Count 1718a 14413b 16131 
Expected Count 1782.2 14348.8 16131.0 
% within CAF 10.7% 89.3% 100.0% 
% within KLK4 92.3% 96.1% 95.7% 
% of Total 10.2% 85.5% 95.7% 
Adjusted Residual -7.8 7.8   
Total Count 1862 14991 16853 
Expected Count 1862.0 14991.0 16853.0 
% within CAF 11.0% 89.0% 100.0% 
% within KLK4 100.0% 100.0% 100.0% 
% of Total 11.0% 89.0% 100.0% 
 
  Exact Sig. (2-sided) 
Fisher's Exact Test .000 
 
Subscript letters denotes a subset of categories whose column proportions do not differ significantly 
from each other at the .05 level.  
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Supplementary Table 5.5. Fisher’s exact test comparing regulation of genes up- and down- 
regulated by KLK4 and in CAFs versus NPFs.  
  
KLK4 
Total Regulated Not regulated 
CAF Regulated Count 33a 45a 78 
Expected Count 29.3 48.8 78.0 
% within CAF 42.3% 57.7% 100.0% 
% within KLK4 61.1% 50.0% 54.2% 
% of Total 22.9% 31.3% 54.2% 
Adjusted Residual 1.3 -1.3   
Not 
regulated 
Count 21a 45a 66 
Expected Count 24.8 41.3 66.0 
% within CAF 31.8% 68.2% 100.0% 
% within KLK4 38.9% 50.0% 45.8% 
% of Total 14.6% 31.3% 45.8% 
Adjusted Residual -1.3 1.3   
Total Count 54 90 144 
Expected Count 54.0 90.0 144.0 
% within CAF 37.5% 62.5% 100.0% 
% within KLK4 100.0% 100.0% 100.0% 
% of Total 37.5% 62.5% 100.0% 
 
  Exact Sig. (2-sided) 
Fisher's Exact Test .228 
 
Subscript letters denotes a subset of categories whose column proportions do not differ significantly 
from each other at the .05 level.  
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Supplementary Table 5.6. Fisher’s exact test comparing regulated genes with non-regulated 
genes in KLK4- or TGFβ1-treated WPMY-1 myofibroblasts.  
  
TGFβ1 
Total Regulated Not regulated 
CAF Regulated Count 134a 783b 917 
Expected Count 36.8 880.2 917.0 
% within CAF 14.6% 85.4% 100.0% 
% within TGFβ1 28.6% 7.0% 7.8% 
% of Total 1.1% 6.7% 7.8% 
Adjusted Residual 17.0 -17.0   
Not 
regulated 
Count 335a 10433b 10768 
Expected Count 432.2 10335.8 10768.0 
% within CAF 3.1% 96.9% 100.0% 
% within TGFβ1 71.4% 93.0% 92.2% 
% of Total 2.9% 89.3% 92.2% 
Adjusted Residual -17.0 17.0   
Total Count 469 11216 11685 
Expected Count 469.0 11216.0 11685.0 
% within CAF 4.0% 96.0% 100.0% 
% within TGFβ1 100.0% 100.0% 100.0% 
% of Total 4.0% 96.0% 100.0% 
 
  Exact Sig. (2-sided) 
Fisher's Exact Test .000 
 
Subscript letters denotes a subset of categories whose column proportions do not differ significantly 
from each other at the .05 level.  
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Supplementary Table 5.7. Fisher’s exact test comparing regulation of genes up- and down 
regulated by KLK4 and TGFβ1 in WPMY-1 myofibroblasts. 
  
TGFβ1 
Total Up-regulated Down-regulated 
CAF Up-regulated Count 27a 49b 76 
Expected Count 34.6 41.4 76.0 
% within CAF 35.5% 64.5% 100.0% 
% within TGFβ1 44.3% 67.1% 56.7% 
% of Total 20.1% 36.6% 56.7% 
Adjusted Residual -2.7 2.7   
Down-regulated Count 34a 24b 58 
Expected Count 26.4 31.6 58.0 
% within CAF 58.6% 41.4% 100.0% 
% within TGFβ1 55.7% 32.9% 43.3% 
% of Total 25.4% 17.9% 43.3% 
Adjusted Residual 2.7 -2.7   
Total Count 61 73 134 
Expected Count 61.0 73.0 134.0 
% within CAF 45.5% 54.5% 100.0% 
% within TGFβ1 100.0% 100.0% 100.0% 
% of Total 45.5% 54.5% 100.0% 
 
  Exact Sig. (2-sided) 
Fisher's Exact Test .009 
 
Subscript letters denotes a subset of categories whose column proportions do not differ significantly 
from each other at the .05 level.  
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Supplementary Table 5.8. Comparison of gene regulation by KLK4 and TGFβ1.  
DE, differentially expressed genes (1, up-regulated; -1, down-regulated); SHARED ID's, HUGO gene 
symbol of genes measured in both the present study and the Solomon et al. study (2014).  
 
Please view this table in Supplementary Material accompanying this published 
thesis. 
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D.2 Figures 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5.1, see over 
 Appendices    353 
Supplementary Figure 5.1. KLK4-regulated genes in the canonical KEGG-annotated TGFβ1 
signalling pathway. Orange and blue circles represent genes up- (red arrow) or down-regulated 
(green arrow) by KLK4, respectively, in a manner predicted to promote TGFβ1 activity, according to 
the pathway. Yellow circles show genes regulated in a direction predicted to promote the inhibition of 
TGFβ1 activity. Genes for other pathway intermediates were not regulated or not measured in the 
present study. Definitions for gene symbols can be found in Supplementary Table 5.2. 
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Appendix E- Supplementary Tables and Figures (Chapter 6)  
E.1  Tables 
Supplementary Table 6.1. Proteins identified in WPMY-1 prostate myofibroblast CM which 
were not mapped in the IPA database.  
Description SeqID 
Ras-related protein Rap-1b-like protein A6NIZ1 
Small nuclear ribonucleoprotein G-like protein A8MWD9 
Serine/arginine-rich-splicing factor 2 B4DN89 
HCG2043275 C9J1V9 
DNA replication licensing factor MCM4 E7ER43 
Follistatin E9PC48 
Lupus La protein E9PFH8 
AP-2 complex subunit alpha-2 E9PJJ7 
Homo sapiens F6WGS5 
Proliferation-associated protein 2G4 F8VTY8 
Chromobox homolog 5 (HP1 alpha homolog, Drosophila), isoform CRA_a G3V1X9 
Proline synthase co-transcribed bacterial homolog protein (Fragment) H0YBB9 
Enoyl-CoA delta isomerase 1, mitochondrial (Fragment) H3BP91 
Homo sapiens I3L2M0 
Homo sapiens I3L4J1 
Basigin I3L4S8 
Heat shock 70 kDa protein 1A/1B P08107 
Histone H4 P62805 
Uncharacterized protein Q6ZU42 
 
 Description, UniProtKB recommended name; SeqID or sequence identifier, UniProtKB accession. 
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E.2  Figures 
Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.1. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 1 (untreated comparison). Figure legend as per 
Supplementary Figure 3.8. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.2. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 2 (untreated comparison). Figure legend as per 
Supplementary Figure 3.8. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.3. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 3 (untreated comparison). Figure legend as per 
Supplementary Figure 3.8. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.4. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 1 (mKLK4-treated comparison). Figure 
legend as per Supplementary Figure 3.8, excepting the mKLK4-treated sample appears in green, as 
opposed to the corresponding untreated sample. 
 
  
 Appendices    359 
Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.5. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 2 (mKLK4-treated comparison). Figure 
legend as per Supplementary Figure 3.8, excepting the mKLK4-treated sample appears in green, as 
opposed to the corresponding untreated sample. 
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Please view this figure in Supplementary Material accompanying this published 
thesis. 
Supplementary Figure 6.6. Peptographs for proteins identified by the PROTOMAP approach, 
in WPMY-1 prostate myofibroblast CM, replicate 3 (mKLK4-treated comparison). Figure 
legend as per Supplementary Figure 3.8, excepting the mKLK4-treated sample appears in green, as 
opposed to the corresponding untreated sample. 
  
 
